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Abstract 
Background: Sleep is one of the most widely observed and naturally occurring 
phenomena in multi-cellular organisms, and is typically considered to be pivotal 
for maintaining optimal organism functioning.  Disruptions to these processes - 
which may be of exogenous and/or endogenous origins-, have substantial 
implications for numerous biological, physiological and psychiatric facets of 
health. Despite this, identification of the causes, implications and treatment of 
sleep disorders and its peripheral effects have been largely drawn from clinical 
observations and studies employing experimental manipulation, and thus the 
implication for non-clinical groups is currently equivocal. A growing body of 
research has supported and postulated the role of peripheral facets of sleep as 
both a determinant and outcome of overall health. There is a need for further 
empirical evaluation of these relationships among non-clinical samples within a 
population-based framework. The current study aimed to therefore develop a 
comprehensive and detailed description of several aspects of disturbed sleep, 
such as Excessive Daytime Sleepiness (EDS), sleep duration, and defined sleep 
disorders [Insomnia, Obstructive Sleep Apnoea Syndrome (OSA) and comorbid 
OSA/insomnia] and associated lifestyle and health factors.  
 
Methods: Information was sourced using existing data available as part of 
several epidemiological databases, including; 1.) The Geelong Osteoporosis 
Study (GOS), an ongoing, population-based study aimed at assessing a number 
of health, psychiatric and anthropomorphic information in a large sample of men 
and women residing in the Barwon Statistical Division, South Eastern Australia. 
2.) The Norwegian Longitudinal Health Behaviour Study (NLHB), a nine-wave, 
cluster-sample research study which followed a cohort of adolescents from age 
13 (initial testing period 1990) to 30 years (final follow-up in 2007) who reside in 
Hordaland County, Western Norway. 3.) The National Health and Nutritional 
Examination Survey (NHANES), an age-stratified, cross-sectional population-
based examination of non-institutionalised individuals, spanning all adult age 
groups from 15 counties across the USA.  
 
Results: Results of these assessments are presented as independent, peer-
reviewed manuscripts within this thesis; the primary results can be summed as 
follows. Study 1: This study aimed to determine the prevalence of EDS measured 
by the Epworth Sleepiness Scale (ESS) in a representative Australian 
population-based sample, spanning the full adult age spectrum. For men, the 
age-specific prevalence of EDS was 5.1% (ages 20–29 years), 6.4% (ages 30–
39 years), 9.8% (ages 40–49 years), 15.5% (ages 50–59 years), 12.0% (ages 
60–69 years), 12.0% (ages 70–79 years), and 29.0% (ages >80 years). For 
women, the age-specific prevalence of EDS was 14.7% (ages 20–29 years), 
8.7% (ages 30–39 years), 15.0% (ages 40–49 years), 16.0% (ages 50–59 
years), 12.6% (ages 60–69 years), 13.2% (ages 70–79 years), and 17.0% (ages 
>80 years). Overall standardized prevalence of EDS was 10.4% (95% confidence 
interval, 9.7–11.2) for men and 13.6% (95% confidence interval, 12.8–14.4) for 
women. Further, EDS was temporally associated with several maladaptive health 
and lifestyle factors and instances of physical disease. Study 2: This study aimed 
to investigate the relationship between EDS and a number of body composition 
markers in a population-based sample of men and women. Results indicated that 
for women, after adjusting for age, alcohol intake, antidepressant medication use 
and physical activity, EDS was associated with greater waist circumference and 
body mass index (BMI). EDS was also associated with 1.5–1.6-fold increased 
odds of being overweight or obese. For men, after adjusting for age, alcohol use, 
physical activity and smoking status, EDS was associated with greater BMI. 
These findings were not explained by the use of sedative or antidepressant 
medication. EDS was also associated with 1.5-fold increased likelihood of being 
obese, independent of these factors. No differences in lean mass, %body fat, or 
%lean mass were detected between those with and without EDS for men or 
women. Study 3: The aim of this study was to assess whether EDS was 
associated with defined metabolic syndrome. Results indicated that 138 (14.0%) 
of the women reported EDS; and those with EDS were heavier, had a greater 
body mass index (BMI) and were more likely to have metabolic syndrome. The 
association between EDS and metabolic syndrome was sustained following 
adjustment for age and hours sleep (adjusted OR = 1.90, 95% CI 1.16–3.09), 
however BMI attenuated the relationship (adjusted OR = 1.64, 95% CI =1.05–
2.57). These findings were independent of smoking status, alcohol intake, 
medication use, socioeconomic status, physical activity and current diagnosis of 
a depressive illness. Among men, 111 (13.2%) reported EDS; and those with 
EDS had a greater waist circumference and were more likely to have metabolic 
syndrome. Analysis of age-stratified data (<60 years vs. 60 years) revealed that 
the older men with EDS were more likely to have metabolic syndrome (OR = 
1.71, 95% CI 1.01–2.92), however, age explained this association (age adjusted 
OR = 1.51, 95% CI 0.88–2.60). In the younger age group, no association was 
detected between EDS and metabolic syndrome. For both men and women, the 
prevalence of combined EDS and metabolic syndrome increased progressively 
with age. Study 4: This study aimed to assess the relationship between EDS and 
falls among a cohort of population-based older adults. Among women, 50 
(13.6%) individuals reported EDS. Women with EDS were more likely to report a 
fall, and were more likely to report the fall occurring outside. EDS was similarly 
associated with an increased risk of a fall following adjustment for use of a 
walking aid, cases of nocturia and antidepressant medication use (adjusted OR= 
2.54, 95%CI 1.24-5.21). Multivariate modelling revealed antidepressant use 
(current) as an effect modifier (p <.001 for the interaction term). After stratifying 
the data by antidepressant medication use, the association between EDS and 
falls was sustained following adjustment for nocturia among antidepressant non-
users (adjusted OR= 2.63, 95%CI 1.31-5.30). Among men, 72 (16.0%) 
individuals reported EDS. No differences were detected for men with and without 
EDS in regard to reported falls, and a trend towards significance was noted 
between EDS and a high falls risk as assessed by the EFST (p= 0.06), however, 
age explained this relationship (age adjusted OR= 2.20, 95%CI 1.03-1.10). Study 
5: The aim of this study to examine the association between EDS and depressive 
and anxiety disorders in a population-based sample of women. Overall, 125 
(13.2%) of the 944 women included for analyses were identified with EDS. EDS 
was associated with an increased likelihood for both current (OR = 2.11, 95% CI 
1.10–4.06) and lifetime history (OR = 1.95, 95% CI 1.28–2.97) of depressive 
disorders, but not anxiety disorders, independent of age and alcohol 
consumption. These findings were not explained by antidepressant or sedative 
use, body mass index, physical activity, smoking, or socioeconomic status. Study 
6: This study examined the trajectories and stability of self-reported sleep 
duration recorded at ages 13, 15 and 23 years on reported sleep duration at age 
30 years among 1105 students (55% male) who participated in the Norwegian 
Longitudinal Health and Behaviour Study. Results indicated a significant overall 
reduction in total sleep duration (hours/night) across age groups. Sleep duration 
(continuous) at age 15 and 23 years (whole group) was moderately but positively 
correlated with sleep duration at age 30 years (p<0.01). When stratified by sex, 
at age 15 years, this association was present among females only (p<0.01), 
however at age 23 years, this association was present in both males and females 
(both p< 0.001). Categorical short sleep at age 23 years (whole group) was 
associated with short sleep at age 30 years (unadjusted OR = 3.67, 95% CI 2.36-
5.69). Following sex stratification, this effect was significant for both males 
(unadjusted OR= 3.77, 95% CI: 2.22-6.42) and females (unadjusted OR= 2.71, 
95% CI: 1.46-5.04). No associations were noted for categorical short sleep at 
ages 13 or 15 years and subsequent short sleep at 30 years. Study 7: This study 
assessed the direction of the relationship and degree of shared associations 
between symptoms of depression and difficulty initiating sleep (DIS) from early 
adolescence to early adulthood. Results indicated that symptoms of depression 
and instances of DIS were assessed during each data collection wave. 
Symptoms of depression and DIS were associated in all data waves, and one-
step cross-lagged bivariate correlations were significant and comparatively high 
for both factors. Structural equation modelling indicated that DIS and symptoms 
of depression at wave 1 remained relatively stable across waves (all p<0.001), 
and a significant and consistent unidirectional cross-lagged effect was noted 
running from symptoms of depression to DIS from early adolescence to early 
adulthood. DIS was only marginally and inconsistently associated with the lagged 
symptoms of depression score across waves. Study 8: This study aimed to 
determine the association between insomnia, obstructive sleep apnoea (OSA), 
and comorbid insomnia-OSA and depression, while controlling for relevant 
lifestyle and health factors, among a large population-based sample of US adults. 
Results indicated that those who reported insomnia, OSA or comorbid insomnia-
OSA symptoms reported higher rates of depression (33.6%, 22.2%, 27.1%, 
respectively), and consistently reported poorer physical health outcomes than 
those who did not report sleep disorders. After adjusting for sex, age, poverty 
level, smoking status and BMI (kg/m2), insomnia (OR 6.57, 95% CI 3.89-11.11), 
OSA (OR 5.14, 95% CI 3.14–8.41) and comorbid insomnia-OSA (OR 6.67, 95% 
CI 4.44–10.00) were associated with an increased likelihood of reporting 
depression. 
 
Conclusion: This series of studies provides both cross-sectional and longitudinal 
evidence which demonstrate a strong association between EDS, disturbed sleep 
and pathological sleep disorders and deleterious health outcomes in 
representative, population-based samples. Comprehensive and systematic 
epidemiological assessments of these factors are advantageous if the nature and 
mechanistic features of these relationships are to be described, and if greater 
dissemination of the role of peripheral lifestyle and health factors are to be 
considered. Given the substantial personal and societal burden associated with 
sleep disturbances and compromised health, assessing and describing the 
antecedent and consequences of these factors is important for the development 
of both clinical and allied-health treatment initiatives.     
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1CHAPTER 1: Literature Review 
1.1 The History and Development of Sleep Medicine 
 
The role of sleep as a determinant of optimal biological and physiological 
functioning has been the subject of enquiry for millennia. Early etiological 
perspectives of this phenomenon were limited, with then-theoretical and clinical 
models primarily viewing deviations from optimal or expected  sleep as the result 
of an ‘unquiet mind’ – secondary only to guilt, conflict or depression (1). Thus, 
only the identification of underlying or precipitating medical or psychiatric 
disorders would result in resolution of these symptoms. Indeed, Hippocrates 
frequently made references to the importance of sleep and the consequences of 
poor or insufficient sleep in numerous maxims, often indicating that these sleep 
disturbances were indicative of poor health or disease (1). Following the 
Hippocratic era of medicine, philosophers Aristotle and Plato made significant 
contributions to the understanding of sleep. According to Aristotle, the sleep-
wake cycle represented opposing but mutually necessary functions that resulted 
from the ingestion of food, which was seen to produce ‘vapours’ which would 
induce sleepiness (2). This process was seen to continue unabated provided the 
cyclical intake of food was not disrupted. Thus, disruptions to the sleep-wake 
cycle were attributed to disturbances to this process. Subsequent perspectives 
regarding sleep arose as a consequence of the Greek medical movement in 
Rome in 300 B.C. Democritus of Abdera (ca. 420 B.C.) considered sleep to 
represent a consequence of the complete or partial splitting-off of atoms, and 
2Leucippus of Miletus (ca. 430 B.C.) considered insomnia as a result of poor or ill-
health resulting from an unhealthy diet (3). 
 
Interestingly, it was the widely-held notion that sleep was merely an antithesis of 
the waking state and that sleep disorders were secondary only to other 
recognizable health concerns that most likely informed early treatment models. 
Early approaches, which aimed to remedy sleep disturbances typically focussed 
on immediate symptomatic relief, often in the form of analgesic or narcotic use. 
Concordant with beliefs of the time, the consumption of wine and other alcoholic 
drinks was recognised to alleviate the symptoms of insomnia, among other 
medical complaints (3). Conversely, however, this may have also been pivotal to 
the development and maintenance of the disorder itself. Subsequent treatment 
models utilized the analgesic effects of medicinal plants, such as opium. The use 
of this plant has been reported in the literature to be used as far back as the 
Sumerian age (3500 B.C.), suggesting that this was perhaps the earliest use of 
hypnotic medication in the treatment of sleep disturbances (3). Successive 
perspectives, such as those held by the ancient Chinese and Indians, 
emphasised the importance of a holistic approach to medicine and, 
consequently, the treatment of sleep disturbances. The ancient Chinese, in 
particular, were firm supporters of the importance of the universe and the 
environment as a determinant of health and prosperity (3). Thus, treatment 
modalities aimed to encompass all aspects of bodily and spiritual health. Here, it 
was the interplay between the basic elements of nature; the light, active, dry, 
3positive Ying, and the passive, dark and negative Yang that determined aspects 
of good and bad, and health and wellness, among others (3). Interestingly, 
modern adaptations of approaches to sleep medicine have retained this symbol 
of health and wellbeing, as is evident in the current emblem for the American 
Association for Sleep Medicine (AASM). 
 
Evidently, early theoretical models often attributed maladaptive sleep patterns 
and sleep disorders to imbalances in overall health, or secondary only to 
additional general health complaints. Indeed, despite great devotion given to the 
immediate remedy of symptoms, little or no descriptions were made regarding 
the etiological origins of the disorder (1). Although a number of theories were 
developed in the beginning of the19th century, which assisted in explaining the 
functions of sleep, information regarding the causes or consequences of sleep 
disturbances and their consequences were still lacking (1). The typically narrow 
viewpoint that proposed sleep as a form of ‘reversible death’- that is, an 
intermediate phase between wakefulness and death (4) dominated theoretical 
models of the early 19th century. Despite this, medical advancements which 
occurred in the mid-19th century highlighted the need for a scientific approach to 
medicine, and thus saw a growing emphasis on the need for theories related to 
the physiological basis of sleep. Specifically, the tentative (and often fiercely 
debated) proposal of a four-tiered model of sleep physiology; vascular 
(mechanical, anemic), chemical (humoral), neural (histological), and behavioural 
(psychological, biological) (3, 4), saw the beginning of rapid clinical advancement 
4in sleep medicine. The basis on which these perspectives were drawn typically 
expanded on earlier models. The earliest of the four theories, vascular, expanded 
on first known model of sleep, proposed by Alcmaon of Greece (c.a 500 B.C.) 
(3). Alcmaon, and later Hill (1896) (5) and Howell (1897) (6), ascribed sleep as a 
direct result of relative blood flow to the brain- that is; wakefulness was indicated 
by low levels of cerebral blood flow, with high levels attributed to sleep (7). 
Theoretically, it was this ‘congestion’ of blood that was believed to induce sleep, 
expanding the early work of Hippocrates which suggested that sleepiness as a 
result of ingesting food was directly caused by blood flow to the brain. The 
vascular theory of sleep as a consequence of congestion dominated early 19th 
century perspectives, and saw several complimentary variations. Most notably, 
later work by renowned neuroanatomist Johannes Evangelistica Purkinje (1787-
1869) proposed the role of the constriction of blood-vessel cells as a result of 
increased blood flow, thereby severing neural blood flow, as a direct cause of 
sleep (3). Building on this knowledge, subsequent research performed by Jahann 
Fredreich Blumenbacch (1753-1840) demonstrated an observable decrease (as 
seen in a paler brain surface) in cerebral blood flow in the sleeping individual.  
 
The most prominent alternative theory to congestion as a cause of sleep, 
anaemic theory, was proposed by William Alexander Hammond (1828-1900). 
Although this approach was still heavily based in the vascular model of sleep, it 
proposed the role of variations in intracranial blood pressure, and insufficient 
blood in the brain (anaemia) as opposed to relative blood volume in the brain to 
5the body’s extremities, as the cause of sleep and wakefulness. Enthusiasm for 
this approach was bolstered by numerous animal and human studies, which 
demonstrated that variations in cerebral blood flow, combined with associated 
variation of cerebrospinal fluid levels in both the ventricle and subarachnoid 
spaces were consistent with sleep onset (8). Indeed, research conducted on both 
animal and human subjects appeared to support the notion of cerebral blood flow 
as a mediating factor in the sleep/wake cycle. Both Frans Cornelius Donders 
(1818-1889), and Angelo Musso (1826-1910) were firm advocates of the cerebral 
anaemia theory of sleep, and who both proceeded to write prolifically in support 
of the theory. Following human research conducted by Musso investigating 
cerebral blood flow in skull-defect patients, he concluded that not only does blood 
reduce during sleep onset, but that the blood then travels to supply internal 
organs (3). What is more, these findings were found to be consistent with a 
number of clinical observations at the time pertaining to cerebral changes 
following traumatic brain injury (8), as well as previously reported knowledge 
about the metabolic features of medication and the consequences of particular 
illness known to affect cerebral functioning (8).  
 
Despite these advancements supporting the notion of a neural basis of sleep and 
wakefulness, interest in the anaemic model as a complete explanatory theory of 
sleep waned towards the middle of the 18th century. As research proposing the 
involvement of several neural pathways gained momentum, technological 
advancements in instruments designed to measure cerebral brain flow became 
6available. Notably, 20th century research observed that it was in fact cerebral 
hyperaemia (increased blood flow), rather than anaemia, that featured during 
sleep onset (8). 
 
The basis for neural perspectives of sleep and wakefulness were primarily based 
in mid-19th century advancements in the histological understanding of the role of 
the nervous system. Camillo Golgi (1843-1926), the son of a physician, was 
perhaps the first to describe the process and function of the nerve cell, thus 
indicating the beginning of an emphasis on a neurological basis of human 
processes (3). This understanding was furthered by subsequent research 
conducted by Heinreich Waldeyer (1837-1921), who was the first to describe the 
nerve cell- the neuron- and identify the role of afferent axons and efferent 
dendrites (3). The first significant experimental research demonstrating the role of 
neural connections in relation to sleep and wakefulness was conducted by Luigi 
Ronaldo. Indeed, research conducted by Ronaldo in 1809 demonstrated that 
sleepiness can be induced (at least in birds) following the abolition of the cerebral 
hemispheres, thus supporting the notion that sleep is merely a passive state that 
occurred in direct response to reductions in cerebral stimulation; with no explicit 
distinction from other states of reduced consciousness (such as coma) (9).  
   
Despite differing perspectives regarding the etiological origins of sleep 
throughout history, common themes can be identified. That is, an emphasis on 
the gradual development of a rigorous medical model which focuses on a 
7process of hypothesis testing and revaluation of evidence when theories are 
contested. In part, the modern development of these standards can be attributed 
to the modern formation of the AASM (and its various arms), and concurrent 
advancements in clinical assessment via the application of objective, 
standardised testing methods used to assess sleep as a functional state. Despite 
knowledge regarding the electrical activity of the brain being first described by 
Luigi Galvani in the early 18th century, it was not until the 19th century that the use 
of electroencephalography (EEG) to assess electrical activity of the brain was 
utilized. Scottish physiologist Richard Carlton was perhaps the first to investigate 
and record the electrical currents exhibited by the mammalian brain, specifically 
that from rabbits and monkeys (10). Although Hans Berger was the first to 
describe the use of these methods in humans in a publication released in 1929 
(11), it was not until 1937 that Alfred Loomis applied these methods in to assess 
sleep and wakefulness (12). Subsequent collaborations appeared by two 
research groups based at Harvard University and the University of Chicago in the 
mid 1930’s (13). Here, the teams identified and prolifically described the 
characteristic changes in electrical activity in the brain as an individual 
transitioned from wakefulness to sleep, and effectively documented differences 
between deep and non-REM (NREM) sleep (14). Loomis further categorised 
these stages of sleep as; A (alpha), B (low voltage), C (spindle), D (spindle and 
delta), and E (random) (14). Advancements in sleep research practices during 
the 1950’s lead to the discovery of Rapid Eye Movement (REM) sleep, and the 
relationship between the duration, timing, and cyclical nature of REM and non-
8rapid eye movement sleep (NREM) sleep stages (15). This information regarding 
sleep stages and differences between REM and NREM sleep has informed much 
of the modern literature. 
 
1.2 The Economic Cost of Sleep Disorders  
 
To paraphrase one researcher, it has been said that ‘more has been learned 
about sleep in the last 60 years than the last 6000 years’ (16). Indeed, the 
International Classification of Sleep Disorders (ICSD) now identifies in excess of 
80 sleep disorders, many of which can be effectively treated via a variety of 
medical, psychological and physiological intervention (17). The impact of sleep 
disorders resonates on both a societal and monetary level; however, to date; 
there is little indication of the incurred burden as a result of undiagnosed and 
untreated sleep disorders. Indeed, of the available estimates, monetary 
implications of sleep disorders are often derived from data pertaining to direct 
costs incurred as a result of sleep-related disorders or as a function of sleep-
related accidents (17, 18). ‘Direct costs’ refer to those incurred accessing 
healthcare and associated treatments (such as medication and cost of therapy), 
and ‘indirect costs’ pertain to associated tangible and intangible implications of 
experiencing the sleep disorder (such as increased risk of comorbidity and 
reduced quality of life) (17). In this respect, the direct cost implications for sleep 
disorders (i.e., access to healthcare) has been estimated to be as high as $15.9 
billion (US) in 1990, and the incurred cost of sleep-related accidents has been 
cited as high as $56 billion in 1988 (19).  
9Resent estimates regarding the total incurred cost of sleep disorders within the 
Australian population have also indicated significant annual increases in overall 
expenditure. Indeed, a report conducted in 2010 cited an overall healthcare 
burden of $818 million (20), with total indirect costs associated with the 
management of sleep disorders cited as upward of $4.3 billion. Breakdown of 
indirect costs included $3.1 billion in lost productivity, $474 million deadweight 
required for increasing revenue due to lost productivity and as a result of sleep-
related motor-vehicle accidents, and $129 million and $517 million for informal 
care and incurred costs as a result of motor vehicle accidents, respectively (20). 
It was found that these costs were predominantly incurred by those individuals 
suffering OSA (62%), insomnia (36%) and restless leg syndrome (RLS) (3%) 
(20). A subsequent 2011 report of Australian-specific estimates cited an annual 
cost implication of up to $31.4 billion in the local management of sleep disorders, 
including both direct and indirect costs (21). In addition, the report highlighted an 
additional $4.3 billion is spent per annum specifically in the management of 
indirect costs associated with the management of sleep disorders (21).     
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1.3 The Biology of Sleep 
1.3.1 The Process and Functions of Mammalian Sleep: Perspectives 
 
Sleep is considered to be one of the most widely observed phenomena in multi-
cellular organisms (22). Perspectives of sleep, although varied, typically attempt 
to account for all facets of sleep and the associated impact on the functionality 
and processes of the organism. Despite reports proposing that an individual 
typically spends one-third of their lives sleeping (23), no single quantitative theory 
is currently available that adequately accounts for all aspects of physiological, 
biological and behavioural changes that occur during this time. In part, these 
difficulties arise from the particular emphasis placed on the systems responsible 
for the induction of sleep and wakefulness by competing disciplines, and the 
availability of knowledge across generations. Indeed, perspectives regarding the 
origin of sleep and wakefulness have changed dramatically since the turn of the 
20th century, following advancements in scientific research and innovation. As 
such, current understandings, and therefore the most prominent theoretical 
construct, often reflects the most satisfying definition provided at any given time, 
in the context of a variety of theoretical perspectives. Therefore, when 
considering theoretical definitions of sleep, one must address the typically 
integrated nature of these processes. Technological advancements in the past 
decade have allowed for more robust analysis of the role of neurotransmitters 
and genetics as possible mediating factors in the expression of sleep/wake 
processes. Thus, older theoretical persuasions have, on the whole, largely been 
abandoned in favour of a more progressive medical model.     
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1.3.2 Sleep as a Behavioural State 
 
In contrast to observable physiological activities such as eating, breathing, or 
mating; the functional processes and benefits of sleep are unclear (22, 24). From 
an evolutionary perspective, the direct cost/benefit associated with mammalian 
sleep/wake processes appear counterproductive; indeed, sleeping animals forgo 
opportunities for foraging and mating, and may experience greater risk for 
predation (24). Despite this, the ‘benefit’ associated with these processes must 
presumably outweigh the costs, given the perseverance of these functions across 
a variety of organisms (24, 25). Perhaps the most prominent perspective is that 
of a behavioural model of the sleep/wake process. By this definition, sleep is 
conventionally described as a reversible behavioural state of immobility, 
combined with disengagement from, and unresponsiveness to, external 
stimulation (26, 27). This process is perhaps the most easily observable, and is 
distinguished from that of comatose, hypothermic (e.g. hibernation) or 
anaesthesia by ability of rapid state-reversibility (28). Despite these distinctions, 
some similarities can be drawn to these induced states. Most notably, increased 
arousal thresholds are considered a cardinal feature of sleep, in particular deep 
and recovery sleep following a period of sleep restriction or deprivation (25, 29). 
Thus, from this perspective sleep can also be described as a state of reduced 
movement and flattened sensory responsiveness that is homeostatically 
regulated (25). That is, if sleep is restricted or forgone, an individual will 
experience an intense drive for sleep (25). To paraphrase, homeostasis has been 
described as a ‘coordinated physiological process which maintains most of the 
12
steady states of the organism’ (30). Concordantly, some of the strongest 
evidence for this model has come from numerous observational and 
experimental studies investigating the impacts of sleep deprivation on a number 
of physical and biological systems. In respect to sleep, homeostasis is regarded 
as a sleep-wake dependent process of sleep regulation, whereby homeostatic 
mechanisms mediate deviations in optimum ‘reference levels’ of sleep (31). 
Research assessing the role of sleep deprivation has demonstrated that following 
acute sleep deprivation, mammals (including humans) (32) exhibit both an 
increase in deep sleep and tendencies relative to prior time spent awake. 
Increases in delta wave activity are seen to be closely proportionate to, and 
predictive of, prior sleep loss (32). Interestingly, this finding also translates to 
sleep propensity and delta activity of insects (fruit flies- Drosophila melanogaster) 
(33). This is of particular note, as although sleep as a multidimensional 
behavioural state is considered to occur exclusively in mammalian species (34), 
evidence of unidimensional circadian rhythmicity has also been found in simple 
model organisms such as zebra fish and fruit flies (25).  
 
Despite the apparent unanimity regarding observable physiological processes 
associated with sleep, neither the mechanism nor function by which sleep occurs 
is well understood (22). Current understandings of sleep/wake behaviour have 
largely resulted from extensive research into naturalistic observation, 
experimental manipulation and pathological alterations of these processes. As a 
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result, several theoretical positions exist in order to explain all facets of these 
functions.  
1.3.3  Homeostatic Hypothesis of the Sleep/Wake Cycle 
 
The homeostatic model of sleep posits that the sleep-wake dependent aspect of 
sleep regulation functions primarily to counteract deviations from an average 
‘reference level’ of sleep (31). Therefore, it has been suggested that the 
experience of wakefulness results in either the accrual of adverse changes in the 
brain and body (35), or a reduction in the necessary means to maintain 
wakefulness (25). That is, that the physiological drive for sleep is regulated as a 
function of prior wakefulness, thus the longer you stay awake, the greater your 
drive for sleep (36). Several models of sleep homoeostasis exist, which aid in 
conceptualizing the framework upon which these models are derived. 
 1.3.3.1 The Two Process Model 
 
The two-factor model of sleep homeostasis suggests that sleep propensity is 
regulated primarily via the interaction of homeostatic process S and the circadian 
process C (31). This model hypothesizes that a rise in the level of the sleep-wake 
dependent process S occurs after waking, and declines incrementally after sleep 
onset (28). Process C occurs independently of the sleep wake process, and 
mediates two additional thresholds (H and L), which converge to modulate the 
beginning and end of a sleep episode (37). Originally, this model was used to 
account for sleep regulation in the rat (38); however, subsequent adaptations 
have been used to successfully describe the diverse effects of alterations to 
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sleep architecture following periods of sleep deprivation, sleep fragmentation, 
and circadian desynchronization in humans (39). Indeed, there are numerous 
studies investigating sleep architecture that have quantified the expression of this 
model, particularly in evidence derived from EEG slow wave activity (SWA). Early 
research conducted by Dijk Beersma and Daan (1987) (40) sought to investigate 
the relationship between prior wakefulness and EEG spectral density in 
participants exposed to controlled nap opportunities. The authors controlled for 
prior wakefulness (from 2 to 20 hours) via imposed scheduled nap opportunities. 
It was seen that EEG power densities in theta and delta frequencies exhibited 
were significantly mediated by prior wakefulness. As prior wakefulness was 
controlled for, circadian influence was unable to account for these findings, thus 
lending support to the two-factor hypothesis. Subsequent experimental research 
conducted by Dijk & Beersma (1989) (41) demonstrated similar results, as it was 
found that after participants were deprived of the first 5 hours of baseline SWS, 
the power density for delta activity was significantly higher than the control. No 
differences in sleep duration were noted as a result of SWS deprivation. Despite 
the authors conceding that the research provided strong evidence for the two-
factor model of sleep homeostasis, a lack of difference in sleep duration does not 
lend support to this model. That is, although the two-factor model proposes that 
the level of process S at termination of the sleep period would be influenced by 
circadian phase, if the decay of process S is slowed (via external intervention), 
sleep duration is expected to increase independent of process C. Nonetheless, 
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these findings were integral to research that has further described the role of this 
process in the expression of sleep/wake. 
 
Several variations of the two-factor model exist. A later adaptation, initially 
proposed by Beersma et al (42) and Dijk et al., (1987) (43) and subsequently 
formalized by Achermann and Borbely (1990) (44), suggested that the change of 
S, rather than the relative level, is considered proportional to SWS displayed. 
Further, the model aimed to account for global changes to NREM density, which 
had not been addressed in the original model (38). Experimental research has 
been useful in demonstrating the expression of this adaptation. Research 
conducted by Achermann and Borbely (1990) (44) aimed to demonstrate the 
ability of the model to account for global changes to SWA. It was seen that 
increased SWS density rebound was evident in the first 3 hours of sleep, 
therefore supporting the models prediction. Additional adaptations of the model, 
proposed by Achermann and colleagues (1993) (45), aimed to account for both 
the decline in SWA during sleep episodes, as well as the degree of variation 
observed in NREM periods. The degree of fit for the model was compared to 26 
reference SWA baseline nights (16 participants). Sensitivity analyses revealed 
that the model was robust to small changes, exhibiting a close fit between 
simulated and empirical data. These findings suggest that adaptations to the two 
factor model can be useful in predicting changes induced to sleep architecture as 
a result of extended wake or sleep periods (45). Subsequent research has 
employed this model to demonstrate the effect of changes to REM latency on the 
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predicted course of SWA (46), as well as accounting for the dynamics of SWS 
during evening naps (47). Indeed, the predictive power of this model proposes 
that if naps act to reverse SWS propensity, it is therefore expected that the SWA 
observed in the following nighttime sleep will be reduced, and, further, relative to 
the duration and intensity of the nap. Such predictions were demonstrated by 
early experimental research conducted by Werth and colleagues (1996) (47). 
Here, the authors aimed to assess the predictive power of reduced sleep 
propensity in relation to innate homeostatic mechanisms by imposing an evening 
nap schedule in a sample of healthy young men. In accordance with the model, 
the participants exhibited a typical declining trend in SWA among consecutive 
non-REM sleep episodes. Thus, it was concluded that the time-course of SWA 
reduction closely resembled that which was predicted by the model, therefore 
lending support for the role of homeostatic mechanisms in the expression of 
sleep EEG under such conditions.  
 
 
Figure 1.1: The two-factor model of sleep homeostasis 
 
Image source: http://www.howsleepworks.com/how_twoprocess.html 
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1.4 The Mammalian Circadian System 
 
Circadian rhythms are found in most living organisms, ranging from bacteria to 
humans, and are considered a fundamental property of living cells (48). Given 
that the rotation of the earth in relation to the sun allows for reliable predictions 
regarding the availability of food and light, evolution has typically favoured 
organisms that are able to exploit these environmental changes (49). 
Evolutionarily, these systems are conserved and are designed to maintain an 
optimal organism activity (48), and are considered to hold two fundamental 
characteristics: (1) endogenous rhythmicity that functions within a period of 
approximately 24-hours and remains independent of oscillation to external factors 
such as the light/dark cycle; (2) the ability to have its timing shifted by external 
factors such as nutrient and light intake (50). These endogenous ‘clocks’ impart 
evolutionary advantage as they enable organisms to predict daily environmental 
fluctuations in food and resource availability (49). These systems are responsible 
for both global and specific functions, ranging from the regulation of several 
biological processes at the cellular level (48), to overall locomotor activity of an 
organism (51).  
 
These processes are considered to function on a circa  (approximately) 24-hr 
timing mechanism, and are thought to regulate a range of consequential 
physiological and psychological processes, ranging from sleep/wake cycle, 
metabolism of glucose, lipids and drugs (48), to behaviour regulation, physiology, 
and mood (52). It has been substantiated that these rhythms are not merely a 
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passive consequence of cyclic fluctuation in the environment, rather, that they 
rely on a complex network sequence that involves the primary circadian clock, 
synchronizing inputs, various outputs, as well as multiple central and peripheral 
oscillators (53). There is substantial evidence to suggest that the master 
regulator oscillating the mammalian circadian system is located within the 
suprachiasmatic nucleus (SCN), situated within the anterior hypothalamus (54, 
55), with additional clocks recognized to function in peripheral tissues such as the 
liver and kidneys (50). The SCN is a bilateral structure that consists of thousands 
of neurons (approximately 50,000 in humans, and 20,000 in rats) (50) located at 
the midline above the optic chiasm (56) and next to the third ventricle (50). This 
mechanism functions primarily as an endogenous driver of the circadian system 
within the brain and body, and is synchronized to the external light-dark cycle via 
retinal light input through daily autoregulatory transcription/translation feedback 
oscillations (a system of components that interact to produce a rhythmic output) 
(52, 57).  
 
Perhaps the most powerful evidence demonstrating the fundamental role of the 
SCN in circadian rhythmicity can be seen in a number in in vitro and in vivo lesion 
studies. Lesions to the SCN have been found to disturb circadian rhythmicity in a 
variety of behavioural, endocrine and biochemical processes (55), in that these 
systems appear lost following the abolition of the SCN (54). Conversely, explant 
studies demonstrate the persistence of rhythmicity in vitro following SCN cell 
transplantation to SCN lesioned rats- allowing for restoration of circadian 
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rhythmicity in the recipient animals (54, 55, 58). Of note - it has been found that 
the transplant recipient often adopts the circadian characteristics of the donors’ 
biological rhythm (55, 58). In addition, although recent studies have 
demonstrated that lesions of the SCN do not abolish peripheral circadian 
systems (e.g. liver, kidneys) (59), peripheral oscillators have demonstrated 
disrupted synchrony in response the SCN lesions (55).  
 
These findings suggest that although the SCN is required for the coordination of 
peripheral oscillation systems, it is not necessary for the maintenance of these 
functions. In addition, studies have demonstrated that the SCN is able to 
maintain rhythmic activity despite the absence of neural input- in terms of 
isolation or ‘island’ lesions. Here, lesions are made to create a SCN ‘island’ of 
hypothalamic tissue, but with all afferent and efferent pathways severed (60). As 
a result, circadian rhythmicity is lost at all other brain locations but continues to 
persist within the ‘island’ (60). This suggests that individual SCN cells can 
function independently as autonomous circadian oscillators. The SCN has not 
only a self-sustaining property, but also phase adjustability by environmental 
lights (54).  
 
As mammalian circadian systems follow a near 24-hour period (‘circa’, around; 
‘dies’, day), these systems require external input (e.g. time, light input) in order to 
phase-shift and therefore synchronize (or entrain) with the external environment 
(e.g light/dark cycle) by means of both photic and non-photic signals, or 
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‘zeitgebers’ (time-givers) (50, 57). Processes of entrainment allow these systems 
to be sensitive to environmental cues, and therefore allow the ability to adjust its 
phase with the prevailing day/night rhythm (61). Light is considered the major 
zeitgeber for the SCN and master circadian oscillator, which is transmitted via 
novel photoreceptors in the retinal ganglion cells (containing the photopigment 
melanopsin), rods and cones to the SCN via the retino-hypothalamic tract (RHT) 
(50, 57). In addition, the SCN indirectly receives light information via alternate 
pathways that transducer light to the intergeniculate leaflet of the optic tract, then 
to the SCN via the lateral geniculohypothalamic tract (50, 57). From here, a 
serotonergic pathway provides non-photic input to the SCN, and is particularly 
important in the context of depression, as concentrations of serotonin (5-HT) 
within the brain are at their highest in these nuclei (57). The primary output of the 
SCN is to the paraventricular nucleus of the hypothalamus, which functions to 
translate the SCN signals into hormonal and autonomic signals for peripheral 
organs through the automatic neurons (56).  This neural output travels via a 
multi-synaptic pathway to the pineal gland, where melatonin is synthesized 
during the night and suppressed by light input during the day (62).  
 
1.5 Melatonin 
 
The sleep/wake cycle of many organisms is recognized to be mediated by a 
number of physiological systems within the body, primarily orchestrated by 
circadian systems. Complimentary indicators have also been recognized as 
changes in core body temperature, heart rate, renal output, gut motility and 
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concentrations of melatonin and cortisol levels in the body (63, 64). The 
regulation of light input mediated by the aforementioned physiological systems 
has been recognized as a key regulator of hormonal levels of melatonin, often 
thought of as the ‘darkness’ hormone (55). Research indicates that circadian 
entrainment can also occur in the absence of external cues, thus suggesting that 
non-photic signals, -such as melatonin secretion- can phase-shift and 
synchronise circadian clocks, and in turn, regulate the sleep/wake cycle (50, 65). 
The French Philosopher, Rene Descartes was the first to describe the pineal 
gland as the ‘seat of the soul’ (66). Despite this, it was not until the 1950’s that 
melatonin was identified as the primary substance secreted by this gland (66). 
Subsequent studies have postulated its role in a variety of human biological 
systems, most notably circadian rhythms (67), sleep (66) and mood (68). In 
humans, the pineal gland is located in the centre of the brain, deep within the 
third ventricle (66). It is thought that melatonin secretion from the pineal gland is 
regulated by a number of exogenous and endogenous systems (66, 69). Namely, 
the light/dark cycle, of which is mediated by retinal light input (70) is thought to be 
controlled by the SCN; at least in rats and rhesus monkeys (71). However, there 
has been considerable conjecture in regard to the extent that melatonin acts as a 
primary oscillator for circadian systems in mammals.  
 
Animal studies have demonstrated that while pinealectomy surgery does not 
disrupt mammalian rhythms to any large extent (i.e. in birds) (65), early studies 
using rats have shown that exogenously administered melatonin can entrain free-
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running rhythms (72). In vitro studies investigating these mechanisms have 
largely been carried out using animal models. In particular, attempts to link the 
process of hormonal output and its relationship to the SCN as a primary oscillator 
has led to a number of in vitro animal studies. Early research conducted by 
McArthur et al (1991) (73) assessed rat brain slices in vitro for a period of 2-3 
days. It was seen that although exposing the SCN to melatonin both early and 
late in the subjective day induced SCN electrical activation advances to the 
tissue, this finding was not uniform. Indeed, it was concluded that although 
melatonin does play a pivotal role in the modulation of the circadian clock, these 
effects were timing dependent. 
 
In humans, the secretion of melatonin by the pineal gland is minimal during day 
hours, progressively increases with the onset of darkness, reaches its peak in the 
second phase of the night (around 02:00 and 04:00), and gradually decreases to 
daytime levels around 09:00 (56, 68). Therefore, treatment with timed doses of 
exogenous melatonin is thought to entrain free-running circadian systems, as 
seen in blind and depressed individuals, where these rhythms are disrupted (74). 
Indeed, the ability of exogenously administered melatonin to also assist in the 
advancement of sleep phase has been extensively researched (75).  
 
Early studies conducted by Sack and colleagues (1991) (76) assessed the 
phase-shift and entraining abilities of exogenously administered melatonin in a 
group of blind participants. Employing a double-blind placebo-controlled trial over 
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a period of three weeks, significant effects were found for those participants who 
were administered a low dose (5mg) of melatonin. Specifically, it was seen that 
treatment with melatonin was effective in entraining the free-running rhythms in 
these blind individuals. Subsequent research conducted by both Lockley and 
colleagues (2000) (75) and Lewy et al (2001) (77) replicated these findings, with 
additional outcomes in regard to measurable differences in reliable physiological 
markers of circadian functioning, such as cortisol levels, in response to low-dose 
exogenous melatonin. Concordant animal studies investigating this effect have 
found similar results. Early research conducted by Slotten and colleagues (1999) 
(78) administered water-based melatonin to Long Evans rats in order to 
substantiate the role of exogenous delivery independent of possible confounding 
factors associated with previous research, such as animal handling procedures 
(72). The first group of rats was administered via a 1-hr time-fixed vehicle by 
means of subcutaneous catheter, with the other group receiving timed access to 
drinking water containing melatonin. Following this period of entrainment, the rats 
were removed and placed in constant-darkness conditions to foster free-running 
circadian cycles. Melatonin was again administered, and re-entrainment of these 
systems coincided with melatonin delivery. Both groups were assessed in terms 
of core body temperature and activity levels as measured by wheel-running 
activity. Under both conditions, the rats demonstrated equal phase-relation 
following the melatonin administration, and both groups exhibited recurrence of 
free-running cycles once the melatonin administration was ceased. Drawing from 
these models, it can be seen that exogenous melatonin delivery in both humans 
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and animals has the ability to assist in reforming free-running circadian cycles 
that may disturb optimal organism activity and function.  
  
In addition to its proposed properties in regard to the circadian clock and 
circadian timing mechanisms, the direct administration of melatonin may have 
acute sleep-promoting properties (65). Numerous direct and indirect studies have 
suggested a direct link between melatonin and sleep (79). However, studies 
exploring the administration of melatonin have demonstrated that clinical efficacy 
of this treatment is largely dependent on timing (80). Specifically, it has been 
established that melatonin administered in the morning contributes to delayed 
sleep onset by delaying the phase of circadian rhythms (80). Conversely, night-
time administration is seen to facilitate earlier sleep-onset via phase advances in 
circadian rhythms (80). Such evidence is supported by converging behavioural, 
biological and neurogenic evidence to suggest the pivotal role of melatonin 
secretion in both the facilitation and regulation of the sleep/wake system in 
humans. Traditionally, melatonin is thought of as a ‘darkness hormone’ (81), with 
substantial biological research demonstrating the role of this hormone in 
transducing photoperiodic information, therefore defining the length of the night 
(82). In addition, research has demonstrated high levels of melatonin agonists 
within the SCN, therefore supporting the role of melatonin as an important 
regulator of circadian and sleep/wake systems (65).  
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Several in vitro studies have further supported this, with observations 
demonstrating that treatment of SCN neurons with melatonin can phase-shift the 
neuron firing rate and alter neuron activity (65). In combination, this information is 
required to entrain the circadian system to 24-hr light/day cycles (54) and to 
regulate processes of the sleep/wake cycle. Regulation of retinal light input is 
thought to act as a significant zeitgeber that directly influences the output of 
multiple oscillator systems, via entrainment of the master clock in mammals 
(male albino rats) (55). This combined process of endogenous and exogenous 
timekeeping systems allow organisms to both anticipate and prepare for changes 
in the environment that are associated with day/night cycles, in order to function 
effectively (83). Interference or dysregulation to these systems or lesions to the 
SCN can have significant disruptions to circadian rhythmicity, which is often 
evident in a variety of behavioural, endocrine, and biochemical processes (84). 
Concurrent research has demonstrated that lesions to the SCN- and therefore 
disruptions to melatonin regulation- results in the abolition of the circadian 
sleep/wake rhythm (85). Indeed, there is increasing evidence that a dysfunctional 
circadian system may contribute to altered emotional behaviour (61), reduced 
immune function (86), protein synthesis and compromised redox defences (87), 
as well as impaired daytime functioning (88).  
 
1.6 Conclusion 
 
Early developments and subsequent advancements of the medical model has 
allowed for greater identification of the causes, implications and treatment 
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modalities of sleep disorders. Specifically, the transition from speculative to 
empirical models has allowed for more robust and scientific assessment of both 
the biological and neurological underpinnings of many of the common disorders 
identified today. Indeed, the development of the EEG and subsequent movement 
towards measurable models of sleep has been closely linked to this transition. 
Unification of theory and empirical evidence has further allowed for the formation 
of gold-standard tools, used in both the clinical identification and successful 
treatment of these disorders among affected cohorts, and has promoted greater 
consistency in both research and clinical approaches. In part, this occurred in 
conjunction with the development of the AASM, as well as the growth of 
numerous specialist areas, which aimed to profiteer the development and 
progression of scientific assessment of sleep disorders and its associations with 
health and wellbeing.  
 
Despite these advancements, sleep medicine as a discipline is still considered to 
be in its infancy. As demand for knowledge regarding the appropriate diagnosis 
and treatment for sleep disorders grow, there will be increased pressure placed 
on the individual practitioner and health care systems to cope with these 
changes. As outlined, the cost implications for both the personal and societal 
aspects of sleep disorders are on the rise. As such, there is a need for greater 
understanding and emphasis on preventative care in regard to the associated 
implication of undiagnosed sleep disorders. In order to achieve this, particularly 
at a local level, accurate representation of the epidemiology and associated 
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health factors and outcomes need to be assessed. Such investigations will assist 
in the identification and formulation of appropriate and specific areas of need, 
both at a population and clinical level.   
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CHAPTER 2: Measuring Sleep Disruption 
2.1 Measurement Tools: Objective 
2.1.1 Multiple Sleep Latency Test (MSLT). 
The Multiple Sleep Latency Test (MSLT) (89) is the most widely used objective 
measurement tool used to assess physiologic sleepiness. The testing procedure 
originally proposed by Richardson et al (1978) consisted of several (6-7) nap 
opportunities performed at 2 hour intervals in the space of one day. These 
procedures were used to assess the differences in sleep latency among a 
sample of 14 control and 27 diagnosed narcoleptic patients who were free of 
additional underlying sleep pathology. The first nap opportunity is given two 
hours proceeding initial (morning) wake time, conventionally following a full night 
in-lab polysomnography in order to appropriate the prior night’s sleep. The nap 
opportunities consist of assessing the participants’ propensity for sleep when 
placed in a dark, quiet room following explicit permission from the tester to fall 
asleep in the absence of external or competing stimuli (90). The assessment is 
performed using strict standardised measures and instructions, ensuring that 
each testing session is identical to the last (91). EEG (central, occipital and 
frontal), Electromyography (EMG) (submentalis), and electro-oculography (EOG) 
(left and right) parameters are used to assess sleep stages and sleep onset time. 
Guidelines also suggest respiratory and decibel monitoring if snoring is 
suspected (91). Urine drug screening is also performed if indicated by a clinician.  
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Utility of the MSLT in both research and clinical setting allows for objective 
documentation of an individuals’ physiologic sleepiness (92). Primarily, this tool is 
used in patients suspected of experiencing disorders of pervasive sleepiness (as 
with narcolepsy or idiopathic hypersomnia), in patients who exhibit occult 
comorbidity of sleep disorders, poor history of adherence to sleep therapeutics, 
such as prescribed Continuous Positive Air Pressure (CPAP) treatment, or to 
assess the effects of concomitant medication (91). Indeed, the clinical usefulness 
of the MSLT in the accurate diagnosis of narcolepsy and idiopathic hypersomnia 
has been extensively researched, and as such, the tool features as a key non-
invasive tool in the identification of these disorders (92, 93); however, this 
assertion is not considered ubiquitous (94, 95). Nonetheless, research has 
indicated that the high sensitivity of the MSLT in regard to sleep onset times 
(SOT) is useful in distinguishing healthy from pathologically sleepy patients and 
those with narcolepsy (90). By classification, a SOT of <5 minutes is used to 
indicate excessive sleepiness and possible pathology (90), whereas SOT of >10-
20 minutes is indicative of healthy levels of sleepiness (90, 96).  
 
Despite the wide use of these parameters in diagnostic classification, at present, 
somewhat of a clinical ‘grey area’ exists for those individuals who exhibit a SOT 
of between 5-10 minutes (90, 97). Indeed, some variation in regard to SOT 
among narcoleptic patients has been noted, with current guidelines highlighting 
that as many as 16% of narcoleptic patients may have a SOT of >5 minutes (92), 
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and thus some caution must be taken when interpreting these values. Due to 
these inconsistencies, current practice guidelines for clinical use of the MSLT do 
not propose normative values regarding SOT (92). Rather, it is recommended 
that any clinical interpretation of the MSLT must be made in conjunction with 
clinical evaluation in regard to patient history, and additional medical history. 
 
Despite the advantageous aspects of the MSLT as an effective diagnostic tool in 
sleep medicine, two critically discussed limitations remain. Most notably, the 
protocol required for standardized assessment of the MSLT is considered costly, 
complex and time-consuming, requiring administration by specially trained 
personnel under specific conditions, and as such, these measures are not 
routinely practiced throughout sleep laboratories or as part of clinical practice 
(98). Similarly, although the stringent criteria outlined for the MSLT procedure 
results in standardized recordings of an individuals’ sleep onset latency within the 
specific parameters of the testing times, considerable variation has been noted 
across the time of day, as well as a result of exogenous variables, such as prior 
sleep deprivation (96). Moreover, current practice parameters base the validity of 
the test as a gold-standard on the assumption that the degree of sleepiness is 
reflected directly by sleep latency (92). Such assumptions raise several 
theoretical issues, not least those present in the procedural requirements outlined 
for the test. Specifically, as participants are subjected to highly controlled 
environments and required to sleep with a number of electrodes, there is little 
generalisability of these results, and it is unlikely that such results would be 
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replicable in the individuals’ daily life across a number of varied activities and 
situations (99).         
 
At present, no large, multi-centre systematically controlled studies assessing the 
clinical or experimental value of the MSLT has been conducted, and no 
differential guidelines in regard to age or sex have been described. As a result, 
there is large variation in regard to recommended clinical guidelines within the 
available literature, and drawing conclusive indications for patients is difficult.      
 
2.1.2 Maintenance of Wakefulness Test (MWT) 
 
The Maintenance of Wakefulness Test (MWT) is an objective measure commonly 
used to quantify physiological sleepiness in patients (100), and is often 
theoretically considered a modified version of the MSLT (101). The most 
significant difference, however, is that the purpose of the MWT is to assesses an 
individual’s ability to stay awake when placed in a soporific situation (i.e., dimly lit 
room with absence of any external stimulation), as opposed to instructing the 
patient not to resist sleep (91). The development of the test occurred as a 
response to a study commissioned by Hartse and colleagues (1980) (102), where 
it noted that sleep onset times differed amongst a small sample of narcoleptic 
patients when they were told to switch from ‘trying to fall asleep’ (as per MSLT 
protocol) to ‘trying to stay awake’. Mitler and colleagues (1982) (101) expanded 
on this by adding imposed sleep promoting aspects to the protocol. Namely, 
participants were required to remain seated in a dimly lit room devoid of external 
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stimuli, such as windows. The only available light source was provided by a low-
watt globe located behind the participant. Results indicated that although the 
sample of 10 narcoleptic patients reported shorter sleep latency than controls, a 
general increase in sleep onset time was noted among these individuals when 
asked to remain awake as compared to when instructed to fall asleep.  
 
The revised and most current study protocol for the MWT is similar to the MSLT 
with regard to timing procedures. Testing periods occur approximately two hours 
following waking, and are conducted at 2-hour intervals through the day for a 
total of four tests. Sleep latency for each test is scored irrespective of the type of 
sleep sampled; and is instead determined by the first epoch of any stage of 
sleep, whereby the test is to be terminated. Although overnight PSG assessment 
prior to the test is not required for the MWT (as is necessary for the MSLT), the 
PSG recording parameters EEG, EOG and EMG are used throughout the testing 
procedures to determine instances of wakefulness and sleep. 
 
Despite the procedural characteristics of the MWT being well-described; there 
has been a notable lack of standardisation with regard to MWT protocols, and as 
such, a wide variety of procedural interpretations have been cited. Alterations to 
the optimal testing times from 20-60 minutes have been noted, with longer testing 
times often used to counteract ‘ceiling effects’ (103). Based on assessments of 
available clinical normative data, current recommendations suggest a clinical 
testing time of 40 minutes is sufficient to account for this effect (100). Revised 
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guidelines recommend a sleep latency of less than 8 minutes considered 
‘abnormal’, with a sleep latency of >40 minutes considered to represent normal 
levels of alertness (100). Despite these distinctions; a ‘grey area’ currently exists 
with regard to the clinical utility of scores noted which range between 8-40 
minutes (103).  
 
Clinical utility of the MWT has been demonstrated with regard to the ability to 
distinguish differences in mean sleep latencies between normal healthy subjects 
and patients with disorders of excessive sleepiness, such as narcolepsy (103), as 
well as examining the effectiveness of clinical treatment (104). Despite this, 
several limitations have been highlighted with regard to the translational ability of 
the MWT to predict instances of real-life instances of sleepiness. Indeed, 
interpretation of the MWT must account for changes which may result from drug 
use, age, testing time and instances of chronic or acute sleep deprivation; and 
thus any inferences regarding the outcome of the test must be accompanied by 
thorough clinical assessment (103). 
2.2 Measurement Tools: Subjective  
2.2.1 Epworth Sleepiness Scale 
 
Sleepiness is considered an important feature of clinical practice, and constitutes 
a significant phenomenon for researchers in terms of personal and public health 
outcomes. Clinically, the implications of sleepiness have been recognized to 
impair areas of affective (105), neuropsychological (106) and cognitive 
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performance (107), although the latter is typically associated with secondary 
effects attributed to diagnosis of sleep-disordered breathing (108). Further, given 
that sleepiness (whether it be a primary or secondary diagnosis) is known to 
impair aspects of attention and information processing and cognitive acuity (109), 
it is therefore considered a significant risk factor for an increased risk for both 
occupational and road-traffic accidents resulting from human error (110). Despite 
the effects of sleepiness being well recognized in both public and clinical health, 
standardized methods for assessing perceived levels of sleepiness, and cut-off 
values used to indicate when these issues are considered pathological, are often 
impaired due to differing definitions of what ‘sleepiness’ is, and how it can be 
differentiated from ‘fatigue’ or ‘exhaustion’ (96). In part, these difficulties arise 
from conflicting definitions used by individuals to describe the feeling of 
‘sleepiness’ (96). Subjectively, sleepiness has been described as either the state 
in which one feels ‘tired’ or ‘fatigued’ immediately preceding sleep onset (111), or 
a sleep-alertness state in which sleepiness is defined as a low-level of alertness 
(112), among others (113).  
 
Given the inconsistencies regarding a uniform definition for the subjective 
experience of sleep propensity, and the need for a global assessment tool for use 
both clinically and in research, Johns (1991) was the first to provide a simple, 
cost-effective testing measure assessing sleepiness conceptualised as sleep 
propensity (114). The Epworth Sleepiness Scale (ESS) is widely used in both 
clinical practice and experimental sleep research, and is considered an effective, 
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simple and cost-effective tool for assessing global levels of self-reported 
subjective sleepiness. Conceptually, the development of the ESS was derived 
from clinical observations regarding commonplace occurrence of daytime 
sleepiness and sleep, and of dissatisfaction associated with the cost and time-
consuming nature of available objective measures (e.g. MSLT or MWT).  
 
Although both the MSLT and MWT are considered a reliable measure of 
sleepiness on the day of the testing procedure (115), issues arise regarding the 
cumbersome, time-consuming nature of the tests (116). In addition, as these 
tests effectively measure differing aspects of sleep, such as sleep propensity 
(MSLT) and ‘capacity for wakefulness’ (MWT) (116), there is some question as to 
the commonality employed by these measures that is typically used to define 
sleepiness. Thus, the development of the ESS was informed by both the need for 
a clinical tool to be used in conjunction with these established objective 
measures, as well as an easily-assessable independent measure of sleepiness 
levels. Primarily, the concept for the ESS was based in early observations 
regarding the likelihood of healthy individuals choosing to lie down and sleep 
during the day (117), of previously described prevalence of daytime sleepiness 
complaints among army recruits (118), and of commonly endorsed themes 
arising from ‘sleepy’ questions on surveys (119). 
  
Development of standardisation and validity measures of the ESS were first 
performed using a pool of 180 participants, which included 30 controls (14 males, 
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16 females) and 150 individuals previously diagnosed with a range of sleep 
disorders (e.g. snoring, OSA, narcolepsy). Participants were required to rate, on 
a scale of 0-3 (0= would never doze, 1= slight chance of dozing, 2= moderate 
chance, 3= high chance), their chance of dozing or falling asleep in eight different 
situations. Individual items on the ESS refer to differing instances, of which are 
considered soporific or non-soporific in nature (114). Once completed, the scores 
on the ESS can be tabulated, to provide a range of 0-24. In addition to 
completing the questionnaire, 138 participants underwent overnight 
polysomnographic procedures, of which 27 of these participants undertook an 
additional MSLT. Following standardized MSLT procedure, these participants 
had four naps, each at 10:00, 12:00, 14:00, and 16:00, and sleep latency was 
measured as; time from lights out to the first epoch of stage one sleep for at least 
one minute, or evidence of any other stage of sleep (114). The process of the 
MSLT was used primarily in conjunction with the overnight polysomnography to 
distinguish individuals with idiopathic hypersomnia (early-onset REM sleep in two 
or more naps, n= 14), narcolepsy (SL of < 10 mins, n= 11), or OSA (n= 2). All 
patients recognised as experiencing primary snoring (n= 55) had presented to 
the testing facility due to the intensity and persistence of their symptoms, and 
were divided into three subcategories according to symptom severity. Primary 
snorers were classified as experiencing OSA using assessment of the 
Respiratory Disturbance Index (RDI) (number of apnoeas and hypopnoeas, 
which in arterial blood oxygen desaturation > 3%, per hour). Participants were 
then classified as having no OSA (RDI=  5), mild (RDI= >5  15), moderate 
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(RDI= <15  30) or severe OSA (RDI= >30).  In addition, diagnosis of Periodic 
Leg Movement Disorder (PLMD) was applied if there was evidence of > 90 
separate leg movements in both legs per night during the overnight PSG. For the 
study, participants who had combined PLMD and OSA were excluded; however 
nine of the 18 participants with PLMD had symptoms independent of OSA.  
 
Results from this preliminary study revealed that significant inferences regarding 
the absence or presence of a sleep disorder could be obtained via the ESS. 
Specifically, total ESS scores significantly distinguished normal subjects from 
those participants in various sleep-disordered diagnostic groups (114), with 
participants classified as experiencing a sleep disorder recognized to be 
associated with sleepiness (such as narcolepsy) clearly distinguishable from 
controls (96% endorsement on non-soporific items compared to 6%, p<0.001). 
Interestingly, participants with idiopathic insomnia reported either complete 
inability or only slight chance of dozing in soporific situations. Conversely, 94% of 
control participants indicated some likelihood of dozing.  
 
Among 138 participants who underwent an overnight polysomnography, a 
significant correlation was found between ESS scores and sleep latency (r= -
0.379, p<0.001). In the sub-group of participants who underwent an overnight 
polysomnography and daytime MSLT, ESS scores and MSLT SL were 
significantly correlated (r= -0.514, p<0.01). Given that subcategories were 
implemented to distinguish severity of OSA symptoms, the study was effective at 
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proposing tentative cut-points. Specifically, in those patients with narcolepsy, 
idiopathic hypersomnia, and severe OSA, all reported differentially high (ESS 
>10) scores when compared to controls.  
 
Despite the original study reporting a high degree of correlation between 
objective measures of sleepiness (such as the MSLT) and the ESS in normal 
subjects (see above), it must be noted that this finding is not universal. Several 
studies employing greater participant groups have reported low to moderate 
correlations between these measures, and thus previous results cited by Johns 
(1991) must be interpreted with caution. Early research conducted by Chervin 
and colleagues (1997) (120) aimed to investigate the relatedness between MSLT 
sleep latency scores and subjective sleepiness as measured by the ESS in a 
sample of 60 men and women. Total ESS scores were found to correlate 
negatively, but weakly, with MSLT sleep latency (SL) scores (Spearman rank 
correlation coefficient rho=-0.37, p=0.0042). However, it was seen that ESS 
scores > 14 accurately predicted MSLT SL scores. Thus, it can be inferred that 
the ESS is a useful tool in predicting objective measures on sleep onset time, 
particularly in those reporting sleepiness in the highest threshold. This finding 
was also mirrored by Olsen, Cole and Ambrogetti (1998) (121), who aimed to 
investigate the concordance of ESS scores and MSLT SL in a sample of 225 
sleep-disordered patients who had received varied sleep-related diagnoses. Here 
it was found that ESS scores of >10 had poor specificity and sensitivity to Mean 
Sleep Latency (MSL) as measured by the MSLT of <10 (sensitivity 48%, 
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specificity 67%) or <5 minutes (sensitivity 68%, specificity 34%). Thus, it was 
concluded that ESS scores and MSL sores are not interchangeable; that is, that 
ESS scores cannot accurately infer the presence or absence of sleepiness as 
measured by the MSLT.  
 
Indeed, complimentary research conducted by Chervin and Aldrich (1999) (122) 
aimed to further assess the association between the ESS and the MSLT using 
participants with OSA, of whom are likely to qualify for sleepiness rating within 
this higher threshold (>14). Here, the authors employed a retrospective analysis 
to investigate the relatedness of sleep latency MSLT data, self-rated sleep 
problem questionnaire scores (available for 141 patients), and ESS scores, 
among 237 patients. Regression models demonstrated that although ESS scores 
and self-rated sleep-problem scores were significantly correlated, no association 
was found between ESS scores and MSL measures of OSA symptom severity. 
Thus, it was concluded that despite the utilisation of a larger group size, ESS 
scores do not accurately reflect objectively determined MSL. Possible limitations 
of this study can be identified in the fundamental methodological differences to 
similar research (i.e., using retrospective analysis); however the authors highlight 
an important argument. Indeed, it has been proposed that the ESS may in fact 
measure differing aspects of sleepiness than those inferred by objective 
measures such as the MSLT.   
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Sleep propensity, defined as the interplay between homeostatic processes and 
circadian regulation (123), implies that the relative time spent awake mediates 
the degree to which the speed of sleep onset is achieved (two process model; 
see Chapter 1). Thus, disruptions to these processes (whether it be of organic or 
imposed origins) would mediate the extent to which the propensity or need for 
sleep is experienced by an individual. Johns (1991) originally proposed the 
development of the ESS to measure sleep propensity in both pathological and 
healthy adults in a more time and cost-efficient manner than the MSLT. Despite 
this, several authors have argued that the facet of sleepiness originally referred 
to by Johns (1991) does not reflect classically defined process of sleep 
propensity. Indeed, Chervin (1997) highlights that questionnaire items within the 
ESS that appear to have the greatest relatedness to sleep propensity (‘lying 
down in the afternoon’) correlate poorly with MSLT procedural measures that 
closely reflect this statement (such as the afternoon nap opportunity) (120). 
Clinical replication studies have further demonstrated that the ESS correlates 
poorly with objective measures of sleepiness and alternate measures of 
perceived sleep quality, such as the Pittsburgh Sleep Quality Index (PSQI), thus 
suggesting that the questionnaire instead measures orthogonal symptoms of 
sleep-wake mechanisms (124). Moreover, it has been proposed that observed 
associations between the ESS and objective measures are restricted by the 
intermediately characterized soporific situations outlined within the ESS (125), 
which appear to be in part mediated by confounding factors such as sex, race 
and self-perception of tiredness or fatigue (120, 124).  
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Despite this, observed relative discrepancies, in part, may be due to inherent 
differences regarding specificities between these measures. Indeed, in response 
to Chervin’s (1997) (120) argument, Johns (2000) (96) highlights that although 
both the MSLT and MWT assess sleep on a discrete occasion, the ESS aims to 
assess similar attributes habitually. Therefore, he posits that although these 
measures differ in terms of specificity, they are not mutually exclusive and thus 
both have inherent clinical usefulness. Indeed, it must be noted that although 
these limitations are significant in terms of clinical assessment and diagnostic 
procedures, the ESS provides an advantageous tool in research settings, and 
allows for experimental measurement and the ability to qualify both the 
antecedents and consequences of Excessive Daytime Sleepiness (EDS) among 
clinical and population groups.  
 
2.3 Conclusion 
The development and application of objective assessments have been 
advantageous for quantifying both the psychological and physical correlates of 
EDS among both clinical and population-based samples. Specifically, these 
developments have allowed for greater specificity with regard to clinically defined 
normative values, and have thus assisted in the accurate description of 
associated pathologies. The gradual development of standardised methods of 
assessment has facilitated greater unification of methodology for both clinical and 
empirical research purposes, and has created greater consistency among these 
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approaches. Despite these advantages, several fundamental limitations of these 
methods remain. Indeed, the development of subjective assessments of EDS 
such as the ESS were primarily driven by observations of sleep propensity and 
the homeostatic drive of healthy individuals, as well as the apparent 
inconsistencies regarding a uniform definition of sleepiness as measured by the 
MSLT and MWT. Further, there was an apparent need for an easily accessible 
and cost-effective global assessment tool for use in both clinical and research 
settings, as the utility of the available objective measures were hindered by the 
often cumbersome and costly nature of the tests. 
Preliminary assessments of normative ranges for the ESS were originally 
conducted on specific patient groups or among clinical populations; however 
subsequent evaluations among different population groups, between genders, 
and among varied geographical locations have demonstrated the utility of the 
ESS in discriminating instances of both clinical and sub-clinical EDS among 
these individuals. Indeed, the gradual development of the ESS has allowed for 
greater unification of clinical and research practices, and has shown to be an 
effective tool for assessing instances of EDS among varied samples.  
 
As highlighted within Chapter 1, the cost of treating sleep disorders has 
substantially increased in the past decade, and as such, there is a greater need 
for effective and simple measurement tools to quantify the antecedents and 
consequences of the phenomena among both clinical patient groups and general 
population samples. Despite these advancements, considerably more research 
43
needs to be performed if more conclusive arguments are to be drawn, particularly 
when assessing these associations among non-clinical samples. Indeed, much of 
the assumptions derived from both these objective and subjective measures 
have resulted from extensive clinical assessments, however gaps in the literature 
currently exist with regard to the translational nature of these findings among 
population-based samples of men and women. Such assessments may assist in 
the formulation of effective and targeted primary and secondary intervention 
strategies; thus providing improved outcomes for at-risk and affected individuals 
with regard to health, medical and lifestyle outcomes. Chapter 3 will highlight the 
current experimental and epidemiological understanding of the role of EDS and 
sleep disturbances on several facets of health, and will explore the limitations of 
previous research in this area. Such examinations will illustrate the need for 
further comprehensive assessments in this area, and will emphasise the benefits 
of utilising population-based cohorts in order to assess these associations.     
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CHAPTER 3: Daytime Consequences of Sleep Disruption 
3.1  Excessive Daytime Sleepiness (EDS) 
Disruptions to the sleep/wake cycle are recognised to have a variety of negative 
effects to both physiological and psychological systems. Sleepiness, or 
somnolence, is a biologically mediated function, which refers to an increased 
likelihood of falling asleep (126), and is considered a biological process similar to 
that of hunger or thirst (97). Conversely, EDS refers to an objective or subjective 
state where there is an inclination or compulsion to sleep, or to take naps, when 
intending to stay awake (126-128), of which is not adequately satiated by the 
acquisition of sleep. The causes of EDS are considered multifactorial, with 
possible risk factors previously identified as intrinsic sleep disorders (such as 
narcolepsy, obstructive sleep apnoea), circadian rhythm disorders (such as shift-
work disorder), and extrinsic sleep disorders (poor sleep hygiene, insufficient 
sleep), among others  (129). The immediate effects of EDS can be debilitating, 
and in some cases, life threatening (130), with EDS considered to represent a 
significant factor in poorer occupational and social functioning (126). In addition, 
EDS is often associated with impairments in neuropsychological and cognitive 
acuity, which has been found to be directly related to an increased risk for 
workplace and road-traffic accidents (127). 
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3.2 Aetiology of EDS 
Despite both the causes and consequences of sleepiness being well described, 
the neurological mechanism that underlies sleepiness is poorly understood. 
Indeed, theoretical models are yet to define the ‘transit zone’ that exists between 
full wakefulness and overt sleep (97). Despite this, it has been proposed that 
sleepiness, as a function, may represent both the declining of neurological 
processes involved in wakefulness (131), or the increased neural activation of 
systems involved in sleep (132). Various areas of the brain are recognised to 
contribute in the initiation and maintenance of sleep and wakefulness, of which 
have been previously described (see Chapter 1). Primarily, these systems 
involve the activation of the brainstem reticular formation, SCN, basal forebrain, 
thalamus, hypothalamic loci and cortex (132), which interact to generate sleep 
and wakefulness. Conversely, the mechanism which underlies EDS, that is, a 
compulsion to sleep when intending to stay awake throughout the day, as 
opposed to typical somnolence experienced at night or late afternoon, is not well 
described. Interactions between various neuroreceptors and peptides may also 
play a role in the experience of sleepiness (131). Although it has been 
established that norepinephrine, dopamine, serotonin and gamma-Aminobutyric 
acid (GABA) play a significant role in the expression of sleep and wakefulness, it 
is not yet known how these may converge to contribute to clinical disorders 
associated with EDS (131). Further work needs to be done to investigate the role 
of these neurotransmitters in the expression of EDS, and the mechanism by 
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which these neurological abnormalities are articulated as the myriad of daytime 
impairments in these patients.  
 
Proposed aetiologies are therefore typically attributed to one of four main 
categories; (1) central nervous system (CNS) pathological abnormalities (such as 
narcolepsy); (2), qualitative or quantitative sleep deficiencies (such as OSA or 
insufficient nocturnal sleep); (3) Misalignment of the body’s internal timing 
mechanism (as seen in jetlag or shift-work disorders);  or (4) drug use (used to 
induce sleepiness or as a consequential side-effect) (130).  
3.2.1 EDS and the CNS 
Narcolepsy-cataplexy (NC) is a neurological disorder affecting sleep regulation 
mechanisms (133), and is considered the most common neurologic cause of 
EDS (134). Clinical presentation of narcolepsy is typically characterised by four 
primary symptoms; (1) Hypersomnolence (EDS), (2)  recurrent periods of 
complete or partial loss of muscle tone (cataplexy), (3), sleep paralysis and (4), 
hypnogogic hallucinations at the onset of sleep  (134, 135). Baseline levels of 
sleepiness are generally higher in narcoleptic patients than in other sleep-
disordered populations (136), however, the intensity of sleepiness felt by 
individuals is variable throughout the day (137). In contrast to physiologic 
sleepiness (as experienced following sleep deprivation), EDS experienced by 
these patients is often acute, severe and only temporarily alleviated by nap 
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opportunities (134, 138). Typically, there is an increased risk for these individuals 
to nap during sedentary or monotonous tasks (133), but nap periods may also 
occur during inappropriate times (such as whilst eating or talking to someone) 
(136). These periods of irresistible sleepiness are often referred to as ‘sleep 
attacks’, and are typically accompanied by marked reduction in physiological 
arousal and microsleep episodes (136). Although short naps initially relieve 
immediate symptoms of sleepiness in narcoleptic patients (133), individuals often 
report feelings of a return of acute sleepiness within 2-3 hours (138). Generally, 
the onset of excessive sleepiness precedes the occurrence of additional 
symptoms (such as cataplexy) by approximately five years (136, 139) and is 
usually experienced throughout the lifetime of a narcoleptic patient (133). Despite 
this, adaptive behavioural changes, such as timed naps and adjustment of 
nocturnal sleep, assist in alleviation of daytime symptoms (140). 
 
The pathognomonic symptom of NC is the experience of muscle atonia 
(cataplexy) (141), and is experienced by approximately 60-100% of narcoleptic 
patients (142). Cataplexy refers to either complete or partial loss of bilateral 
skeletal muscle tone with preserved consciousness, typically as a result of 
intense emotional or psychological arousal (usually excitement) (143, 144), and 
less frequently in response to negative emotions (such as anger) (140). Patients 
often report feelings of muscle weakness and slurred speech at the onset of a 
cataplexy episode (144). Typically, these episodes are brief- lasting from a few 
seconds (mild) to a few minutes (severe)  (145) – with more prolonged episodes 
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often accompanied by visual or tactile hallucinations as a result of the onset of 
REM sleep (144, 145). Symptomatic cataplexy associated with NC often 
improves with age (140).  
 
NC patients often exhibit several additional abnormal manifestations of REM 
sleep (137). These abnormalities experienced by NC patients often present as 
periods of sleep paralysis- either immediately preceding sleep onset or upon 
awakening (133), hypnogogic hallucinations and disturbed or decreased levels of 
nocturnal sleep (133, 137). Hallucinations experienced by NC patients often 
present as a vivid dream-like state that typically occurs at the onset of sleep 
(137). Although characteristic of NC, hypnogogic hallucinations occur 
concurrently in disorders of increased sleep pressure (such as acute sleep 
deprivation) (137), and both clinical and epidemiological studies have suggested 
a higher prevalence among men compared to women (146, 147). 
 
At present, there is no unanimous histological perspective regarding the 
pathological origins of human narcolepsy (148). However, recent research has 
proposed that genetic immunologic deficits may contribute to disease 
development and symptomology via impaired autoimmune systems (134). 
Specifically, early research demonstrated the presence of the specific human 
leukocyte antigen (HLA) subtype, DR2, in a sample of Japanese narcoleptic 
patients (149), a finding which was later mirrored amongst a sample of 
Caucasian patients (150). Initially, these findings were thought to represent a 
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significant predisposing factor in the genetic mechanism of narcolepsy. Despite 
the associations found, no clinically useful research is currently available to 
provide evidence for this hypothesis. Rather, it has been found that the haplotype 
originally proposed to play a role in the development of narcolepsy is found in 
approximately one-quarter of the population, many of which do not ever go on to 
develop the disorder (134). In addition, more recent research has demonstrated 
that many individuals who experience familial narcolepsy do not display this 
haplotype risk-factor profile (151). Neuroanaomical models of human narcolepsy 
have largely been derived from canine models, due to the phenotypal similarities 
between the expression of the disorder in both species (134). Early research 
utilising animal models to assess canine narcolepsy revealed a mutation of the 
hypocretin receptor 2 (Hcrtr2) gene (152), thus providing the first evidence of 
possible neuroanatomical origins. Given the similarities between human and 
canine models, it was proposed that similar mutations found among humans 
might therefore contribute to the expression of the disorder in humans. Indeed, 
hypocretin cell levels have consistently been found to be depleted or absent in 
both canine and human narcoleptic patients (136), and thus identification of the 
presence or absence of these particular genes could potentially provide evidence 
for future novel therapeutic targets.  Despite these initial results providing 
promising future research avenues in both human and canine narcolepsy 
research, the area of enquiry is still in its infancy.  
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3.3 Qualitative and Quantitative Sleep Deficiencies and 
 EDS 
3.3.1 Sleep Restriction and Duration 
 
Although EDS is typically ascribed as a secondary symptom of an underlying 
medical or psychiatric disorder (153), emerging evidence has suggested that it 
can indeed occur independent of pathology. The most common causes of EDS 
are insufficient, restricted or disrupted sleep, which may be reflective of organic 
or environmental origins (131); however, this finding is not universal (154). 
Chronic sleep restriction is typically defined as habitual nocturnal sleep time of 
between 4-7hrs/night (155), and may be a result of a number of factors- from 
medication (stimulants or caffeine) to alterations in work schedules or lifestyle 
(such as the arrival of a new baby) (156), or as a peripheral effect of underlying 
depressive illness (157). Sleep restriction is a significant issue, and has become 
more apparent in recent times (158). Indeed, it has been reported that 
approximately one fifth of Australian adults residing in NSW report sleeping < 
6.5hrs/night (159), which is comparable to international research that has 
proposed that at least one third of adults report sleeping less than 6.5hrs/night 
during the working week (160).  
 
Pragmatically, chronic sleep restriction is differentiated from that of acute sleep 
deprivation by operational definition- that is, sleep deprivation refers to an acute 
or immediate curtailment of sleep over a period of at least 24 hours, whereas 
chronic sleep restriction refers to the cumulative effects of sleep loss over time, 
primarily from deviations of the normative reference level of recommended sleep 
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time (161). The effects of sleep loss or sleep restriction on a number of cognitive, 
behavioural and physiological systems have been heavily investigated. Early 
research examining this relationship was often poorly controlled and failed to 
adequately account for a number of erroneous variables, such as daytime 
napping, stimulant use and individual differences (161, 162), thereby incorrectly 
concluding that sleep restriction resulted in no ill effects due to individuals 
compensatory mechanisms. Despite this, more recent experimental research has 
demonstrated a strong association between the cumulative negative effects of 
both chronic sleep restriction and total sleep deprivation on a number of 
psychological, physiological and neuro-behavioural systems, of which are often 
compounded by symptoms of daytime sleepiness.  
 
Within the literature, three primary models of experimentally imposed sleep-
deprivation research exist 1.) Long-term sleep restriction (>45 hours), 2.) short-
term sleep restriction ( 45 hours), or 3.) partial sleep deprivation (where sleep is 
restricted to < 7 hours in a 23 hour period) (88). There is a vast amount of 
research investigating the relationship between both long-term and short-term 
sleep restriction and deficits in performance. For example, research conducted 
by Van Dongen and colleagues (2003) (154) aimed to examine the dose-
response relationship between chronic sleep restriction schedules when 
compared to a total sleep deprivation condition on a number of neuro-
physiological and sleep physiology functions. Utilising a sample of 48 healthy 
adults, participants were randomised into either one of three sleep-restriction 
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schedules (4hr, 6hr, or 8hr time in bed) for 14 consecutive days, or into the total 
sleep deprivation group (0h time in bed) for three days. Results indicated that 
performance deficits among the 6hr sleep restriction group was comparable to 
two days of total sleep deprivation. Further, lapses in measures of behavioural 
alertness were similarly affected across all sleep-restriction schedule groups. The 
authors concluded that regardless of degree of sleep curtailment, chronic sleep 
restriction significantly impairs waking neurobehavioural functioning and 
performance. Such findings are important with regard to public health initiatives, 
such as that surrounding accident-reduction management. Indeed, previous 
research conducted by Williamson and Feyer (1999) (163) has shown that even 
modest sleep deprivation (of between 17-19 hours) results in performance 
deficits comparable or worse than that of a blood alcohol content (BAC) of 0.05% 
(the threshold for legal blood alcohol concentration in Australia). Similar findings 
have also been reported by Arnedt and colleagues (2001) (164) and Falleti and 
colleagues (2003) (165).  
 
Several meta-analyses further suggest that sleep deprivation significantly affects 
daytime functioning across a number of parameters. Specifically, Pilcher and 
Hufcutt (1996) (166) analysed data sourced from 19 original research studies. 
Analysis of 143 studies revealed that mood variables were most impaired by 
sleep deprivation, and that partial sleep deprivation incurs stronger impairments 
in functioning than either short or long-term deprivation schedules. Possible 
explanations for this finding may be the use of measures that have greater 
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sensitivity in detecting the effects of sleep deprivation among these types of 
studies, and not a reflection of the schedule, per se. Indeed, recent experimental 
research conducted by Van Dongen and colleagues (2003) (154) indicate that 
total sleep deprivation schedules yield greater indices of performance 
decrements than partial sleep deprivation; a finding which has also been 
replicated by Drake and colleagues (2001) (167).   
 
Despite a large body of existing literature that examines the physical and 
psychiatric outcomes of experimentally manipulated sleep schedules, 
comparably less research is available which assesses these associations from 
an observational perspective. Often, these factors are assessed as secondary or 
peripheral factors of underlying sleep pathology such as OSA, and thus any 
findings are typically attributed to the presence of the pathology, rather than as 
an independent predictive factor. Nonetheless, emerging epidemiological 
research has reflected and expanded on previous experimental findings, with 
several studies citing nocturnal sleep duration as a predictor of the degree of 
immediate daytime symptoms reported (168), as well as a reliable indicator of the 
risk for the later development of negative health outcomes (169). Several studies 
have indicated that both short nocturnal sleep duration and EDS are a common 
occurrence among population-based samples, and that a strong and independent 
association exists between these factors. Studies conducted by Liu and 
colleagues (2000) (170) aimed to assess the prevalence and correlates of sleep 
duration among a randomly selected population-based sample of 4000 Japanese 
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adults aged 20+ years. Results indicated that overall, 29% of the sample 
reported sleeping less than 6 hr at night, 23% reported having insufficient sleep 
and a further 15% reported symptoms of EDS. Multivariate regression analyses 
indicated that EDS was significantly associated with younger age, short sleep 
duration, insomnia symptoms, subjective insufficient sleep and sleep enhancing 
medication use. The final model revealed short sleep duration as the strongest 
predictor of EDS. Complementary population-based research have also cited the 
correlation between short habitual sleep periods and complaints of EDS (171), as 
well as self-reported feelings of insufficient nocturnal sleep (172).  These findings 
have similarly been mirrored among cohorts of adolescents (173), groups of 
young adults (174) and older individuals (175), which suggests that this is not 
solely attributable to age effects. 
 
Although the immediate effects of sleep duration (such as daytime sleepiness 
and neurocognitive deficits) have been examined in some detail, the enduring 
effects of habitual sleep duration (both long and short) have similarly indicated 
deleterious health effects. Indeed, research conducted by Ferrie and colleagues 
(169) aimed to prospectively assess the associations between sleep duration and 
change in sleep duration with all-cause, cardiovascular and non-cardiovascular 
mortality among a sample of 9,781 participants (Phase 1, 1985–88) and 7,729 of 
the same participants (Phase 3, 1991–93) who took part in the Whitehall II study. 
Results indicated that decreases in sleep duration among participants sleeping 6, 
7, or 8hr/night at baseline was associated with cardiovascular mortality at the 
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time of follow up, and that increase in sleep duration among those sleeping 7 or 
8hrs/night at baseline was associated with non-cardiovascular mortality, 
independent of existing morbidity, SES and health-related behaviours. These 
results indicate that even subtle changes to habitual sleep duration can, over 
time, contribute to an increased risk for cardiovascular- related and non-
cardiovascular related mortality, even among groups of healthy, functioning 
adults. Similar findings have also been noted among differing geographical 
cohorts (176), among samples of women only (177), and among different ethnic 
groups (178).    
 
Despite the translational value of epidemiological research into the association 
between sleep duration and EDS assisting in the implementation of a number of 
health initiatives, several limitations must be addressed. Notably, there is often 
great inter-study variability with regard to criteria used to define both ‘short’ and 
‘long’ sleep duration, and there is often little reference to the suggested 
normative values indicated for the target age-group used. For example, 
Cappuccio and colleagues define short sleep as self-reported sleep duration of 
5 hour per night for all individuals included for analyses (aged 35+ years) (179). 
However, it is recognised that normative values for habitual sleep duration is 
often reflective of specific developmental periods throughout the lifespan, and 
thus the level of optimal nocturnal sleep often changes with age. Despite this, 
many authors often implement blanket-ranges with regard to categorical short 
and long sleep duration across all age groups, therefore neglecting the more 
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subtle changes and impact of these important developmental periods. It is 
conceded, however, that a large proportion of research assessing the impact of 
sleep duration is conducted on adults (those aged 18+ years), and this it is 
possible that these normative changes in sleep duration are less critical than 
those observed in children or adolescents. Nonetheless, additional research is 
needed which assesses the role of sleep duration on both immediate daytime 
symptoms as well as longitudinal health outcomes, which is reflective of 
normative sleep duration profiles characteristic of each developmental stage. 
Lastly, there is also often a large degree of variation between studies with regard 
to the measurement tools used to assess instances of EDS, and therefore it is 
difficult to draw cross-study comparisons. Indeed, the prevalence rates cited 
within each study vary significantly, often as a function of the criteria used to 
define instances of EDS.  
 
Quantifying instances of sleep restriction and habitual duration (whether they are 
subjectively or objective assessed) is important when assessing both the 
contextual significance of EDS among population groups, given the 
aforementioned trends and patterns in adult sleep behaviours, in conjunction with 
the deleterious health effects of both acute and chronic sleep restriction. 
Furthermore, inclusion of these factors within this framework may present as a 
possible modifiable factor with regard to optimal therapeutic targets. Indeed, 
additional research is therefore needed which utilises standardised and replicable 
measurement tools for the assessment of EDS and habitual sleep duration if 
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more conclusive arguments are to be drawn regarding the strength and reliability 
of these findings among population samples. Comprehensive descriptions of the 
stability of habitually reported sleep duration will give further indication of the 
possible mechanism of this relationship over time, given that inclusive 
descriptions of these trends are currently lacking.  
 
In order to achieve this, the current thesis employs the use of self-reported sleep 
duration with respect to instances of clinically significant EDS as to better 
describe this association. What is more, complementary longitudinal 
assessments of habitual sleep duration will allow for increased knowledge 
regarding the natural course and stability of these factors over time. In 
combination, these assessments will therefore highlight possible areas of 
therapeutic intervention, and provide additional evidence for the role of sleep 
duration both in the context of, and in isolation of underlying pathology.  
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3.4  The Prevalence of EDS in the General Population 
 
EDS constitutes a common complaint among patients attending sleep clinics, and 
epidemiological research has suggested that between 12-20% of the general 
population experience these symptoms (130, 131). Despite the effects of 
sleepiness being well recognised in both public and clinical health, accurate 
representations of the burden of EDS can vary significantly. In part, these 
difficulties arise from conflicting definitions used by individuals to describe the 
feeling of ‘sleepiness’, and the differing use of standardised assessment tools 
and variations in predetermined questionnaire cut-points (96). For example, 
research conducted by Kaneita and colleagues (2005) employed the use of a 
self-administered 44-item questionnaire that covered aspects of psychological, 
personal and general health information, in addition to sleep and daytime 
sleepiness (180). Here it was reported that excessive sleepiness under these 
specifications affected 2.5% of the population sampled. Despite the use of this 
questionnaire allowing for robust interpretations regarding possible correlates of 
sleepiness, the use of a non-standardised assessment tool does not allow for 
accurate representation of sleepiness levels, and the use of a stricter determinate 
of sleepiness (falling asleep whilst driving only) may mean that true sleepiness is 
under-reported. Similarly, research conducted by Hara and colleagues (2004) 
conducted a questionnaire survey of 1221 randomly selected men and women 
aimed to assess prevalence rates and correlates of excessive sleepiness. Here, 
EDS was defined as ‘sleepiness’ that had occurred ‘three or more times per 
week’ in a month, which was associated with ‘impairment of daily activities’ (181). 
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Using these metrics, it was reported that sleepiness affected 16.8% of the 
population.  
 
These methods were also employed by Baker, Wolfson & Lee (2009) as part of 
the National Sleep Foundation ‘Sleep in America’ poll, with sleepiness defined as 
a response to the extent to which sleepiness interfered with daily activities. Using 
this definition, sleepiness was found to be present in 21% of respondents. 
Multivariate regression further revealed that sleepiness was associated with 
psychological distress, poor health and the presence of a sleep disorder. Similar 
research conducted by Ulfberg and colleagues (1996), aiming to assess EDS in 
both normal and pathological populations defined sleepiness as a positive  
response to a single question regarding participants ability to attend job 
requirements. Using these criteria, prevalence estimates of EDS ranged from 
8.1% (normal controls) to 81% of the sample (OSA patients). These definitions 
may again lead to under or overestimates of self-reported EDS due to lack of 
specificity in questionnaire items, as well as inability to assess sleepiness and 
sleep propensity between soporific and non-soporific activities, which is a 
cardinal feature that distinguishes ‘sleepy’ individuals from healthy controls (114). 
Indeed, lack of uniformity regarding questionnaire items has at least in part, 
contributed to the large variance observed amongst the available studies. As 
authors have typically applied diverse definitions of sleepiness, reported 
prevalence estimates of EDS vary significantly. In particular, there appears to be 
discrepancy between populations sampled, and whether the studies accounted 
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for associated lifestyle and health factors. Thus, the ability to generalise the 
findings from these studies is limited due to the inconsistencies noted within 
study methodology and design.  
3.4.1 EDS in Western and European Populations 
 
Of those international studies that have employed standardised measures of 
sleepiness, such as the ESS, greater consistency of findings have been noted. 
For example, recent research conducted by Pahwa and colleagues (2012) (182) 
aimed to assess the prevalence and determinants of high ESS scores in a 
population of 283 rural-dwelling Canadian adults. Multivariate binary logistic 
regression was used to assess aspects of lifestyle, general medical conditions 
and social conditions (among others) and ESS outcome variables (normal vs. 
abnormal). Analysis revealed a high prevalence of ‘abnormal’ ESS scores 
(defined as ESS score >10), with 20.8% of the sample qualifying as abnormally 
sleepy. Complimentary research conducted by Souza, Magna and Reimao 
(2002) (183) reported the prevalence of excessive sleepiness as measured by 
the ESS to be as high 18.9% in a population-based sample of Brazilian adults 
(not sex specific). Results indicated that no association was noted between total 
ESS score and measures of sex, age, BMI, SES or employment. Indeed, the only 
significant correlate of EDS was insomnia symptoms, and this finding was only 
present in males following the application of sex-specific analysis. The authors 
propose that this lack of findings in regard to commonly associated characteristic 
and demographic variables may be attributed to the wide variety of the causes of 
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EDS, extrapolated to represent a population sample. Despite this, some caution 
must be taken when interpreting these findings. Specifically, the authors 
employed univariate models only in order to assess these relationships, and 
therefore no conclusions can be drawn as to the potential contributing impact of a 
number of lifestyle and health factors in the experience of EDS among this 
sample. Similarly, several important lifestyle factors were not accounted for in the 
research, such as alcohol use and smoking status, which have been shown to 
influence the experience of EDS (184, 185). Therefore, the non-significant 
findings may, in part, be attributed to the lack of breadth of variables employed in 
the study design, and not reflective of possible lack of association.  
 
Somewhat addressing these limitations, Pallesen and colleagues (2007) (108), 
aimed to assess the prevalence and risk factors of EDS among a population 
sample in Norway. Information pertaining to the presence of EDS, demographic 
factors, and history or evidence of sleep disorders was evaluated via telephone 
interview. Results indicated that amongst a sample of 2301 adults, 17.7% of 
individuals reported an ESS score of >10. Further, regression modelling 
techniques demonstrated that being male , night work, region (southern Norway) 
depressive symptoms and evidence of an underling sleep disorder (snoring, 
restless legs, PLMs) were associated with EDS. Moreover, individuals who were 
aged 18-29 (both male and female) demonstrated the highest age-group specific 
prevalence of EDS, in direct opposition to that which has been shown among 
comparable studies (186). However, further application of regression modelling 
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demonstrated that the only significant predictor of EDS was symptoms of restless 
leg syndrome.  
 
Similar early population-based research conducted by Janson and colleagues 
(1995) (187) aimed to assess the geographical variance in the distribution of EDS 
and similar associated sleep problems (snoring, disrupted breathing during sleep) 
among a sub-sample of 2202 men and women who resided in four major 
European cities and participated in the European Community Respiratory Health 
Survey  (Reykjavik in Iceland, Uppsala and Göteborg in Sweden and Antwerp in 
Belgium). Results indicated significant location-specific associations, with those 
individuals located in Uppsala more likely to report symptoms of daytime 
sleepiness than those residing in other cities, despite the prevalence of nocturnal 
snoring being comparable across cities. The authors similarly reported that both 
snoring and symptoms of EDS those participants were more common among 
those participants who identified as suffering gastro-oesophageal reflux. Given 
this finding, the authors propose that further research is needed to assess the 
strength and underlying mechanisms of this relationship, and the association to 
general health outcomes. Indeed, complimentary research conducted by 
Martikainen and colleagues (1992) (188) aimed to assess the prevalence of EDS 
and associated health and lifestyle factors among 1600 middle-aged adults who 
took part in research carried out by the UKK Institute for Health Promotion, 
Finland. Data regarding sleep and health habits were obtained via postal 
questionnaire and results indicated a strong relationship between self-reported 
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disturbed nocturnal sleep and daytime sleepiness, a finding that was particularly 
strong among female participants. In addition, poor physical health status was 
found to be associated with the experience of EDS 
3.4.2 EDS in Asian Populations 
 
Research conducted in traditionally Western regions typically yield higher 
prevalence rates of EDS than those examined in Asian populations. Although the 
breadth of literature available for Asian countries is limited, of those available, 
standardised measures such as the ESS are often employed. Research 
conducted by Takegami and colleagues (2005) (189) aimed to assess the 
distribution of subjective daytime sleepiness among a population-based sample 
of Japanese adults. From a possible cohort of 10,000 included in the survey, the 
authors assessed over 5000 individuals aged 20 years and over, and factors 
associated with EDS were included for analysis. Data regarding age effects were 
standardised to the Japanese census figures for 2000. Results indicated that 
estimated overall prevalence of EDS was 8.9% (males 9.6%, females 8.8%), and 
EDS was associated with age, sleep duration (under 6 hours/night) and self-
reported snoring. Indeed, this study is the only representative literature available 
regarding the prevalence of EDS among an Asian sample spanning the full adult 
age-range. Complimentary studies typically focus on specific age-groups, ethnic 
groups or developmental stages, and thus give little indication of the wider scope 
of EDS among these population groups. 
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For example, research conducted by Joo and colleagues (2009) (190) aimed to 
assess the prevalence of EDS (as measured by the ESS) among a cross-
sectional, population-based sub-section of 4405 adults aged 40-69 years who 
had taken part in the larger Korean Genome Epidemiology Study. When stratified 
by age groups (40-49, 50-59, 60-69 years), results indicated that those 
individuals in the 50-59 year age group had a 1.42-fold increased likelihood of 
reporting symptoms of EDS compared to those in the other age groups. Similarly, 
following the application of multivariate regression modelling, several 
characteristic (such as physical activity and education level), and sleep related 
factors (such as self-reported insufficient nocturnal sleep and waking feeling 
unrefreshed) were associated with EDS. Interestingly, high levels of education 
were inversely associated with EDS, and those who reported high levels of 
physical activity were found to be at a risk for EDS. The findings of this study 
suggest that several psychosocial and sleep-related factors are associated with 
EDS among middle-aged Korean adults. Indeed, the breadth of information 
regarding sleep-related factors collected as part of this study address some of 
the limitations of other population-based research studies conducted among 
Asian communities (see (189)).  
 
Despite this, a notable limitation of this research is evident in the inability to 
generalise these findings to other Asian populations or across different age 
brackets. Indeed, earlier research conducted by Joo and colleagues (2005) 
aimed to assess the prevalence of EDS (as measured by the ESS) and its 
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association with nocturnal sleep habits, perceived problems with sleep and 
subsequent school performance among a sample of 3871 male and female 
Korean high-school students (aged 15-18 years). Demographic variables (e.g. 
weight, height, smoking status) and information regarding sleep habits and 
perceived problems with sleep (e.g. frequency of snoring, insomnia symptoms), 
and academic performance were obtained via self-report (then ranked as 
quintiles of performance- lower performance equals lowest/bottom quintile). 
Descriptive analysis revealed that the overall prevalence of EDS was 15.9%, and 
female students reported significantly higher rates of EDS when compared to 
male students (18.2% vs. 14.9%, respectively). Similarly, female students 
reported higher frequency of insomnia symptoms and reported longer sleep 
latencies than their male counterparts. When the authors assessed the 
characteristics of those with and without EDS (male and female collapsed), those 
with EDS were more likely to be a current smoker add/or alcohol drinker and 
report more daily internet usage than those who were not sleepy. Moreover, 
those with EDS were less likely to be ranked in the top quintile of academic 
performance, and more likely to be ranked in the intermediate or lowest quintile. 
Thus, the authors conclude that given the relatively high prevalence of EDS 
among this population-group, the negative associations with a number of lifestyle 
and academic outcomes, and the inverse relationship between EDS and 
academic performance, intervention may provide improved both lifestyle and 
academic outcomes in these individuals. 
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Several complementary studies assessing sleepiness using non-standardised 
measurement tools have been conducted among Asian populations. For 
example, research completed by Ng and colleagues (2005) (191) aimed to 
assess the prevalence of EDS among a diverse, multi-ethnic population sample 
of adults residing in Singapore. Symptoms of EDS were ascertained via 
telephone interview, and EDS was indicated via the combined total of positive 
responses to frequency variables pertaining to the propensity for an individual to 
‘doze off or become drowsy’ across a number of occupational, social, and 
sedentary situations.  Results indicated that among a total sample of 2298 adults, 
9.0% of individuals reported significant EDS, and marked inter-ethnic differences 
were observed. Indeed, those individuals who identified as Chinese or Malay 
were significantly more likely to report EDS than Indians. No differences were 
detected in terms of overall prevalence between men and women, nor among 
differing age groups. However, it was noted that older individuals (60+ years) 
generally reported lower rates of EDS than those in the younger age-brackets. 
Following the application of logistic regression analysis, several detrimental sleep 
habits and sleep-disorder symptoms were associated with EDS, such as 
perceived insufficient sleep (reported by 18.2% of participants), snoring (12.6% of 
participants) and pauses in breathing during sleep (9.2% of participants). 
Similarly, several occupational and psychological factors were associated with 
increased risk of EDS, such as shift work (reported by 15.1% of participants), 
psychiatric comorbidity (6.7% of participants), and current pharmacological 
treatment for chronic medical disorders. Possible explanations for the differences 
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observed among these ethnic groups include intra-linguistic differences among 
these populations and among age brackets, thereby confounding results. Despite 
this, the authors concede that most (80%) of the interviews used to ascertain 
EDS symptoms were conducted in English. As the strength of the associations 
drawn from logistic regression analyses were not found to be explained by age, it 
is therefore unlikely that these results are skewed by a select subsample of older, 
non-English speaking participants.  
 
Indeed, the limitation of the cross-cultural adaptability of the ESS has been 
highlighted in each of the aforementioned population-based studies. Despite 
several versions of the ESS having being adapted for Japanese (192), Chinese 
(193) and Korean (194), issues arise in terms of cultural adaptability and 
reproductive value of the ‘soporific’ or ‘sleep-inducing’ situations presented in the 
questionnaire. As the normative values for the ESS were formulated utilising 
Western population cohorts, and were based on typical Western ideals and 
situations, it is unclear whether the epidemiological estimates are truly 
representative of the populations sampled, and thus truly capture these 
symptoms. For example, a validation study of the Japanese version of the ESS, 
conducted by Takegami and colleagues (2009) (192), highlights that the prolific 
use of public transport among this population may inadvertently contribute to the 
high rate of missing data often seen pertaining to the questionnaire item ‘falling 
asleep while driving’. As incomplete or partial responses on the ESS render the 
assessment of the questionnaire tool invalid (114), the true prevalence of EDS 
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among these populations may be underestimated. Indeed, differences in cultural 
and clinical values and how they may influence responses to questionnaire items 
may, in part, account for the typically lower prevalence rates yielded among both 
meta-analyses and epidemiological research conducted in these regions, when 
compared to Western populations (195). 
3.4.3 EDS in the Australian Population 
 
Despite a large body of research available for other Western regions, there is 
paucity of information available for Australian populations. This is surprising, 
given that the ESS was specifically developed to be used among Australian 
patient groups. Nonetheless, the first research investigating the prevalence of 
EDS using the ESS in Australian population was conducted by Johns and 
Hocking (1997) (127). Here, the authors aimed to describe the prevalence of 
EDS amongst a group of Australian workers and to assess the associated 
relationship with demographic variables and self-reported sleep habits. Results 
demonstrated that those individuals who identified as ‘sleepy’ were clearly 
distinguishable from those who reported no sleepiness by means of the ESS 
score. In addition, EDS was found to affect 10.9% of the individuals tested and 
that these findings related to self-reported instances of snoring, insomnia 
symptoms and time spent in bed. However, these results were not explained by 
sex, age, obesity or the use of hypnotic drugs, of which are known to represent 
common factors in the experience of EDS in normal populations. However, 
identifiable limitations of this study that may be attributed to these non-significant 
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findings were noted primarily as the small sample group (n= 507), as well as the 
lack of more inclusive demographic and lifestyle information. Despite this, Johns 
and Hockings (1997) (127) study provided the first insight into the sleep habits 
and correlates of EDS in an Australian population.  
 
Subsequent research conducted by Bartlett and colleagues (2007) (159) aimed 
to address these limitations, and further investigate the role of lifestyle factors by 
assessing the prevalence of EDS among a population-based sample of 
community-dwelling Australian adults. Here, the prevalence of sleepiness was 
assessed in a sample of 3300 adults residing in NSW, and information regarding 
sleep habits, lifestyle and medical information was assessed. Results indicated 
that middle age, sleep duration, insomnia and depressive symptoms were 
associated with the experience of EDS in this sample. Overall prevalence were 
noted as 11.7%, with no distinction made between sexes. Despite this study 
providing the first representative data for the Australian general population, 
several identifiable limitations of this study are noted, of which do not accurately 
address those identified by Johns and Hocking (1997) (127) study. Primarily, 
despite several lifestyle and health factors being addressed in this study, no 
attempt was made to assess maladaptive lifestyle habits of which have been 
known to impact EDS. In particular, no attention was given to lifestyle and health 
factors that may represent a modifiable variable when addressing the impact of 
EDS in the general community. Specifically, the association between factors such 
as cigarette smoking, physical activity or alcohol use was not addressed- all of 
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which represent items of clinical usefulness when considering the impact of EDS 
in population samples. Further, although the prevalence rates reported by both 
Johns and Hocking (1997) (127) and Bartlett and colleagues (2008) (159) 
provides clinically useful information regarding the occurrence of EDS amongst 
the selected populations sampled, no attempt was made to allow for 
generalisability of findings to the wider Australian community. In part, this is due 
to the selected age ranges specified in each study; between 22-69 years in the 
Johns and Hocking (1997) study, and 18-65 years in Bartlett and colleagues 
(2007) study, as well as the specific population groups sampled. Particularly, as 
these groups sampled were confined to either occupational or geographically 
contained participants, such findings do not accurately represent individuals 
outside of these specifications.  
 
Accurate representations regarding the prevalence rate of EDS in adults are 
currently lacking. In part, this is due to the inherent differences in the 
methodology employed between studies and among different geographical 
locations and target population-groups. As yet, there is no quantified evidence 
adequately reflects the prevalence of EDS and associated lifestyle and health 
factors in the wider Australian adult population. Indeed, as far as can be 
ascertained, these two studies represent the only current assessments of the 
epidemiological impact of EDS within the Australian community. Therefore, 
international research has seemingly been utilised when formulating treatment 
plans and healthcare initiatives for affected patients. This can be detrimental for a 
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variety of reasons. Most notably, such assumptions allow for non-population-
specific inferences to be made regarding the course and outcomes of the 
disorder among local patients. To adequately assess the impact of these 
symptoms, up to date, local information is necessary if aspects of ongoing health 
and care are to be provided.  
 
The current study will aim to address these limitations by several means. 
Primarily, there is a current need for extensive evaluation of both immediate and 
peripheral factors associated with the disorder in order to effectively describe the 
strength of these associations. Indeed, the inclusion of a comprehensive 
assessment of the aforementioned lifestyle and health factors will enable more 
thorough conclusions to be drawn, and will provide population-specific 
information pertaining to the degree of the observed relationship. Moreover, the 
reported findings will be standardised to local Australian Bureau of Statistics 
(ABS) data for 2006, thus providing the first evaluation of the prevalence of EDS 
in the Australian general population.    
3.5 Lifestyle, Health and Demographic Factors and EDS 
3.5.1 Sex 
 
There is a substantial literature base which demonstrates a largely comparable 
expression of objectively monitored normative sleep architecture between 
healthy, young to middle-aged men and women (196-198); however, this finding 
is not universal (199). Variances in regard to sleep latency, total SWS, REM 
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density and sleep efficiency between sexes have been previously attributed to 
differences in circadian phase (199), differential decrements in sleep quality 
during the aging process (197), as well as different pathology risk profiles and 
associated clinical presentation (200). Despite this, significant sex differences 
exist in terms of subjectively evaluated nocturnal sleep, with women significantly 
more likely to report poorer nocturnal sleep (198), longer sleep onset time, and 
more nocturnal awakenings than men (201).  
 
Research pertaining to the self-reported daytime impairments associated with 
disrupted sleep has similarly been mixed. Of the available literature, detriments in 
daytime functioning are often non-descript in terms of sex-specific differences 
(202), or focus on select age groups (see; (173)). At present, there is only one 
research article assessing the risk factors for the experience of EDS exclusively 
among women. Indeed, the research conducted by Theorell-Haglow and 
colleagues (2006) (203) aimed to assess a number of identifiable risk factors for 
EDS and fatigue among a general-population cohort of women. Within this cross-
sectional assessment of 5508 women who resided in Uppsala, Sweden, several 
characteristic and demographic factors were accounted for, such as age, 
occupation, and body mass index (BMI), among others. Results indicated that 
overall, 16.1% of the women surveyed met classification criteria for EDS. Further, 
those women in the 20-29 age group displayed the highest overall age-specific 
prevalence of EDS, with the risk for EDS decreasing by 10% for each increasing 
age bracket. Univariate analysis of characteristic factors revealed that younger 
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age, self-reported snoring, higher BMI, smoking, psychiatric and somatic disease 
were all associated with increased likelihood of experiencing EDS among this 
sample. Following the application of multivariate modelling techniques, 
psychological disorders (depression and anxiety) were the strongest predictor of 
EDS, followed by insomnia, self-reported snoring and being overweight. Further 
analysis of the impact of somatic disease on EDS revealed that asthma or 
chronic obstructive pulmonary disease (COPD), back or joint problems, 
neurological illness and fibromyalgia were all related to sleepiness. Given these 
findings, the authors propose that further research is warranted to validate the 
prevalence of EDS among population samples of women. Specifically, given that 
these data were obtained from a geographically contained location, it is unclear 
as to whether these findings are transferrable to other population groups. Indeed, 
earlier research conducted by Janson and colleagues (1995) has shown that 
individuals residing in Uppsala typically report higher rates of EDS compared to 
other European cities (187), of which was not explicitly acknowledged by the 
authors.  
 
At present, it can be seen that a large degree of variation exists within the 
available literature with regard to the mediatory role of sex in the expression of 
EDS. Indeed, there is a paucity of literature examining the differential 
characteristic expression of EDS between men and women, which appears, in 
part, to be due to the general overrepresentation of men among these types of 
studies. As a result, there is a notable discrepancy between the quantity of 
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available literature examining the antecedents and consequences of EDS in 
cohorts of men and women, and as such, several gaps exist in the current 
understanding of these associations. The systematic examination of EDS in such 
cohorts is advantageous for several reasons, not least in providing preliminary 
assessments of the possible differential expression of this pathology between 
genders. Indeed, such systematic assessments would provide preliminary 
evidence of the expression of this pathology between comparable samples of 
men and women; thus addressing the limitations of the aforementioned studies 
with regard to the ability to generalise reported findings.  Moreover, such 
investigations would allow for greater dissemination and identification of possible 
therapeutic targets, of which can be tailored to each sex and thus promote the 
most appropriate mode of intervention for affected individuals. 
 
Given the possible personal and clinical advantages of providing assessments of 
these associations, the current study will aim to examine and describe the 
expression of EDS between men and women, and systematically assess the role 
of a number associated health and lifestyle factors, thereby addressing the 
limitations of past research. The utilisation of standardised assessment of EDS 
by means of the ESS will similarly allow for greater generalisation of the reported 
findings, and provide greater understanding of whether differential expression of 
EDS exists between non-clinical samples of men and women.   
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3.5.2  Age and EDS 
 
Normative sleep patterns are differentially represented across the full human 
age-span, which are often influenced by aspects of chronobiological profiles and 
maturation stages characteristic of each general age-group (204). Although these 
profiles are often influenced by factors such as chronic disease and age-
dependent physiologic processes (such as menopause)  (205), four characteristic 
age-related changes have been identified; reduction in total sleep time, (206) 
sleep efficiency (206, 207), and slow wave sleep (208) and a typical overall 
increase in wake after sleep onset (WASO) are associated with increased age 
(204). Despite this, several studies have failed to demonstrate differences among 
a number of key PSG characteristics, such as sleep latency (209-211) and 
percentage of time spent in different stages of NREM sleep (212, 213) between 
younger and older adults.  
 
Nonetheless, these associated changes in both objective and subjective aspects 
of sleep architecture across the lifespan have been implicated in the functional 
outcomes of those individuals, and have clinical implications for aspects of both 
mental and physical health, wellbeing and mortality risk (214). Poorer sleep 
quality among older individuals has been linked to increased risk for 
cardiovascular disease, depression and issues with EDS (170, 215, 216). 
International research has shown that EDS is both highly prevalent among older 
adults, and is associated with a number of deleterious health outcomes (217, 
218). Specifically, epidemiological research has demonstrated that instances of 
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EDS have been independently associated with poorer outcomes on measures of 
self-rated daytime functioning (219), cognitive impairment (107), increased risk 
for later development of dementia (109), increased risk for falls and fractures 
(220) and reduced social functioning (221). 
 
Although the relationship between EDS and age have been described in greater 
detail among older adults, less information is available assessing this association 
in younger adults. Therefore, it is unclear as to whether the degree of the 
relationship between EDS and overall health is equally represented among this 
cohort. Of the available literature, there are few studies assessing this 
association among population groups. For example, early research conducted by 
Breslau and colleagues (1997) (174) utilized a sample of 1007 young adults 
(aged 21-30 years) who attended a large health facility in Michigan, USA. Follow 
up interviews were conducted 3.5 and 5.5 years after baseline, with an overall 
97% retention rate. Daytime sleepiness was assessed via 5-point Likert scale, 
and characteristic data were collected. Results indicated that EDS was 
associated with self-reported sleep latency, weekday hours of sleep, and 
symptoms of snoring, depression and anxiety. Multivariate analysis further 
revealed that hours of nocturnal sleep, sex (female) and major depression were 
predictive of EDS.  
 
Despite the findings outlined in the aforementioned studies, several areas of 
investigation remain. Notably, at present, there is no systematic assessment of 
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the prevalence of EDS across age-groups, particularly that which spans the full 
adult age spectrum. Of the available literature, the association between EDS and 
age is often assessed exclusively within the confines of a particular age group 
(i.e., young or older individuals), and thus it is difficult to draw any conclusive 
arguments regarding the natural occurrence of EDS among differing age 
brackets. Such assessments would provide valuable information regarding the 
natural representation of these symptoms across age-groups, and may assist in 
targeting at-risk individuals. As such, the current study will aim to address these 
limitations by examining the expression of EDS among a representative sample 
of Australian adults, spanning the full adult age-range. Such assessments will 
provide comprehensive information regarding both the distribution and specific 
correlates of EDS among different age-groups using a population-based sample, 
and assist in identifying areas of possible therapeutic intervention among affected 
individuals. Furthermore, the use of standardised measures of assessing EDS by 
means of the ESS will ensure accuracy and the ability to generalise the reported 
findings, and provide a valuable platform for future research in this area of 
enquiry.  
3.5.3  EDS and Falls 
Reductions in nocturnal sleep quality and continuity are considered to be 
reflective of advancing chronological age and maturation stage (204). Age-
related changes across the lifespan have been assessed in some detail, and 
several observational, experimental and meta-analyses have identified several 
characteristic objective alterations to nocturnal sleep which occur relative to 
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increasing age (212, 222). Indeed, a general reduction in total sleep time, sleep 
efficiency, REM (223) and slow wave sleep (210, 224), coupled with a general 
increase in sleep latency and wake time after sleep onset (WASO) (225) have 
been noted among healthy groups of older individuals; however these 
observations are not universal, with some studies reporting no such associations 
(206). 
 
Sleep problems are relatively common among older individuals, which can, in 
part, be considered somewhat attributable to both normal alterations in sleep 
architecture, coupled with peripheral medical and/or health factors generally 
associated with the ageing process, such as increased mediation use and/or 
polypharmacy (226, 227) and medical comorbidity (228), which may interact to 
affect both objective and subjective aspects of nocturnal sleep. Cumulatively, 
these factors impact on several measures of waking functioning, and contribute 
to instances of daytime sleepiness. EDS is a common complaint among older 
adults, approximately 18-20% of individuals aged over 60 years citing these 
symptoms (221, 229). Among older individuals, EDS has been consistently and 
independently associated with an increased risk for several adverse health 
outcomes, such as reduced functional outcomes (219), depressive illness (217), 
deficits in cognitive abilities (107), as well as a two-fold increased risk for falls 
(220). Approximately 30% of older adults report sustaining one or more falls per 
year (230), and as many as 10-20% of these incidents are associated with 
moderate to severe injury, such as fractures or severe head trauma (231). 
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Common singular determinants of EDS, such as short sleep duration (232), poor 
sleep quality (233) and subjective sleep complaints (234) have been implicated in 
an increased risk for falls among older adults, however direct evaluations of the 
degree of association between EDS and falls are limited. Indeed, at present only 
one cross-sectional study exists which assesses this relationship in a cohort of 
community-dwelling women (220). This study indicated that that those with 
clinically significant EDS (ESS score >10) were more likely to report a fall than 
those who did not report EDS (univariate analysis), and that EDS was the 
strongest risk factor for reported falls after controlling for other recognised falls 
risk factors (medication use) when assessed in multivariable analyses (OR 2.05; 
95% CI 1.21 to 3.49). Despite these preliminary findings providing valuable 
assessment of these associations; several areas of investigation remain. Notably, 
although the previous study controlled for a limited number of confounding 
variables, no indication was made regarding the relative impact of several 
peripheral health, lifestyle and medical factors, of which are theoretically and 
pragmatically associated with both EDS an falls, such as mobility and alcohol 
intake. Moreover, no evaluation was made for older men, and thus assumptions 
regarding the strength of these associations in this group are currently equivocal. 
Lastly, evaluations of both the circumstances preceding and functional outcomes 
of the falls are currently lacking, and thus quantifying these factors would assist 
in characterising peripheral risk factors associated with these associations.  
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Both EDS and falls represent important sources of personal and societal burden 
for older adults. Despite this, systematic evaluations of these associations, 
particularly in population-based, non-clinical samples are currently lacking. At 
present, there is insufficient information regarding the nature of the falls and the 
degree of disability incurred as result of a fall, and little detailed information 
regarding details such as the location, circumstances and consequences 
surrounding the fall with regard to EDS. Furthermore, there is inadequate 
collation of data pertaining to the relative contribution of factors such as 
concurrent medication use and other health behaviours on this association. 
Given both the high frequency of EDS and the health burden associated with falls 
in older adults, direct assessment of the relationship between these factors may 
assist in identifying possible modifiable factors, and thus, substantially improve 
primary preventative strategies for falls in these populations. As such, the current 
study aims to address these limitations by examining the association between 
EDS and falls among a population-based sample of older adults. Such 
assessments will provide further information as to these observed associations 
among population-based samples of older adults, and therefore contribute further 
knowledge to the currently limited research base. 
 
3.5.4 Drug/Medication Use and EDS 
Adverse events associated with both acute and prolonged use of medications 
have previously been cited as reduced cognitive functioning (235), impaired 
psychomotor abilities (236), and increased instances of fatigue and daytime 
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sleepiness (237). Several classes of medication, such as sedatives, hypnotics, 
antihistamines, antidepressants and neuroleptics, amongst others, have been 
implicated in the expression of EDS (131). Administration of many classes of 
barbiturates and benzodiazepines act to reduce sleep latency, increase sleep 
continuity, reduce REM latency and time spent in REM, and promote increased 
periods of NREM sleep (238, 239). Although these classes of medications have 
been found to be effective in the treatment of disorders associated with sustained 
and chronic impaired sleep quality, such as insomnia, there is a significant risk 
for carry-over effects in regard to daytime functioning and safety. Indeed, many 
studies have demonstrated residual effects on objectively measured sleepiness 
associated with both acute and repeated administration of long-acting 
benzodiazepines (specifically flurazepam and diazepam) (240-242), as well as 
deficits in psychomotor performance (243). Due to these deficits, the use of these 
medications (i.e., opium alkaloids and benzodiazepines) have been found to 
increase the risk of road-traffic accidents post-administration, and for as long as 
one-week post administration (244). Slight increases in the risk for motor vehicle 
accidents following the administration of both sedating antidepressants (tricyclic 
antidepressants, mianserin, and mirtazapine), sedative antipsychotics, as well as 
newer, non-sedating antidepressants (selective serotonin reuptake inhibitors, 
SSRIs) have also been noted (245).  
 
The observed association between medication use (such as sedatives) and 
increased rates of daytime sleepiness at a clinical level may be somewhat 
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paradoxical; individuals whom experience difficulties initiating and maintaining 
sleep, such as those patients with insomnia, may increase the use of sleep-
enhancing medication, which in turn may lead to increased rates of carry-over 
daytime effects (246). Similarly, individuals with pre-existing sleep disorders and 
medical disorders which are often characterized by, or feature EDS, such as 
OSA or narcolepsy, have been shown to exhibit high rates of psychiatric 
comorbidity (such as depression) (247) which in turn may require the use of 
sedative or antidepressant medication. Indeed, the intended action of a chosen 
medication for a specific purpose may have unintended side effects and thus 
become undesirable; dependent on the time of day the drug is administered. For 
example, the use of sedative medication taken during the day may impair 
daytime functioning and affect levels of daytime sleepiness, and medications that 
are intended to promote wakefulness may inadvertently disrupt nocturnal sleep, 
therefore implicating the level of daytime somnolence experienced by the 
individual (248). Lastly, cases of EDS have also been noted among those 
individuals who have withdrawn from some types of medications, such as some 
opioid analgesics (249) and hypnotics (250), which may result from periods of 
rebound insomnia or disturbed sleep which occur as part of the withdrawal 
process. 
 
Typically, the observations regarding the association between medication use 
and EDS are drawn from specific sleep-disordered populations or individuals with 
concordant psychiatric or medical conditions. These associations, however, have 
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also been consistently observed among non-clinical population groups, thus 
suggesting that such associations may represent an independent factor, free of 
underlying sleep pathology. Indeed, several population-based studies have 
demonstrated that the use of sleep enhancing medication is significantly 
associated with the subjective experience of daytime sleepiness among 
population groups. Liu and colleagues (2007) (170) aimed to assess the 
association between and sleep duration and predictors of daytime sleepiness 
among a population-based sample of over 3000 Japanese adults. Results 
indicated that approximately one quarter of those interviewed reported obtaining 
insufficient sleep, and 6% reported the use of sleep-enhancing medication. 
Multiple regression analysis revealed that subjective daytime sleepiness was 
associated with self-reported insomnia symptoms, short sleep duration, and the 
self-reported use of sleep-enhancing medication. These findings, however, are 
not universal, with several studies reporting no association between the use of 
hypnotics (127) or antihistamines (251) and instances of increased daytime 
somnolence.  
 
Further evidence of this association can be drawn from a number of treatment 
studies that investigate the use of sympathomimetic medication (such as 
dexamphetamine or newer generation classes) to counteract symptoms of EDS 
among clinical samples. Briefly, these medications work to enhance monoamine 
neurotransmission by both enhancing the release of neurotransmitters (such as 
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dopamine, noradrenalin and serotonin) and similarly inhibiting the reuptake sites 
(129). 
 
Despite the findings outlined in the aforementioned studies, several areas of 
investigation remain. Specifically, it is currently unclear whether an administration 
or dosage threshold exists for these patients, and whether length of exposure or 
degree of habituation to the medication confounds the observed relationship. In 
part, this is due to differing methodological approaches taken by the authors, and 
discrepancies between optimal dosages used. Further, at present, there is little 
indication as to the role of these observed relationships within an epidemiological 
context, as there is often lack of specificity in regard to the medication indicated. 
Moreover, the direct mechanism by which currently recommended stimulant-
based medication works to counteract symptoms of EDS are unclear, and the 
long term efficacy of these medications requires further elucidation.  
 
As a result, in this thesis I will address these limitations in a systematic manner, 
as to effectively elucidate any reported associations, and provide valuable 
information as to the possible mediatory role of medication in the expression of 
EDS among non-clinical populations. Primarily, this will be achieved via the use 
of a standardised method of assessing instances of EDS by means of the ESS. 
The use of this methodology ensures the ability to replicate any reported findings 
among similar groups, and provides a platform for future studies in this field. 
Secondly, the use of well-defined methods of classifying medication use will 
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enable greater dissemination of the specific role of several classes of medication, 
and thus allow for more detailed conclusions to be drawn regarding the 
contributory role of these factors in the expression of EDS.    
3.5.5 Cigarette Smoking 
 
Cigarette smoking constitutes a significant health burden, and is considered a 
key factor in preventable morbidity and mortality in both developed and 
developing countries (252). Several epidemiological studies have suggested that 
the rate of cigarette smoking is on the rise in developing countries (253) and 
among women (254). Although the impact of cigarette smoking on aspects of 
cardiovascular (255) and psychiatric health (256) have been well documented, 
information regarding its effects on sleep physiology and architecture are poorly 
defined. The effect of nicotine intake on sleep physiology is thought to be 
primarily mediated by the stimulation of a combination of neurotransmitters 
directly related to sleep-wake processes (257, 258), such as Į7 and Į4b2 
nicotinergic acetylcholine (ACh) which indirectly affect dopamine and serotonin 
expression (259). The cumulative effect of nocturnal nicotine withdrawal has also 
been cited as a contributory factor (260). Peripheral factors affecting sleep 
architecture have also been recognized as possible secondary mechanistic 
effects resulting from smoking-related illnesses (such as COPD) (261).  
 
A number of animal (262) and human studies (see; (263, 264)) have indicated 
that nicotine use negatively affects both subjective and objective parameters of 
sleep. Research has demonstrated that current smokers report longer sleep 
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latency and less total sleep time (263), increased nocturnal awakenings (265), 
and higher rates of daytime sleepiness and insomnia than individuals who do not 
smoke (264, 265). Longitudinal studies have also demonstrated that current 
smoking status represents an independent risk factor for the later development 
of, and sustained experience of; sleep complaints, particularly amongst 
adolescents (266). Smoking cessation studies have found similar results, with 
objective studies reporting that nicotine withdrawal is associated with higher rates 
of sleep fragmentation (indicated by increased number of awakenings) (267, 
268); increased sleep latency (269) and higher rates of anxiety (270). The 
cumulative effects of decreased sleep time and impaired sleep quality are often 
expressed as increased levels of daytime sleepiness (267, 271). Research has 
indicated a bidirectional relationship between smoking status and the experience 
of EDS. For example, recent studies have demonstrated that individuals who 
report EDS are more likely to be a current smoker than those who report no EDS 
(185, 272)). Conversely, exposure to passive smoking has been found to 
increase the levels of EDS in asthmatic children (273) and smoking has been 
found to be a significant independent risk factor for later development of EDS 
(153).  
 
EDS is associated with increased accident risk due to associated impairments in 
sustained vigilance levels and reduced information processing capacity (161). 
Similar findings have been reported in the context of the effect of nicotine on 
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sleep architecture, whereby deficits in sleep quality as a direct result of nicotine 
use have been found to be a contributory factor for increased accident risk (264).  
 
Despite considerable evidence suggesting the deleterious effect of nicotine on 
overall health and sleep architecture, several areas of investigation remain. 
Specifically, little information is available regarding the relatedness of nicotine 
use as a factor in the prevalence of excessive sleepiness in Australian 
populations. Moreover, as individuals who exhibit sleep complaints often practice 
maladaptive lifestyle habits complementary to nicotine use (such as alcohol use 
or low activity levels) (274-276), it is unclear whether the cumulative effects of 
these converge to influence the experience of daytime sleepiness. Although 
previous research has proved fruitful in assessing these effects in isolation, 
further research is warranted to assess the impact of these factors 
systematically.  
 
Given the aforementioned limitations evident within the existing literature, within 
this thesis I will systematically address these issues to better elucidate the 
possible contributory and/or peripheral role of cigarette smoking in the expression 
of EDS. Specifically, the current study will utilise self-report data pertaining to 
daily nicotine use in order to assess whether cigarette smoking represents a 
significant effect-modifier in instances of EDS among a population-based sample 
of men and women. Given the previously well-described deleterious effects of 
cigarette smoking on a number of physical and psychiatric health domains, as 
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well as the reported associations with sleep disruption and pathology, it is 
surprising that little research exists which considers the role of nicotine use on 
EDS. Thus, this thesis will contribute valuable information to the limited amount 
of literature which assesses the contributory role of nicotine use in the expression 
of EDS. It is hoped that such descriptions will provide a platform for future 
research to consider the possible role of peripheral deleterious health behaviours 
on instances of EDS, and further expand on the available literature base in this 
field of enquiry.    
3.5.6 Physical Activity 
 
The benefit of physical activity has been well documented with regard to overall 
health improvements (277), and there is substantial research to suggest that 
engagement in regular, moderate to high intensity exercise effectively reduces 
the relative risk of a number of chronic conditions which typically impair an 
individual’s quality of life, such as cardiovascular disease (for review, see; (278)), 
numerous cancers (such as colon or breast) (279, 280), diabetes mellitus (281), 
and premature death as a cumulative result of these factors. Conversely, 
physical inactivity has been demonstrated to be a modifiable risk factor for the 
later development of many of these same chronic conditions (277, 282). Despite 
the effect of exercise on physical health outcomes being well described, the 
relationship between these factors and sleep pathology is less defined. Of the 
available literature, research studies tend to focus primarily on the effect of 
physical activity on the expression of sleep architecture and additional sleep 
physiology metrics. Indeed, although research examining this relationship have 
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typically indicated a favourable outcome in regard to objectively monitored sleep 
onset time and improved sleep quality via increased density of SWS (283, 284); 
this finding is not universal (285). Nonetheless, substantial research has 
illustrated a similar therapeutic effect on health outcomes seen among a number 
of sleep-related disorders. In particular, the effect of physical exercise on 
outcome measures for patients with OSA has been well described. A lack of 
exercise has been linked to both increased risk for determinants of sleep 
disordered breathing (i.e., obesity) (SDB) (286), and engagement in regular 
exercise has been seen to represent a protective factor for a reduction in both the 
severity of the disorder (287, 288), assist in amelioration of peripheral health 
deficits associated with the condition (289) and prevents the later development of 
the disorder, particularly among obese men (290). Similarly, participation in 
regular exercise has been found to improve symptom outcomes for insomnia 
patients via stress reduction pathways, as well as improvements in mental health 
variables in clinical studies (291).  
 
Given that exercise does not always equate to improved sleep, particularly 
among habitually normal sleepers (see; (285)), it is surprising that so little 
information is available exploring the daytime consequences of nocturnal 
disturbance, such as EDS. As physical inactivity has been linked to a number of 
adverse health outcomes, and that these factors have further been associated 
with maladaptive lifestyle habit commonly associated with EDS, it is surprising 
that there is little research available looking at these outcomes in combination. 
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Physical activity levels are typically considered a significant interceding 
component in the relationship between EDS, particularly when assessed in 
combined with a number of additional lifestyle factors. Thus, there is a need to 
explore the impact of this both as an independent mediating factor. Specifically, 
given the mediating role of exercise, and the combined predictive value of 
associated lifestyle factors as possible determinants of underlying sleep 
pathology, assessment can be made of the impact of EDS independent of 
possible underlying pathology. Moreover, at present, there is a lack of population-
based data that is representative within an Australian sample, as many of the 
research previously cited utilizes international participant groups. Therefore, 
there is currently a need for representative data that is clinically relevant to 
Australian populations, particularly those which utilize assessments of self-
reported habitual physical activity levels and its association with EDS.  
 
This thesis will address these limitations in several ways. Primarily, it will 
systematically assess the possible peripheral/adjunct role of physical activity (or 
lack thereof) in the expression of EDS among non-clinical populations. This will 
be achieved by employing standardised measures of self-reported physical 
activity (see Appendix 9 for questionnaire), thereby allowing for the improved 
ability to generalise any reported findings to different populations and/or patient 
groups. Further, the role of physical activity in the expression of EDS will be 
assessed in the context of several contributory health and lifestyle factors, such 
as those previously described (e.g. nicotine and medication use). The holistic 
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evaluation of these factors will provide a more representative assessment of any 
observed association, as it is unlikely that these factors would occur in isolation 
within real-life contexts. Such descriptions would therefore provide 
comprehensive and translational evidence as to the role of physical activity levels 
in the expression of EDS among Australian adults.  
 
3.5.7 Alcohol consumption  
 
The ingestion of alcohol is recognised to adversely affect the expression of 
normal sleep architecture via inhibiting REM periods (292), reducing sleep 
latency and amount of stage 1 sleep (293) and increasing periods of SWS (294). 
Moreover, the ingestion of alcohol immediately prior to bedtime has also been 
found to be a significant risk factor for EDS (294); however, these results have 
been mixed, with some studies citing no association (153). Indeed, although 
nocturnal ingestion of alcohol negatively affects the expression of sleep 
architecture, alcohol is generally metabolised rapidly and thus the deleterious 
effects are often confined to the first half of the night, whereas disturbances 
within the second half of the night are often due to the rebound effects of alcohol 
withdrawal (293, 295). Peripheral factors associated with alcohol’s influence on 
sleep disruption have also been cited as headaches, nocturia and tachycardia 
(293). Despite the effect of alcohol consumption on sleep architecture being well 
described; there is currently a paucity of information pertaining to the cumulative 
influence of these nocturnal disturbances on daytime sleepiness levels. First, 
there is little information regarding this association at a population level, 
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particularly among adult samples of Australian men and women. International 
research has yielded mixed results. Tsuno and colleagues (2007) (296) assessed 
the presence of EDS and a myriad of lifestyle and health factors among a sample 
of over 2,200 adults aged 65 years. Univariate analysis revealed that although 
EDS was associated with a number of sleep and health issues, alcohol 
consumption was not. However, a possible explanation for this finding is evident 
in indiscriminate questionnaire items referring to alcohol use. Indeed, alcohol use 
was dichotomised via self-disclosure of a ‘yes/no’ question to participants’ use of 
alcohol. As participants were required to identify as ‘drinker’ or ‘non-drinker’, this 
may have caused some individuals to under or over-report their usage due to 
non-specificity of questionnaire items. Moreover, as the authors did not quantify 
the amount of alcohol consumed per day, the effect of this consumption on EDS 
may be underreported, and thus specific conclusions regarding level of alcohol 
use cannot be made.  
 
Despite the effect of alcohol consumption on sleep architecture being well 
described; there is currently a paucity of information pertaining to the cumulative 
influence of these nocturnal disturbances on daytime sleepiness levels. Firstly, 
there is little information regarding this association at a population level, 
particularly among adult samples of Australian men and women. Of the 
international research available, results have largely been mixed, and thus it is 
difficult to draw any conclusive arguments regarding the strength of this 
association. Secondly, there is a lack of data assessing the effect of alcohol on 
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EDS levels utilizing well validated and standardized measures, as a large degree 
of variation exists within previously employed methodology. Therefore, in order 
for more conclusive arguments to be drawn, there is a need for considerably 
more research which utilises both a representative population-based sample, as 
well as that which employs standardised methodology.  
 
This thesis will therefore systematically assess the contributory role of alcohol 
consumption in the expression of EDS among a population-based sample of 
Australian adults. Indeed, the use of standardised methods of assessment (see 
Appendix 9) will provide valuable information regarding habitual alcohol use 
(obtained as part of a food frequency questionnaire), and will allow for greater 
dissemination of any observed associations. As this factor will be assessed in the 
context of several other peripheral health and lifestyle factors, such methods will 
provide representative data pertaining to the strength of this association, and 
provide value information to this understudied area of enquiry. 
3.5.8 Obesity, BMI and EDS 
Obesity rates have grown exponentially over the past 30 years (297), and current 
studies suggest that the prevalence is increasing globally (298-300). International 
research has indicated that approximately 35% of adults residing in the USA now 
meet the criteria for overweight or obesity (BMI 25k/g2) (299), and local data 
mirror this trend, with an estimated 60% of Australian adults also exceeding this 
threshold (300). The impact of obesity on a range of health and lifestyle 
outcomes is well documented, and those individuals with a high BMI (BMI 
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25kg/m2), a large waist/hip circumference (exceeding 102cm for men and 88cm 
for women) or a large proportion of body fat are recognised to have poorer 
general (301) and mental health outcomes (302), as well as a lower overall life 
expectancy that is comparable to rates associated with cigarette smoking and 
excessive alcohol consumption (299, 303).  
 
In addition to obesity’s impact on areas of health and functioning, the effects on 
sleep architecture and sleep health outcomes have been well documented. The 
link between obesity and risk for OSA is well established, however, additional 
peripheral effects associated with increased body fatness independent of 
underlying breathing pathology have been recognised as increased periods of 
nocturnal wakefulness and confusion on awakening (possibly linked to increased 
sleep inertia) (304).  
 
Despite the association between OSA and EDS being well established clinically, 
recent literature has shown that increased body adiposity affects the expression 
of regular sleep architecture, even in the absence of underlying sleep disordered 
breathing (305-307). Indeed, studies employing validated scales such as the ESS 
have found no associations between the Apnoea Hypopnoea Index (AHI) and the 
degree of daytime sleepiness, particularly in population samples (308). 
Individuals who are classified as overweight or obese display similar deficits in 
sleep quality to individuals with OSA, such as increased wake time after sleep 
onset (WASO), lower percentage of total sleep time and poorer sleep efficiency, 
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and lower REM density compared to healthy controls (305, 306). The mechanism 
by which obesity affects sleep architecture in this way, however, is currently 
unclear. Although research investigating this association employed non-apnoeic 
populations, some evidence of nocturnal respiratory disturbance remained. Non-
apnoeic obese patients were more likely to report symptoms of nocturnal 
choking, awakenings and unrefreshing sleep (306). Some degree of respiratory 
disturbance is not uncommon, even among those who have no typical markers 
of, or do not meet criteria for, complete diagnosis of the disorder (309, 310). 
Therefore, it may be that the combined presence of obesity and minor nocturnal 
events act to create sustained physiological disruptions that mirror that of an 
individual with OSA, albeit not as severe. Similarly, it has been proposed that the 
degree of daytime sleepiness seen in non-apnoeic obese individuals may be due 
to impaired nocturnal metabolic or endocrine circadian functioning, which is 
instead associated with daytime hypo-arousal and nocturnal hyper-arousal (305, 
306, 311). 
 
Despite the association between obesity and compromised sleep architecture 
being well described for clinical cohorts, there is less information pertaining to 
non-clinical cohorts. Theoretically, it is feasible to assume that the expression of 
EDS among groups of population-based obese individuals would mirror those 
which have been shown clinically; and thus it is possible that this association 
similarly results from a combination of disturbed nocturnal sleep and minor 
nocturnal respiratory events. What is more, there is currently very limited 
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information regarding the more subtle characteristic profiles of body composition 
and its association with EDS. Indeed, much of the available research typically 
focuses on total measures of adiposity (such as total BMI) or is limited to the 
upper limits of adiposity classification groups (such as BMI groups). Therefore, it 
is unclear as to whether the observed associations are translatable to more 
subtle measurements, and whether these factors represent possible points of 
clinical significance. Indeed, despite the aforementioned assumptions with regard 
to EDS and adiposity, at present, there is little to no research available assessing 
these associations systematically, particularly among representative samples, 
and it is currently unclear as to the peripheral role of several complementary 
lifestyle and health factors. Further elucidation of these factors would provide 
valuable information as to the mechanistic relationship between obesity and 
EDS, and would extend the previously existing body of clinical studies in the 
area. Such investigations may provide translational evidence for possible areas 
of interventions by providing rudimentary characteristic profiles of at-risk or 
affected individuals. 
 
This thesis will utilise comprehensive and systematic evaluations of both EDS 
and body composition by means of standardised and thorough investigation of 
adiposity factors (such as weight, waist-to-hip ratio, BMI etc.) and EDS (ESS). 
This will provide the first assessment of this association among a population-
based cohort, and will enable more conclusive arguments to be drawn regarding 
the strength of these associations among these populations. Such assessments 
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may provide valuable information regarding the more subtle mechanisms of this 
relationship, and thus provide possible areas of clinical and/or sub-clinical 
intervention.   
3.5.9 EDS and Metabolic Disturbance 
 
EDS is a common symptom among individuals presenting to sleep disordered 
clinics, and is often attributed to the presence of underlying sleep pathology such 
as OSA, and to a lesser extent, narcolepsy and idiopathic hypersomnolence. 
OSA is a highly prevalent condition both clinically and in the general population, 
particularly among overweight or obese, middle aged men (312); although these 
symptoms have also been noted among both clinical and community-dwelling 
populations of women (313) and among those considered to present with normal 
body habitus (314). Given the discrepancies regarding the typical characteristics 
of individuals presenting with both EDS and OSA, emerging research has 
suggested the possible mediating role of underlying metabolic abnormalities as a 
primary driving factor in the expression of these conditions. 
 
Several clinical features characteristic of OSA syndrome is suggestive of 
underlying metabolic disturbances, such as the natural course and typical 
increase in the incidence rate of OSA symptoms as a function of increasing age 
(315), the close association between OSA and increased adiposity (316) a 
general overrepresentation of OSA symptoms among men (android-central 
factors), as well as a peripheral association with cardiovascular and endocrine 
health (317, 318).  EDS is similarly linked to instances of metabolic disturbance 
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with regard to dysfunction within the physiological systems thought to govern 
sleep processes and sleep regulation, of which are similarly involved in metabolic 
processes. The endogenous inflammatory cytokines, tumour necrosis factor-Į 
(TNFĮ) and interleukin-1ȕ (IL-1ȕ) are thought to be involved in the natural 
regulatory processes of the sleep-wake cycle in humans (86, 319), whereas 
increases in subjective sleepiness and/or increased sleep have been found to be 
associated with the exogenous administration or increased secretions of  
interleukin-6 (IL-6) (320). Research conducted by Vgontzas and colleagues (321) 
examined this association in detail, and demonstrated that that among OSA 
patients, both TNFĮ and IL-6 plasma concentrations were positively correlated 
with the presence of EDS, and that that IL-6 plasma levels were positively 
correlated with BMI. Further, TNFĮ levels were naturally elevated in OSA 
patients and narcoleptics compared with that in normal controls, and IL-6 
concentrations were markedly elevated in OSA patients compared to normal 
controls, which is suggestive of a naturally occurring metabolic dysfunction 
among these patients.  Although this original study did not control for BMI, 
subsequent complementary research by the same group (322) examined 
whether this association was sustained independent of obesity. Three groups 
were assessed: obese, middle-aged men with sleep apnoea; nonapnoeic age- 
and BMI-matched, obese men; and age-matched, lean controls. It was observed 
that men with OSA had higher naturally occurring plasma concentrations of 
TNFĮ and IL-6 compared to nonapnoeic, obese men or lean controls. Further, 
99
both TNFĮ and IL-6 were positively correlated with BMI, and IL-6 and leptin 
levels were correlated with plasma insulin concentrations.  
 
Additional research has also demonstrated that EDS is associated with obesity in 
the absence of underlying sleep pathology (305, 306), and that EDS is correlated 
with metabolic abnormality among obese individuals without OSA  (321). From a 
mechanistic standpoint, these findings suggest the mediatory role of both 
environmental and biological factors, which inform the progression of metabolic 
disturbance, which in turn impact the expression and natural course of underlying 
sleep pathology. Further, the progressive and accelerated deterioration of sleep 
apnoea into more severe and chronic cases may then in turn increase the rate of 
deterioration in peripheral metabolic processes via sustained release and 
increased concentration of physiological and metabolic stress hormones such as 
insulin, which may promote increased adiposity and visceral fat deposition.  
 
Although there is a growing number of studies which suggest that clinically, the 
association between EDS, obesity and metabolic syndrome is maintained beyond 
that of OSA symptoms, there is less research available assessing this 
relationship among community-based, representative samples. Of the limited 
research available, studies conducted by Bixler and colleagues (153) aimed to 
assess the association between the complaint of EDS and instances of OSA 
whilst including a wide range of possible risk factors. Multivariate logistic 
regression analyses demonstrated that depressive symptoms were the most 
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significant risk factor for EDS, followed by BMI, subjective sleep duration and 
diabetes. OSA was found to have the weakest predictive value. These results 
indicate that mental health complaints and nocturnal sleep disruption are more 
valuable in predicating instances of EDS among population-based samples, and 
further demonstrate that EDS among non-clinical samples extends beyond that of 
sleep-related breathing pathology.  
 
Although these findings lend support to research assessing the role of alternative 
biological and physiological aetiologies of EDS, several areas of investigation 
remain. Most notably, systematic assessment of these factors utilising 
standardised assessments of sleepiness are currently lacking, as available 
research has typically employed questionnaire items that lack quantified reliability 
and/or stability metrics (e.g. see (306)), or only assess a limited number of 
metabolic factors (e.g. see (153)). Further, there is no research that assesses 
whether this association is sustained beyond individual symptom clusters (i.e., 
whether it is applicable to metabolic syndrome).  
 
This thesis will provide the first assessment of the association between EDS and 
metabolic factors. It is anticipated that the use of well-defined measures of EDS 
and metabolic syndrome will allow for greater ability to generalise any reported 
findings, and will provide a platform for any future research in the field. Moreover, 
it is predicted that such investigations would have significant implications for 
general health practices for these patients with regard to the relatedness of the 
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two conditions and the natural disease course, and would thus add valuable 
information to the etiological origins of EDS with regard to metabolic factors.  
3.6 Sleep Pathology and EDS 
3.6.1  Obstructive Sleep Apnoea (OSA) 
 
Traditionally, clinical research has suggested that the greatest proportion of those 
individuals presenting with EDS also suffer concordant sleep-related breathing 
disorders such as OSA (323). EDS is indeed considered a common complaint of 
individuals with OSA, and is the most heavily investigated feature of the disorder 
(324). OSA effects sleep via disruptions to physiologically mediated sleep 
mechanisms, typically expressed as oxygen desaturation due to cessation in 
nocturnal breathing, increased WASO, reduced REM periods and higher 
proportion of stage 1 sleep (325, 326). Daytime consequences of nocturnal 
disruptions among these individuals often manifests as poorer vigilance and 
attentional capacity during tasks requiring sustained attention (such as driving) 
(327), lower mood and quality of life (328) , and instances of daytime sleepiness 
(326).  
 
There has been some degree of conjecture as to the ability and usefulness of 
assessing and quantifying instances of subjective sleepiness utilising objective 
measurement tools. Indeed several studies have noted a lack of correlation 
between aspects of nocturnal sleep architecture and anthropometric 
measurements and EDS as measured by the MSLT (329, 330); however, others 
have noted a positive correlation using this test, or have suggested that it 
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represents a strong predictive indicator of OSA severity (331). Additional 
objective tests used to assess levels of EDS include attention-vigilance tasks 
such as the Oxford Sleep Resistance test (OSLER), which has demonstrated 
good predictive value in discriminating OSA patients from controls based on 
sustained vigilance abilities (332). 
 
It is possible that the discrepancies among objective and subjective measures in 
the assessment of EDS in OSA are in part due to the different clinical 
presentation of these conditions, and a possible bias towards the assessment of 
more symptomatic populations among clinical samples. Such assumptions are 
supported by a number of population-based studies which have demonstrated 
the lack of associations between EDS and OSA among non-clinical populations. 
Most notably, research conducted by Bixler and colleagues (153) examined the 
association between EDS and OSA among a representative sample of 6,583 
men and women from central Pennsylvania as part of the Penn State Cohort 
study. Multivariate modelling revealed that EDS was more strongly associated 
with depressive illness, perceived short sleep and metabolic factors than OSA 
symptoms per se. It is possible that the use of a non-standardised EDS 
assessment tool influenced these findings; as only two questionnaire items were 
included (“do you feel drowsy or sleepy most of the day but manage to stay 
awake?” and “do you have any irresistible sleep attacks during the day?”). The 
lack of more comprehensive assessment of sleepiness during both active and 
soporific tasks may therefore under-represent more subtle, activity-dependent 
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associations. Arguably, however, this may contribute to an under-representation, 
rather than an over-representation, regarding the proposed strength of these 
associations. Despite this, the authors employed robust assessment of several 
possible contributory etiologic factors, and such findings present valuable insight 
into the peripherally associated health and lifestyle facets. Complementary 
research conducted by Vgontzas and colleagues (305) aimed to describe the 
factors influencing the expression of EDS among non-apnoeic obese patients. 
Results indicated that obese subjects reported a significantly higher overall level 
of EDS compared to matched controls, and that the degree of EDS was 
associated with the extent of disturbed nocturnal sleep, with obese patients 
demonstrating higher levels of WASO, total wake time, and lower percentage of 
sleep time compared to non-obese individuals.  
 
That the degree of EDS among both OSA and non-apnoeic obese patients may 
be attributable to underlying disturbed sleep rather than disease pathology has 
been investigated by several other studies. Indeed some research has noted a 
weak association between EDS and physiological markers of OSA among 
population-based samples (333, 334), thereby supporting the possibility that the 
reported relationship may instead be attributable to underlying sleep disturbance, 
peripheral etiological markers of the condition (such as metabolic disturbance 
and obesity) and insomnia-type symptoms, rather than the physiological markers 
characteristic of OSA pathology. 
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3.6.2 Insomnia 
Clinical assessments of EDS among individuals presenting with insomnia 
typically occurs secondary to psychiatric complaints or instances of circadian 
misalignment, rather than as a primary symptom (335). However, a number of 
studies have cited nocturnal sleep disruption, short sleep duration and insomnia 
symptoms as significant predictors of the degree of EDS experienced by these 
patients (203, 336). Theoretically, it is feasible to assume that nocturnal 
disruption or insufficient sleep- which is characteristic of insomnia- would incur 
deleterious daytime effects. Indeed, a substantial proportion of research 
assessing the daytime consequences of both experimentally-imposed and 
naturally occurring sleep disruptions cite daytime sleepiness as a common 
outcome (154, 337, 338). Epidemiological research has mirrored this, with 
studies by Liu and colleagues (170) demonstrating that among a population-
based sample of Japanese adults, short sleep duration, insomnia symptoms and 
subjective insufficient sleep were significantly associated with daytime 
sleepiness, with short sleep duration constituting the strongest predictive factor.  
 
Similar results have also been cited among populations from different study 
regions and geographical locations. Indeed, finding published by Hublin and 
colleagues (172) demonstrated that among a representative sample of Finnish 
adults, daytime sleepiness was strongly associated with symptoms of insomnia 
and self-reported insufficient nocturnal sleep. These findings were further 
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mirrored by studies conducted among a sample of adult males who resided in 
Northern Ireland (171), and among a selected adult population in Korea (190).  
 
Despite the high concordance of nocturnal sleep disruption, insomnia and 
reported symptoms of EDS, particularly among population samples, it must be 
noted that a dose-response effect exists which is often dependent on definition 
criteria of these factors utilised among these types of studies. Such discrepancies 
between studies with regard to the tools used to evaluate both EDS and insomnia 
mean that accurate cross-evaluations of the degree of associations among 
different study populations and regions are complex. Indeed, it is not uncommon 
for studies to utilise non-standardised assessments of EDS (171), or to employ 
the use of a single-item assessment of sleep difficulties (181). As a result, 
detailed assessments of the mechanistic processes underlying this association 
are understudied, and conclusions are instead often drawn from studies 
examining other associated neurobehavioural and cognitive factors. Further, it is 
unclear as to the degree of association between EDS and different specific 
insomnia subtypes, with little to no research existing in this area. Of the limited 
studies, an association has been noted between nocturnal awakenings and the 
experience of daytime sleepiness (339). Additional studies of this nature would 
lend valuable information to the theoretical constructs pertaining to the role of 
sleep disruption in the experience of daytime symptoms. For example, evidence 
of increased EDS from insomnia sub-type ‘early morning awakening’ may lend 
support for the role of total sleep time, as opposed to sleep continuity and ‘sleep-
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maintenance’ sub-type insomnia (i.e., degree of nocturnal awakenings), and 
assist in better characterising at-risk individuals.     
 
Despite the negative effects of EDS on a number of behavioural, physiological 
and psychiatric outcomes being well documented among other primary sleep 
disorders such as OSA and narcolepsy, it is often assessed as either a 
secondary or peripheral factor of characteristic insomnia symptoms. Of the 
available research, high amounts of variation with regard to study populations 
and measurement tools preclude the ability to generalise reported findings and 
draw conclusive arguments as to the direct etiological origin of EDS among these 
patients. Additional research is needed to better describe the more subtle 
mechanistic actions that underlie this association; and thus provide insight into 
these processes. 
3.7  EDS and Psychiatric Health 
 
Sleep disturbances are considered to be a common element in psychiatric 
disorders, particularly in the psychopathology of mood disorders (340). As such, 
these disturbances are considered an essential component in all major sets of 
criteria for both diagnosis and symptom rating scales in depression (341), and 
feature as a complimentary marker of anxiety and bipolar disorder (342, 343). 
Consequently, it is estimated that up to 80-90% of individuals who suffer from a 
major depressive disorder also report experiencing sleep disturbances (340, 344, 
345). Increased recognition regarding the association between sleep quality, 
subsequent impairments in daytime functioning, and the prevalence of mood 
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disorders constitutes an important consideration for the efficacy of ongoing 
treatment. Indeed, the relationship between sleep quality and symptoms of 
anxiety and depression are considered to be well established in the field of 
psychiatry (346), and as such these disturbances are considered to be clinically 
significant in terms of indicating predicted symptom severity, course, and 
consequent markers of relapse (346, 347). 
 
Within a clinical framework, EDS is considered a common behavioural feature of 
depression (348), and a high concordance rate is typically observed between 
these symptoms (105). Sleepiness levels have been found to be a reliable 
indicator of symptom severity among depressive patients (349), and degree of 
depressive symptomology is considered to be a stronger predictor than 
underlying OSA in the expression of EDS among population-samples (153). 
Indeed, a number of clinical and epidemiological studies have identified several 
possible lifestyle and health factors that may influence the pattern of EDS in 
depression, such as young age (180), short sleep duration or disturbed sleep 
(188), insufficient or non-restorative sleep, psychological stress (180), and/or 
female sex (181, 188). Although the direct mechanisms which underlie these 
relationships are uncertain, it is believed that poor sleep quality or inadequate 
sleep arising from psychiatric disturbances, or sedative effects of treatments may 
contribute to the expression of daytime symptoms (130).  
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Anxiety has also been cited as a secondary factor in the experience of EDS, 
however these results have been mixed (174, 203). Comparably less research is 
available assessing this association, and any inferred associations are typically 
investigated in the context of underlying medical pathology (350), as a secondary 
feature of pharmacotherapy treatment (351), or assessed as part of a dual 
depression/anxiety diagnosis (352). Only one study has assessed the association 
between EDS and anxiety within a longitudinal framework. Research conducted 
by Hasler and colleagues (353) aimed to explore the associations between self-
reported EDS, sleep disorder symptoms, episodes of major depression and 
anxiety among a longitudinal community study of young adults. This prospective 
study was conducted from 1978 through to 1999, and information was derived 
from six interviews when participants were aged 20, 22, 27, 29, 34, and 40 years. 
Results indicated that the prevalence of EDS increased with age. Cross-sectional 
analyses showed that EDS was associated with insomnia symptoms, anxiety 
disorders, nocturnal hypersomnia and reduced quality of life. Longitudinally, 
impaired sleep quality, waking up too early, and anxiety symptoms were 
associated with the later development of EDS, however no association was noted 
between EDS at baseline and the later development of depressive or anxiety 
disorder. Given the limited amount of research in this area, any conclusions 
provided regarding the possible mechanistic properties of this association are 
tentative. However, it is possible that the association between EDS and anxiety 
are similar to that which has been found for insomnia or insomnia symptoms (as 
described in the above study). Given the large clinical overlap between anxiety 
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and insomnia with regard to symptoms of daytime hyper-arousal and nocturnal 
sleep disruption (354), it is plausible to assume that any investigations would 
yield similar findings. However, more comprehensive research is needed to 
better describe this association.  
 
Currently available literature suggests that there is a relationship between non-
restorative or poor sleep, daytime sleepiness, depression and to a lesser extent 
anxiety; with sleep disturbances considered to represent a mediating factor (355). 
However, there is considerable controversy as to whether EDS constitute a 
primary factor in depression and anxiety, or whether these disturbances act as a 
proxy for additional causal factors that influence the development of mood 
disturbances, in light of possible confounding factors. Arguably, research 
investigating the direct role of EDS within the context of a variety of mood and 
anxiety disorders can still be considered to be in its infancy. At present, as there 
is little to no explicit longitudinal research in this area; it is unclear whether these 
symptoms truly represent an independent predictive factor, or whether they 
instead can be considered an epiphenomenon in light of associated health and 
lifestyle variables. As a result, there is a paucity of research assessing this 
association among well-defined cases of anxiety and depression (i.e., with 
clinical interview techniques). Moreover, the availability of up-to-date and well-
controlled studies examining EDS in the context of a number of lifestyle and 
health factors among an Australian cohort is currently lacking.  
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This thesis will employ well-defined, standardised assessments of both mood and 
anxiety disorders and EDS in order to better describe these associations. The 
use of such methods will address previous issues regarding the ability to 
generalise reported findings, and will provide valuable information regarding the 
relatedness of these factors among non-clinical cohorts. Specifically, the use of 
comprehensive clinical assessments of mood and anxiety disorders will provide 
more in-depth conclusions to be drawn regarding the strength of these 
associations, and thus build of previous findings which have primarily utilised 
questionnaire data alone to assess this relationship.  
 
3.8 Conclusion 
  
Information regarding both the impact and burden of sleep disorders within a 
clinical and population setting, has expanded exponentially since they were first 
described in the 1930’s. The gradual development of both objective and 
subjective assessment tools, which arose from a need to quantify the daytime 
effects of nocturnal sleep disruption has allowed for greater breadth of 
investigation into those disorders which are most prevalent, and have aided in 
describing both the personal and societal outcomes of such disorders. Indeed, 
the development of standardised and quantifiable assessment of sleep 
disturbances and EDS has enabled greater understanding as to the antecedents 
and consequences of the pathology and associated outcomes of these disorders. 
Although these advancements have appropriated preliminary investigation into 
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precedents and associated outcomes, several important areas of enquiry remain. 
Firstly, there is a need to collate a representative population sample in order to 
assess the relatedness of these symptoms to the broader community. As a large 
proportion of current information available is typically drawn from international 
cohorts, assessment of local data is needed to both ascertain the impact of 
disease symptomology and to assess trends within a local context. At present, it 
is unclear whether international findings are applicable to the Australian 
population, particularly amongst a representative sample of both men and 
women. Moreover, research investigating the role of a number of lifestyle and 
health factors in the impact of EDS has typically been assessed in isolation, or 
offers an incomplete assessment of these factors. Currently, there are currently 
few studies that focus on a number of these factors within one methodological 
framework, and whether these factors interact to influence the outcome of EDS. 
Therefore, there is in immediate need to expand these areas of enquiry in a 
systematic and comprehensive manner. Such investigations would broaden the 
currently limited amount of knowledge of this field, and would provide additional 
information pertaining to the role of sleep disturbances and EDS in a number of 
health and lifestyle outcomes.  
 
Such descriptions may assist in the formulation of both primary and secondary 
health initiatives and clinical intervention techniques by means of identifying 
areas of immediate and relevant significance, as well as working to identify at-risk 
or affected individuals. More specifically, the systematic assessment of sleep 
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behaviours and associated health and lifestyle factors may help in identifying 
possible areas of modifiable intervention, thereby assisting in informing public 
healthcare planning and treatment of these individuals.   
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CHAPTER 4: Thesis Overview and Aims 
4.1 Thesis Overview  
 
The overall objective of this research was to develop a comprehensive and 
detailed description of disturbed sleep and EDS and the associated lifestyle and 
health factors. Information was sourced using existing data available as part of 
several epidemiological databases, including; 1.) The GOS, an ongoing, 
population-based study aimed at assessing a number of health, psychiatric and 
anthropomorphic information in a large sample of men and women residing in the 
Barwon Statistical Division. 2.) The NLHB, a nine-wave, cluster-sample research 
study which followed a cohort of adolescents from age 13 (initial testing period 
1990) to 30 years (final follow-up in 2007). 3.) The NHANES, an age-stratified, 
cross-sectional population-based sample of non-institutionalised individuals, 
spanning all adult age groups.  The specific aims of this thesis are as follows: 
4.2 Specific Aims 
 
x Aim 1 is to investigate the prevalence of EDS and associated health and 
lifestyle factors among a representative population-based sample of adults 
(Chapter 6). 
 
x Aim 2 is to investigate whether EDS is associated with increased adiposity 
among a population-based sample of men and women (Chapter 7).  
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x Aim 3 is to investigate whether the association between EDS and 
metabolic dysfunction was sustained beyond that of individual symptoms, 
and found among adult men and women who meet criteria for the whole 
syndrome (Chapter 8). 
 
x Aim 4 is to investigate the relationship between EDS and falls among older 
adults (Chapter 9).  
 
x Aim 5 is to provide detailed assessment of the association between EDS 
and psychiatric health in a population-based sample of women (Chapter 
10).  
 
x Aim 6 is to explore the natural trajectory and predictive value of short 
sleep duration at ages 13, 15, 23 years on short sleep duration at age 30 
years (Chapter 11). 
 
x Aim 7 is to assess the longitudinal and cross-sectional relationship and 
between symptoms of depression and difficulty initiating sleep (DIS) from 
early adolescence (13 years) to early adulthood (23 years) (Chapter 12). 
 
x Aim 8 is to describe the relationship between insomnia, OSA, and 
comorbid insomnia-OSA and depression, while controlling for relevant 
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lifestyle and health factors, in a large population-based sample of US 
adults (Chapter 13). 
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CHAPTER 5: General Methods 
5.1 Study Descriptions 
5.1.1 Geelong Osteoporosis Study (GOS) 
 
Data utilised for studies 1-5 was gathered as part of the larger GOS assessment. 
Originally, the GOS study was designed to investigate the epidemiology of 
osteoporosis in Australian women; however, the study has since expanded to 
include a male cohort, as well investigation into a number of other health 
outcomes. Participants were recruited from the Barwon Statistical Division (BSD), 
a well-defined area surrounding Geelong, Victoria in South-Eastern Australia, as 
described by the Australian Bureau of Statistics (ABS) (Figure 5.1). The BSD 
includes the Australian Electoral Commission (AEC) division of Corio, Lalor 
(partial) and Corangamite (partial). Nationwide census data for 2008 indicates the 
overall population of BSD to be over 278,000 individuals, comprising of 
approximately 138,000 men and 140,000 women  aged 0-85+ years (356). The 
sampling frame was the Australian Electoral Roll. As voting is compulsory, males 
and females aged 18 years were randomly selected from the electoral roll, and 
mailed a letter of invitation, accompanied by a request to submit a response slip 
or to alternatively contact the research centre located at Barwon Health 
(University Hospital Geelong, formerly known as the Geelong Hospital). 
Population characteristics of the BSD are considered comparable with national 
levels for each census taken in the years 1996, 2001 and 2006. Differences did 
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not exceed 1.1% for age, 9.5% for country of birth, 7.5% for school leavers’ age, 
2.6% for marital status and 2.1% for weekly income (357).  
 
Women: 
Between 1993-1997, 1494 women were recruited (aged 20-93 years), 
representing 77.1% participation (357). At the 10-year follow up (2004-2008), 881 
women from the original sample returned (82.1%), which was complemented by 
the inclusion of an additional 246 women aged 20-29 years to allow for the 
continued investigation of the full adult age range. This resulted in a total sample 
of 1067 eligible women participants (357). 
 
Men: 
Between the years of 2001-2006, 1,540 men were recruited (aged 20-93 years), 
representing 67.0% participation (357) . At the 5-year follow-up (2006-2010) 978 
men from the original sample returned, representing an overall response of 81% 
(357). 
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Figure 5.1: Barwon Statistical Division 
 
Included area denoted by yellow shading and indicated with blue circle. Source: 
http://www.barwonml.com.au/our-healthy-region/characteristics 
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5.1.2 Norwegian Longitudinal Health Behaviour Study (NLHB) 
 
The NLHB is a nine-wave, cluster-sample research study which followed a cohort 
of adolescents from age 13 (initial testing period 1990) to 30yr (final follow-up in 
2007). As part of the initial wave in 1990, a total of 1,195 13 year olds and their 
parents were invited to participate in the study. As the data collection was 
conducted during school hours in waves 1-3, 47 students who joined the sampled 
school classes after wave 1 were invited to participate during the two subsequent 
waves, resulting in a total sample of 1,242. 29 of these did not participate in 
waves 1-3, but participated at least once during waves 4-7. Inclusion for the 
study required consent from both the adolescent and the parent/guardian (see 
Appendices 12 and 13), which resulted in a total of 1105 (55% male) students 
(89% of the total invited sample). Study questionnaires were distributed at the 
participants’ schools at the time of the first few years of the study (age 13–15 
years), and were later distributed by mail to the respondents’ home addresses at 
the time of each follow-up assessment wave. 
 
Study 6 included in this thesis presents data from the years 1990, 1991, 1992, 
1993, 1996, 1998 and 2000 (that is, at ages 13, 14, 15, 16, 19, 21 and 23 years). 
Study 7 included within this thesis presents data from waves 1990, 1992, 2000 
and 2007 in order to assess sleep variables among the age-groups of 13, 15, 23 
and 30 years, respectively. Data from wave 5 (age 18 years) was not included in 
either manuscript as no sleep variable item was included in this survey wave.  
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5.1.3 National Health and Nutrition Examination Survey (NHANES) 
NHANES is a stratified, cross-sectional population-based sample of non-
institutionalised individuals, spanning all age groups, designed to assess the 
health and nutritional status of adults and children in the USA. Approximately 
5000 individual assessments are performed each year, aimed at assessing 
aspects of health (disease burden) and nutrition. The NHANES combines a 
series of personal interviews and physical examinations, which focus on different 
population groups or different aspects of health or disease during each wave. 
These surveys have been conducted by the National Center for Health Statistics 
on a periodic basis. As part of the NHANES 2005-2006 assessment series, 
10,348 persons were selected for the sample, with a total of 10,122 (79.3%) of 
those undergoing clinical health interviews, and another sub-set of 9,643 (75.6%) 
individuals underwent examination in the mobile examination centres, of which 
were located in approximately 15 counties across the USA.  All health interviews 
were conducted in respondents’ homes, and health measurements were 
performed in the mobile examination centres. Interview teams conducting these 
assessments consisted of physicians, medical and health technicians, and 
trained dietary and health interviewers. From these interviews, comprehensive 
data was collected which included information gained from physical examination, 
nutritional assessment, and laboratory tests. Demographic information was 
obtained which included information regarding age, race, ethnicity, number of 
people living in the household, current marital status, highest educational level 
attained and estimation of the total family income. Nutritional and health 
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assessment data gathered for all data collection waves included: anthropometric 
data (weight, height, BMI etc.), information pertaining to average daily food 
intake, blood pressure measurements, assessments of oral health and 
information regarding physical activity (gathered from physical activity monitor), 
mental health status, self-reported use of illegal drugs, housing conditions, level 
of current health insurance as well as degree of healthcare utilisation.  
 
Lab-based data collected as part of the NHANES pertained to the results of a 
number of blood and saliva tests which assessed: HIV status, tests assessing 
hepatitis antibodies, as well as assessments of current levels of various vitamins, 
minerals. NHANES 2005-2006 was the first time during which questionnaire data 
were used to assess the presence of both physician-diagnosed sleep disorders 
and sleep-related subjective questionnaire items.  
 
The aforementioned items were also included for the 2007-2008 testing period. 
As part of the NHANES wave for the years 2007-2008, a total of 12,946 adults 
were selected for the sample. Of these, 10,149 (78.4%) underwent health 
interviews (see details above), and a sub-set of 9,762 (75.4%) were further 
examined in the mobile examination centres (see details above).  
 
For the purpose of the study included within this thesis (Study 8), adults (aged  
18 years) who participated in NHANES at the two sampling time points; 2005-
2006 and 2007-2008, and whom had complete sleep (OSA and insomnia) and 
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psychiatric data were included for analysis, resulting in a total sample of 11,329 
individuals. The overall response for these combined surveys was 76.4% (358).  
 
For the study utilising data from the NHANES, and throughout the thesis, the use 
of the abbreviation OSA is used, and implies the inclusion of daytime symptoms 
(daytime sleepiness).  
 
5.2 Ethics and Informed Consent 
5.2.1 Ethics Approval 
 
Studies conducted as part of this research project were previously approved 
according to the appropriate ethical bodies. Approval was granted by the Human 
Ethics Committee (HREC) at Barwon Health (Chapters 6-10) (Approval 92/01 for 
the female arm, and 00/56 for the male arm) Approval was granted by the 
Regional Committee for Medical Research Ethics in Western Norway (Chapters 
11 and 12) and the National Center for Health Statistics Research Ethics Review 
Board (Chapter 13).  
 
In all studies, participants were allocated participant identification codes. 
Analyses were performed using de-identified data in order to maintain participant 
confidentiality.  
5.2.2 Informed Consent 
 
Written informed consent was obtained for all participants as part of the GOS  
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(Chapter 6-10) (see Appendix 8, 10), the NLHB study (Chapters 11 and 12) (see 
Appendix 12 and 13) and the NHANES (Chapter 13) (see Appendix 14).  
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CHAPTER 6: The Prevalence of Excessive Daytime 
Sleepiness in the Australian Adult Population. 
 
 
 
 
 
 
 
Reference: Hayley A.C., Williams, L.J., Kennedy. G.A., Berk, M., Brennan, S.L., 
& Pasco, J.A. Prevalence of excessive daytime sleepiness in a sample of the 
Australian adult population. Sleep Medicine. Mar;15(3): Doi: 
http://dx.doi.org/10.1016/j.sleep.2013.11.783. (2014) (359) 
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Objectives: Excessive daytime sleepiness (EDS) is associated with signiﬁcant personal and medical bur-
den. However, there is little indication of the impact of these symptoms in the broader population.
Participants and methods: We studied 946 men ages 24–92 years (median age, 59.4 [interquartile range
{IQR}, 45–73 years]) and 1104 women ages 20–94 years (median age, 50 [IQR, 34–65 years]) who resided
in the Barwon Statistical Division, South-Eastern Australia, and participated in the Geelong Osteoporosis
Study (GOS) between the years of 2001 and 2008. EDS was deﬁned as an Epworth Sleepiness Scale (ESS)
score of P10. Lifestyle factors, history of medical conditions, and medication history were documented
by self-report.
Results: For men, the age-speciﬁc prevalence of EDS was 5.1% (ages 20–29 years), 6.4% (ages 30–
39 years), 9.8% (ages 40–49 years), 15.5% (ages 50–59 years), 12.0% (ages 60–69 years), 12.0% (ages 70–
79 years), and 29.0% (ages P80 years). For women, the age-speciﬁc prevalence of EDS was 14.7% (ages
20–29 years), 8.7% (ages 30–39 years), 15.0% (ages 40–49 years), 16.0% (ages 50–59 years), 12.6% (ages
60–69 years), 13.2% (ages 70–79 years), and 17.0% (ages P80 years). Overall standardized prevalence
of EDS was 10.4% (95% conﬁdence interval, 9.7–11.2) for men and 13.6% (95% conﬁdence interval,
12.8–14.4) for women.
Conclusions: The prevalence of EDS increased with age, affecting approximately one-third of those aged
P80 years. Because EDS has been associated with poorer health outcomes in the older age strata, these
ﬁndings suggest that routine screening may be beneﬁcial in ongoing health assessments for these indi-
viduals. Overall, more than one-tenth of the Australian adult population has EDS, which is indicative
of possible underlying sleep pathology.
 2014 Elsevier B.V. All rights reserved.
1. Introduction
Excessive daytime sleepiness (EDS) is considered an important
clinical feature of sleep medicine and constitutes a signiﬁcant phe-
nomenon for personal and public health outcomes. Functionally,
EDS refers to an objective or subjective state in which there is an
inclination or compulsion to sleep or take naps when intending
to stay awake [1–3]. The causes of EDS are multifaceted, with pos-
sible risk factors previously identiﬁed as intrinsic sleep disorders,
(i.e., narcolepsy, obstructive sleep apnea), circadian rhythm disor-
ders (i.e., shift-work disorder), extrinsic sleep disorders, (i.e., poor
sleep hygiene and insufﬁcient sleep) [4], and other contributory
lifestyle and health factors [5]. The immediate effects of EDS can
be debilitating, and in some cases life threatening [6]. EDS is con-
sidered to represent a considerable contributing factor towards
poorer occupational and social functioning [1], and it is strongly
associated with an increased risk for both workplace and road traf-
ﬁc accidents [7].
Despite the effects of sleepiness being well-recognized in public
and clinical health setting, accurate representations of the burden
of EDS can vary in psychometric tools and differ in pathologic
thresholds used among study populations. Indeed little standard-
http://dx.doi.org/10.1016/j.sleep.2013.11.783
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ized information is available regarding the general Australian pop-
ulation, as much of the literature available often is restricted to
speciﬁc sleep-disordered patient groups [8], working populations
[2], or geographically conﬁned populations [9], and thus gives little
indication of the burden of these symptoms among the broader
population. Therefore, the accurate representation of EDS and
identiﬁcation of possible health and lifestyle correlates in an Aus-
tralian representative population requires further elucidation. The
aim of our study was to determine the prevalence of EDS measured
by the Epworth Sleepiness Scale (ESS) in a representative Austra-
lian population-based sample, spanning the full adult age spec-
trum. Characteristics of men and women with and without EDS
in a number of lifestyle and health factors also were identiﬁed.
2. Methods
2.1. Participants
Our study examined data collected from men and women en-
rolled in the Geelong Osteoporosis Study (GOS). Individuals were
randomly selected from the Barwon Statistical Division electoral
role, South-East Australia. Both men and women were recruited
utilizing an age-stratiﬁed sampling method including 12 strata
for each gender. Population characteristics of the Barwon Statisti-
cal Division are considered comparable with national levels for
each census taken in the years 1996, 2001, and 2006. Differences
did not exceed 1.1% for age, 9.5% for country of birth, 7.5% for
school leavers’ age, 2.6% for marital status, and 2.1% for weekly in-
come [10].
Between the years of 1993 and 1997, a random recruitment of
1494 women was performed representing a participation rate of
77.1% [10]. At the 10-year follow-up (2004–2008), 881 women
from the original sample returned (82.1%) and were complemented
by the inclusion of an additional 246 randomly selected women
between the ages of 20 and 29 years to allow for the continued
investigation of the full adult age range. Of the 1127 women who
participated in the 10-year follow-up, participants for whom sleep
data were not available were excluded (n = 23), resulting in a total
of 1104 eligible women aged 20–94 years (inclusion rate of 73.9%).
Between the years of 2001 and 2006, a random recruitment of
1540 men was performed (response 67.0%) [10], and the partici-
pants have since returned for follow-up (n = 978; response rate,
81.0%). Of the 978 men who participated in the 5-year follow up,
participants for whom sleep data were not available were excluded
from analysis (n = 32), resulting in a total of 946 eligible men be-
tween the ages of 24 and 92 years.
Our study was conducted with the approval of the Barwon
Health Human Research Ethics Committee, and written informed
consent was obtained from each participant.
2.2. Measurements
2.2.1. Epworth Sleepiness Scale
EDS was assessed using the Epworth Sleepiness Scale (ESS) [8].
The ESS is a self-administered 8-item questionnaire that has been
widely used as a simple, reliable, and valid method for assessing
daytime sleepiness in adults. Participants are required to respond
to items regarding perceived levels of sleepiness on a 4-point rat-
ing scale (0 = would never doze; 1 = slight chance of dozing;
2 = moderate chance of dozing; and 3 = high chance of dozing).
Possible scores range from 0 to 24, with higher scores reﬂecting
greater subjective sleepiness [8]. The use of the ESS is advanta-
geous for population-based research, as it is recognized to effec-
tively assess participants’ levels of daytime sleepiness, sleep
propensity, and dozing likelihood during both soporiﬁc and nonso-
poriﬁc tasks. The ESS also is considered an effective tool for differ-
entiating sleepiness among varied populations [2]. Although there
is no universally accepted cutoff point to rate excessive sleepiness
in healthy populations, many studies [2,11,12] have chosen the
pragmatic score ofP10 to indicate pathologic levels of sleepiness.
For the purpose of our study, we made the a priori decision that
scores between 0 and 9 would indicate normal levels of sleepiness
and scores of 10–24 would indicate excessive sleepiness.
2.3. Demographic, lifestyle, and medical information
Wedocumented information regarding demographics, history of
medical conditions, health, and additional lifestyle factors. Habitual
physical activity was self-reported and transformed into a binary
variable. Participants were classiﬁed as active if vigorous or light
exercise was performed most days; otherwise, participants were
classiﬁed as sedentary (for more detailed descriptions of criteria
see [10]). Similar studies assessing physical activity levels at a pop-
ulation level also have employed dichotomized criteria [13]. Medi-
cation use was classiﬁed as current if participants noted use
through self-report at the time of assessment. Tobacco smoking
wasdocumented andgrouped as current or not. Information regard-
ing alcohol consumptionwas obtained from the Cancer Council food
frequency questionnaire [14] and daily intake was expressed as
gram intake per day (g/day). Weight and height were measured
and body mass index (BMI) was calculated as weight/height2 (kg/
m2). Socioeconomic status was determined by use of the Socio-Eco-
nomic Index for Areas index values ascertained from the 2006 Aus-
tralian Bureau of Statistics data. The Socio-Economic Index for Areas
valueswere applied to obtain an aggregated Index of Relative Socio-
Economic Advantage and Disadvantage, and participantswere cate-
gorized into ﬁve groups according to quintiles of the Index of Rela-
tive Socio-Economic Advantage and Disadvantage for the study
region. Quintile 1 represented the most disadvantaged group and
quintile 5 the most advantaged. Participants’ perceived general
health status was obtained through self-report and classiﬁed on a
5-point Likert-type scale (1 = excellent, 2 = very good, 3 = good,
4 = fair, and 5 = poor) [15]. Exposure to medical conditions from a
number of disease groups commonly associatedwith EDSwere doc-
umented by self-report and grouped as zero, 1, 2, or 3 or more pres-
ent during the past 12 months. Cardiovascular and neurologic
disease included stroke, blackouts or fainting, dizzy spells, Parkin-
son disease (PD), andmuscle weakness or muscle disease. The pres-
ence of diabetes mellitus (DM) was identiﬁed by combination of
self-report and use of oral or insulin hypoglycemic agents. Cancer
included that of the lung, bowel, breast, uterus, cervical, throat,mel-
anoma, nonmelanoma skin cancer, leukemia, myeloma, and brain
tumor. Respiratory illnesses included asthma, emphysema, chronic
bronchitis, and other unspeciﬁed lung disease. Musculoskeletal dis-
eases included self-reported osteogenesis imperfecta, osteoarthri-
tis, or rheumatoid arthritis. Osteoporosis was independently
identiﬁed using bone mineral density scans of the femoral neck
and posterior-anterior spine (L2–L4) performed using Lunar DPX-L
or Prodigy (Lunar, Madison,WI, USA) densitometers. The Australian
reference ranges for men and women were used to identify bone
mineral density cutoff points for osteoporosis at the femoral neck
or spine, corresponding to a T score of 2.5 [16,17].
2.4. Statistical analysis
Values are given as median (interquartile range [IQR]), mean
(±standard deviation), or n (%). Characteristic differences between
participants with and without EDS were analyzed using t tests for
parametric continuous variables, Mann–Whitney U tests for non-
parametric continuous variables, and v2 tests for categorical vari-
ables. The Fisher exact test was used for categorical variables
when cell sizes were less than ﬁve. Continuous ESS data were
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dichotomized at 0–9 and 10–24 to represent the absence or pres-
ence of EDS, respectively. Self-reported sleep duration was grouped
into predetermined cutoff ranges (>6, 6–7.5, 7.5–8, and <8 h per
night), and age was grouped into categories (20–29, 30–39, 40–49,
50–59, 60–69, 70–70, and P80 years) to determine age-speciﬁc
prevalence rates. Overall prevalence was standardized to the Aus-
tralian bureau of Statistics 2006 census data. All statistical analyses
were completed using Minitab (Version 15; Minitab, State College,
PA, USA).
3. Results
3.1. Characteristics
Characteristic data for men and women with and without EDS
are shown in Table 1. Overall, 153 women (13.9%) and 128 men
(13.5%) reported EDS. Women with EDS were more likely to have
a higher BMI and be less active than those who reported no day-
time sleepiness; they also were more likely to report poor self-
rated health status. Men who reported EDS were older, had an in-
creased BMI, reported a lower alcohol intake, and were more likely
to be using antidepressant medication than those who were not
sleepy. No differences were found for socioeconomic status, smok-
ing status, or sedative medication use between those with and
without EDS for men or women. Among women with EDS, a higher
proportion reported having DM or a neurologic or cardiovascular
disorder than those without EDS. Among men with EDS, a higher
proportion reported having respiratory illness, osteoporosis, or
cancer; they also had an overall increased comorbidity than those
without EDS.
3.2. Prevalence of EDS
The median level of sleepiness as measured by the ESS was
comparable for both men (median ESS score, 4 [IQR, 4–7]) and wo-
men (median ESS score, 4 [IQR, 2–7]) (P = .67). Age-speciﬁc preva-
lence of EDS (ESS P10) for men and women is shown in Fig. 1.
Overall age-standardized prevalence of EDS was 10.4% (95% conﬁ-
dence interval, 9.7–11.2) for men and 13.6% (95% conﬁdence inter-
val, 12.8–14.4) for women. For men, the age-speciﬁc prevalence of
EDS was 5.1% (ages 20–29 years), 6.4% (ages 30–39 years), 9.8%
(ages 40–49 years), 15.5% (ages 50–59 years), 12.0% (ages 60–
69 years), 12.0% (ages 70–79 years), and 29.0% (P80 years)
(Fig. 1). For women, the age-speciﬁc prevalence of EDS was 14.7%
(ages 20–29 years), 8.7% (ages 30–39 years), 15.0% (ages 40–
49 years), 16.0% (ages 50–59 years), 12.6% (ages 60–69 years),
13.2% (ages 70–79 years), and 17.0% (ages P80 years) (Fig. 1).
Table 1
Characteristics of men and women with and without excessive daytime sleepiness*.
Women Men
All No Yes* P value All No Yes* P value
n = 1104 n = 951 n = 153 n = 945 n = 817 n = 128
Age (y) 50.7 (34.0–65.6) 50.4 (33.8–66.0) 51.2 (36.2–64.3) .51 59.4 (45.7–72.8) 58.5 (44.5–71.6) 66.3 (53.0–80.5) .001
BMI (kg/m2) 26.3 (23.4–30.9) 26.1 (23.3–30.5) 27.9 (24.4–32.7) .01 27.2 (24.7–29.6) 27.0 (24.7–29.6) 27.9 (25.3–30.4) .06
Smoking (current) 156 (14.1%) 139 (89.1%) 17 (11.0%) .25 104 (11.0%) 95 (91.4%) 9 (8.7%) .12
Physically active 854 (77.5%) 745 (87.2%) 109 (12.8%) .05 678 (71.7%) 589 (86.9%) 89 (13.1%)a .56
Alcohol intake (g/d) 2.7 (0.3–11.7) 3.1 (0.3–11.9) 1.6 (0.3–10.1) .11 12.0 (2.1–28.6) 12.8 (2.4–29.7) 8.0 (0.9–26.6) .01
Hours of sleep/night 7.0 (6.0–8.0) 7.0 (6.0–8.0) 7.0 (6.0–8.0) .54 7.0 (6.0–8.0) 7.0 (6.0–8.0) 7.0 (6.0–8.0) .001
Health status (current) .03 .36
Excellent 173 (15.7%) 153 (16.1%) 20 (13.1%) 124 (13.1%) 114 (14.0%) 10 (7.8%)
Very good 468 (42.4%) 411 (43.3%) 57 (37.6%) 416 (44.0%) 358 (43.8%) 58 (45.3%)
Good 333 (30.2%) 281 (29.6%) 52 (34.0%) 310 (32.8%) 265 (32.4%) 45 (35.2%)
Fair 109 (9.9%) 92 (9.7%) 52 (11.1%) 81 (8.6%) 69 (8.5%) 12 (9.4%)
Poor 20 (1.8%) 13 (1.4%) 7 (4.6%) 14 (1.5%) 11 (1.4%) 3 (1.5%)
Socioeconomic status (current) .24 .78
Quintile 1 (most disadvantaged) 175 (16.0%) 144 (15.3%) 31 (20.4%) 155 (16.4%) 132 (16.4%) 23 (18.0%)
Quintile 2 230 (21.1%) 206 (21.9%) 24 (15.8%) 188 (19.9%) 166 (20.3%) 22 (17.2%)
Quintile 3 249 (22.8%) 211 (22.5%) 38 (25.0%) 180 (19.0%) 156 (19.1%) 24. (18.8%)
Quintile 4 216 (19.8%) 184 (19.6%) 32 (21.1%) 205 (21.7%) 173 (21.2%) 32 (25.0%)
Quintile 5 222 (20.3%) 195 (20.7%) 27 (17.8%) 218 (23.0%) 191 (23.3%) 27 (21.1%)
Medication use (current)
Sedatives 30 (2.7%) 26 (2.7%) 4 (2.6%) 1.00 10 (1.1%) 10 (1.2%) 0 (-) .40
Antidepressants 135 (12.2%) 111 (11.7%) 24 (15.7%) .16 65 (6.9%) 51 (6.2%) 14 (10.9%) .05
Medical conditions
Respiratory 315 (28.5%) 269 (28.3%) 46 (30.1%) .65 77 (8.1%) 59 (7.2%) 18 (14.1%) .008
Neurological/cardiob 112 (10.4%) 86 (9.0%) 26 (17%) .003 61 (6.5%) 51 (6.2%) 10 (7.8%) .50
Musculoskeletalc 12 (1.1%) 10 (1.7%) 2 (1.3%) .68 85 (9.0%) 70 (8.6%) 15 (11.7%) .25
Osteoporosis 95 (8.6%) 87 (9.1%) 8 (5.2%) .11 43 (4.5%) 31 (3.8%) 12 (9.4%) .005
Cancer 14 (1.3%) 13 (1.4%) 1 (0.7%) .71 23 (2.4%) 13 (1.6%) 10 (7.8%) .001
Diabetes mellitus 64 (5.8%) 48 (5.1%) 16 (10.5%) .008 51 (5.4%) 45 (5.5%) 6 (4.7%) .70
Medical comorbidities .25 .002
None 610 (55.3%) 533 (56.1%) 77 (50.3%) 674 (71.3%) 598 (73.1%) 76 (59.3%)
One condition 391 (35.4%) 334 (35.1%) 57 (37.3%) 219 (23.2%) 182 (22.3%) 37 (28.9%)
Two conditions 89 (8.1%) 74 (7.8%) 15 (9.8%) 40 (4.2%) 29 (3.6%) 11 (8.6%)
P3 conditions 14 (1.3%) 10 (1.1%) 4 (2.6%) 13 (1.4%) 9 (1.1%) 4 (3.1%)
Values are expressed as median (interquartile range), mean (±standard deviation), or n (%).
Abbreviations: y, years; BMI, body mass index; g/d, grams per day.
Figures in bold indicate statistical signiﬁcance.
* Epworth Sleepiness Scale (ESS) score P10.
a n = 1 missing value.
b Cardio = Self-reported cardiovascular disease.
c Musculoskeletal = Self-reported osteogenesis imperfecta, osteoarthritis, or rheumatoid arthritis.
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3.3. Self-reported sleep duration
The median self-reported sleep duration was 8 h (IQR, 6–8 h)
for women and 7 h (IQR, 6–8 h) for men (P = .06). However, this
ﬁgure varied among age groups, with younger women (ages
20–29 years) reporting more sleep per night than older women
(ages P30 years). Fig. 2 shows the age- and gender-speciﬁc dis-
tribution of self-reported hours of sleep per night. For men, those
in the older age groups (ages P60 years) reported more sleep
than those in the younger age groups. Fig. 3 shows the percent-
age of men and women in each group who reported sleeping less
than 6 h per night. Both genders in the age group of 50–59 years
reported the highest percentage of less than 6 h of sleep per
night.
4. Discussion
In our study we present new data that describe the prevalence
of EDS and associated lifestyle and health factors in a randomly se-
lected population-based sample of Australian men and women. We
found that EDS was common in this population, affecting 10.4% of
men and 13.6% of women.
These data are comparable to a number of studies conducted in
Western countries using similar metrics and cutoff points [18,19].
We report that EDS was more common among women than men,
which contrasts with a number of studies that have found male
gender to be an independent predictor of EDS [19,20]. Although
men have been found to be more likely to endorse sleepiness items
in questionnaires [21], women have been shown to be more likely
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Fig. 3. Percentage of men and women participants who report less than 6 h of sleep per night.
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to complain of daytime sleepiness and score higher on measures of
sleepiness in community-based studies [22]. Indeed several popu-
lation-based studies have found no signiﬁcant gender difference
for EDS [5,23] or reported a higher overall ESS score [24] and in-
creased prevalence rate in women compared to men [25,26]. This
inconsistency may in part be attributed to differences in sampling
methods used, differential participation rates among women in
these types of studies, or differences in the way measurements of
daytime sleepiness were obtained.
Both men and women in our study had a high prevalence of EDS
during middle (ages 50–59 years) and old (ages P80 years) age.
This ﬁnding may be attributed to a number of health and lifestyle
factors that have been shown to inﬂuence EDS within these cohorts
[27], such as a reduction in child-rearing duties or changes to work
schedules, which may contribute to greater opportunity for volun-
tary activities that are highly soporiﬁc; reduced activity levels from
illnesses that affect general health (i.e., metabolic disease, cardio-
vascular disease); and declining sleep quality, particularly in those
ages P80 years [28]. For women between the ages of 50 and
59 years in particular, these ﬁndings may in part be explained by
hormonal changes that occur during menopause and the conse-
quent inﬂuence on sleep patterns during pre- and postmenstrual
periods [29,30].
Additional lifestyle correlates of EDS for women in our cohort
include being overweight, being physically inactive, and having
low perceived health status. For men older age, lower self-reported
alcohol use, and higher rates of antidepressant use was associated
with increased daytime sleepiness. Physical inactivity has been
found to be strongly associated with obesity and high BMI [31]
and physical activity, obesity, and perceived health status are
interrelated [32,33]. Although the cross-sectional nature of our
study does not allow for interpretation of these factors as a causa-
tive feature of EDS, it is possible that the culmination of physical
inactivity and perception of general health contributed to higher
rates of EDS through a combination of possible comorbid diseases
and environmental factors associated with obesity that may impair
exercise levels (e.g., DM, motivation levels) [34]. As expected, both
men and women who reported EDS in our study had a higher BMI
than those who reported no EDS. Obesity has been shown to be a
signiﬁcant predictor of sleepiness in both clinical and epidemiol-
ogic samples, independent of underlying obstructive sleep apnea
(OSA) symptoms [35,36]. Although it is possible that a proportion
of the men and women in our sample may have had underlying
sleep-disordered pathology, several community-based samples
have demonstrated that OSA symptoms poorly correlate with
sleepiness [37–39]. Therefore, it is possible that reported EDS
may result from alternate maladaptive lifestyle factors.
Medication use has been cited as a signiﬁcant contributory fac-
tor in the experience of EDS [40]. Despite this ﬁnding, no differ-
ences were found between men and women for those with and
without EDS for sedative use, and overall reported usage in our
sample was low. Therefore, it is unlikely that the EDS found in
our study was associated with additional underlying sleep pathol-
ogy often requiring these medications such as insomnia. Antide-
pressant use has been similarly associated with increased EDS in
a number of studies [41]. Moreover, depression is considered both
an independent associated factor [42] and a robust risk factor for
EDS among nonclinical population-based samples [5]. Interestingly
no association was found between antidepressant use and EDS for
women, which is not in agreement with previous studies that have
demonstrated increased sleepiness among medicated groups [41].
An inverse relationship was proposed to exist between hours of
nocturnal sleep and the experience of EDS [23,43]. Men, but not
women, who reported EDS in our sample reported fewer hours of
nocturnal sleep than those who reported no EDS. However, be-
cause self-reported sleep has previously been noted as having only
moderate reliability when compared to objective measures [44], it
is possible some individuals may have overestimated or underesti-
mated actual nocturnal sleep [44,45].
Alcohol use has been recognized as an additional contributory
lifestyle factor in the experience of EDS [46] through the expres-
sion of disturbed sleep architecture [47–49]. We found that men
with EDS reported lower alcohol use than those with no EDS. It
may be possible that the men in our study underreported alcohol
use. Nevertheless, this ﬁnding does not adequately explain the dif-
ferences between groups, as self-report measures of alcohol use
have been found by others to be accurate in these types of studies
[50]. Further analysis is warranted to assess this relationship at a
population level.
We observed that women who reported EDS were more likely
have DM, which is consistent with previous research that demon-
strated a link between sleepiness and the presence of underlying
metabolic syndrome [51]. Untreated EDS has previously been iden-
tiﬁed as a risk factor for DM among women, both in conjunction
with and independent of underlying snoring [52]. Clinically, this
ﬁnding highlights the need to routinely screen for instances of
DMwhenever symptoms of EDS are present in women, particularly
when there is no history of underlying sleep-related breathing dis-
order. In our sample, women who reported EDS also were more
likely to self-report instances of cardiovascular or neurologic dis-
ease. EDS has previously been found to be a common symptom
of PD [53] and a risk factor the disorder, independent of possible
explanatory lifestyle factors [54]. Because persistent EDS has previ-
ously been found to be associated with impaired functional out-
comes in PD patients [55], adequate identiﬁcation and treatment
of these symptoms may assist in improving quality of life in these
individuals. Respiratory illness has previously been reported as
common among those with EDS [56]; however, this ﬁnding is not
universal [57]. Both chronic respiratory illness and a variety of can-
cers are possible contributors to EDS through disturbed sleep, fre-
quent awakenings, and increased instances of nocturnal
hypoxemia [58,59]. We observed that men with EDS were more
likely to report respiratory illness, osteoporosis, or cancer than
men who were not sleepy. It may be that the men who reported
such illnesses were more likely to be within the older age group,
and thus more likely to report such illnesses. Indeed men who re-
ported any type of respiratory illness in our sample had a median
age of 64.4 years (IQR, 54.4–78.49 years), which is consistent with
previous ﬁndings [60]. However, further research is warranted to
explore possible links between age groups and disease representa-
tion at a population level.
To our knowledge, our study is the ﬁrst epidemiologic study to
demonstrate that men of all ages who report medical comorbidity
are more likely to exhibit EDS. Previous studies have shown that
disease comorbidity considerably inﬂuences daytime symptoms,
particularly among older populations [42]. Therefore, the ﬁndings
from our study may be beneﬁcial in the understanding of the link
between disease severity and functional sleep outcomes, particu-
larly in men. However, further investigation is required to deter-
mine the possible inﬂuence of particular disease groups on
functional daytime outcomes, thus enhancing the speciﬁcity of
any future public health messages.
Interpretation of the ﬁndings presented in our study must con-
sider several identiﬁable limitations. First, the cross-sectional nat-
ure of our study means that no inferences can be made regarding
causality. Furthermore, these data pertain to individuals assessed
at follow-up appointments as part of their participation in an ongo-
ing study. It would seem unlikely that loss to follow-up would be
differentially biased by EDS and this bias combined with the high
retention of eligible participants in the study (83% of women and
81% of men) sustain the validity of the data. Second, the self-report
nature of questionnaire items used in our study may mean that
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sleepiness and associated factors may be under- or overreported.
Speciﬁcally, differing situational and emotional states may inﬂu-
ence how questionnaire items are endorsed [61]. An individual in
a negative state typically will report higher EDS and more illness
than an individual in a more positive state [25,62–64]. Thus an
inﬂation of the associations reported in our study cannot be ex-
cluded. Despite this limitation, self-report measures regarding life-
style and health factors have been found to be reliable in similar
studies [65,66]. Moreover, several studies have demonstrated that
self-report data on perceived sleepiness yields moderate correla-
tion with comparable laboratory data regarding objective mea-
sures of sleepiness, such as the multiple sleep latency test or
maintenance of wakefulness test [11]. Both of these tests are
widely used within a clinical setting and are considered to have
adequate test–retest validity [67], and thus present an effective
measure of objective sleepiness. Despite this beneﬁt, both mea-
sures are relatively time consuming and labor intensive, and thus
are inappropriate for large-scale research [68]. Similarly both
methods lack speciﬁcity in general levels of sleepiness and instead
are thought to represent sleepiness on the day of the test only
[8,69]. Third, it is acknowledged that not all conditions that may af-
fect EDS were assessed, including insomnia, OSA, or to a lesser ex-
tent narcolepsy. There are limited data regarding the prevalence of
narcolepsy within Australian samples; however, international
studies generally have cited low instances of between 0.03% and
0.05% in the general population [70,71]. Therefore, it is unlikely
that this condition considerably inﬂuenced our results. However,
it is possible that individuals with OSA were included in our sam-
ple. Although the presence of OSA pathology was not explicitly as-
sessed within our study, several biologic and lifestyle predictors of
the disorder were indeed identiﬁed, such as age, BMI, and physical
activity levels, all of which are associated with OSA symptoms [72].
Over one-tenth of the Australian population has EDS, which is
most common in elderly men and women, affecting approximately
one-third of individuals aged 80 years and older. EDS is associated
with a number of adverse health and lifestyle outcomes. Our
ﬁndings suggest the need for both ongoing research assessing
trends in EDS prevalence rates in the Australian population over
time, assessment of possible links to disease comorbidity, and
the potential utility of additional routine screening in ongoing
health evaluations for these individuals.
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Abstract
Background: Excessive daytime sleepiness (EDS) is often associated with increased adiposity, particularly when assessed in
the context of samples of sleep-disordered patients; however, it is unclear if this relationship is sustained among non-
clinical, population-based cohorts. This study aimed to investigate the relationship between EDS and a number of body
composition markers among a population-based sample of men and women.
Methods: This study assessed 1066 women aged 21–94 yr (median = 51 yr, IQR 35–66), and 911 men aged 24–92 yr
(median = 60 yr, IQR 46–73) who participated in the Geelong Osteoporosis Study (GOS) between the years 2001 and 2008.
Total body fat mass was determined from whole body dual-energy X-ray absorptiometry scans, and anthropometric
parameters (weight, height, and waist circumference) were measured. Lifestyle and health information was collected via
self-report. Sleepiness was assessed using the Epworth Sleepiness Scale (ESS). Scores of $10 were considered indicative of
EDS.
Results: Women: After adjusting for age, alcohol intake, antidepressant medication use and physical activity, EDS was
associated with greater waist circumference and body mass index (BMI). EDS was also associated with 1.5–1.6-fold increased
odds of being overweight or obese. Men: After adjusting for age, alcohol use, physical activity and smoking status, EDS was
associated with greater BMI. These findings were not explained by the use of sedative or antidepressant medication. EDS
was also associated with 1.5-fold increased likelihood of being obese, independent of these factors. No differences in lean
mass, %body fat, or %lean mass were detected between those with and without EDS for men or women.
Conclusions: These data suggest that EDS is associated with several anthropometric adiposity profiles, independent of
associated lifestyle and health factors. Among women, symptoms of EDS are pervasive at both overweight and obese BMI
classifications; suggesting a need for further clinical examination to assess possible temporal associations with underlying
sleep pathology.
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Introduction
Prevalence of overweight and obesity are increasing significantly
throughout both the developed [1] and developing worlds [2].
Recent local studies report that between 3.5–7.6% of children and
approximately 20% of adults are classified as obese (kg/m2) [3–5].
This trend is consistently mirrored in most countries, across
socioeconomic standings [2] and gender [6]. The clinical and
societal implications of obesity have been well documented. Excess
weight and body fat, particularly that which is viscerally or
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centrally located, has been found to be a predisposing factor for an
increased risk for type 2 diabetes, poorer cardiovascular outcomes,
stroke, heart attacks, increased medical comorbidity, depression
and increased risk of sleep disorders [7,8].
Obesity has been proposed to affect sleep architecture via a
combination of impairment to physiological mechanisms, which
act to maintain upper airway patency, and functional alterations
between respiratory drive and load compensatory mechanisms [9].
Consequently, obese individuals are more likely to exhibit
decreased respiratory function, resulting in periods of hypoxemia,
hypercapnia and respiratory resistance [10,11]. Nocturnal respi-
ratory disturbances observed in obese individuals often manifest as
instances of compromised sleep architecture and excessive daytime
sleepiness (EDS) [12]. Indeed, obese individuals are more likely to
report symptoms of EDS than are non-obese individual [13], and
this association has also been found among non-apnoeic obese
populations [12]. Although the relationship between OSA and
obesity has been well documented, particularly among clinical
samples [14], several authors have described a lack of association
between these factors, particularly at a population level [14,15];
and have instead cited peripheral indicators such as metabolic
syndrome and lifestyle factors as having a closer association with
EDS [16].
The role of lifestyle and health factors as contributing factors in
the association between EDS and body composition is unclear.
Longitudinal research has shown that engagement in regular
exercise aids in the reduction of total body fat, %body fat, BMI
and weight and improves sleep quality especially slow wave sleep
[17,18], and dietary improvements contribute to a greater
reduction of body weight and abdominal fat [19]. Conversely,
poor diet, maladaptive lifestyle habits, and physical inactivity have
all been associated with greater index of adiposity and obesity [20],
as well as poorer sleep quality [21]. Despite these findings, there is
a paucity of studies incorporating these factors as possible
contributory factors when assessing EDS and body composition.
Indeed, many of these studies investigate aspects of lifestyle and
health in isolation, or among specific patient groups [19], and thus
it is unclear whether these factors represent possible modifiable
factors.
The mechanism by which EDS influences body composition
requires further elucidation; particularly in population-based
samples. Similarly, the role of a number of lifestyle and health
variables as contributory factors to this association is equivocal.
Daytime sleepiness is a common symptom among obese people,
and lifestyle and health factors have been shown to represent
possible modifiable factors in the expression of both conditions.
Therefore, there is a need to assess the relationship between EDS
and body composition in a representative, population-based
cohort, whilst controlling for a number of commonly associated
lifestyle and health factors.
Methods
Participants
This study examined men and women who participated in the
Geelong Osteoporosis Study (GOS). The GOS is a large,
population based, age-stratified cohort study conducted in south-
eastern Australia. Participants were selected at random from
Commonwealth electoral rolls for the Barwon Statistical Division.
Between the years 1993–1997, 1494 women were randomly
recruited, representing 77.1% participation [22]. At the 10-year
follow up (2004–2008), 881 women from the original sample
returned (82.1%) and were complemented by the inclusion of an
additional 246 randomly-selected women aged between 20–29
years. Of the 1126 women who participated in the 10-year follow
up, participants for whom weight and/or height (n = 38) and sleep
data (n = 22) were not available, were excluded, resulting in a total
of 1066 eligible women aged 20–94 years.
Between the years 2001–2006, 1540 men were recruited for
baseline analysis, representing a response of 67% [22]. Of the 979
men who participated in the 5-year follow up (81% response),
participants for whom follow-up (n= 1) weight and/or height
(n = 35) and sleep data (n = 32) were not available were excluded
from analysis, resulting in a total of 911 eligible men aged between
24–92 years.
Written informed consent was obtained from each participant.
Approval to conduct this study was granted under the project
numbers 92/01 and 00/56 from the Barwon Health Human
Research Ethics Committee.
Measurements
Epworth Sleepiness Scale. Instances of EDS were identified
using the Epworth Sleepiness Scale (ESS). Detailed descriptions of
the psychometric properties of the ESS have been detailed
elsewhere [23]. The ESS is considered to have good internal
validity and retest reliability, and is considered a low-cost and
effective measure of assessing sleepiness in adults [24]. The ESS
assesses an individual’s sleep propensity and likelihood of dozing
off in both soporific and engaging tasks via a self-administered 8-
item scale [24]. Sleepiness is assessed using a 4-point Likert scale,
referring to an individuals’ likelihood of dozing in that particular
situation (0 =would never doze, 1 = slight chance of dozing,
2 =moderate chance of dozing, 3 = high chance of dozing). Scores
range from 0–24, with higher scores reflecting higher levels of
sleepiness. At present, there are no universally adapted cut-off
ranges for the ESS; however similar studies have utilized a cut-off
score of $10 to indicate EDS [25].
Body composition. Anthropometric measurements were
recorded objectively. Height and weight were measured to the
nearest 60.1 cm and 60.1 kg, respectively. Body mass index
(BMI) was calculated as weight/height squared (kg/m2). A BMI of
,25 kg/m2 was considered normal weight, $25 kg/m2 to ,
30 kg/m2 was considered overweight, and $30 kg/m2 as obese.
Waist circumference was measured halfway between the margin of
the lower rib and iliac crest using a narrow metal anthropometric
tape measure. Participants were classified as obese if they reported
a waist measurement of$102 cm (men) or$88 cm (women) [26].
Fat mass was determined from whole body dual-energy X-ray
absorptiometry scans. Total percentage fat mass, lean mass and
bone mineral content (BMC) were calculated by dividing fat mass,
lean mass or BMC by the sum of fat mass, lean mass and BMC
(expressed as %). Automated upper arm digital blood pressure
monitors (UA-767) were used to measure systolic and diastolic
blood pressures (mmHg).
Lifestyle and heath factors. Information regarding alcohol
consumption and daily energy intake were obtained from the
Cancer Council food frequency questionnaire [27]. Daily alcohol
usage was expressed as gram intake per day (g/day), and energy
intake was assessed as kilojoule intake per day (kJ/day). Physical
activity levels were assessed via self-report and transformed into a
binary variable. Participants were classified as ‘active’ if they
reported ‘moving, walking and working energetically and partic-
ipating in vigorous exercise’. Alternatively, participants were
classified as sedentary. Self-reported tobacco smoking was
documented, and grouped as ‘current’ or ‘not’. Medication use
(sedatives and antidepressants) was determined using self-report
and usage was classified as ‘current’ if participants reported use at
the time of assessment. Socioeconomic Status was determined by
Excessive Daytime Sleepiness and Body Composition
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use of the Socio-economic Index for Areas (SEIFA) index values
ascertained from the 2006 Australian Bureau of Statistics data.
SEIFA values were applied to obtain an aggregated Index of
Relative Socio-Economic Advantage and Disadvantage (IRSAD).
Participants were categorised into five groups, according to
quintiles of IRSAD for the study region. Quintile 1 represented
the most disadvantaged group, and quintile 5 represented the most
advantaged. Participants’ perceived general health status was
obtained via self-report and classified on a 5-point Likert scale,
expressed as (1) Excellent, (2) Very good), (3), Good, (4), Fair, and
(5) Poor. The presence of diabetes was identified by combination
of self-report and/or use of insulin or oral hypoglycemic agents.
Statistical analysis
Differences in characteristics between those with and without
EDS were analysed using t-tests for parametric continuous data,
Mann-Whitney test for non-parametric continuous variables and
Chi-Square test analysis for discrete variables. Fisher’s Exact Test
was used for non-parametric variables where expected cell sizes
were less than five. Differences in body composition (those
expressed as continuous variables) between those with and without
EDS were compared using linear regression techniques. Differ-
ences in body composition expressed as categorical variables (waist
circumference, BMI categories) were tested using logistic regres-
sion models. In all models, EDS (yes/no) was applied as the
exposure variable. Age, alcohol use, physical activity levels,
smoking status, energy intake, sedative and antidepressant use
were tested sequentially, and potential confounders and effect
modifiers were checked in statistical models. All statistical analyses
were completed using Minitab (Version 16; Minitab, State College
Pa).
Results
Women
Subject characteristics are presented in Table 1. Overall, 146
(13.7%) women were classified as having EDS. The median age
for this sample was 51 yr (range 20.9–93.6 yr), and women with
EDS tended to be slightly older than those who did not report
EDS. Median BMI for this cohort was 26.3 kg/m2. A large
percentage (60.0%) of this sample was considered overweight
(31.1%) or obese (28.9%) based on BMI criteria.
Those who reported EDS were more likely to be overweight or
obese. Women who report EDS were more likely have a greater
waist circumference, were more likely to be classified as centrally
obese (waist circumference $88 cm), and had greater fat mass
than those who were did not report EDS. No differences were
detected between women with and without EDS in terms of
%body fat, % BMC, %lean mass, energy intake, or blood pressure
(diastolic and/or systolic).
Relationships between EDS and lifestyle factors are also shown
in Table 1. Those with EDS were more likely report negative
health status, and higher instances of ‘poor’ self-perceived health.
Those with EDS were more likely to have diabetes than those who
were not sleepy. No differences were found in terms of
socioeconomic status, smoking status, medication use, physical
activity or alcohol intake between those with and without EDS.
After adjusting for age, alcohol intake, antidepressant medica-
tion use and physical activity, EDS was associated with greater
total waist circumference [Mean IQR: 93.6 (91.2–96.1) vs. 91.0
(89.5–92.6) cm, p= 0.03] and BMI [Mean IQR: 30.0 (29.0–31.1)
vs. 29.1 (28.4–29.7) kg/m2, p= 0.07]. Compared to women of
normal weight, having EDS was also associated with 1.5-fold
increased odds of being overweight (adjusted OR=1.5, 95%CI
1.0–2.3, p = 0.04), and 1.6-fold increased odds of being obese
(adjusted OR=1.6, 95%CI 1.1–2.3, p = 0.02) (Figure 1). These
findings were not explained by the use of sedative medication,
energy intake, or smoking status. A trend towards significance was
noted for overall weight [Mean IQR: 78.6 (48.2–109.0) vs. 76.0
(74.3–77.8) kg, p = 0.07], and for those with a waist circumference
$88 cm (adjusted OR=1.4, 95%CI 1.0–2.0, p = 0.08). No
differences in %body fat, %lean mass or fat mass were detected
between those with and without EDS when assessed using
multivariate modelling.
Men
Subject characteristics are presented in Table 1. Of the 911
men included in this study, 122 (13.4%), were classified as having
EDS. Men with EDS were more likely to be older and tended to
be shorter in height than those men who did not report EDS.
Overall, a considerable proportion of this sample of men met
criteria for overweight (50.3%) and obesity (22.4%). Those men
who reported EDS were more likely to have a larger overall waist
circumference, and were more likely to be classified as centrally
obese (waist circumference $102 cm). Those with EDS reported
lower daily energy intake and %BMC than those who did not
report EDS, and reported lower mean diastolic blood pressure. No
differences were found in terms of overall weight, overweight and/
or obesity based on BMI, %body fat, % lean mass, lean mass or fat
mass between groups.
Differences between lifestyle factors among those men with and
without EDS are presented in Table 1. Men with EDS were more
likely to report lower daily alcohol intake and report higher rates of
antidepressant medication use than those who were not sleepy. No
differences were found with regard to smoking status, sedative use,
diabetic status, health status, or socioeconomic status between
those with and without EDS.
After adjusting for age, alcohol use, physical activity and
smoking status, EDS was associated with greater BMI [Mean
IQR: 28.6 (27.5–29.7) vs. 27.2 (26.9–28.6) kg/m2, p= 0.03].
These findings were not explained by the use of sedative or
antidepressant medication use or energy intake. Compared to men
of normal weight, having EDS was also associated with a 1.5-fold
increased odds of being obese (adjusted OR=1.5, 95%CI 1.0–2.4,
p = 0.08) (Figure 2), independent of these factors. No differences in
total weight, total waist circumference, being overweight, %body
fat, % BMC or fat mass were found between those men with and
without EDS.
Discussion
This cross-sectional study identified a positive association
between EDS and several measures of adiposity among Australian
men and women. For women, after adjusting for medication and
lifestyle factors, EDS was associated with greater total weight,
waist circumference and BMI. Compared to women of normal
weight, having EDS was also associated with 1.5-fold increased
odds of being overweight and 1.6-fold increased odds of being
obese (on BMI criteria). A trend towards significance was also
noted for those women with EDS similarly having a waist
circumference greater than 88 cm. For men, following adjust-
ments, compared to men of normal weight, having EDS was
associated with 1.5-fold increased odds of being obese, as well as
greater BMI. These findings were not explained by the use of
sedative or antidepressant medication use or energy intake.
A novel finding of this study was the relationship between EDS
and several markers of adiposity, particularly among women,
following the application of waist circumference [28]. To our
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knowledge, this is the first study to demonstrate an association
between EDS and objectively measured viscerally located fat as
waist circumference has previously been shown to be an effective
measure of abdominal obesity, particularly when used in
conjunction with BMI [29]. Women who reported EDS were
more likely to have greater weight and BMI, and were more likely
to be overweight or obese than women who were not sleepy. This
finding is consistent with most, but not all of the existing literature
[30]. In a population-based study of 5508 women residing in
Sweden, participants who reported EDS were more likely to be
classified as obese, as indicated by, and less likely to be within the
ideal BMI range (defined as 20-,25 kg/m2) than women who
were not sleepy [28]. This finding is similar to comparable
research investigating EDS and BMI among population samples
[16]. Bixler and colleagues (2005) found a robust relationship
between EDS and BMI, demonstrating that the prevalence of
EDS increased exponentially in those classified as overweight
(average BMI= 28 kg/2). A similar finding was reported by both
Vgontzas et al (1998) and Resta et al (2003). Notably, our research
suggests that this association is comparably strong among both
overweight and obese women. Clinically, this finding is important
as it suggests the pervasiveness of these symptoms. Moreover, such
findings address the need for greater emphasis on gender-specific
treatment of EDS. Of the observed studies, a lack of specificity
regarding BMI classifications among female populations [28] or
the use of a combination of both male and female participants [16]
means that current recommendations regarding female patients
T
a
b
le
1
.
C
o
n
t.
W
o
m
e
n
M
e
n
A
ll
N
o
Y
e
s*
p
A
ll
N
o
Y
e
s*
P
N
=
1
0
6
6
n
=
9
2
0
n
=
1
4
6
n
=
9
1
1
n
=
7
8
9
n
=
1
2
2
Q
u
in
ti
le
5
2
1
7
(2
0
.4
%
)
1
9
2
(1
8
.1
%
)
2
5
(2
.4
%
)
2
0
6
(2
2
.6
1
%
)
1
8
0
(1
9
.8
%
)
2
6
(2
.9
%
)
V
al
u
e
s
ar
e
g
iv
e
n
as
m
e
d
ia
n
(i
n
te
rq
u
ar
ti
le
ra
n
g
e
),
m
e
an
(6
st
an
d
ar
d
d
e
vi
at
io
n
)
o
r
n
(%
).
*E
D
S
=
ES
S
sc
o
re
$
1
0
.
B
M
I
g
ro
u
p
s:
N
o
rm
al
=
B
M
I
,
2
5
kg
/m
2
,
O
ve
rw
e
ig
h
t
=
B
M
I
$
2
5
–
,
3
0
kg
/m
2
,
O
b
e
se
=
B
M
I
$
3
0
kg
/m
2
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
1
2
2
3
8
.t
0
0
1
Figure 1. Adjusted odds ratios for women with EDS for BMI
groups. Error bars represent the 95% CI. Group 1 (ideal BMI) is the
reference group, with a broken line indicating the threshold of
significance.
doi:10.1371/journal.pone.0112238.g001
Figure 2. Adjusted odds ratios for men with EDS for BMI
groups. Error bars represent the 95% CI. Group 1 (ideal BMI) is the
reference group, with a broken line indicating the threshold of
significance.
doi:10.1371/journal.pone.0112238.g002
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presenting with EDS is limited. Assessment of factors associated
with increased adiposity where female patients present with
symptoms of EDS may assist in streamlined treatment.
We demonstrated that men who reported EDS were more 1.5
times more likely to be classified as obese, and were more likely to
report a greater overall BMI than those who were not sleepy.
These findings are, in part, concordant with previous research,
which has demonstrated significant associations between EDS and
measure of obesity [16]. Compared to women, men with EDS
reported less overall energy intake, and reported less alcohol use
than those men who were not sleepy. Identification of adaptive
lifestyle and health behaviours, may therefore, present as
protective factors, however further examination is warranted in
order to assess the magnitude of these associations.
Waist circumference has previously been cited as a risk factor
for both obesity-related health risks such as sleep apnoea,
metabolic disturbance and all-cause mortality [31], however, this
finding is not universal [32]. We demonstrated that both men and
women who reported EDS were more likely to report greater waist
circumference. As waist measurements of $88 cm in women has
been associated with increased risk for cardiovascular disease,
diabetes and metabolic syndrome [33], further analysis is
warranted to assess the impact of both the antecedent and impact
of these factors within population samples, and the relationship to
sleep heath. These findings were similarly represented among men
when univariate models were applied; however this was not
replicated following the application of multivariate regression
modelling. Indeed, traditional measures of abdominal obesity have
been shown to correlate poorly with sleep disturbances [34].
Therefore, assessment of upper abdominal obesity and measure-
ments of neck circumference may be more effective in assessing the
degree of sleep disturbances in these populations [11], however,
this guideline is contentious [35]. More detailed study is required
to assess the relationship between EDS and the relative
distribution of visceral fat in men if more definitive conclusions
are to be drawn.
The association between EDS and markers of adiposity within
this sample may, in part, be mediated by increased inflammatory
processes. Obesity is considered to represent a state of low-grade
inflammation of white adipose tissue, as a result of chronic
activation of the immune response [36]. Such processes increase
the risk for subsequent development of diabetes mellitus via insulin
resistance and reduction in glucose tolerance [36]. The inflam-
matory cytokine, Interleukin 6 (IL-6), has previously been shown
to be a primary determinant for EDS [37], and serum IL-6 levels
are associated with visceral adiposity [38]. Increased inflammatory
responses have also been attributed to diseases often associated
with obesity, such as diabetes. We demonstrated that women with
EDS exhibited higher rates of diabetes than those who did not
report these symptoms, which is consistent with previous research
that demonstrated a link between sleepiness and the presence of
underlying metabolic syndrome [39], and in line with studies
suggesting that untreated EDS is an independent risk factor for the
later development of diabetes among women [40]. However, we
report that no differences were found between men in regard to
diabetic status. It is acknowledged that information regarding
diabetes within this sample was assessed via self-report. Moreover,
blood pressure assessments were not routinely obtained at the
same time each day, and therefore some diurnal variation may
remain unaccounted for in these results. Thus, further data
regarding the role of EDS in metabolic functioning may assist in
clarity of results.
Increased prevalence of EDS among obese individuals have also
been cited to result from underlying psychiatric illness [12].
Indeed, we have previously demonstrated that women with EDS
are more likely to meet criteria for current or lifetime history of a
depressive disorder [41]. As mental disorders were not examined
for this study, it is possible that symptoms of EDS may, in part, by
mediated by these underlying disorders. Research conducted by
Williams et al (2009) reported that women with a lifetime history
of psychiatric illness are more likely to meet criteria for adiposity
than controls, therefore alluding to an association between body
composition and mental health [42]. To our knowledge, however,
no such comparison has been made between EDS and psychiatric
disorders specifically, and thus, any interpretations at this time are
premature.
No association was noted between EDS and measures of body
composition as assessed by the whole body DXA scans for women
or men, with the exception that men with EDS had lower %BMC
than those who did not report EDS. As we did not have regional
DXA assessment of the central area, we are unable to make
inferences regarding central fat deposition. Further research is
therefore needed to assess the association between EDS and the
distribution of body fat.
Several methodological limitations must be identified when
interpreting the findings of the current study. Given that the study
was cross-sectional, no inferences can be made as to the
directionality of the observed relationships between EDS and
adiposity. Therefore, it is possible that the relationship may be
bidirectional. Moreover, interpretation of the results may not
generalizable to other populations or regions. Third, it is
acknowledged that not all conditions that may affect EDS were
assessed, including insomnia or obstructive sleep apnoea (OSA),
which have been shown to be associated with EDS, particularly in
clinical samples [24]. We did not explicitly assess the presence of
underlying sleep disorders such as OSA, and therefore cannot
exclude that this may have contributed to our findings. Despite
this, research has shown a poor correlation between OSA and
EDS in population-based cohorts [16] and we have included a
comprehensive number of body composition assessments, which
have been shown to correlate with disease severity. Nevertheless,
to our knowledge, this is the first research to investigate the
relationship between EDS and adiposity utilizing several anthro-
pometric assessment measures in a population-based sample of
men and women. Moreover, we assessed and accounted for a
number of lifestyle and health factors, which are recognised as
being implicated in EDS, therefore addressing limitations of past
research.
We demonstrated that EDS is associated with increased
measures of adiposity, particularly in women, independent of
age, lifestyle factors and medication use. Given that both EDS and
markers of adiposity constitute significant markers for disease, the
findings of the study highlight the need to incorporate anthropo-
metric measures in routine clinical assessment of patients.
Author Contributions
Conceived and designed the experiments: ACH LJW JAP. Performed the
experiments: ACH LJW JAP. Analyzed the data: ACH LJW JAP GAK
SLB MB. Contributed reagents/materials/analysis tools: ACH LJW JAP
GAK SLB MB. Contributed to the writing of the manuscript: ACH LJW
JAP GAK SLB MB.
Excessive Daytime Sleepiness and Body Composition
PLOS ONE | www.plosone.org 7 November 2014 | Volume 9 | Issue 11 | e112238
References
1. Baskin ML, Ard J, Franklin F, Allison DB (2005) Prevalence of obesity in the
United States. Obes Rev 6: 5–7.
2. Misra A, Pandey RM, Devi JR, Sharma R, Vikram NK, et al. (2001) High
prevalence of diabetes, obesity and dyslipidaemia in urban slum population in
northern India. Int J Obes Relat Metab Disord 25: 1722–1729.
3. Vaska V, Volkmer R (2004) Increasing prevalence of obesity in South Australian
4-year-olds: 1995–2002. J Paediatr Child Health 40: 353–355.
4. Thorburn A (2005) Prevalence of obesity in Australia. Obes Rev 6: 187–189.
5. Pasco JA, Nicholson GC, Brennan SL, Kotowicz MA (2012) Prevalence of
obesity and the relationship between the body mass index and body fat: cross-
sectional, population-based data. PloS one 7: e29580.
6. Olds TS, Tomkinson GR, Ferrar KE, Maher CA (2010) Trends in the
prevalence of childhood overweight and obesity in Australia between 1985 and
2008. Int J Obes (Lond) 34: 57–66.
7. Sowers JR (2003) Obesity as a cardiovascular risk factor. Am J Med 115 Suppl
8A: 37S–41S.
8. Must A, Spadano J, Coakley EH, Field AE, Colditz G, et al. (1999) The disease
burden associated with overweight and obesity. JAMA 282: 1523–1529.
9. Strobel RJ, Rosen RC (1996) Obesity and weight loss in obstructive sleep apnea:
a critical review. Sleep 19: 104–115.
10. Pi-Sunyer FX (1993) Medical hazards of obesity. Ann Intern Med 119: 655–660.
11. Resta O, Foschino-Barbaro MP, Legari G, Talamo S, Bonfitto P, et al. (2001)
Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness
in obese subjects. Int J Obes Relat Metab Disord 25: 669–675.
12. Dixon JB, Dixon ME, Anderson ML, Schachter L, O’Brien PE (2007) Daytime
sleepiness in the obese: not as simple as obstructive sleep apnea. Obesity (Silver
Spring) 15: 2504–2511.
13. Vgontzas AN, Bixler EO, Tan TL, Kantner D, Martin LF, et al. (1998) Obesity
without sleep apnea is associated with daytime sleepiness. Arch Intern Med 158:
1333–1337.
14. Gami AS, Caples SM, Somers VK (2003) Obesity and obstructive sleep apnea.
Endocrinology & Metabolism Clinics of North America 32: 869–894.
15. Serafini FM, MacDowell Anderson W, Rosemurgy AS, Strait T, Murr MM
(2001) Clinical predictors of sleep apnea in patients undergoing bariatric surgery.
Obes Surg 11: 28–31.
16. Bixler EO, Vgontzas AN, Lin HM, Calhoun SL, Vela-Bueno A, et al. (2005)
Excessive daytime sleepiness in a general population sample: the role of sleep
apnea, age, obesity, diabetes, and depression. J Clin Endocrinol Metab 90:
4510–4515.
17. Guo SS, Zeller C, Chumlea WC, Siervogel RM (1999) Aging, body
composition, and lifestyle: the Fels Longitudinal Study. Am J Clin Nutr 70:
405–411.
18. Kline CE, Irish LA, Krafty RT, Sternfeld B, Kravitz HM, et al. (2012)
Consistently High Sports/Exercise Activity Is Associated with Better Sleep
Quality, Continuity and Depth in Midlife Women: The SWAN Sleep Study.
Sleep 36: 1279–1288.
19. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, et al. (2000)
Effect of long-term treatment with metformin added to hypocaloric diet on body
composition, fat distribution, and androgen and insulin levels in abdominally
obese women with and without the polycystic ovary syndrome. J Clin
Endocrinol Metab 85: 2767–2774.
20. Fogelholm M, Kronholm E, Kukkonen-Harjula K, Partonen T, Partinen M,
et al. (2007) Sleep-related disturbances and physical inactivity are independently
associated with obesity in adults. Intern J Obes 31: 1713–1721.
21. Chaput J-P (2013) Sleep patterns, diet quality and energy balance. Physiol
Behav.
22. Pasco JA, Nicholson GC, Kotowicz MA (2012) Cohort profile: Geelong
Osteoporosis Study. Int J Epidemiol 41: 1565–1575.
23. Johns MW (1992) Reliability and factor analysis of the Epworth Sleepiness Scale.
Sleep 15: 376–381.
24. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth
sleepiness scale. Sleep 14: 540–545.
25. Johns M, Hocking B (1997) Daytime sleepiness and sleep habits of Australian
workers. Sleep 20: 844–849.
26. AusDiab (2008) Risk factors for diabetes.
27. Giles GG, Ireland PD (1996) Dietary Questionnaire for Epidemiological Studies
(Version2). Melbourne: The Cancer Council Victoria.
28. Theorell-Haglo¨w J, Lindberg E, Janson C (2006) What are the im-portant risk
factors for daytime sleepiness and fatigue in women. Sleep 29: 751–757.
29. Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R (2002) Body mass
index and waist circumference independently contribute to the prediction of
nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr 75:
683–688.
30. Souza JC, Magna LA, Reimao R (2002) Excessive daytime sleepiness in Campo
Grande general population, Brazil. Arq Neuropsiquiatr 60: 558–562.
31. Seidell JC (1999) Obesity: a growing problem. Acta Paediatr Suppl 88: 46–50.
32. Punjabi NM (2008) The epidemiology of adult obstructive sleep apnea.
Proceedings of the American Thoracic Society 5: 136.
33. Janssen I, Katzmarzyk PT, Ross R (2002) Body mass index, waist circumference,
and health risk: evidence in support of current National Institutes of Health
guidelines. Arch Intern Med 162: 2074.
34. Levinson P, McGarvey S, Carlisle C, Eveloff S, Herbert P, et al. (1993) Adiposity
and cardiovascular risk factors in men with obstructive sleep apnea. CHEST
Journal 103: 1336–1342.
35. Grunstein R, Wilcox I, Yang T-S, Gould Y, Hedner J (1993) Snoring and sleep
apnoea in men: association with central obesity and hypertension. Intern J Obes
Relat Metab Disord: 17: 533–540.
36. Bastard J-P, Maachi M, Lagathu C, Kim MJ, Caron M, et al. (2006) Recent
advances in the relationship between obesity, inflammation, and insulin
resistance. Eur Cytokine Netw 17: 4–12.
37. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, et al. (1997)
Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of
sleep disturbance and obesity. J Clin Endocrinol Metab 82: 1313–1316.
38. Parks S, Housemann R, Brownson R (2003) Differential correlates of physical
activity in urban and rural adults of various socioeconomic backgrounds in the
United States. J Epidemiol Commun H 57: 29–35.
39. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, et al. (2001) Polycystic
ovary syndrome is associated with obstructive sleep apnea and daytime
sleepiness: role of insulin resistance. J Clin Endocrinol Metab 86: 517–520.
40. Lindberg E, Berne C, Franklin KA, Svensson M, Janson C (2007) Snoring and
daytime sleepiness as risk factors for hypertension and diabetes in women–a
population-based study. Respir Med 101: 1283–1290.
41. Hayley AC, Williams LJ, Berk M, Kennedy GA, Jacka FN, et al. (2013) The
relationship between excessive daytime sleepiness and depressive and anxiety
disorders in women. ANZJP 47: 772–778.
42. Williams LJ, Pasco JA, Henry MJ, Jacka FN, Dodd S, et al. (2009) Lifetime
psychiatric disorders and body composition: a population-based study. JAD 118:
173–179.
Excessive Daytime Sleepiness and Body Composition
PLOS ONE | www.plosone.org 8 November 2014 | Volume 9 | Issue 11 | e112238
146 
CHAPTER 8: Excessive Daytime Sleepiness and 
Metabolic Syndrome: A Cross-Sectional Study. 
 
 
Reference: Hayley, A.C., Williams, L.J., Kennedy, G. A., Berk, M., Brennan, S. 
L., & Pasco, J.A. Excessive daytime sleepiness and metabolic syndrome: a 
population-based study. Metabolism: Clinical and Experimental. Feb; 64(2): 244–
252. Doi: 10.1016/j.metabol.2014.09.011. (2014) (361) 



Excessive daytime sleepiness and metabolic
syndrome: a cross-sectional study
Amie C. Hayleya, b,⁎, Lana J. Williamsa, Gerard A. Kennedyb, d, Michael Berka, c, f, g,
Sharon L. Brennana, e, Julie A. Pascoa, e
a IMPACT SRC, School of Medicine, Deakin University, Geelong, Australia
b Institute for Breathing and Sleep, Austin Health, Melbourne, Australia
c Department of Psychiatry, The University of Melbourne, Parkville, Australia
d School of Psychology, Counselling & Psychotherapy, Cairnmillar Institute, Camberwell, Australia
e NorthWest Academic Centre, Department of Medicine, The University of Melbourne, St Albans, Australia
f Orygen Research Centre, Parkville, Australia
g Florey Institute for Neuroscience and Mental Health Parkville Australia
A R T I C L E I N F O A B S T R A C T
Article history:
Received 12 June 2014
Accepted 23 September 2014
Objective. Excessive daytime sleepiness (EDS) has been associated with singular
independent symptoms of metabolic syndrome, such as insulin resistance and diabetes.
The aim of this study was to assess whether this relationship is sustained among
individuals who meet criteria for the whole syndrome.
Materials/methods. 994 women aged 21–94 years (median 50.2 years, IQR 34–65) and 840
men aged 24–92 years (median 60.4 years, IQR 47–73) who resided in the Barwon Statistical
Division, South-Eastern Australia, and participated in the Geelong Osteoporosis Study (GOS)
between the years of 2001 and 2008. Anthropometric measurements, lifestyle, mood,
demographic and health-related factors were obtained. Sleep duration was categorized as
short (<6 h), average (6–9 h) and long (>9 h). Sleepiness was assessed using the Epworth
Sleepiness Scale (ESS), and scores of ≥ 10 indicated EDS. The presence of metabolic syndrome
was assessed using a modified version of criteria as outlined by the International Diabetics
Federations recommendations (2005).
Results. Women: 138 (14.0%) of the women reported EDS; those with EDS were heavier,
had a greater body mass index (BMI) and were more likely to have metabolic syndrome. The
association between EDS and metabolic syndrome was sustained following adjustment for
age and hours sleep (adjusted OR = 1.90, 95% CI 1.16–3.09), however BMI attenuated the
relationship (adjusted OR = 1.64, 95% CI =1.05–2.57). These findings were independent of
smoking status, alcohol intake, medication use, socioeconomic status, physical activity and
current diagnosis of a depressive illness. Men: 111 (13.2%) of the men reported EDS; those
with EDS had a greater waist circumference and were more likely to have metabolic
syndrome. Analysis of age-stratified data (<60 years vs. ≥60 years) revealed that the older
men with EDS were more likely to have metabolic syndrome (OR = 1.71, 95% CI 1.01–2.92),
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however, age explained this association (age adjusted OR = 1.51, 95% CI 0.88–2.60). In the
younger age group, no association was detected between EDS and metabolic syndrome. For
both men and women, the prevalence of combined EDS and metabolic syndrome increased
progressively with age.
Conclusion. For women, the association between EDS andmetabolic syndrome appears to
be driven by adiposity measures; while for men, the association is somewhat attributed to
older age. Additional research is required to assess temporal associations with underlying
sleep pathology.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
Excessive daytime sleepiness (EDS) is common among adults,
with recent local estimates suggesting that as many as one-
third of the adult population experiences these symptoms [1].
The sleep-related disorder, obstructive sleep apnea (OSA), is the
most commonly linked condition associated with EDS among
both clinical [2] and population-based samples [3]. The daytime
symptoms experienced by these individuals are often attributed
to the degree of nocturnal impairment characteristic of the
disorder, such as periods of hypoxemia or sleep fragmentation
[4]. Despite this, some studies have found a poor correlation
between measures of OSA disease severity and symptoms of
EDS [5,6], and have instead suggested that symptoms of EDS
may be related to other factors associated with OSA, such
as obesity [7]. These symptoms similarly appear associatedwith
a number of independent factors, such as sleep restriction [6]
and/or associated lifestyle, health or medical factors [1,8].
A large body of research has highlighted the role of several
health, lifestyle anddisease factors in the expressionof EDS, thus
indicating that the mechanism of EDS exists beyond that of
underlying sleep-related pathology. There is some evidence that
EDS is associated with indices of increased adiposity [6], and
similar research has shown that EDS can be present in the
absence of underlying sleep disordered breathing among obese
individuals [9,10]. Body composition markers, in particular
visceral adiposity, have previously been linked to disorders of
insulin resistance and independent features of metabolic
syndrome, such as type 2 diabetes and hypertension [11,12]. In
addition, several studies have demonstrated that the presence of
EDS isdirectly associatedwith independent featuresofmetabolic
syndrome, such as insulin resistance [13] and diabetes [6], even
after controlling for sleep disordered breathing [14]. Mechanisti-
cally, such associationsmay have peripheral associations with a
number of inflammatory processes characteristic of metabolic
disturbance [13,15].
Characterizing the relationship between metabolic factors
and EDS has several implications for overall health outcomes,
not least in assisting with appropriate and effective treatment
modalities for these patients. However, there is currently a
paucity of information assessing the association between EDS
andmetabolic syndrome, particularly beyond that of individual
symptom clusters. Therefore, the aim of the current study was
to assess whether the observed relationship between EDS and
metabolic syndrome is sustained among individuals who meet
criteria for the syndrome among a large, population-based
sample of adults, while assessing the relative contribution of
associated lifestyle and health factors.
2. Methods
2.1. Participants
This cross-sectional study examined men and women who
participated in the Geelong Osteoporosis Study (GOS). The GOS
is a large, population based age-stratified cohort, located in
south-eastern Australia. Participants were randomly-recruited
using the Commonwealth electoral rolls for the Barwon
Statistical Division (BSD) as a sampling frame.
Between the years of 1993 and1997, 1494 women were
randomly recruited, representing a participation of 77.1% [10].
At the 10-year follow up (2004–2008), 881 women from the
original sample returned (82.1%). This cohortwas complemented
by the inclusion of an additional 246 randomly-selected women
aged between 20 and 29 years, in order to allow for the continued
investigation of the full adult age range. Of the 1127 womenwho
participated in assessments conducted during the period 2004–8,
participants for whom sleep (n = 25), body composition (n = 59),
or blood pressure (n = 49) datawere not availablewere excluded;
this resulted in a total of 994womenaged21–94 years included in
this analysis.
Between the years of 2001 and 2006, 1540 men were
recruited (response 67.0%) [10], and have since returned for
follow up (n = 978) (response 81.0%). Of the 978 men who
participated in the 5-year follow up, participants for whom
sleep data (n = 32), body composition (n =45) or blood
pressure (n = 61) data were not available were excluded from
analysis, resulting in a total of 840 men aged between 24 and
92 years eligible for this analysis. A comprehensive descrip-
tion of the male and female GOS cohorts and the related
recruitment procedures can be found elsewhere [16].
This study was conducted with the approval of Barwon
Health Human Research Ethics Committee, and written
informed consent was obtained from each participant.
2.2. Measurements
2.2.1. Epworth Sleepiness Scale
EDS was assessed using the Epworth Sleepiness Scale (ESS) [17].
The ESS assesses an individual’s sleep propensity and likelihood
of dozing among a number of hypothetical soporific and
engaging tasks via a self-administered 8-item scale [17].
Sleepiness is assessed using a 4-point Likert scale, referring to
an individual’s likelihood or probability of dozing in that
particular situation (0 = no probability, 3 = high probability).
Total scores range from 0 to 24, with higher scores reflecting
higher levels of sleepiness. While there are no universally
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adapted cut-off ranges for the ESS, similar studies haveutilized a
cut-off score of ≥10 to indicate EDS [18–20].
2.2.2. Metabolic syndrome
The presence of metabolic syndrome was classified using a
modified version of the criteria outlined by the International
Diabetics Federations 2005 [21]. Information regarding serum
levels of triglyceride, high-density lipoprotein (HDL) cholesterol
and/or fasting blood glucose levels was unavailable. Therefore,
the prevalence of metabolic syndrome was identified if
participants met criteria for the variables; waist circumference
≥80 cm (women) and ≥94 (men) (yes/no); and any two of; raised
diastolic (≥85 mm Hg) and/or systolic (≥130 mm Hg) blood
pressure (yes/no), positive response to self-reportedmedication
used to treat hypertension (self-reported use of any; diuretics,
β-adrenergic agents, antihypertensive or hypoglycemic agents)
(yes/no), and/or a positive indication of physician-diagnosed
diabetes in the past 12-month period (yes/no), as previously
applied [22]. Metabolic syndrome was then classified if
participants met criteria for three of these four conditions
and expressed as binary variable (yes/no).
2.2.3. Lifestyle, health and demographic factors
Anthropometric measurements were recorded objectively.
Height and weight were measured to the nearest ±0.1 cm
and ±0.1 kg, respectively. Body mass index (BMI) was calcu-
lated as weight/height squared (kg/m2). Waist (minimum
circumference between the margin of the lower rib and iliac
crest) and hip (maximal gluteal) circumference was measured
using a narrow anthropometric tape measure. Waist to hip
ratio (WHR) was calculated by dividing waist circumference
by hip circumference. Automated upper arm digital blood
pressure monitors (UA-767) were used to assess systolic and
diastolic blood pressures (mmHg).
Information regarding alcohol consumption and daily
energy intake were obtained from the Victorian Cancer Council
food frequency questionnaire [23]. Daily alcohol usage was
expressed as mean gram intake per day (g/day), and energy
intake was assessed as mean kilojoule intake per day (kJ/day).
Physical activity levels were assessed via self-report and
transformed into a binary variable. Participants were classified
as ‘active’ if they reported ‘moving, walking and working
energetically and participating in vigorous exercise’; alterna-
tively, participants were classified as sedentary. Self-reported
tobacco smoking was documented, and participants were
grouped as ‘current smokers’ if they reported tobacco use at
the time of the follow-up. Medication use (sedatives and
antidepressants) was obtained via self-report and classified as
‘current’ if participants reported use at the time of assessment.
Information regarding average hours’ sleep per night was
obtained via retrospective self-report. Values were assessed
both continuously and categorically. Sleep duration categories
were classified as short (<6 h), average (6–9 h) and long (>9 h).
The presence of current depressive illnesses was assessed
using the Structured Clinical Interview for DSM-IV-TR
Research Version, Non-patient edition (SCID-I/NP), which
was administered by trained personnel [24]. The use of this
assessment tool allowed for the identification of lifetime or
current depressive disorders including; Major Depressive
Disorder (MDD), bipolar disorder, dysthymia,minor depression,
substance-inducedmooddisorder, andmooddisorders due to a
general medical condition.
Given the well-documented social gradient of health, we
included socioeconomic status (SES) as a potential confounder.
We determined SES by cross-referencing the residential
addresses of each participant to the Australian Bureau of
Statistics (ABS) 2006 Census data from which Socio-economic
Index for Areas (SEIFA) index values were obtained. SEIFA values
indicated the level of advantage or disadvantage at the area level,
by using the aggregated Index of Relative Socio-Economic
Advantage and Disadvantage (IRSAD). Participants were catego-
rized into quintiles based on the BSD, whereby a low score
as characterized by IRSAD (quintile 1) represented the most
disadvantaged group, andhigh scores (quintile 5) represented the
most advantaged.
2.2.4. Statistical analysis
Univariate analyses were initially performed to assess the
characteristics and associated lifestyle and health factors of
those with and without EDS. Differences in characteristic data
between those with and without EDS and those with and
without metabolic syndrome were analyzed using a t-test
for parametric continuous data, Mann–Whitney U for non-
parametric continuous variables, χ2 analysis for discrete vari-
ables and Fisher’s Exact Test where cell sizeswere less than five.
EDS (yes/no) was applied as the exposure variable and differ-
ences among those with and without EDS in regard to the
presence or absence of metabolic syndrome were tested using
logistic regression models. Age (continuous), age (categorized),
alcohol use, physical activity levels, smoking status, energy
intake, medication use (sedative and antidepressant), and the
presence of depressive disorders were tested sequentially. All
potential confounders and interaction terms were checked in
the statistical models. All statistical analyses were completed
using Minitab (Version 16; Minitab, State College Pa).
3. Results
3.1. Women
Characteristic data for women with and without EDS are
presented in Table 1. 138 (14.0%) women reported EDS. The
median age for female participants was 50.2 years (range 21–
94 years), and no differenceswere detected in age between those
with andwithout EDS. Thosewomenwho reported EDS recorded
greater weight, in addition to a greater overall BMI and waist
circumference than thosewhodid not report EDS. Overall, a large
proportion (68.4%) of the women met criteria for central obesity
(waist circumference ≥80 cm), and those with EDS were more
likely to be classifiedwithin this category than thosewho did not
report these symptoms. Thosewith EDSweremore likely tomeet
criteria for a current mood disorder, indicate a positive response
in regard to previously diagnosed diabetes, and weremore likely
to meet criteria for metabolic syndrome than those who did not
report EDS (see Fig. 1). One third of those with EDS reported
concurrent antihypertensive medication use (33.3%). Overall, 26
(25.9%) women met criteria for comorbid EDS and metabolic
syndrome, and these women tended to be older (data not
shown). No differences were detected between women with
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Table 1 – Characteristics of men and women, with and without EDS. a
Women Men
All N = 994 No n = 856 Yes a n = 138 p All n = 840 No n = 729 Yes a n = 111 p
Age (years) 50.2 (34.2–65.1) 49.7 (34.0–65.5) 51.1 (38.0–64.3) 0.38 60.4 (47.2–73.3) 59.9 (45.9–72.4) 66.1 (52.7–80.5) <0.01
Height (cm) 162.2 (157.8–167.0) 162.0 (157.9–167.0) 163.0 (157.0–166.8) 0.76 174.6 (170.0–179.5) 175.0 (170.5–179.6) 173.0 (168.0–178.4) 0.02
Weight (kg) 69.1 (61.3–80.2) 68.4 (60.9–79.7) 73.0 (63.1–83.0) 0.01 82.6 (74.0–92.4) 82.4 (74.4–92.0) 83.4 (72.5–93.9) 0.73
BMI (kg/m2) 26.2 (23.3–30.5) 26.0 (23.2–30.3) 28.0 (24.4–32.2) 0.01 27.1 (24.7–29.6) 27.0 (24.7–29.5) 27.7 (25.4–30.1) 0.09
Waist circumference total (cm) 85.0 (77.0–96.3) 85.0 (76.0–96.0) 88.0 (81.4–100.0) <0.01 97.2 (90.1–105.0) 97.0 (90.0–104.0) 100.0 (91.0–107.0) 0.05
Waist circumference b
≥94 cm (men) – – – 545 (64.9%) 466 (63.9%) 79 (71.2%) 0.12
≥80 cm (women) 680 (68.4%) 568 (66.4%) 112 (81.1%) <0.01 – – – –
Energy intake (kJ/d) 6277 (5046–7800) 6228 (5021–7757) 6548 (5302–7950) 0.13 408.8 (71.0–1013) 424.0 (76.6–1035.8) 258.6 (35.9–789.22) 0.03
Blood Pressure (mmHg)
Systolic 124 (112.0–136.0) 124.0 (112.0–135.0) 126.0–116.0–139.0) 0.08 138.0 (128.0–151.0) 138.0 (128.0–151.0) 140.0 (128.0–152.0) 0.90
Diastolic 76.0 (68.0–83.0) 76.0 (68.0–83.0) 76.0 (68.8–84.0) 0.27 83.0 (76.0–89.8) 83.0 (76.0–90.0) 81.0 (73.0–88.0) 0.07
Raised blood pressure c 399 (40.1%) 339 (39.6%) 60 (43.2%) 0.40 644 (76.7%) 561 (77.0%) 83 (74.8%) 0.61
Lifestyle/health factors
Hours sleep (total) 7.0 (6.0–8.0) 7.0 (6.0–8.0) 7.0 (6.0–8.0) 0.50 7 (6.0–8.0) 7.0 (6.0–8.0) 6.8 (6.0–8.0) <0.01
Hours sleep/night 0.80 <0.01
(<6 h) 127 (12.8%) 107 (12.5%) 20 (14.5%) 112 (13.3%) 86 (11.8%) 26 (23.4%)
(6–9 h) 766 (77.1%) 661 (77.2%) 105 (76.1%) 674 (80.2%) 594 (81.5%) 80 (72.1%)
(>9 h) 101 (10.2%) 88 (10.3%) 13 (9.4%) 54 (6.4%) 49 (6.7%) 5 (4.5%)
Smoking (current) 137 (13.8%) 123 (14.4%) 14 (10.1%) 0.20 94 (11.2%) 85 (11.7%) 9 (8.1%) 0.30
Physically active 785 (79.0%) 686 (80.1%) 99 (71.7%) 0.03 603 (71.8%) 522 (71.6%) 81 (73.0%) 0.80
Alcohol intake (g/d) 2.9 (0.3–11.8) 3.2 (0.3–12.0) 1.7 (0.4–11.2) 0.21 11.6 (1.9–28.3) 12.0 (2.1–28.4) 7.4 (1.1–25.4) 0.03
Sedative/antidepressant medication
use (current)
120 (12.1%) 99 (11.6%) 21 (15.2%) 0.22 65 (7.7%) 52 (7.1%) 13 (11.7%) 0.09
Hypertensive medication use (current)d 248 (25.0%) 202 (23.6%) 46 (33.3%) 0.01 308 (36.7%) 260 (35.7%) 48 (43.4%) 0.12
Mood disorder (current) 50 (5.0%) 37 (4.3%) 13 (9.4%) 0.01 11 (1.3%) 10 (1.4%) 1 (0.9%) 0.70
Diabetic status 54 (5.4%) 40 (4.7%) 14 (10.1%) <0.01 57 (6.8%) 48 (6.6%) 9 (8.1%) 0.55
Metabolic syndrome 175 (17.6%) 139 (16.2%) 36 (26.1%) <0.01 239 (28.5%) 197 (27.0%) 42 (37.8%) 0.02
Socioeconomic status (current)e 0.35 0.84
Quintile 1 (most disadvantaged) 155 (15.7%) 130 (15.3%) 25 (18.1%) 139 (16.6%) 120 (16.5%) 19 (17.1%)
Quintile 2 210 (21.2%) 187 (22.0%) 23 (16.7%) 169 (20.1%) 149 (20.4%) 20 (18.0%)
Quintile 3 224 (22.6%) 187 (22.0%) 37 (26.8%) 156 (18.6%) 138 (18.9%) 18 (16.2%)
Quintile 4 195 (19.7%) 166 (19.5%) 29 (21.0%) 182 (21.7%) 154 (21.1%) 28 (25.2%)
Quintile 5 206 (20.8%) 182 (21.4%) 24 (17.3%) 194 (23.1) 168 (23.1%) 26 (23.4%)
Values are given as median (interquartile range), mean (±standard deviation) or n (%). Bold font is used to highlight statistically significant (p< .05) findings.
a Denotes ESS score ≥10.
b As outlined by the International Diabetics Federations recommendations (2005) (see; methods).
c Indicated as Systolic ≥130 mmHg and/or Diastolic ≥85 mmHg.
d Self-reported use of any; diuretics, β-adrenergic agents, antihypertensive or hypoglycaemic agents.
e Denotes n = 4 missing value. 247
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and without EDS in terms of height or blood pressure (diastolic
and/or systolic).
Relationships between EDS and lifestyle factors are also
shown in Table 1. Women who reported EDS were less likely
to be classified as physically active; however, no other
differences were detected in terms of total hours sleep,
hours sleep category, smoking status, alcohol intake, medi-
cation use, or SES between those with and without EDS.
Characteristics for women with and without metabolic
syndrome are displayed in Table 2. Overall, 175 (17.6%) of
women met criteria for metabolic syndrome. Women with
metabolic syndromewere older, shorter in height, heavier, had
a greater BMI,weremore likely to have central obesity andwere
more likely to report the use of antidepressant/sedative
medication use than women without metabolic syndrome.
With regard to lifestyle factors, women with metabolic syn-
drome similarly reported less hours sleep/night (total), were
more likely to report average short sleep duration (<6 h/night)
and less alcohol intake, and were less likely to be physically
active. No differences were detected between groups with
regard to SES, current mood disorder status or energy intake.
Fig. 1 presents the percentage of women who report EDS,
metabolic syndrome, and combined EDS and metabolic
syndrome, per age group. The prevalence of EDS appeared
variable among age groups, with those aged 40–49 years and
50–59 years reporting the highest values, followed by those
aged 20–29 years. An increase in metabolic syndrome was
noted across age groups, with those aged 60–69 years
reporting almost double the prevalence of metabolic syn-
drome than those aged 50–59 years, and those aged 70+ years
reporting approximately a three-fold increased prevalence of
metabolic syndrome than those aged 50–59 years. A similar
trendwas noted for prevalence of combined EDS andmetabolic
syndrome, with values increasing with age, with the highest
prevalence noted among those women aged 70+ years.
No women aged 20–29 years reported comorbid EDS and
metabolic syndrome.
The relationship between EDS andmetabolic syndromewas
sustained following adjustment for age and hours sleep
(categories) (adjusted OR = 1.90, 95% CI 1.16–3.09, p = 0.01).
These findings were independent of smoking status, alcohol
intake, medication use, SES, physical activity and current
diagnosis of a depressive illness. Subsequent adjustment for
BMI in the final model was found to attenuate the relationship
between EDS andmetabolic syndrome (adjustedOR = 1.64, 95%
CI 1.05–2.57, p = 0.03).
3.2. Men
Characteristic data formenwith andwithout EDSare presented
in Table 1. 111 (13.2%) ofmen reported EDS. Themedian age for
male participants was 60.4 years (range 24–92), and those men
who reported EDS were older than those who did not report
EDS. Men with EDS were taller and had a greater overall waist
circumference than those who did not report EDS. Over half
(64.9%) of the men met criteria for central obesity (waist
circumference ≥94 cm); however, no differences were detected
between those with and without EDS for this measure. No
differences were detected in regard to blood pressure or use of
hypertensive medication. Overall, 239 (28.5%) men met criteria
for metabolic syndrome. Those with EDS were more likely to
have metabolic syndrome. Men who reported comorbid EDS
and metabolic syndrome (37.8%) were older (data not shown)
than those who did not report comorbidity.
Associations between EDSandhealth and lifestyle factors are
also shown in Table 1. The men with EDS were similarly more
likely to report an average ‘short’ sleep duration (<6 h/night),
less likely to report ‘normal’ (6–9 h/night) sleep duration per
night, and reported less alcohol use and energy intake than
those who did not meet criteria for EDS. No differences were
observed in regard to smoking status, physical activity level,
current depressive illness status, diabetic status,medication use
or SES.
Characteristic data for men with and without metabolic
syndrome are presented in Table 2. Overall, 239 (28.5%)
reported metabolic syndrome. Men with metabolic syndrome
were older, were shorter, weighed more, had a higher BMI,
were more likely to have central obesity and were more likely
to report the use of sedative/antidepressant medication use
than those men without metabolic syndrome. With regard to
the association between metabolic syndrome and lifestyle
and health factors, men who met criteria were more likely to
report shorter sleep duration (<6 h/night), were less likely to
be a current smoker, were less physically active, and were
more likely to be socially disadvantaged than men who did
not have metabolic syndrome No differences were detected
between groups for mood disorder status (current), alcohol or
energy intake, or hours sleep/night.
The proportion of men who reported EDS, metabolic
syndrome or comorbid EDS and metabolic syndrome per
age-group are presented in Fig. 2. The proportion of men with
metabolic syndrome alone, or combined EDS and metabolic
syndrome increased with age, with men within the age-group
of 60–69 years and 70+ years having the highest prevalence of
these symptoms. There were no reported instances of
comorbid EDS and metabolic syndrome among those aged
20–29 years. The prevalence of EDS alone was variable among
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Fig. 1 – Percentage of women who report EDS, metabolic
syndrome or comorbid EDS and metabolic syndrome per
age-group.
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Table 2 – Characteristics of men and women, with and without metabolic syndrome. a
Women Men
All N = 994 No n = 819 Yes a n = 175 p All n = 840 No n = 601 Yes a n = 239 p
Age (years) 50.2 (34.2–65.1) 45.7 (30.8–59.9) 60.4 (77.3) <0.001 60.4 (47.2–73.3) 55.0 (43.1–67.7) 72.3 (62.3–80.4) <0.001
Height (cm) 162.2 (157.8–167.0) 163.0 (158.7–167.9) 160.0 (154.0–163.0) <0.001 174.6 (170.0–179.5) 175.6 (170.8–180.2) 172.2 (167.9–176.0) <0.001
Weight (kg) 69.1 (61.3–80.2) 67.9 (60.7–79.0) 74.9 (65.3–84.5) <0.001 82.6 (74.0–92.4) 81.2 (73.2–91.8) 86.1 (77.4–94.3) <0.001
BMI (kg/m2) 26.2 (23.3–30.5) 25.7 (23.0–29.5) 29.9 (26.1–33.8) <0.001 27.1 (24.7–29.6) 27.0 (24.2–28.8) 29.0 (26.5–31.1) <0.001
Waist circumference total (cm) 85.0 (77.0–96.3) 83.0 (75.0– 94.0) 96.0 (86.5–105.0) <0.001 97.2 (90.1–105.0) 94.0 (88.0–102.0) 103.0 (98.0–109.4) <0.001
Waist circumference b
≥94 cm (men) – – – 545 (64.9%) 313 (52.1%) 232 (97.1%) <0.001
≥80 cm (women) 680 (68.4%) 508 (62.0%) 172 (98.3%) <0.001 – – – –
Energy intake (kJ/d) 6277 (5046–7800) 6266 (5049–7779) 6383 (5007–7905) 0.61 408.8 (71–1013) 415 (82–968) 371 (39–1118) 0.62
Lifestyle/health factors
Hours sleep (total) 7.0 (6.0–8.0) 7.0 (6.0–8.0) 6.5 (5.5–7.5) <0.001 7.0 (6.0–8.0) 7.0 (6.0–8.0) 7.0 (6.0–8.0) 0.60
Hours sleep/night <0.001 <0.001
(<6 h) 127 (12.8%) 82 (10.0%) 45 (25.7%) 112 (13.3%) 65 (10.8%) 47 (19.7%)
(6–9 h) 766 (77.1%) 655 (80.0%) 111 (63.4%) 674 (80.2%) 504 (83.9%) 170 (71.1%)
(>9 h) 101 (10.2%) 82 (10.0%) 19 (10.9%) 54 (6.4%) 32 (5.3%) 22 (9.2%)
Smoking (current) 137 (13.8%) 123 (15.0%) 14 (10.2%) 0.01 94 (11.2%) 81 (13.5%) 13 (5.4%) 0.001
Physically active 785 (79.0%) 683 (83.4%) 102 (58.3%) <0.001 603 (71.8%) 452 (75.2%) 151 (63.2%) <0.001
Alcohol intake (g/d) 2.9 (0.3–11.8) 3.7 (0.5–12.5) 0.5 (0.0–6.2) <0.001 11.6 (1.9–28.3) 11.7 (2.3–27.5) 12.0 (1.1–32.5) 0.60
Sedative/antidepressant medication
use (current)
120 (12.1%) 87 (10.6%) 33 (18.9%) 0.002 65 (7.7%) 34 (6.0%) 31 (13.0%) <0.001
Mood disorder (current) 50 (5.0%) 42 (5.1%) 8 (4.7%) 0.80 11 (1.3%) 8 (1.3%) 3 (1.3%) 0.93
EDSd 138 (14.0%) 102 (12.5%) 36 (21.0%) 0.005 111 (13.2%) 69 (11.5%) 42 (17.6%) 0.02
Socioeconomic status (current)e 0.09 0.01
Quintile 1 (most disadvantaged) 155 (15.7%) 116 (14.2%) 39 (22.3%) 139 (16.6%) 86 (14.3%) 53 (22.2%)
Quintile 2 210 (21.2%) 178 (21.8%) 32 (18.3%) 169 (20.1%) 115 (19.1%) 54 (22.6%)
Quintile 3 224 (22.6%) 183 (22.5%) 41 (23.4%) 156 (18.6%) 111 (18.5%) 45 (18.8%)
Quintile 4 195 (19.7%) 163 (20.0%) 32 (18.3%) 182 (21.7%) 141 (23.5%) 41 (17.2%)
Quintile 5 206 (20.8%) 175 (21.5%) 31 (17.7%) 194 (23.1) 148 (24.6%) 46 (19.3%)
Values are given as median (interquartile range), mean (±standard deviation) or n (%).
a As outlined by the International Diabetics Federations recommendations (2005) (see; methods).
b Indicated as Systolic ≥130 mmHg and/or Diastolic ≥85 mmHg.
d Denotes ESS score ≥10.
e Denotes n = 4 missing.
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age groups, with those men aged 50–59 years reporting the
highest prevalence of these symptoms, followed by those
aged 70+ years. Men aged under 39 years report the lowest
prevalence of EDS.
Initial multivariate modeling revealed a significant EDS*age
interaction, with exploratory scatterplot data demonstrating
a point of interaction between ESS score (total) and age
(continuous) among those aged approximately 60 years (data
not shown). Data were therefore stratified into two age
groups, <60 years and 60+ years. It must be noted, however,
that following age-stratification, small cell sizes were noted for
those men aged both >60 years (n = 5) and 60+ years (n = 37)
who reported comorbid EDS and metabolic syndrome.
Among men aged 60+, those with EDS were more likely to
havemetabolic syndrome (OR = 1.71, 95%CI 1.01–2.92); however,
age explained this association (age adjusted OR = 1.51, 95% CI
0.88–2.60). In the younger age group (<60 years), no association
was detected between EDS and metabolic syndrome (p = 0.97).
4. Discussion
In this large, representative and well characterized sample of
Australian men and women, we assessed the association
between EDS and metabolic syndrome. To our knowledge,
this is the first study of its kind to assess the relationship
between EDS and metabolic syndrome among a population-
based sample of adults, beyond that of individual symptom
clusters. We found that several lifestyle and health factors
characteristic of metabolic symptoms are associated with EDS
among both men and women, and suggest that the observed
relationship between EDS and metabolic syndrome for
women is primarily driven by adiposity measures, while the
association among men is somewhat mediated by older age.
Further, the data suggest that the prevalence of metabolic
syndrome alone and cases of combined EDS and metabolic
syndrome increased with advancing age.
We observed a robust relationship between EDS and
metabolic syndrome among women, with those who met
classification for EDS reporting an approximately 2-fold in-
creased odd of similarly reporting metabolic syndrome; inde-
pendent of a number of associated lifestyle and heath factors.
This is concordant with previous research which has shown a
strong association between subjective sleepiness and a number
of independent markers of metabolic syndrome, more so than
that observed with underlying sleep pathology such as obstruc-
tive sleep apnea (OSA) [6,25]. Indeed, EDS has previously been
shown to be an independent risk factor for diabetes among
women aged >50 years, independent of snoring [26], and ESS
scores have been observed to be associated with high fasting
plasma glucose, low high-density lipoprotein-cholesterol, and
hyperinsulinemia among obese individuals without a diagnosis
of OSA [5].
Although a large portion of the available research assessing
metabolic syndrome among clinically sleep disordered patients
typically focuses on the role of underlying sleep-related
breathing pathology [27], assertions of a direct relationship
between OSA and all aspects of metabolic syndrome have not
been satisfied [28]. Therefore, alternate explanations for this
association have been proposed as self-reported sleep duration
[29] and quality [30], and adiposity measures [31]. Waist
circumference is considered indicative of both visceral adipose
tissue and abdominal subcutaneous adipose tissue; ameasure-
ment which has also been closely associated with relative
cardiovascular risk and metabolic disturbance [31–33]. We
report that women who met criteria for EDS were similarly
classified as being centrally obese (as measured by waist
circumference ≥80 cm), and that a large proportion of the
overall sample met this criterion. These observations have
several clinical implications which directly align with the
observation of current increases in both international [34] and
local [35–37] obesity trends and the concurrently noted
increased prevalence rates of EDS among population-based,
non-clinical samples of women [1,38]. While increases in
obesity are closely linked with increases in instances of
metabolic syndrome [39], the temporal relationships of these
relationships over time remain unclear.
It is likely that BMI may not be as sensitive at characterizing
the metabolic syndrome compared to alternative anthropo-
metric measurements, such as waist circumference [31].
Despite this, we report that BMI somewhat moderated the
association between EDS and metabolic syndrome for women.
As the prevalence of metabolic syndrome has been found to
increase as a function of BMI classification category [31], the
targeting of prevention strategies at lower BMI thresholds may
assist in providing improved outcomes for these patients.
Although we identified a positive association between EDS
and the metabolic syndrome among men, this was not
sustained during multivariate modeling techniques, and a
statistical interaction between EDS and age was noted for
men. Previous epidemiological research performed among
non-clinical populations has demonstrated a sharp increase
in the prevalence of metabolic syndrome among those aged
60+ years compared younger age groups [40], and we have
previously demonstrated a high overall prevalence of EDS
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Fig. 2 – Percentage ofmenwho report EDS,metabolic syndrome
or comorbid EDS andmetabolic syndrome per age-group.
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among this older age bracket [1]. In our sample, the overall
median age formen was higher than that observed for women,
thus these characteristics may partially explain our finding.
Specifically, the role of older agemay be more important in the
expression of metabolic syndrome among these men, rather
than that of body composition factors per se. However, we
acknowledge that cell sizes for each age group were small
following age stratification, and thus the findings should be
interpreted with caution. Future research, therefore, is war-
ranted which assesses a larger number of older men, or that
which is conducted on a sample of older adults only; in order
assess the degree of this relationship in more detail.
Prevalence of EDS was variable among different age-groups
for both men and women, with women reporting the highest
rates during peri and post-menopausal age (40–49, 50–59 years),
and two peaks were noted for men in the middle (50–59 years)
and older age (70+ years) groups. These findings are similar to
a previous age-standardized epidemiological study which
described differential representation of EDS prevalence
between age-groups and gender [1]. Interestingly, we noted
that women who were classified in the younger age group
(20–29 years) similarly reported a higher instance of EDS,
which supports previous research [41], and suggests that
unmet sleep needs, associated maladaptive lifestyle factors
and mental health issues may increase incidences of EDS
among this age bracket [6,8,41]. We report that the preva-
lence of metabolic syndrome and combined EDS/metabolic
syndrome increased with age for both men and women, with
a sharp rise noted among those aged 50+ years. These
findings for both metabolic syndrome and EDS are in line
with previous research which has noted an increased overall
prevalence of metabolic syndrome among these age groups,
which appears to be associated with increases in age-related
health deficits, such as cardiovascular disease and stroke
[31,40]. We propose that the rise in incidence of combined
EDS/metabolic syndrome similarly aligns with the aging
process and instances of increased medical comorbidity
and medication use among these age groups.
A notable strength of the current study included utilizing a
large, representative population-based sample of men and
women, spanning the full adult age range. Such assessments
allowed for detailed investigation of the proposed relationships
of different age groups, therefore providing age-appropriate
data which may assist in tailoring age-specific intervention
models.Weacknowledge some limitations of the current study.
First, as the study is cross-sectional, we are unable tomake any
inferences regarding the direction of the observed relationship.
Second,wedidnotmeasure fasting serumglucose, triglycerides
or HDL-cholesterol; however some, but not all, of the partici-
pants with diabetes and/or dyslipidemia would have been
identified from drug exposures. Other studies [6,26] have
similarly assessed EDS and aspects of metabolic syndrome
symptoms by relying on body composition markers or other
metabolic data as proxy indicators of the presence or absence of
disease. Lastly, we did not explicitly assess the presence of
underlying sleep disorders such as OSA, and therefore cannot
exclude that thismay have contributed to our findings. Despite
this, similar studies assessing the relative contribution of sleep-
related breathing disorders to EDS and metabolic syndrome
have found no significant association [6], and given that OSA
has been shown to correlate poorly with EDS among non-
clinical population samples [42,43], we do not anticipate that
this substantially influenced our findings.
In summary, these data suggest that a robust relationship
exists between EDS and metabolic syndrome among women,
which appears to be driven primarily by adiposity measures.
For men, the relationship is somewhat mediated by age, and
those men aged ≥60 years who present with EDS may be at
an increased risk for metabolic syndrome. Instances of EDS
and metabolic syndrome increased across age groups, with
the prevalence of metabolic syndrome and combined EDS
increasing exponentially among those aged 50+ years. To our
knowledge, our study is the first assessment of metabolic
syndrome, beyond that of independent symptom clusters,
and the first research to describe this positive association. As
metabolic syndrome is considered an important predictor of
morbidity and mortality, patients who present with symp-
toms of EDS should be adequately assessed for underlying
metabolic disturbance, particularly among older individuals.
Author contributions
ACH, LJW and JAP were involved in the development and
design of the study. ACH, LJW, JAP and SLB collected the data.
ACH interpreted the data and wrote the manuscript. ACH,
LJW, GAK, SLB, MB and JAP were involved in drafting, editing
and critical appraisal of the manuscript. All authors have
approved the manuscript for submission.
Acknowledgments
The study was supported by grants from the NHMRC. MB is
supported by an NHMRC Senior Principal Research Fellowship
(1059660), LJW is supported by an NHMRC of Australia Career
Development Fellowship (GNT1064272), and SLB is supported
by an NHMRC of Australia Early Career Fellowship (1012472).
Declaration of conflicts of interest
ACH, GAK, SLB and JAP have no conflicts of interest, including
specific financial interests and relationships and affiliations
relevant to the subject matter or materials discussed in
the manuscript.
MB has received Grant/Research Support from the NIH,
Simons Foundation, CRC for Mental Health, Stanley Medical
Research Institute, MBF, NHMRC, Beyond Blue, Geelong
Medical Research Foundation, Bristol Myers Squibb, Eli Lilly,
Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier
and Astra Zeneca. He has been a paid consultant for Astra
Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline,
Janssen Cilag, Lundbeck and Pfizer and a paid speaker for
Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline,
Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo,
Solvay and Wyeth.
LJW has received Grant/Research support from Eli Lilly, Pfizer,
The University of Melbourne, Deakin University and the NHMRC.
251M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 4 ( 2 0 1 5 ) 2 4 4 – 2 5 2
R E F E R E N C E S
[1] Hayley AC, et al. Prevalence of excessive daytime sleepiness
in a sample of the Australian adult population. Sleep Med
2014;15(3):348–54.
[2] Johns MW. Daytime sleepiness, snoring, and obstructive
sleep apnea. The Epworth Sleepiness Scale. Chest 1993;103
(1):30–6.
[3] Seneviratne U, Puvanendran K. Excessive daytime sleepiness in
obstructive sleep apnea: prevalence, severity, and predictors.
Sleep Med 2004;5(4):339–43.
[4] Colt HG, Haas H, Rich G. Hypoxemia vs sleep fragmentation
as cause of excessive daytime sleepiness in obstructive sleep
apnea. Chest J 1991;100(6):1542–8.
[5] Dixon JB, et al. Daytime sleepiness in the obese: not as simple
as obstructive sleep apnea. Obesity (Silver Spring) 2007;15(10):
2504–11.
[6] Bixler EO, et al. Excessive daytime sleepiness in a general
population sample: the role of sleep apnea, age, obesity,
diabetes, and depression. J Clin Endocrinol Metab 2005;90(8):
4510–5.
[7] Vgontzas AN, et al. Obesity without sleep apnea is associated
with daytime sleepiness. Arch Intern Med 1998;158(12):1333–7.
[8] Hayley AC, et al. The relationship between excessive daytime
sleepiness and depressive and anxiety disorders in women.
Aust N Z J Psychiatry 2013;47(8):772–8.
[9] Resta O, et al. Low sleep quality and daytime sleepiness in
obese patients without obstructive sleep apnoea syndrome.
J Intern Med 2003;253(5):536–43.
[10] Resta O, et al. Sleep-related breathing disorders, loud snoring
and excessive daytime sleepiness in obese subjects. Int J
Obes Relat Metab Disord 2001;25(5):669–75.
[11] Björntorp P. Metabolic implications of body fat distribution.
Diabetes Care 1991;14(12):1132–43.
[12] Despres J-P. Is visceral obesity the cause of the metabolic
syndrome? Ann Med 2006;38(1):52–63.
[13] Vgontzas AN, et al. Polycystic ovary syndrome is associated
with obstructive sleep apnea and daytime sleepiness: role of
insulin resistance. J Clin Endocrinol Metab 2001;86(2):517–20.
[14] Vgontzas A, Bixler E, Chrousos G. Metabolic disturbances in
obesity versus sleep apnoea: the importance of visceral
obesity and insulin resistance. J Intern Med 2003;254(1):32–44.
[15] Vgontzas AN, et al. Elevation of plasma cytokines in
disorders of excessive daytime sleepiness: role of sleep
disturbance and obesity. J Clin Endocrinol Metab 1997;82(5):
1313–6.
[16] Pasco JA, Nicholson GC, Kotowicz MA. Cohort profile: Geelong
Osteoporosis Study. Int J Epidemiol 2012;41(6):1565–75.
[17] Johns MW. A new method for measuring daytime sleepiness:
the Epworth Sleepiness Scale. Sleep 1991;14(6):540–5.
[18] Johns M, Hocking B. Daytime sleepiness and sleep habits of
Australian workers. Sleep 1997;20(10):844–9.
[19] Hublin C, et al. Daytime sleepiness in an adult, Finnish
population. J Intern Med 1996;239(5):417–23.
[20] Doi Y, Minowa M. Gender differences in excessive daytime
sleepiness among Japanese workers. Soc Sci Med 2003;56(4):
883–94.
[21] Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a
new worldwide definition. Lancet 2005;366(9491):1059–62.
[22] Brennan SL, et al. Socioeconomic status and risk factors for
obesity and metabolic disorders in a population-based
sample of adult females. Prev Med 2009;49(2):165–71.
[23] Giles GG, Ireland PD. Dietary questionnaire for epidemiological
studies (version 2). Melbourne: The Cancer Council Victoria;
1996.
[24] First MB, et al. Structured clinical interview for DSM-IV-TR
axis I disorders, research version, patient edition. New York:
Biometrics Research, New York State Psychiatric Institute;
2002.
[25] Vgontzas AN, Bixler EO, Chrousos GP. Obesity‐related sleepiness
and fatigue. Ann N Y Acad Sci 2006;1083(1):329–44.
[26] Lindberg E, et al. Snoring and daytime sleepiness as risk factors
for hypertension and diabetes in women—a population-based
study. Respir Med 2007;101(6):1283–90.
[27] Coughlin SR, et al. Obstructive sleep apnoea is independently
associatedwithan increasedprevalenceofmetabolic syndrome.
Eur Heart J 2004;25(9):735–41.
[28] Kono M, et al. Obstructive sleep apnea syndrome is associated
with some components of metabolic syndrome. Chest J 2007;
131(5):1387–92.
[29] Hall MH, et al. Self-reported sleep duration is associated with
the metabolic syndrome in midlife adults. Sleep 2008;31(5):
635–43.
[30] Jennings J, Muldoon M, Hall M. Self-reported sleep quality is
associated with the metabolic syndrome. Sleep 2007;30(2):
219–23.
[31] Park Y-W, et al. The metabolic syndrome: prevalence and
associated risk factor findings in the US population from the
Third National Health and Nutrition Examination Survey,
1988–1994. Arch Intern Med 2003;163(4):427–36.
[32] Pouliot M-C, et al. Waist circumference and abdominal
sagittal diameter: best simple anthropometric indexes of
abdominal visceral adipose tissue accumulation and related
cardiovascular risk in men and women. Am J Cardiol 1994;73
(7):460–8.
[33] Alam I, et al. Obesity, metabolic syndrome and sleep apnoea:
all pro‐inflammatory states. Obes Rev 2007;8(2):119–27.
[34] Rennie K, Jebb S. Prevalence of obesity in Great Britain. Obes
Rev 2005;6(1):11–2.
[35] Cameron AJ, et al. Overweight and obesity in Australia: the
1999–2000 Australian Diabetes, Obesity and Lifestyle Study
(AusDiab). Med J Aust 2003;178(9):427–32.
[36] Pasco JA, et al. Prevalence of obesity and the relationship
between the body mass index and body fat: cross-sectional,
population-based data. PLoS One 2012;7(1):e29580 [1-7].
[37] Pasco JA, Brennan SL, Kotowicz MA. Morbid obesity in women
on the rise: an observational, population-based study. BMC
Public Health 2013;13(1):290 [1-4].
[38] Bartlett DJ, et al. Sleep health New SouthWales: chronic sleep
restriction and daytime sleepiness. Intern Med J 2008;38(1):
24–31.
[39] Steinbaum SR. The metabolic syndrome: an emerging health
epidemic in women. Prog Cardiovasc Dis 2004;46(4):321–36.
[40] Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic
syndrome among US adults: findings from the third National
Health and Nutrition Examination Survey. JAMA 2002;287(3):
356–9.
[41] Theorell-Haglöw J, Lindberg E, Janson C. What are the
important risk factors for daytime sleepiness and fatigue in
women. Sleep 2006;29(6):751–7.
[42] Young T, et al. The occurrence of sleep-disordered breathing
among middle-aged adults. N Engl J Med 1993;328(17):1230–5.
[43] Baldwin CM, et al. The association of sleep-disordered
breathing and sleep symptoms with quality of life in the
Sleep Heart Health Study. Sleep 2001;24(1):96–105.
252 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 4 ( 2 0 1 5 ) 2 4 4 – 2 5 2
159 
CHAPTER 9: Excessive Daytime Sleepiness and Falls 
among Older Men and Women: Cross-Sectional 
Examination of a Population-Based Sample. 
 
 
Reference: Hayley, A. C., Williams, L. J., Holloway, K. L., Kennedy, Berk, M., & 
Pasco, J. A. Excessive daytime sleepiness and falls among older adults: cross-
sectional examination of a population-based sample. Accepted for publication in 
BMC Geriatrics 04/06/2015.  
AUTHORSHIP STATEMENT 
1.  Details of publication and executive author 
Title of Publication Publication details 
Excessive daytime sleepiness and falls among older adults: cross-
sectional examination of a population-based sample 
 
Accepted to BMC Geriatrics 
01/06/2015 
Name of executive author School/Institute/Division if based 
at Deakin; Organisation and 
address if non-Deakin 
Email or phone 
Amie C. Hayley School of Medicine achayley@deakin.edu.au 
2.  Inclusion of publication in a thesis 
Is it intended to include this publication in a higher degree 
by research (HDR) thesis? 
Yes  
 
If Yes, please complete Section 3 
If No, go straight to Section 4. 
3.  HDR thesis author’s declaration 
Name of HDR thesis author if 
different from above. (If the same, 
write “as above”) 
School/Institute/Division if based at 
Deakin 
Thesis title 
As above 
 
School of Medicine Sleep Disturbances and Associated 
Health Outcomes: An 
Epidemiological Study. 
If there are multiple authors, give a full description of HDR thesis author’s contribution to the publication (for 
example, how much did you contribute to the conception of the project, the design of methodology or 
experimental protocol, data collection, analysis, drafting the manuscript, revising it critically for important 
intellectual content, etc.) 
I was responsible for the formulation of study design, writing the manuscript, data analysis, sourcing 
references/resources, compiling reference list, editing and authorising the final copy of the manuscript. 
 
I declare that the above is an accurate description of 
my contribution to this paper, and the contributions of 
other authors are as described below. 
Signature 
and date 
 14/01/2015 
4.  Description of all author contributions 
Name and affiliation of author  Contribution(s) (for example,  conception of the project, design of 
methodology or experimental protocol, data collection, analysis, drafting 
the manuscript, revising it critically for important intellectual content, etc.) 
Lana J. Williams1,3 
1 IMPACT SRC, School of Medicine, 
Deakin University, Barwon Health, 
Geelong, Australia. 3 Department 
of Psychiatry, The University of 
Melbourne, Parkville, Australia. 
 
Assist in study design, interpreting results, preparation and critical review 
of manuscript. 
Gerard A. Kennedy2,4 
2 Institute for Breathing and Sleep, 
Austin Health, Melbourne, 
Australia. 4 School of Psychology, 
Counselling & Psychotherapy, 
Cairnmillar Institute, Camberwell, 
Australia 
Interpretation of results, preparation and critical review of manuscript. 
Kara Holloway1 
1 IMPACT SRC, School of Medicine, 
Deakin University, Barwon Health, 
Interpretation of results, assist in statistical methods, preparation and 
critical review of manuscript. 


163 
9.1 Abstract 
Background: Excessive daytime sleepiness (EDS) has been associated with an 
increased risk for falls among clinical samples of older adults. However, there is 
little detailed information among population-representative samples. The current 
study aimed to assess the relationship between EDS and falls among a cohort of 
population-based older adults. Methods: This study assessed 367 women aged 
60-93years (median 72, interquartile range  65-79) and 451 men aged 60-
92years (median 73, interquartile range 66-80) who participated in the Geelong 
Osteoporosis Study between the years 2001 and 2008. Falls during the prior year 
were documented via self-report, and for men, falls risk score was obtained using 
an Elderly Fall Screening Test (EFST). Sleepiness was assessed using the 
Epworth Sleepiness Scale (ESS), and scores of  10 indicated EDS. Differences 
among those with and without EDS in regard to falls were tested using logistic 
regression models Results: Among women, 50 (13.6%) individuals reported 
EDS. Women with EDS were more likely to report a fall, and were more likely to 
report the fall occurring outside. EDS was similarly associated with an increased 
risk of a fall following adjustment for use of a walking aid, cases of nocturia and 
antidepressant medication use (adjusted OR= 2.54, 95%CI 1.24-5.21). 
Multivariate modelling revealed antidepressant use (current) as an effect modifier 
(p <.001 for the interaction term). After stratifying the data by antidepressant 
medication use, the association between EDS and falls was sustained following 
adjustment for nocturia among antidepressant non-users (adjusted OR= 2.63, 
95%CI 1.31-5.30). Among men, 72 (16.0%) individuals reported EDS. No 
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differences were detected for men with and without EDS in regard to reported 
falls, and a trend towards significance was noted between EDS and a high falls 
risk as assessed by the EFST (p= 0.06), however, age explained this relationship 
(age adjusted OR= 2.20, 95%CI 1.03-1.10). Conclusions: For women, EDS is 
independently associated with at least one fall during the previous year, and this 
is more likely to occur whilst located outside. Amelioration of EDS may assist in 
improving functional outcomes among these individuals by reducing the risk for 
falls.  
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9.2 Introduction 
Incidence of sleep-related problems are observed to increase with age (359), and 
a reduction in both the quality and quantity of nocturnal sleep and an increase in 
daytime symptoms are often considered a normal aspect of the aging process 
(204). Excessive daytime sleepiness (EDS) is a common complaint among older 
adults, with research indicating that approximately 15% of those aged 60years 
and older experience these symptoms (359). The aetiology of EDS is 
multifactorial, particularly among older adults, and has been associated with 
individual markers of underlying sleep pathology, such as cases of obstructive 
sleep apnoea (OSA) (362). These symptoms may similarly be associated with a 
number of medical or psychiatric conditions (363), or a number health or lifestyle 
factors, such as physical inactivity (221), that overlap with the risks for 
osteoporosis. 
 
Among older individuals, EDS has been consistently and independently 
associated with an increased risk profile for several adverse health outcomes, 
such as reduced functional outcomes (219), depressive illness (217), deficits in 
cognitive abilities (107), as well as a two-fold increased risk for falls (220). 
Research has suggested that approximately 30% of older adults report sustaining 
one or more falls per year (230), and as many as 10-20% of these incidents are 
associated with moderate to severe injury, such as fractures or severe head 
trauma (231). Local estimates have suggested that one-tenth of time spent in 
hospital for those aged 65+ years is directly attributable to an injurious fall (364), 
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and that these incidences account for the largest proportion of hospital admission 
for injuries among this age cohort (365). Most hip fractures result from falls (366), 
the majority of which are treated in hospital (366, 367). Thus, falls among older 
adults constitute a significant health burden and  account for a large proportion of 
injury-related deaths in Australia (364).  
 
Although a few studies have reported an association between EDS and 
increased risk of falls among older adults, there is currently insufficient 
information regarding the nature of the fall and degree of disability incurred as 
result of the fall. Specifically, there is currently little detailed information regarding 
details such as the location, circumstances and consequences surrounding the 
fall with regard to EDS. Moreover, there is inadequate collation of data pertaining 
to the relative contribution of factors such as concurrent medication use and 
other health behaviours on this association. Given both the high frequency of 
EDS and the health burden associated with falls in older adults, direct 
assessment of the relationship between these factors may assist in identifying 
possible modifiable factors, and thus, substantially improve primary preventative 
strategies for falls in these populations. Therefore, the aim of the current study is 
to describe the association between EDS and falls among a population-based 
sample of older adults. 
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9.3 Methods 
9.3.1 Participants 
 
This cross-sectional study examined men and women aged 60years who were 
enrolled in the Geelong Osteoporosis Study (GOS). The GOS is a large, 
population-based research project conducted in South-Eastern Australia. 
Population characteristics of the Barwon Statistical Division (BSD) are 
comparable with national levels in terms of age, income, education level and 
marital status for each census taken in the years 1996, 2001 and 2006 (357). 
Participants were randomly recruited using the Commonwealth electoral rolls for 
the region as a sampling frame. Both men and women were recruited utilizing an 
age-stratified sampling method. 
 
Between the years 1993 and 1997, 1938 eligible women were randomly selected 
for inclusion into the study and 1494 agreed, representing 77.1% participation 
(357). At the 10-year follow up (2004-2008), 881 women returned for assessment 
(82.1% retention rate). Of the total 881 women who participated in the 10-year 
follow up and who were aged 60 years (n=453), participants whom complete 
sleep (n=23), or anthropometry (weight and/or height) (n=38) data were not 
available were excluded from analyses, resulting in a total of 367 eligible women 
aged 60-93 years. 
 
Between the years 2001 and 2006, 3273 eligible men were randomly selected for 
inclusion into the study and 1540 agreed, representing 77.1% participation (357). 
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Of those who were recruited, 978 men have since returned for follow-up 
(response 81.0%). Of the total 978 men who participated in the 5-year follow up, 
participants who were aged <60 years (n=479) for whom sleep data (n=33), or 
anthropometry data (n =15) were not available were excluded from analyses, 
resulting in a total of 451 eligible men aged between 60-92 years.  
Comprehensive descriptions of the male and female GOS cohorts and the 
related recruitment procedures can be found elsewhere (357). 
 
This study was conducted with the approval of Barwon Health Human Research 
Ethics Committee, and written informed consent was obtained from each 
participant. 
9.3.2 Excessive Daytime Sleepiness (EDS) 
 
EDS was assessed using the Epworth Sleepiness Scale (ESS) (114). The ESS is 
a 4-point Likert-style questionnaire designed to assess participants’ average 
sleep propensity and likelihood of dozing among a number of hypothetically 
proposed activities, which include both active and soporific situations. 
Psychometric assessment of the ESS have demonstrated good overall internal 
consistency (Cronbach’s alpha = 0.88, p < 0.001) and test-retest reliability 
(Pearson’s r = 0.82, p < 0.001) (98), and has demonstrated good internal 
consistency, reliability and construct validity among older, community-dwelling 
adults (368, 369). Although there is currently no universally accepted cut-off 
range for the ESS, similar studies have applied a cut-off of 10 to indicate EDS 
(370). 
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9.3.3 Falls 
 
Fall history was determined via a self-report questionnaire for both sexes. Falls 
were defined as an instance ‘when you suddenly find yourself on the ground, 
without intending to get there, after you were either in a lying, sitting or standing 
position’. Participants were classified as having had a fall if they reported one or 
more falls in the 12-month period prior to the time of assessment. Details of the 
fall(s) included the location of the fall, how the fall occurred, if the fall occurred 
from greater than standing height, whether the fall resulted in injury, and whether 
treatment was sought post-fall. Details of the fall(s) including the location and 
how the fall occurred were obtained as open-ended questions, and were 
transformed into categorical responses for analyses. Fall description was 
categorised using similar criteria used by comparable studies (371). Responses 
that did not align with the descriptive categories were listed as ‘other’ (example 
includes response of ‘climbing on object’). Fall location was transformed into 
location-specific responses, which included ‘inside’ and ‘outside’.  
 
A falls risk score was also obtained for male participants only using criteria 
outlined by Cwikel and colleagues (1998) (372). The elderly fall screening test 
(EFST) consists of five items, in which a positive response to each item is 
counted as one point. Three items in the EFST refer to falls history which 
included: (1) number of falls; (2) falls resulting in injury; and (3) reporting ‘near 
falls’ occasionally or often and clinical assessments included: (4) measured 
walking speed (taking longer than 10 sec to cover 5 m); and (5) evidence of an 
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unsteady or uneven gait. The risk profile has a total range of 0 (low risk) to 5 
(high risk), with a positive indication to each item considered to equal one point. 
Total scores of >2 were considered as a high falls risk (372). Using these criteria 
for statistical analysis, men were classified according to falls risk as having either 
a low or high risk. The EFST has been validated previously using a community-
based sample of functional adults aged 60+years (372). Independent 
assessment of the EFST describes the measure as having good sensitivity and 
specificity (93% and 78%, respectively) (373). 
9.3.4 Lifestyle and heath factors 
 
Anthropometric measurements were recorded objectively. Height and weight 
were measured to the nearest ±0.1cm and ±0.1kg, respectively. Body mass 
index (BMI) was calculated as weight/height squared (kg/m2). Waist (minimum 
circumference between the margin of the lower rib and iliac crest) and hip 
(maximal gluteal) circumference were measured using a narrow anthropometric 
tape measure. Participants were classified as centrally obese if they reported a 
waist measurement of  102 cm (men) or >88cm (women) (374).  
 
Information regarding alcohol consumption and daily energy intake were obtained 
from the Cancer Council food frequency questionnaire (375). Daily alcohol intake 
was expressed as gram intake per day (g/day), and energy intake was assessed 
as kilojoule per day (kJ/day). Level of mobility was assessed via a self-report 
questionnaire and transformed into a binary variable. Participants were classified 
as ‘active’ if they indicated a positive response to engaging in ‘moving, walking 
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and working energetically and participating in vigorous exercise’; alternatively, 
participants were classified as sedentary. Current use of a mobility aid was 
assessed via self-report. Nocturia was assessed via self-report: participants 
indicated if they ‘often rose at night to use the toilet’ and how many times, on 
average, they needed the toilet during the night. Frequency responses were 
pooled into the categories 0-1, 2 times/night. Cases of nocturia were identified 
as those who used the toilet 2 times/night. Similar methods have been 
employed when assessing nocturia among samples of community-dwelling older 
adults (376). Self-reported hours sleep per night was assessed as both a 
continuous and catagorised factor. Short sleep duration was defined as <6 
hours/night, average sleep duration was 6-9 hours/night, and long sleep duration 
was classified as >9 hours/night. Similar methods have been employed to 
characterise sleep duration among comparable population-based studies (377). 
Current use of tobacco smoking and medication use (sedatives/hypnotics and 
antidepressants) were documented by questionnaire. The presence of diabetes 
was identified by fasting plasma glucose >7.0mmol/L and/or positive self-
reported diagnosis and/or use of insulin and/or hypoglycemic agents.  
 
The presence of current depressive illnesses was assessed using the Structured 
Clinical Interview for DSM-IV-TR Research Version, Non-patient edition (SCID-
I/NP) (378). The use of this assessment tool allowed for the identification of 
current depressive disorders including; Major Depressive Disorder (MDD), bipolar 
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disorder, dysthymia, minor depression, substance -induced mood disorder, and 
mood disorders due to a general medical condition.  
 
Socio-economic status (SES) was assessed by cross-referencing the residential 
addresses of each participant to the Australian Bureau of Statistics (ABS) 2006 
Census data; from which Socio-Economic Index for Areas (SEIFA) index values 
were obtained. SEIFA values were applied to obtain an aggregated Index of 
Relative Socio-Economic Advantage and Disadvantage (IRSAD). Participants 
were categorised into quintiles of SES based on the BSD, where quintile 1 
represented the most disadvantaged group, and quintile 5 represented the most 
advantaged.  
9.4 Statistical analyses 
 
Univariate analyses were initially performed to assess the characteristics and 
associated lifestyle and health factors of those with and without EDS. Differences 
in characteristic data between those with and without EDS were analysed using a 
t-test for parametric continuous data, Mann-Whitney U for non-parametric 
continuous variables, Ȥ2 analysis for discrete variables and Fisher’s Exact Test 
where expected cell sizes were less than five. EDS (yes/no) was applied as the 
exposure variable and differences among those with and without EDS in regard 
to fall history were tested using multivariate logistic regression models. Variables 
which were significantly associated with EDS in univariate analyses were added 
simultaneously to multivariable regression models. Interaction terms were 
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checked to identify effect modification. Significance was set at p<0.05. Statistical 
analyses were completed using Minitab (Version 16; Minitab, State College Pa).
9.5 Results: Women 
9.5.1 Characteristics 
Characteristic data for women with and without EDS are presented in Table 1. A 
total of 50 (13.6%) women reported EDS. No differences were detected in regard 
to age, weight, height, BMI or waist circumference between groups. No 
differences were detected between groups with regard to self-reported hours 
sleep (total) or hours sleep (categorised), current mood disorder status, alcohol 
intake, energy intake or SES. Compared to women without EDS, those with EDS 
were more likely have diabetes, report nocturia, and use a walking aid.
9.5.2 Falls 
 
In total, 118 (32.2%) of women reported at least one fall (range 1-4), and 24 
(20.3%) reported both EDS and fall history. A total of 22 women (6.0%) reported 
2 falls. Of the women who reported at least one fall, 14 (11.8%) reported that 
the fall occurred greater than from standing height, and 80 (67.8%) reported 
sustaining an injury as a result.  Of those who sustained injuries, 55 (68.8%) 
reported a soft tissue injury only (such as bruise or sprain) and 25 (31.3%) 
reported a fracture as a result of the fall. No differences were noted between 
women with and without EDS in regard to the type of fall-related injury. 
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Falls were reported to occur most frequently as a result of tripping (44.3%), 
slipping (15%), other (15%), loss of support/surface structure (10.6%), knocked 
over (6.2%), loss of balance (5.3%) and legs giving way (3.5%) (data not shown).  
Numbers were too small to detect differences in cause of fall among those with 
and without EDS. 
 
Women with EDS were more likely to fall outside (34.8% inside vs. 65.2% 
outside), and women without EDS were more likely to fall inside (59.6% inside vs. 
40.4% outside) (p= 0.03).  
 
EDS was associated with an increased risk of reporting a fall in the previous 12 
months (unadjusted OR= 2.19, 95%CI 1.20-4.01, p= 0.01), and this was 
attenuated following adjustment for use of a walking aid, cases of nocturia and 
antidepressant medication use (adjusted OR= 2.54, 95%CI 1.24-5.216, p= 0.01). 
These findings were independent of age and diabetic status (Table 2).  
 
Initial multivariate modelling revealed antidepressant use (current) as an effect 
modifier (p <.001 for the interaction term). Data were thus stratified by exposure 
to antidepressant medication, and a relationship among antidepressant non-
users, EDS and self-reported falls in the previous 12 months was noted 
(unadjusted OR= 2.74, 95%CI 1.37-5.49, p< 0.01). The relationship between 
EDS and falls was further sustained following adjustment for nocturia (adjusted 
OR= 2.63, 95%CI 1.31-5.30, p< 0.01). These findings were independent of 
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smoking status, BMI, alcohol intake, sedative medication use and use of a 
walking aid.  No relationship was observed between EDS and falls for 
antidepressant users.
9.6 Results: Men  
9.6.1 Characteristics 
 
Characteristic data for those men with and without EDS is presented in Table 1. 
A total of 72 (16.0%) men reported EDS. Those men who reported EDS were 
older than men without EDS (p<0.01). No differences were noted between 
groups in regard to weight, BMI or waist circumference. 
 
Compared to men without EDS, men with EDS were more likely to use a walking 
aid, were more likely to report nocturia, current depressive illness, fewer total 
hours of sleep/night, and <6 hours sleep/night (all p<0.05). No differences were 
detected in regard to smoking status, physical activity level, alcohol intake, 
energy intake, diabetic status, SES, or medication use. 
9.6.2 Falls 
 
In total, 94 (20.8%) men reported any fall (range 1-3) during the previous year, 
and 19 (20.2%) reported both EDS and a fall. Multiple falls were reported by 7 
(2.0%) men. Of those men who reported falls, 25 (26.6%) reported that the fall 
occurred from greater than standing height, and 47 (50.0%) reported sustaining 
an injury as a result of the fall. Of the men who reported sustaining an injury, 38 
(80.9%) reported a soft-tissue injury and 9 (19.1%) reported a fracture (see 
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Figure 1). No differences were noted between men with and without EDS in 
regard to the type of fall-related injury.  
 
Falls were reported to occur most frequently as a result of tripping (45.6%), 
followed by other (32.2%), slip or loss of support/surface structure (both 7.8%), 
loss of balance (5.6%), and from being knocked over (1.1%).   
 
No difference was noted between the fall location between those with and without 
EDS (data not shown).  
 
No differences were detected for those men with and without EDS in regard to 
self-reported falls in the previous 12 months. As a result, a multivariable model 
was not developed for this outcome. 
 
EFST scores displayed a range of 0-4. A total of 73 (16.2%) men met criteria for 
a high falls risk. A trend towards significance was noted between men who 
reported EDS and the likelihood of having a high falls risk (p= 0.06), however, 
age explained this relationship (age adjusted OR= 2.20, 95%CI 1.03-1.10). 
These findings were independent of height, hours sleep/night, cases of nocturia 
and mood disorder (current) (Table 2). 
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 Women Men 
 All No Yes* p All No Yes* p
 N=367 n=317 n=50  N=451 n=379 n=72  
Age 71.7 (65.1-78.5) 71.3 (65.2-78.4) 73.7 (63.6-80.1) 0.51 73.0 (66.3-80.3) 72.3 (65.6-79.2) 78.1 (69.4-85.1) <0.01 
Height (cm) 158.6 (154.0-
162.8) 
158.9 (154.0-
162.7) 
157.6 (154.0-
163.1) 
0.81 172.8 (167.8-
177.0) 
173.1 (168.0-
177.1) 
171.2 (167.1-
175.1) 
0.05 
Weight (kg) 68.8 (60.5-78.2) 67.7 (60.1-76.8) 71.1 (64.4-82.6) 0.08 81.2 (73.7-91.7) 81.2 (73.8-91.2) 81.2 (72.1-93.3) 0.90 
BMI (kg/m2) 27.4 (24.1-31.1) 27.0 (24.1-30.8) 28.6 (24.7-33.6) 0.09 28.0 (25.2-30.0) 27.5 (25.2-29.9) 27.9 (25.2-31.0) 0.27 
Waist circumference1          
     102 cm (men)± - - -  202 (45.0%) 164 (43.4%) 38 (53.5%) 0.12 
     88 cm (women) 211 (58.9%) 178 (57.8%) 33 (66.0%) 0.27     
Lifestyle/health 
factors  
        
Reported at least one 
fall 
118 (32.2%) 94 (29.7%) 24 (48.0%) 0.01 94 (20.8%) 75 (19.8%) 19 (26.4%) 0.21 
2 falls 22 (6.0%) 16 (5.1%) 6 (12.0%) 0.05     
Hours’ sleep (total)† 7.0 (6.0-8.0) 7.0 (6.0-8.0) 7.0 (6.0-8.0) 0.12 7 (6.0-8.0) 7.5 (6.0-8.0) 7.0 (5.5-8.0) <0.01 
Hours’ sleep/night †    0.26    0.01 
  (<6hr) 79 (21.8%) 70 (22.4%) 9 18.0%)  78 (17.3%) 57 (15.0%) 21 (29.2%)  
  (6-9hr) 237 (65.3%) 206 (65.8%) 31 (62.0%)  330 (73.1%) 283 (74.7%) 47 (65.3%)  
  (>9+hr) 47 (13.0%) 37 (11.8%) 10 (20.0%)  43 (9.5%) 39 (10.3%) 4 (5.6%)  
Use of walking aid 52 (14.5%) 37 (11.8%) 15 (30.0%) <0.01 48 (10.6%) 30 (7.9%) 18 (25.0%) <0.001
Nocturia 113 (30.8%) 91 (28.7%) 22 (44.0%) 0.03 142 (31.5%) 108 (28.5%) 34 (47.2%) <0.01 
Smoking (current) 26 (7.1%) 20 (6.3%) 6 (12.0%) 0.14 28 (6.1%) 27 (7.1%) 1 (1.4%) 0.07 
Physically active 225 (61.3%) 198 (62.5%) 27 (54.0%) 0.25 294 (65.2%) 251 (66.2%) 43 (60.0%) 0.30 
Alcohol intake (g/d) 0.9 (0.0-8.4) 0.9 (0.0-8.8) 0.4 (0.0-3.7) 0.36 9.3 (1.0-25.1) 10.5 (1.0-25.6) 5.5 (0.2-20.2) 0.11 
Energy intake (kJ/d) 6165 (4995-7701) 
6065 (4991-7576) 6730 (5230-
8246) 
0.07 355.2 (32.2- 
825.8) 
370.2 (36.9-
837.0) 
230.8 (7.1-
731.1) 
0.12 
Sedative/hypnotic 
medication use 
(current) 
21 (5.7%) 19 (6.0%) 2 (4.0%) 0.75 8 (1.8%) 8 (2.1%) 0 (-) 0.21 
Table 1: Characteristics of men and women, with and without EDS*. Values are given as median (interquartile range), mean (±standard deviation) or n 
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* denotes ESS score 10. 
1 as outlined by the International Diabetics Federations recommendations (2005) (see; methods). 
± denoted n=2 missing values. 
† denotes n=4 missing values. 
 
 
 
 
 
 
 
Antidepressant 
medication use 
(current) 
58 (15.8%) 46 (14.5%) 12 (24.0%) 0.09 36 (8.0%) 27 (7.1%) 9 (12.5%) 0.12 
Mood disorder 
(current) 
25 (6.9%) 21 (6.7%) 4.0 (8.0%) 0.80 8 (1.8%) 4 (1.1%) 4 (5.6%) 0.03 
Diabetic status 26 (7.1%) 16 (5.1%) 10 (20.0%) <0.001
34 (7.6%) 28 (7.4%) 6 (8.3%) 0.78 
Socioeconomic status 
(current) 
   0.67    0.43 
    Quintile 1 (most 
disadvantaged) 
60 (16.4%) 53 (16.7%) 7 (14.0%)  85 (18.9%) 73 (19.3%) 12 (16.7%)  
    Quintile 2 68 (18.5%) 55 (17.4%) 13 (26.0%)  94 (20.8%) 83 (21.9%) 11 (15.3%)  
    Quintile 3 103 (28.1%) 89 (28.1%) 14 (28.0%)  91 (20.2%) 78 (20.6%) 13 (15.3%)  
    Quintile 4 66 (18.0%) 58 (18.3%) 8 (16.0%)  87 (19.3%) 69 (18.2%) 18 (25.0%)  
    Quintile 5 (most 
advantaged) 
70 (19.1%) 62 (19.6%) 8 (16.0%)  94 (20.8%) 76 (20.1%) 18 (25.0%)  
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Table 2. Odds Ratios (OR) and 95% Confidence Intervals (CI) for the association 
between excessive daytime sleepiness (EDS)* and falls for women1 and men2, 
unadjusted and fully adjusted models 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Denotes Epworth Sleepiness Scale (ESS) score >10 
1Self-reported falls in the previous 12 months 
2Elderly Falls Screening Test (EFST) scores (referent value EFST score <2) 
Significant values are indicated by bold font. 
 
 
 OR 95% CI p-value 
Women    
Unadjusted    
   EDS 2.19 1.20, 4.01 0.01 
Adjusted    
   EDS 2.54 1.24, 5.21 0.01 
   Age 0.99 0.96, 1.03 0.80 
   Walking aid 2.20 1.00, 4.18 0.05 
   Nocturia 1.56 1.01, 2.80 0.05 
   Diabetic status 0.88 0.34, 2.01 0.70 
Antidepressant 
medication use 
4.54 2.34, 8.83 0.001 
EDS*Antidepressant  
medication use 
0.19 0.04, 0.85 0.03 
    
Men    
Unadjusted    
   EDS 1.78 0.04, 1.19 0.06 
Adjusted    
   EDS 1.26 0.65, 2.52 0.48 
   Age 1.10 1.03, 1.10 <0.01 
   Height 1.00 1.00, 1.00 0.74 
   Hours sleep/night 0.92 0.77, 1.09 0.32 
   Nocturia 1.05 0.60, 1.85 0.85 
   Mood disorder      
(current) 
1.98 0.36, 10.75 0.43 
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9.7 Discussion 
Over one tenth of men and women aged >60years assessed in this study report 
clinically significant levels of EDS. The results from this cross-sectional study 
suggest that for women, EDS is associated with an approximate two-fold 
increased likelihood of reporting at least one fall during the previous year, 
independent of a number of confounding factors. Further, women with EDS were 
more likely to report a fall occurring whilst located outside, whereas women 
without EDS were more likely to report a fall whilst located inside. No association 
was observed for men with regard to EDS and falls history; however, a trend 
towards significance was noted between EDS and an increased risk profile for 
falls as assessed by the EFST. Both men and women reported falls occurring 
most frequently as a result of tripping and indicated that soft-tissue injuries were 
the most common reported injury sustained as a result of the fall.   
 
Over one-tenth of older men and women sampled in this study report EDS (16% 
and 13.6%, respectively), which is comparable to population-based prevalence 
we have cited previously (359), but higher than that cited by others (220). 
Healthy, independent community-dwelling older adults often report lower rates of 
EDS than those who reside within aged-care facilities (379). This may in part be 
attributed to typically higher levels of physical functioning and greater levels of 
independence among these individuals (380), as well as lower overall rates of 
peripheral factors often associated with EDS, such as disease comorbidity (381) 
and increased rates of polypharmacy (382). We further report an overall fall 
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prevalence for both men and women that is comparable to (234), but lower than 
some [36] of the previous research assessing falls among healthy, community-
dwelling adults. Higher rates of falls are often observed among older adults living 
within aged care or assisted living facilities compared to those living within the 
community (233, 383). Indeed, individuals living in long-term institutionalised care 
have as much as a threefold increased risk of reporting a fall, and a 10-25% 
increased risk of sustaining injuries such as a fracture or laceration as a direct 
result of a fall (384). Falls are often considered independent determinants of 
functional decline and worse disability outcomes among older community-
dwelling adults (385); and are often cited as the primary contributing factor for 
later admission to institutionalised care (384). Community-based prevention 
strategies are therefore pivotal in the reduction of nursing home admissions 
among at-risk individuals.  
 
The associations between EDS and falls among population-based samples of 
older adults have only been examined among a limited number of studies. Similar 
research conducted by Teo and colleagues (220) assessed the role of nocturnal 
sleep disturbance, cases of urinary incontinence and instances of EDS in regard 
to the relative risk for falls among a cohort of older Australian women. It was 
reported that those with EDS were more likely to report a fall than those who did 
not report EDS (univariate analysis), and that EDS was the strongest risk factor 
for reported falls after controlling for other recognised falls risk factors. We report 
similar increased odds for falls among women with EDS as those presented by 
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Teo and colleagues (220); moreover, we were able to address some limitations 
of this research by accounting for and assessing the relative contribution of a 
larger number of associated health and lifestyle factors, such as mobility levels 
and exposure to sedative/antidepressant medication. We report that the 
association between EDS and falls among women is observed only among non-
users of antidepressant medications, however, and thus the role of this 
relationship in the expression of falls risk among affected individuals is unclear. It 
is possible that other drug classes, as well as drug interactions are contributing to 
these findings. As a comprehensive examination of medication classes and drug 
interactions were beyond the scope of this study, further research would benefit 
from direct and comprehensive assessment of the association between EDS, 
antidepressant and other medication use and falls risk.  
 
Among men, no relationship was detected between EDS and falls, and only a 
trend towards significance was noted between EDS and falls risk as assessed by 
the EFST score. These findings, in part, mirrors previous research which has 
typically suggested a lower overall prevalence of falls among older men 
compared to women (234, 386), and reported that female gender represents a 
risk factor for falls (234); however this finding is not universal (230). Singular 
aspects of the EFST have been shown to be accurate predictors of falls risk in 
men, such as slow and/or unsteady or gait (387), however balance and/or gait 
assessments alone are not considered effective predictors of relative falls risk 
(388). We acknowledge that we did not observe an association between EDS 
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and falls, and suggest that this finding may, in part, be due to underreporting of 
falls by the male participants. Furthermore, as only a small proportion of men 
reported both a fall and EDS, we cannot exclude the possibility of a type 2 error. 
Future research would benefit from corroborating both objective and subjective 
fall records in order to recognise any possible sources of personal bias in 
responses.   
 
We report that a greater proportion of women with EDS report a fall occurring 
whilst located outside. These findings may reflect the sample population; as 
activities such as gardening are often cited as the most frequently engaged form 
of physical activity among healthy older adults, particularly during the warmer 
months (i.e., summer/autumn) (389). Further, this may in part provide 
explanations for the observation of a greater proportion of women with EDS 
reporting a fall whilst located outside; however, the direct mechanism driving this 
association is unknown. Indeed, other studies have noted no significant seasonal 
variation in fall incidence rates in the study region which is located in a temperate 
climate (390). We did not have access to seasonal markers as part of this study, 
however, further research may benefit from investigating seasonal correlations 
and patterns associated with fall location to better target at-risk individuals during 
these times. Additional research would benefit from tabulation of the amount of 
time spent indoors/outdoors, either in the form of a questionnaire or objective 
assessment of indoor/outdoor activity (such as Actigraphy monitoring) in order to 
evaluate this association in more detail. 
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Injuries resulting from falls represent a significant factor in hospitalization and 
subsequent functional decline among older adults (391). Soft-tissue injuries were 
the most common injury sustained as a result of a fall for both men and women, 
and we report a higher proportion with these injuries than has reported elsewhere 
(e.g., (379)). It is possible that within our study, the methodology employed to 
classify sustained injuries was more inclusive of reported injuries. As the 
questionnaire used was an open-ended item, we were able to classify all 
responses into injury categories (soft-tissue, fracture etc.), thus possibly resulting 
in higher incidence. Prevention strategies aimed at older individuals, such as 
strength and/or gait training, reduction in tripping hazards, typically emphasise 
the risk-reduction of incidences occurred inside the home only. As we similarly 
report a high rate of falls occurring among women with EDS when situated 
outside, similar programs and/or education aimed at addressing possible risks 
and hazards among these locations may assist in reducing the number of falls 
and incurred injuries within these settings.    
 
When considering the mechanistic pathways which may drive an association 
between sleepiness and falls, it is feasible to assume that diurnal disruptions 
characteristic of the aging process, such as a reduction in total sleep time, 
reduced sleep efficiency and increased sleep fragmentation may contribute to 
impairments in behavioural and cognitive functions similarly implicated in falls 
(392). Coupled with increased rates of polypharmacy often observed among 
these age groups, it is also likely that these factors interact to contribute to and 
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compound impaired levels of cognition; which is directly associated with 
increased falls occurrence and future falls risk. Indeed, reduced executive 
function capabilities, which can be  impaired as a result of sleepiness (393) and 
often are associated with increased or excessive poly-medication use (such as 
sedatives, painkillers, cardiac medications etc.) (394); have also been shown to 
contribute to falls among older men and women (395), and measures of these 
variables have demonstrated efficacy in predicting later falls (396). Differences in 
mechanistic properties driving an association between EDS and falls between 
men and women may, in part, be due to differing sex-specific characteristic sleep 
and medical profiles. Among men, it is possible that both indirect (weight, neck 
circumference, BMI) and direct (snoring, nocturnal choking) factors associated 
with underlying OSA represents a more salient factor contributing to EDS and 
subsequent falls. Among women, it is possible that poor nocturnal sleep quality 
or instances of insomnia, which is more common among older women (397) 
contribute to EDS, and that subsequent compensatory mechanisms (taking 
sleep-enhancing medication) contribute to reported falls as a function of reduced 
alertness and attention during waking hours. Therefore, it is proposed that both 
the transient and chronic effects of sleep loss or poor sleep, compounded by the 
effects of poor-health and disease and subsequent compensatory measures 
(such as increased medication use), which typically differ between sexes, may 
directly affect neurocognitive functions commonly implicated in falls, such as 
alertness, attention and executive functioning. As a comprehensive examination 
of many of these domains were beyond the scope of this study, further 
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assessment of the association between EDS, medication use, objective sleep 
factors and falls risk factors may assist in further describing these mechanistic 
pathways.  
 
A notable strength of the current study included utilizing a large, representative 
population-based sample of older men and women. Due to the study design, we 
were able to obtain a representative sample of elders, and thus we overcame the 
limitations of previous research which often utilise techniques that are sensitive to 
volunteer bias (371, 379). Furthermore, the use of population-based older adults 
in the current study addresses the limitations of previous studies which have 
often utilised sample populations solely drawn from assisted living or retirement 
facilities [see (362)]. Similarly, we were able to obtain and collate detailed 
information regarding the nature and circumstances of the reported falls, such as 
information pertaining to the number of falls, the fall location, the reason for falls, 
and whether any injuries occurred as a result of the fall; therefore highlighting 
some possible areas of intervention.  
 
Although we present a significant association between the presence of EDS and 
falls in women, it must be acknowledged that inferences regarding the 
directionality of the relationship cannot be made due to the cross-sectional study 
design. We assessed falls history using a retrospective questionnaire design over 
the past 12 month period; a method which has been employed by previous 
population-based studies of older adults (220, 234). Although this technique is 
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useful with regard to assessing approximations of the burden of disease, poor or 
inaccurate fall recollection over this time period cannot be excluded. Despite this, 
meta analyses have shown good overall specificity (91-95%) and adequate 
sensitivity (80-89%) of self-reported recollection of falls occurring in the preceding 
12 months among healthy older individuals (398), and we report similar rates to 
previous studies (220). Due to the small number of individuals who reported 
multiple falls, we did not assess this association in detail with regard to EDS. 
Further research would benefit from investigating whether symptoms of 
sleepiness contribute to reporting multiple falls, and whether it represents an 
independent risk factor. Further, some research has highlighted the limitations of 
the ESS as a measure of daytime somnolence among some groups of older 
adults due to individuals being unable to fully complete the questionnaire despite 
reporting symptoms of EDS (399). However, assessments of the reliability of the 
ESS among these individuals are typically conducted on cohorts of clinical 
groups from selective hospital outpatient departments (399), and therefore the 
same issues may not be present in all adults. Lastly, as we did not explicitly 
assess instances of sleep disordered breathing such as OSA, we cannot exclude 
that this may have contributed to the current findings. Despite this, previous 
studies have found that among community dwelling adults, a weak correlation 
exists between instances of sleep disordered breathing and daytime impairment 
(400).  
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These data suggest that among this population-based group of older adults, EDS 
is associated with an increased incidence of falls for women, independent of a 
number of associated health and lifestyle factors, and that these falls are most 
likely to occur whilst located outside. For men, a trend towards significance was 
noted for the association between EDS and an increased falls risk profile. As 
EDS is a common symptom among older adults, and falls are often considered a 
precipitating factor of assisted living admission, amelioration of these symptoms 
may improve functional outcomes for these individuals and preserve independent 
living status and thus reduce the risk for morbidity among these individuals. 
Future research would benefit from the inclusion of more comprehensive 
assessments of specific sleep pathology in order to explicate their role in the 
reported relationship. 
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CHAPTER 10: The Relationship Between Excessive 
Daytime Sleepiness and Depressive and Anxiety 
Disorders in Women 
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Introduction
Sleep disorders represent a significant public health concern, 
including excessive daytime sleepiness (EDS) (Johns and 
Hocking, 1997). The term EDS refers to a broader set of 
symptoms of unplanned daytime sleep, and the inability to 
remain alert or awake in passive situations (Ohayon, 2008). 
Factors contributing to EDS vary, but generally include insuf-
ficient nocturnal sleep, the presence of underlying sleep dis-
orders such as obstructive sleep apnoea, narcolepsy or 
circadian rhythm disturbances (Roth and Roehrs, 1996), as 
well as factors associated with mental disorders (psychosis, 
depression, anxiety) (Ohayon et al., 1997). Epidemiological 
studies have suggested that the general population prevalence 
of EDS is between 0.3% and 13.3% (Johns and Hocking, 
1997). Implications of untreated EDS include an increased 
risk of cardiovascular disease (Rockwood et al., 2001) and 
work-related injuries (Melamed and Oksenberg, 2002), a 
negative effect on daily activities (Johns and Hocking, 1997) 
and poorer mental health outcomes (Bixler et al., 2005).
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Objective: Excessive daytime sleepiness (EDS) is a common clinical symptom that affects women more than men. 
However, the association of excessive sleepiness with depressive and anxiety disorders in the broader population 
is unclear. The aim of this study was, therefore, to examine the association between excessive daytime sleepiness as 
measured by the Epworth Sleepiness Scale, and depressive and anxiety disorders in a population-based sample of women.
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Sleep disturbance in general and EDS in a subgroup rep-
resents both a prodromal symptom reflecting depressive 
symptom relapse in patients in remission (Gillin, 1998), as 
well as a residual symptom following psychiatric treatment 
(Judd et al., 1998). Within a clinical framework, EDS is 
considered a common behavioural feature of depression, 
and sleepiness levels have been found to be an indicator of 
symptom severity in depressive patients (Chellappa and 
Araújo, 2006). Anxiety has also been cited as a secondary 
factor in the experience of EDS; however, these results 
have been mixed (Breslau et al., 1997; Theorell-Haglow 
et al., 2006). Although mechanisms which underlie these 
relationships are uncertain, it is believed that poor sleep 
quality or inadequate sleep arising from psychiatric distur-
bances, or sedative effects of treatments may contribute to 
the expression of daytime symptoms (Roth and Roehrs, 
1996). Indeed, several clinical and epidemiological studies 
have identified several possible factors that may influence 
the pattern of EDS, such as young age (Kaneita et al., 
2005), short sleep duration or disturbed sleep (Martikainen 
et al., 1992), insufficient or non-restorative sleep, psycho-
logical stress (Kaneita et al., 2005), and/or female gender 
(Hara et al., 2004; Martikainen et al., 1992).
Although epidemiological studies have suggested that 
EDS is more common in women than men (Hublin et al., 
1996; Rockwood et al., 2001), much of the previous popu-
lation-based research has focused on men only (Doi et al., 
2002; Nugent et al., 2001), or on mixed samples of men 
and women (Kim and Young, 2005). Moreover, despite 
current epidemiological research suggesting a possible 
relationship between mental disorders and sleepiness 
(Olson et al., 1998), particularly in women (Hara et al., 
2004; Lindberg et al., 1997), there is a paucity of informa-
tion investigating the interrelatedness of these two disor-
ders in the broader population. In the available literature, 
interpretation of effect differences between depressive dis-
orders, anxiety disorders and sleepiness are often compli-
cated by variations between study population samples 
(Lader, 2007), outcome measures used (Taylor et al., 2007) 
and whether the studies controlled for possible confound-
ing variables such as tobacco smoking (Taylor et al., 2007), 
age (Tsuno et al., 2005), alcohol consumption (Johns and 
Hocking, 1997) and medication use (Kripke et al., 2002). 
Consequently, there is limited knowledge regarding the 
association between EDS and depressive and anxiety dis-
orders in population-based cohorts of women. In addition, 
the availability of well-controlled studies examining the 
relationship between EDS and these disorders in a large 
cohort is currently lacking. The aim of this study was, 
therefore, to examine the association between EDS, as 
measured by the Epworth Sleepiness Scale, and depressive 
and anxiety disorders in a population-based sample of 
women, while controlling for relevant lifestyle and medi-
cal factors.
Methods
Participants
This study examined data collected from women participat-
ing in the Geelong Osteoporosis Study (GOS) – a large, 
population-based study designed to assess individuals 
residing in south-eastern Australia, who were randomly 
selected from electoral rolls. Originally, 1494 women were 
recruited, representing 77.1% participation (Pasco et al., 
2012). At the 10-year follow-up (2004–2008), 881 women 
from the original sample returned (82.1% of eligible 
women), which was complemented by the inclusion of an 
additional 246 randomly selected women aged between 20 
and 29 years to allow for the continued investigation of the 
full adult age range (82% response) (Pasco et al., 2012). Of 
the 1095 women who participated in the 10-year follow-up, 
participants for whom sleep data were not available (n = 
20) or whom were current users of antidepressant medica-
tion (n = 131) were excluded, resulting in a total of 944 
eligible women aged between 20 and 97 years old. This 
study was conducted with the approval of Barwon Health 
Human Research Ethics Committee, and written informed 
consent was obtained from each participant.
Measurements
EDS was assessed using the Epworth Sleepiness Scale 
(ESS) (Johns, 1991). The ESS is a self-administered eight-
item questionnaire that has been widely used as a simple, 
reliable and valid method for assessing daytime sleepiness 
in adults. Participants are required to rate their self-per-
ceived likelihood of falling asleep or dozing off in eight 
passive situations. Examples of situations include: watch-
ing television, sitting and reading, and as a passenger in a 
car. Participants are required to respond to items on a four-
point rating scale (0 = would never doze, 1 = slight chance 
of dozing, 2 = moderate chance of dozing, 3 = high chance 
of dozing). Possible scores range from 0 to 24, with higher 
scores reflecting greater subjective sleepiness (Johns, 
1991). Distribution of the ESS to a group of 72 healthy sub-
jects who had no reported sleep or respiratory disorders 
yielded average scores of 0–10 (Johns and Hocking, 1997). 
Subsequent studies replicating this method have self-
reported average scores of 0–11 in a group of 188 healthy 
volunteers (Parkes et al., 1998). Thus, although there are no 
universally used cut-off points to rate excessive sleepiness 
in normal populations, many studies have chosen the prag-
matic score of ≥ 10 to indicate pathological levels of sleepi-
ness (Johns, 2000; Johns and Hocking, 1997). For the 
purpose of this study, we made an a priori decision that 
scores between 0 and 9 would indicate normal levels of 
sleepiness and scores between 10 and 24 would indicate 
EDS. The questionnaire has previously been considered to 
have high internal validity as measured by Chronbach’s 
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alpha (0.88) (Johns, 1992), as well as high 5-month re-test 
reliability in normal samples (Pepin et al., 2011).
Demographic information regarding medical history, 
health and additional lifestyle factors was also documented. 
Habitual physical activity was self-reported. Participants 
were classified as active if exercise was performed regu-
larly, otherwise participants were classified as sedentary. 
Participants’ history of tobacco smoking was classified as: 
(1) currently smoking; (2) past history; or (3) had never 
smoked. Information regarding alcohol consumption was 
obtained using the Cancer Council Food Frequency 
Questionnaire (FFQ) (Giles and Ireland, 1996) and daily 
usage was expressed as gram intake per day. Weight and 
height were measured and body mass index (BMI) was cal-
culated as weight/height2 (kg/m2). Medication use was 
classified as ‘current’ if participants reported use at the time 
of the follow-up. Socioeconomic status (SES) was deter-
mined from the Socio-economic Indexes for Areas (SEIFA) 
index scores gathered from the 2006 Australian Bureau of 
Statistics data. SIEFA values were applied to obtain an 
Index of Relative Socio-Economic Advantage and 
Disadvantage (IRSAD), and participants were categorised 
into five groups, according to quintiles of IRSAD for the 
study region.
The presence of depressive and anxiety disorders was 
assessed using the Structured Clinical Interview for 
Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Non-Patient edition (SCID-I/NP). The 
SCID-I/NP is considered ‘gold standard’ for assessing 
depressive and anxiety disorders in non-psychiatric popula-
tions. The use of this assessment tool allowed for the iden-
tification of lifetime or current depressive disorders 
including: major depressive disorder (MDD), bipolar disor-
der, dysthymia, minor depression, substance-induced mood 
disorder and mood disorder due to a general medical condi-
tion, and/or anxiety disorders including panic disorder, 
agoraphobia, social phobia, specific phobia, obsessive-
compulsive disorder, generalised anxiety disorder, anxiety 
disorders due to a general medical condition, substance-
induced anxiety disorder and anxiety disorders not other-
wise specified. All interviews were conducted by trained 
personnel.
Statistical analysis
Differences in characteristics between those with and 
without EDS were analysed using Kruskal–Wallis for 
non-parametric continuous variables and chi-squared 
analysis for non-parametric discrete variables. Fisher’s 
Exact Test was used for non-parametric variables where 
cell sizes were less than 5. Odds ratios (ORs), with 95% 
confidence intervals (CIs) were determined using logistic 
regression models to investigate the association between 
EDS and depressive and anxiety disorders, both past and 
current. Separate statistical models were developed for 
depressive and anxiety disorders. In all models, the ESS 
score was applied as a binary outcome (EDS yes/no). 
Age, BMI, physical activity, smoking, alcohol use and 
SES and use of sedative, analgesic, antipsychotic and 
anti-anxiety agents were tested sequentially, and poten-
tial confounders and effect modifiers were checked in all 
statistical models. Covariates that significantly influ-
enced the outcome variable (EDS) were retained and 
applied for all final statistical models. To assess the 
strength of the associations when a more conservative 
cut-point (ESS score ≥ 12) was applied to identify EDS, 
the same methods were used. All statistical analyses were 
completed using Minitab (Version 15; Minitab, State 
College, PA, USA).
Results
Characteristics of the whole group and according to EDS 
status are shown in Table 1. The range for all ESS scores 
was 0–18 (median score 4.0). Overall, 125 (13.2%) of the 
women reported EDS. Those who reported EDS had a 
greater BMI and were more likely to meet criteria for a life-
time or current depressive disorder compared to those with 
no EDS. There were no differences detected in age, smok-
ing, physical activity, anxiety disorders, SES or psycho-
tropic medication use between the groups.
After adjustment for age and alcohol intake, EDS was 
associated with an increased likelihood of a lifetime 
history of a depressive disorder (OR = 1.95, 95% CI 1.28–
2.97, p = 0.002). A similar relationship was observed 
between EDS and current depressive disorders (OR = 2.11, 
95% CI 1.10–4.06, p = 0.03). The relationship between 
EDS and a lifetime history of a depressive disorder was 
sustained following the application of a more conservative 
cut-point (≥ 12) (OR = 1.77, 95% CI 1.0–3.1, p = 0.05), 
although no association was found between EDS and cur-
rent depressive disorders at this cut-off (OR = 1.72, 95% 
CI 0.71–4.19, p = 0.23).
These findings were not explained by medication use, 
BMI, physical activity, smoking, or SES. There was no 
association between EDS and lifetime or current anxiety 
disorders.
Discussion
Our data demonstrate that in a population-based sample of 
women, those who report EDS had an increased likelihood 
of experiencing current and/or a lifetime history of depres-
sive disorders compared to those without EDS. The asso-
ciation between EDS and depressive disorders was 
independent of sedative and hypnotic use as well as other 
psychotropic medications, socioeconomic standing, BMI, 
physical activity, smoking and alcohol consumption. This 
relationship was sustained when a more conservative cut-
point (ESS ≥ 12) was applied for those with a lifetime 
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history of depression. In contrast, no association was found 
between EDS and current or lifetime history of anxiety 
disorders.
The current study demonstrated a significant association 
between EDS and women’s current and/or past experience 
of depressive disorders. This finding supports previous epi-
demiological research demonstrating a strong relationship 
between EDS and current depression (OR = 3.12), more so 
than with common underlying contributory factors, such as 
obesity and/or sleep-related breathing disorders (Bixler 
et al., 2005). Obesity is linked to adverse mental health out-
comes (Pasco et al., 2013; Williams et al., 2009). The cur-
rent study demonstrated a significant association between 
EDS and depressive symptoms, even after controlling for 
BMI. Previous research has established that EDS in non-
pathological populations is not necessarily attributable to 
BMI and/or obesity (Johns and Hocking, 1997). Thus, 
despite the established link between EDS and depression 
(Bixler et al., 2005) and BMI and depression (Scott et al., 
2007), future research may benefit from additional epide-
miological studies assessing the prevalence of EDS while 
controlling for BMI to assess the mechanisms of this rela-
tionship. It has further been suggested that EDS may be 
related to weight gain related to the use of both antidepres-
sant medication (Guillemenault and Brooks, 2001) and 
neuroleptic medications, or a combination of these (Stanton, 
1995). The relationship between EDS and mental health in 
the current study was found to be independent of BMI and 
the use of these medications. Therefore, EDS may repre-
sent an independent risk factor for depressive disorders. 
Thus, it may be clinically useful to routinely assess mental 
health issues in patients presenting with EDS, even when 
BMI is considered to be within the normal range.
To our knowledge, this is the first population-based 
research to demonstrate a significant relationship between 
lifetime history of depressive illness and EDS in women. 
Concurrent epidemiological-based psychiatric research has 
previously demonstrated a link between EDS and lifetime 
history of manic and hypomanic episodes (Tsuno et al., 
2005); however, definitive research in this area is currently 
lacking. There is new evidence that a preceding maladap-
tive lifestyle and health factors often associated with the 
development of depression, such as tobacco smoking 
(Cassidy et al., 2004), physical inactivity and obesity 
(Pasco et al., 2008, 2011a, 2011b; Roberts et al., 2003; 
Williams et al., 2009), contribute to maintain negative 
Table 1. Characteristics for the whole group and women with and without excessive daytime sleepiness (EDS).
EDS 
 All No Yesa p
 n = 944 n = 819 n = 125  
Age 49.0 (33.0–65.0) 49.0 (33.0–65.0) 50.0 (37.3–62.8) 0.60
BMI, kg/m2 26.1 (23.4–30.6) 25.9 (23.3–30.3) 27.4 (24.3–32.2) 0.02
Smoking, current 133 (14.1%) 118 (14.4%) 15 (12.0%) 0.47
Physically active 755 (80.0%) 658 (80.3%) 97 (77.6%) 0.48
Alcohol intake, g/day 3.0 (0.4–12.0) 3.2 (0.4–11.7) 2.2 (0.4–12.5) 0.46
Socioeconomic status 0.22
 Quintile 1, lowest 140 (15.0%) 117 (14.4%) 23 (18.4%)  
 Quintile 2 205 (21.9%) 186 (22.9%) 19 (15.2%)  
 Quintile 3 217 (23.2%) 185 (22.8%) 32 (25.6%)  
 Quintile 4 178 (19.0%) 150 (18.5%) 28 (22.4%)  
 Quintile 5 196 (20.9%) 173 (21.3%) 23 (18.4%)  
Sedative use, current 19 (2.0%) 18 (2.2%) 1 (0.8%) 0.50
Depressive disorders  
 Lifetime 216 (22.9%) 175 (21.4%) 41 (32.8%) 0.005
 Current 59 (6.3%) 46 (5.6%) 13 (10.4%) 0.04
Anxiety disorders  
 Lifetime 99 (10.5%) 84 (10.3%) 15 (12.0%) 0.56
 Current 60 (6.36%) 53 (6.5%) 7 (5.6%) 0.71
aEpworth Sleepiness Scale score ≥ 0.
Values are given as median (IQR) or n (%).
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lifestyle and health outcomes which are recognised to share 
pathology with EDS, such as sleep disturbances and/or 
medical comorbidity. Despite this, we demonstrate that this 
relationship is independent of a number of possible explan-
atory lifestyle and health factors. As this relationship was 
found to be sustained following the application of a more 
conservative cut-point (ESS ≥ 12), this suggests that the 
relationship between EDS and lifetime depression may, in 
part, be mediated by degree of sleepiness pathology, rather 
than by complimentary maladaptive lifestyle habits. Thus, 
higher scores on the ESS may reflect degree of depressive 
symptomology, which in turn is sustained via persistent 
excessive sleepiness. ESS scores have previously been 
demonstrated to reflect depressive symptomology in 
patients who report current depression (Chellappa and 
Araújo, 2006); however, no comparable research is availa-
ble in regard to lifetime history of depression. As depres-
sive patients are recognised to typically score higher on 
measures of sleepiness than healthy individuals (Chellappa 
and Araújo, 2006), additional research is therefore war-
ranted to determine whether ESS scores can accurately 
reflect degree of symptomology, particularly where depres-
sive illnesses are longstanding.
Research exploring the relationship between EDS and 
psychiatric illness typically focuses on the impact of symp-
toms within a depressive framework alone (Bixler et al., 
2005; Chellappa and Araújo, 2006). It is therefore surpris-
ing that few studies have investigated the role of EDS in 
anxiety, which is commonly comorbid with depression. 
Although no significant association was found between 
EDS and anxiety in the current study, further longitudinal 
research to determine both the clinical usefulness of assess-
ing EDS levels in patients with anxiety and whether this is 
mediated by comorbid symptomology, is warranted.
We acknowledge some limitations of the current study. 
Given that the study was cross-sectional, the reported asso-
ciations do not give an indication of the direction of the 
relationships. Hence, as the presence of these sleep distur-
bances often coexist with depressive disorders, it is often 
difficult to draw conclusions as to the causative effects of 
one on the other. There is a suggestion in the literature that 
this may be bidirectional, as EDS has been found to repre-
sent both a risk factor for (Theorell-Haglow et al., 2006) 
and residual symptom of depressive illness (Bixler et al., 
2005). Moreover, data on the presence of past or current 
sleep disorders were not available, thus it is possible that 
this or other unrecognised confounding variables may 
account for the findings. Subjective reports of excessive 
sleepiness cannot provide a clinical diagnosis to explain the 
causes of EDS. Nevertheless, subjective reports of the rela-
tionship between ESS scores of 10 or more for the sub-
group of women with high levels of EDS, combined with 
previously established correlates of EDS, suggest that poor 
or disturbed sleep (Bixler et al., 2005) and pathological 
sleep disorders, such as obstructive sleep apnoea syndrome 
(OSA), may have contributed to sleepiness levels (Johns, 
1993).
A notable strength of this study is that we investigated a 
large, representative and randomly selected population of 
women spanning the full adult age-spectrum. However, 
interpretation of results may not be generalisable to other 
populations of women, or to men. Despite this, the current 
study addresses the need for population-based data, and the 
growing recognition of a need for a gender-specific 
approach to mental-health care (Judd et al., 2009). 
Furthermore, the use of ‘gold-standard’ clinical interviews 
to determine the presence of depressive and anxiety disor-
ders, the consideration of several possible confounding fac-
tors such as medication use, SES and lifestyle factors, as 
well as high participant retention, address the limitations of 
previously conducted research (cf. Johns and Hocking, 
1997; Kripke et al., 2002; Lader, 2007; Taylor et al., 2007).
In conclusion, the current study supports previous 
research demonstrating a link between EDS and depressive 
disorders, while also suggesting possible future research 
avenues. EDS is a common issue presenting in clinical 
practice, particularly in individuals with depressive disor-
ders (Chellappa et al., 2009). Clinically significant EDS is 
associated with an increased risk of both current and life-
time risk of experiencing a depressive illness, suggestive of 
a possible mediating and sustaining factor in the expression 
of both disorders. Thus, the findings of the current research 
may assist in the diagnosis and treatment of a range of 
depressive disorders, while providing novel insight into 
possible future research investigating a role of anxiety in 
EDS. Consequently, direct identification and treatment of 
EDS in suspected depressive disorder patients may improve 
long-term health outcomes via the application of symptom 
monitoring over time, particularly when these symptoms 
are longstanding.
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11.1 Abstract 
 
Aim: We examined the trajectories and stability of self-reported sleep duration 
recorded at ages 13, 15 and 23 years on reported sleep duration at age 30 years 
among 1105 students (55% male) who participated in the Norwegian Longitudinal 
Health and Behaviour Study. Method: Questionnaire data was used to obtain 
demographic and sleep variables. Dichotomised short sleep duration was based 
on normative values and set as  8.5 hours (age 13 years), 8 hours (age 15 
years) and  7 hours (ages 23 and 30 years). Results: Results indicated a 
significant overall reduction in total sleep duration (hrs/night) across age groups. 
Sleep duration (continuous) at age 15 and 23 years (whole group) was 
moderately but positively correlated with sleep duration at age 30 years (p<0.01). 
When split by sex, at age 15 years, this association was present among females 
only (p<0.01), however at age 23 years, this association was present in both 
male and females (both p< 0.001). Categorical short sleep at age 23 years 
(whole group) was associated with short sleep at age 30 years (unadjusted OR = 
3.67, 95% CI 2.36-5.69). Following sex stratification, this effect was significant for 
both males (unadjusted OR= 3.77, 95% CI: 2.22-6.42) and females (unadjusted 
OR= 2.71, 95% CI: 1.46-5.04). No associations were noted for categorical short 
sleep at ages 13 or 15 years and subsequent short sleep at 30 years 
Conclusion: Habitual short sleep duration during middle adulthood is not 
sustained from the time of early adolescence. Rather, these trends appear to be 
formed during early adulthood.
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11.2 Introduction  
Effective and regular regulation of the sleep/wake cycle is fundamental in order to 
maintain optimal biological, metabolic and physical functioning; however it is 
often exogenously mediated by aspects of socio-cultural, psychosocial, 
occupational and familial demands (402). A number of cross sectional and 
longitudinal studies have demonstrated that both long and short habitual sleep 
periods present as independent risk factors for impaired cardiovascular 
functioning and subsequent increased rates of cardiovascular disease (403, 404), 
increased weight (405) and higher rates of obesity (406), reduced immune 
function (407), and an increased risk for all-cause mortality (169, 408). 
 
Sleep problems are common among children and adolescents, with as many as 
76% of 11–15 year olds surveyed reporting some degree of sleep difficulties 
(409). Complaints of difficulty initiating or maintaining sleep constitute some of 
the most common issues (410, 411), however these symptoms appear to 
decrease somewhat with age (412, 413). Habitual total sleep duration has been 
shown to be highly variable, at least among young children and during periods of 
early adolescence (402, 414), however the onset of early maladaptive sleep 
habits may have implications for the later development of sleep problems during 
subsequent developmental phases. Evidence from cross-sectional and 
longitudinal analyses suggests that the natural course of human sleep maturation 
has important developmental phases during infancy. Sleep patterns formed 
during infancy are to some extent carried forward later periods of childhood 
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(415), and may have further implications in the expression of habitual short and 
long sleep duration and continuity throughout early adolescence to adulthood 
(324, 416).  
 
Despite the significant clinical implications of assessing sleep duration from 
periods of adolescence to adulthood, several areas of investigation still remain. 
Most notably, there is currently a paucity of detailed longitudinal analyses 
assessing the stability of sleep duration over time, and it is unclear whether 
critical age-ranges exist in the expression and development of these 
associations. Moreover, little research is available, which examines these factors 
across extended assessment periods. Of the available studies assessing the 
natural course and stability of sleep duration and periods of short sleep, much of 
the literature focuses on periods of childhood (414) or restricted periods of 
adolescence (417).  
 
Given that sleep duration is strongly associated with many chronic yet 
preventable conditions, a more accurate description of these associations may 
augment available treatment modalities and improve clinical outcomes for these 
patients. As a result, the aims of the current study are to (1) assess the natural 
development and stability of sleep duration from ages 13 years, 15 years, and 23 
years to 30 years and (2) identify the association between short sleep duration at 
ages 13 years, 15 years, and 23 years on cases of short sleep duration at age 30 
years. 
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11.3 Method 
11.3.1 Participants 
 
This study utilises data collected as part of the Norwegian Longitudinal Health 
and Behaviour Study (NLHB). The NLHB is a nine-wave, cluster-sample research 
study which followed a cohort of adolescents from age 13 (initial testing period 
1990) to 30 years (final follow-up in 2007). As part of the initial wave in 1990, a 
total of 1,195 13 year olds and their parents were invited to participate in the 
study. An additional 47 students were invited to participate during the two 
subsequent data collection waves 2 and 3 in 1991 and 1992, resulting in a total 
sample of 1,242. Inclusion for the study required consent from both the 
adolescent and the parent/guardian, which resulted in a total of 1105 (55% male) 
students (89% of the total invited sample).  
 
The retention rate at age 30 years is 49 % (based on the number of persons who 
had participated at least once during ages 13-21), representing 43% of the 
original sample.    
 
 A more detailed description of the sampling procedures and data collection 
methods used in the NLHB-study can be found elsewhere (Jakobsen, 1997, 
Birkeland et al., 2009). 
 
Study questionnaires were distributed at the participants’ school initially (at ages 
13–15 years), and were then distributed by mail to the respondents’ home 
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addresses for each subsequent follow-up assessment period. Sleep variables 
were not measured during all data collection waves, and for this reason we only 
used data from the 1990, 1992, 2000 and 2007 waves, for the age-groups of 13, 
15, 23 and 30 years, respectively.   
 
Written informed consent was obtained for each study participant and the study 
has been approved by the Norwegian Data Inspectorate. The study was 
approved by The Regional Committee for Medical Research Ethics in Western 
Norway. 
11.3.2 Demographics 
Sex was first reported in the initial data collection wave in 1990, and was noted at 
the time of each follow-up in order to assess gender distribution for each study 
wave. 
11.3.3 Sleep variables 
 
Information regarding subjective sleep was collected at the time of each data 
collection wave, and information regarding self-reported bed times and wake-
times were obtained separately for both week days and weekends. For the 
current study, only information regarding weekday sleep duration was used. 
Questionnaire items were modified slightly to include age-relevant statements 
(i.e. refers to school/work). Response options for bed-times were graded on a 5-
point scale. Response options for week-day bed times included the following; 
‘about 21:30 or earlier’, ‘about 22:00’, ‘about 22:30’, ‘about 23:00’, ‘about 23:00 
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or later’. Questionnaire items ‘time getting up on a school/work day’ were 
presented on a 4-point scale and included response options; ‘about 6:30 or 
earlier’, ‘about 07:00’, ‘about 7:30’, or 08:00 or later’.  
 
Total sleep duration was calculated by the self-reported time in bed (calculated 
from total difference between bedtime and rise time) minus self-reported sleep 
latency. For this study, we classified ‘short’ and ‘normal’ sleep duration differently 
for each data collection wave, in order to account for age-related differences with 
regard to normative sleep values and self-reported sleep duration frequently 
reported for each age group (402, 418). Short sleep duration at age 13 years 
(wave 1- 1990) was defined as  8.5 hours (31.4%), and normal sleep was >8.5 
hours/night. Short sleep duration at age 15years (wave 2- 1993) was defined as 
8 hours (31.9%), and normal sleep duration was >8 hours. Sleep duration of  7 
hours was considered ‘short’ for those aged 23 (25.5%) and 30 years (29.8%) 
(waves 3 and 4; 2000 and 2007, respectively), with >7 hours considered within 
normal range.
 
For this study, we classified ‘short’ and ‘normal’ sleep duration differently for each 
data collection wave, in order to account for age-related differences with regard 
to normative sleep values and self-reported sleep duration frequently reported for 
each age group (402, 418). Short sleep duration at age 13 years (wave 1- 1990) 
was defined as  8.5 hours (31.4%), and normal sleep was >8.5 hours/night. 
Short sleep duration at age 15years (wave 2- 1993) was defined as 8 hours 
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(31.9%), and normal sleep duration was >8 hours. Sleep duration of  7 hours 
was considered ‘short’ for those aged 23 (25.5%) and 30 years (29.8%) (waves 3 
and 4; 2000 and 2007, respectively), with >7 hours considered within normal 
range.
11.4 Statistical analyses 
 
To illustrate the trajectories of short sleep across the four waves (Figure 1A and 
1B), the dichotomized sleep duration variables (using the age-based cut-offs) 
were used to create the 6 most common courses from age 13 to 30 (1A), and 30 
to 13 (1B). Assessment of the association between sleep duration in 2007 and 
previous waves indicated a reasonable number of categories, and dispersion, 
and little indication of a marked non-monotonic association was noted. The 
number of categories and dispersion were similar when stratified for gender 
(results not shown). Chi-square analyses were used to assess differences in 
dichotomised sleep duration (short vs. normal) between those who completed all 
data waves and those who had missing sleep data on any of the four data waves. 
One-way ANOVA was used to assess differences in average sleep duration 
between those who completed all data collection waves and those who had 
missing sleep data on any of the four data waves. ANOVA with repeated 
measures with Greenhouse-Geisser correction and Bonferroni post hoc tests 
were used to test for differences in sleep duration across the four waves. 
Spearman rank-order correlation coefficients (Spearman’s Rho) were used to 
assess the correlations between sleep duration (continuous) at ages 13, 15 and 
23 with sleep duration at age 30. Binary logistic regression modelling was used to 
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examine short sleep duration (yes/no) at ages 13, 15 and 23years as a predictor 
of reporting poor sleep at age 30years (yes/no). Statistical analyses including 
Chi-square analyses, one-way ANOVA and Spearman rank-order correlation co-
efficient (Spearman’s Rho) were assessed using the SPSS statistical software 
package version 21 (SPSS Inc., Chicago, IL), and all tests were two-tailed with 
conventional p< 0.05 as significance threshold. Due to missing information about 
sleep duration across waves, we employed multiple missing imputation 
procedure using the multivariate normal approach with five imputations as 
available in Stata 13.1 for the binary logistic regression models. 
11.5 Results 
11.5.1 Characteristics 
 
Characteristics data and information for sleep variables across all data collection 
waves for the whole group are presented in table 1. Sex distribution was 
comparable for each data collection waves, however more female participation 
was noted for the two later waves (waves 3 and 4, ages 23 and 30years, 
respectively), and more males were noted for the first two waves (waves 1 and 2, 
ages 13 and 15years, respectively). Total sleep duration (hh:mm) was noted to 
decrease significantly as per each data collection wave (F(2.7,621.5)=281.6, 
p<.001). While the average sleep duration at age 13 and 15years was 9:01 and 
8:38, this was reduced to 7:50 and 7:38 at age 23 and age 30years, respectively 
(all p<. 001). A general reduction was observed for those reporting both  10 and 
9-<10 hours of sleep per night (p/night) across age groups, and a general 
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increase was seen among those reporting 7-<8 hours across age groups. Sleep 
duration of 8 to < 9 hours was most stable across age groups. 
 
Table 1. Demographic and sleep variables for the whole sample. 
 Age 13 
(n= 653) 
Age 15 
(n=855) 
Age 23 
(n=560) 
Age 30 
(n=493) 
Sex         
 Girls, % (n) 46.9% (306) 45.3% (387) 54.8% (307) 54.6% (269) 
 Boys, % (n) 53.1% (347) 54.7% (468) 45.5% (253) 45.4% (224) 
Sleep duration, 
mean (SD) 
8:58 (0:33) 8:31 (0:35) 7:45 (0:50) 7:36 (0:45) 
Sleep duration, 
% (n) 
        
< 7 hours - - - - 11.4% (64) 11.6% (57) 
7 to < 8 hours 2.6% (17) 8.4% (72) 37.5% (210) 48.1% (237) 
8 to < 9 hours 28;8% (188) 56.4% (482) 39.5% (222) 35.1% (173) 
9 to <10 hours 62.0% (405) 33.1% (283) 9.8% (55) 4.5% (22) 
 10 hours 6.6% (43) 2.1% (18) 1.6% (9) 0.8% (4) 
11.5.2 Short sleep vs. Normal sleep 
 
Figure 1(a) describes the developmental trajectory of those individuals who self-
reported short sleep duration compared to normal sleep duration at age 13years 
through to age 30years. A large proportion of individuals (39%) who reported 
short sleep at age 13years reported a stabilization of normal sleep duration by 
age 15years, of which remained until age 30years. The second most common 
developmental trajectory profile (22.1%) was noted for those individuals who 
reported short sleep at age 13years and were noted to alternate between short 
and normal sleep duration over the duration of the assessment waves. Only a 
small proportion (5.8%) of individuals reported instances of sustained short sleep 
from early adolescence (age 13years) through to mid adulthood (age 30years). A 
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comparable proportion of individuals (5.8%) was noted to initially report short 
sleep duration at age 13years then report normal sleep duration during late 
adolescence/early adulthood (ages 15 and 23years), only to again report short 
sleep at age 30yrs. 7% of individuals who reported short sleep during both 
sampling periods of adolescence (ages 13 and 15years, respectively), reported a 
stabilization of normal sleep duration during adulthood (ages 23 and 30years, 
respectively). 
 
Figure 1(b) displays the reverse developmental trajectory of those individuals 
who reported short sleep duration compared to normal sleep duration at age 
30years from age 13years. The most common trajectories leading to short sleep 
duration at age 30years was seen among individuals who reported normal sleep 
duration up until age 23years (34.3%). A small percentage of individuals who 
reported short sleep duration at age 30yrs were seen to initially report normal 
sleep at age 13years until 15years, or alternate between normal and short sleep 
between waves (both 9.0%). Only a small proportion of individuals (7.5%) 
reported consistently short sleep from age 13years until age 30years. 
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Figure 1. Figure 1. The most common trajectories of short sleep duration across 
all 4 time points from age 13 to 30years. Figure A shows the most common 
trajectories leading from short sleep duration at age 13years. For example, 
among participants with short sleep duration at age 13, 5.8% were classified as 
having short sleep duration throughout all waves (trajectory indicated with white 
triangles). Figure B shows the most common trajectories leading to short sleep 
duration at age 30years. For example, among participants with short sleep 
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duration at age 30, 7.5% had short sleep duration also at all previous waves 
(trajectory indicated with white triangles). 
11.5.3 Sleep duration 
 
To assess the predictive value of self-reported short sleep duration 
(dichotomised) at ages 13, 15 and 23years on short sleep duration at 30years of 
age, we applied binary logistic regression modelling (Figure 2). For the whole 
group, short sleep duration at age 23years was associated with short sleep at 
age 30years (unadjusted OR = 3.67, 95%CI: 2.36-5.69). Following sex 
stratification, this association was similarly observed among males (unadjusted 
OR= 3.77, 95%CI: 2.22-6.42) and females (unadjusted OR= 2.71, 95%CI: 1.46-
5.04).    
Chi-square analyses assessing differences between completers versus non 
completers, and short versus normal sleep duration (data not shown) revealed 
that the proportion of short sleepers is lower among those who completed all data 
waves for ages 15, 23 and 30 years  (all p<0.05), but not age 13 years. 
Associations between self-reported sleep duration (continuous) at ages 13, 15 
and 23years, and at age 30years were assessed using Spearman rank-order 
correlation coefficient (Spearman’s Rho). A moderate positive association was 
noted for self-reported sleep duration at age 15years and similarly reported sleep 
habits at age 30years (Spearman’s Rho 0.208, p< 0.001) (See supplemental file 
1), however when split by sex, this association was present among females only 
(Spearman’s Rho 0.246, p< 0.001). The corresponding correlation between self-
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reported sleep duration at ages 23 and 30years was notably stronger 
(Spearman’s Rho 0.362, p< 0.001) (See supplemental file 2). When split by sex 
this association was present among both males (Spearman’s Rho 0.422, p< 
0.001) and females (Spearman’s Rho 0.291, p<0.001). No associations were 
noted for self-reported sleep duration for those aged 13years on sleep duration at 
age 30years (See supplemental file 3).   
One-way ANOVA revealed that compared to non-completers, participants who 
completed all four data (13, 15, 23 and 30years) waves reported increased sleep 
duration during the second data collection wave (1992) (15 years) than those 
who did not complete data collection (p= 0.004). No differences were noted 
between groups for any other data collection wave.  
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Figure 2. Short sleep duration (dichotomized) at ages 13, 15 and 23years and 
risk factor for short sleep duration at age 30years, and spearman rank order 
correlations (rho) based on the continuous sleep duration variables. Bars 
represent odds-ratios (OR) and error bars represent 95% confidence intervals (Y-
axis has a logarithmic scale). For example, the bar furthermost to the right shows 
that participants with short sleep duration at age 23 had 3.67-fold increased odds 
of having short duration at age 30. Similarly, the corresponding correlation 
between (continuous) sleep duration at age 23 and age 30 was 0.362. 
Note: logistic regression analyses are based on a multiple imputed dataset, 
whereas correlation analyses are based on the non-imputed dataset. 
*** indicates p<0.001. 
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11.6 Discussion 
 
The findings of the current study were in line with previous research, which has 
demonstrated that a general trend exists for a reduction in self-reported sleep 
duration with increasing age. We also report that self-reported sleep duration at 
age 15 years and 23years (whole group) is positively associated with self-
reported habitual sleep duration at age 30years; however when split by sex, this 
association is differentially represented between males and females across ages. 
Assessment of the most common developmental trajectories of poor sleep 
showed that a large proportion of those who reported short sleep duration during 
early adolescence (13years) had stabilised into periods of normal sleep at the 
time of mid adolescence to adulthood (ages 15 to 30years), and that the 
development of poor sleep at age 30years occurs most frequently during periods 
of early adulthood (23years).  
 
We report a gradual reduction in total sleep duration (hh:mm) as a function of 
increasing age. These findings mirror other longitudinal assessments of sleep 
duration among population-based cohorts which have used similar age ranges 
(415) and self-report measures (402). Such changes are thought to primarily 
reflect changes in biologically driven sleep homeostatic needs as we age (329), 
however are similarly recognised to be mediated and influenced by a number of 
sociocultural, familial and occupational demands characteristic of each life stage. 
A large portion of the participants in the current study reported obtaining a 
habitual nightly sleep duration, which is considered to fall within the normative 
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limits for each age-range (402, 419), however approximately 1/10th of those aged 
both 23 and 30 years reported obtaining less than 7 hours of sleep/night. Given 
the aforementioned health implications of short sleep duration, some vigilance is 
needed among these individuals in order to maintain optimal associated health 
outcomes.  
 
Habitual sleep duration has been shown to be highly variable among individuals 
from periods of childhood and adolescence (173, 402, 417), however 
interpretation of the stability of these factors over time is often impeded by the 
relatively short assessment duration. We demonstrated that for the whole group, 
self-reported sleep duration at age 15 and 23 years is moderately positively 
associated with reporting similar sleep duration at age 30 years. Indeed, a trend 
of late onset cases of short sleep duration was noted among this cohort, a finding 
was somewhat similarly reflected in the assessment of common developmental 
trajectories leading to short sleep duration at age 30 years (see figure 1a and b). 
When split by sex, this association is differentially represented between males 
and females across ages. At age 15 years, this association was present among 
females only. At age 23 years, this relationship was found in both sexes.. The 
strength of the trajectories of sleep duration through the adolescent to adulthood 
transition period was weaker than is often asserted for younger age-groups 
(416). Thus, it is possible that interplay between occupational and socio-cultural 
demands during these life stages, particularly during periods of later 
adolescence, contribute to sleep duration (417). Indeed, that there was no 
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association between sleep duration at age 13 years and age 30 years suggests 
that sleep disturbances experienced early resolve themselves with age and are 
not persistent; a finding which is concurrent with the limited research describing a 
general reduction in sleep complaints as a function of increasing age (412). 
Despite these observations, a large degree of intra-individual variation exists with 
regard to self-reported sleep duration across the lifespan; often as a function of 
differing occupational, social and health-related factors associated with that 
particular life stage. As the causative pathways attenuating this relationship 
remain unconfirmed, there is a need for additional comprehensive longitudinal 
assessments of the stability of these trends over time.  
 
There is little research assessing the stability of categorical short sleep duration 
from periods of early adolescence to mid adulthood. As short sleep duration has 
been previously linked to deleterious health outcomes (405, 406), it is therefore 
surprising that little detailed assessment in this area is currently available. We 
demonstrated that those who reported categorical short sleep duration at age 23 
years (whole group) had greater than a 3.6-fold increased odds of similarly 
reporting short sleep at age 30 years. Following sex stratification, it was 
demonstrated that men who reported short sleep duration at age 23 years had 
greater than a 3.7-fold increased odds of similarly reporting short sleep at age 30 
years, and among women, this odds was increased approximately 2.7-fold. No 
such effect was noted for those who reported categorical short sleep at age 13 
years or 15 years similarly reporting short sleep at age 30 years. To our 
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knowledge, this is the first research to demonstrate that self-reported short sleep 
during early adulthood (23 years) predicts instances of short sleep duration in 
mid adulthood (30 years). Research investigating the stability and trajectory of 
sleep duration across the lifespan is typically restricted to periods of childhood or 
adolescence, or measures different aspects of maladaptive sleeping behaviours 
(324). This may in part be due to the greater perceived necessity of these 
developmental periods in respect to health outcomes later in life. Whilst 
assessments during these times are indeed valuable, descriptions of these 
trends during later developmental periods may have implications for sleep habits 
later in life. Given the organic changes in sleep architecture as we age, the early 
development of adaptive sleep habits may foster improved outcomes during 
these periods.     
 
The current study has several identifiable strengths. Most notably, to our 
knowledge, this study is the largest assessment of the trajectories and stability of 
self-reported sleep duration across an extended period of time from early 
adolescence to mid adulthood. The use of a longitudinal design and inclusion of a 
representative cohort of participants allowed us to track the stability of these 
trends over time, and across several critical developmental phases, thus 
addressing several of the limitations of past research. Moreover, the use of a 
large, representative, community-based sample combined with the generally high 
retention rate of participants across data collections waves enables greater 
generalisability of the reported findings to comparable populations.    
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The result from this study must be interpreted in light of some methodological 
limitations. Most notably, the sleep variables used in this study were obtained via 
self-report questionnaire only, and were not corroborated by additional objective 
sleep monitoring devices. However, in depth analyses and description of 
objective sleep variables among these participants was not an aim of this study. 
Secondly, self-reported sleep duration was not assessed to the exact hours and 
minutes, and were instead defined using predefined categories. Therefore, some 
of the more subtle changes over time may have been overlooked, and thus we 
are unable any inferences on these trends. Further, it is possible that participants 
under-or overestimated their total sleep time; a factor which may have somewhat 
attenuated the reported findings. Despite this, a number of longitudinal and cross 
sectional studies have utilised similar methods (420, 421), and the use of pre-
determined response categories may better assist in describing overall trends in 
sleep duration at a population level. Lastly, although the overall participant 
retention rate across data waves was high, some attrition was noted between 
study waves; particularly among males, and thus this may have somewhat 
influenced the reported findings. Indeed, assessment of sleep characteristics 
between those who participated in all data collection waves compared to those 
who missed one or more wave revealed a generally lower proportion of short 
sleepers among those who completed data collection. Thus, there may be an 
underestimation of the effect of the reported findings.  Despite this, we noted that 
the differences were largely negligible with regard to overall sleep duration 
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across waves between completers and non-completers, and thus we do not 
anticipate that these differences are clinically significant.  
 
In this longitudinal sample of individuals, we report the first research assessing 
the stability and trajectory of sleep duration characteristics from early 
adolescence through periods of mid adulthood. Instances of self-reported short 
sleep in mid adulthood appear to be formed in late adolescence/early adulthood, 
and these associations are seen to be comparably strong for both men and 
women. Habitual short sleep duration in early adolescence typically resolves by 
the end of adolescence and does not predict short sleep during mid-adulthood. 
Given the natural decline in a number of sleep parameters associated with the 
natural aging process, proactive maintenance of adaptive sleep habits during 
these critical periods of early adulthood may assist in associated functional sleep 
outcomes during periods of mid to late adulthood and/or older age. 
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12.1 Abstract 
 
Study objectives: To assess the direction of the relationship and degree of 
shared associations between symptoms of depression and difficulty initiating 
sleep (DIS) from early adolescence to early adulthood. Design: Cross-sectional 
and longitudinal assessment of the symptoms of depression-DIS association 
from early adolescence (age 13yr) to early adulthood (age 23yr). Setting: 
Hordaland, Norway. Participants: 1105 individuals (55% male) who took part in 
the Norwegian Longitudinal Health Behaviour Study (NLHB) and participated at 
least once across seven data collection waves during the years 1990-2000. 
Measurements and results: : Characteristic data were obtained during the first 
assessment. Symptoms of depression and instances of DIS were assessed 
during each data collection wave. Symptoms of depression and DIS were 
associated in all data waves, and one-step cross-lagged bivariate correlations 
were significant and comparatively high for both factors. Structural equation 
modelling indicated that DIS and symptoms of depression at wave 1 remain 
relatively stable across waves (all p<0.001), and a significant and consistent 
unidirectional cross-lagged effect was noted running from symptoms of 
depression to DIS from early adolescence to early adulthood. DIS is only 
marginally and inconsistently associated with the lagged symptoms of depression 
score across waves. Conclusions: These results suggest that symptoms of 
depression established in early adolescence are a moderate predictor of DIS in 
early adulthood, while the reverse association of DIS predicting depression was 
not convincingly supported. These findings are in contrast to previous findings 
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that suggest sleep problems as a risk factor for the later development of 
depression.    
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12.2 Introduction 
 
A number of cross-sectional and longitudinal studies have demonstrated that 
both individual symptomatic components of insomnia, such as sleep onset 
difficulties (266, 422) as well as defined clinical instances of insomnia are closely 
related to depressive illness (423, 424). Prospective studies have shown that 
instances of insomnia in early adulthood predict the later development of 
depressive symptoms (425), and that depressive symptoms can precede the 
later onset of sleep problems (266). Despite this, there is lack of specificity in 
regard to the age of onset of these symptoms, the developmental course of these 
symptoms across time, and whether each condition is differently represented with 
respect to directionality of the association, particularly among population-based 
cohorts.  
 
Mechanistically, it has been suggested that the reciprocal association between 
depression and insomnia is primarily driven by shared neurobiological and 
behavioural deficits with regard to the sleep-wake regulatory dysfunction, which 
in turn acts to mediate deficits in emotional reactivity (419). Indeed, successful 
amelioration of sleep difficulties among depressed individuals demonstrates 
improvements in self-reported mood states as well as higher remission rates 
among these individuals (426). As such, the causal association of underlying 
sleep pathology leading to the subsequent development of depressive illness is 
perhaps the most prominent theoretical perspective. (see; Baglioni and 
colleagues(427)). Many of the available epidemiological studies assessing sleep 
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pathology at baseline and the subsequent development of depressive illness 
have yielded range risk estimates of between 3.8- 6.7 (354, 428). Meta-analytic 
studies have similarly demonstrated that depressive illness and sleep problems 
are often observed to naturally co-occur (427); a finding which has been shown 
to be relatively consistent among cohorts of children, adults and older individuals 
(427). 
 
The reverse model, whereby depression predicts the later development of sleep 
problems has also been explored, albeit in less detail and with less specificity 
(425). To our knowledge, there are only a few prospective studies which have 
examined, and found, depression to be a risk factor for the future development of 
general sleep problems(266, 349) or clinically defined insomnia(421, 429, 430). 
Some studies utilizing retrospective analysis design have reported no association 
between depressive symptoms at baseline and the subsequent development of 
sleep problems at follow-up (354). Other studies assessing the depressive 
symptoms-sleep problems relationship often feature sleep as a function of 
underlying physical disease (431), and thus any confirmative conclusions 
regarding the strength of the observed relationship are equivocal. Compared to 
the amount of literature focussing on sleep difficulties as a proxy for the later 
development of depressive symptoms, the proposed evidence supporting the 
reverse path is less clear, with the implication that sleep disturbance is an 
emergent symptom of a depressive phenotype. Evidence supporting the 
depression-to-sleep problem association has been primarily derived from clinical 
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treatment studies, of which have demonstrated improvements in insomnia 
symptomology following the application of CBT-I or pharmacotherapy targeting 
depressive symptoms (426).  
 
Although a significant amount of data has demonstrated a link between sleep 
problems and depressive illness, particularly among adults, several areas of 
investigation remain. Indeed, much of the available literature spans only brief 
periods of early adolescence or adulthood (266), includes only a limited number 
of sampling phases (431), or fails to accurately describe the strength of these 
associations and role of possible peripheral confounders. Consistent assessment 
of these factors over several time points will allow for greater specificity in regard 
to subtle changes over time, and assist in describing the natural course of these 
associations. Moreover, there is a paucity of information assessing the specific 
role of sleep onset difficulties with regard to depressive symptomology, as the 
available literature typically focusses on instances of general insomnia 
complaints only. At present, there is a lack of empirical evidence which 
accurately quantifies the developmental trajectory of these associations from the 
time of early adolescence through to early adulthood. Such investigations may 
lend evidence to help delineate whether this relationship can be considered 
causal, or if it instead represents an epiphenomenon or occurs as a result of 
peripheral factors.    
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12.3 Method 
12.3.1 Participants 
 
For the current study, we utilised data from the Norwegian Longitudinal Health 
Behaviour Study (NLHB). The NLHB is a nine-wave, cluster-sample research 
study which followed a cohort of adolescents from age 13 (initial testing period 
1990) to 30yr (final follow-up in 2007). As part of the initial wave in 1990, a total 
of 1,195 13 year olds and their parents were invited to participate in the study. As 
the data collection was conducted during school hours in waves 1-3, 47 students 
who joined the sampled school classes after wave 1 were invited to participate 
during the two subsequent waves, resulting in a total sample of 1,242. Inclusion 
for the study required consent from both the adolescent and the parent/guardian, 
which resulted in a total of 1105 (55% male) students (89% of the total invited 
sample).  
 
627 of the 1105 students responded in wave 8 (at age 23), indicating a retention 
rate of 57% (and representing 50% of the original sample). A more detailed 
description of the sampling procedures and data collection methods used in the 
NLHB-study can be found elsewhere 16, 17. Actual participation rates across 
data waves are presented in Table 1. 
 
Study questionnaires were distributed at the participants’ schools at the time of 
the first few years of the study (age 13–15yr), and were later distributed by mail 
to the respondents’ home addresses at the time of each follow-up assessment 
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wave. This paper presents data from the years 1990, 1991, 1992, 1993, 1996, 
1998 and 2000 (that is, at ages 13, 14, 15, 16, 19, 21 and 23yr). Data from wave 
5 (age 18yr) was not included as no sleep item was included in this survey. To 
use the longitudinal data in an optimal way, full information maximum likelihood 
(FIML) were used in order to obtain a likelihood function for each individual based 
on the variables that were present for each data wave (N=1,076).  
 
Written informed consent was obtained for each study participant and the study 
has been approved by the Norwegian Data Inspectorate. The study was 
approved by The Regional Committee for Medical Research Ethics in Western 
Norway. 
Table 1. Age and number of participants included for analyses for each data 
collection wave. 
 
 1990 1991 1992 1993 1995 1996 1998 2000 2007 
Age  13  14  15  16  18  19  21  23  30 
N  924  958  963  789  779  643  634  627  536 
 
12.3.2 Variables 
 
Sex was first reported in the initial data collection wave, and was noted at the 
time of each follow-up in order to assess sex distribution for each wave. 
 
Symptoms of depression were assessed using the 7-item depression inventory 
originally proposed by Alsaker 18. Inventory items include statements which 
relate to hopelessness, sadness, and depressive feelings. Assessment of the 
internal consistency yielded acceptable values, with Chronbach’s Į being high 
237 
across all 7 waves, ranging from .82 to .92, and also Guttman Split-half 
correlations were comparably acceptable (ranging from .79 to .92 across all 7 
waves). Test–retest reliability was assessed during the data assessment wave 
1991 among 80 respondents. Results indicated an acceptable temporal stability 
between total scores (Guttman Split-half correlations .87), however this was 
variable for assessment of single items (between .52 and .80). Questionnaire 
items included the following statements; ‘I often feel depressed without knowing 
why’, ‘Sometimes I think everything is so hopeless that I don’t feel like doing 
anything’, ‘I don’t think I have anything to look forward to’, ‘Sometimes I am just 
so depressed that I feel like staying in bed for the whole day’, ‘I am often sad 
without seeing any reason for it’, ‘I think my life is mostly miserable’ and 
‘Sometimes I think my life is not worth living’. Response options were presented 
on a 5-point likert-style scale, and included the statements ‘Does not apply at all’, 
‘Does not apply well’, ‘Applies somewhat’, ‘Applies fairly well’, ‘Applies well’ and 
‘Applies exactly’ (scored as 0-5, respectively).  
 
Difficulties initiating sleep (DIS) at all 7 waves (at ages 13, 14, 15, 16, 18 , 21 and 
23yr) were measured using the following item ”Have you had difficulties falling 
asleep during the last 3 months?”. For the first three waves (ages 13, 14, and 
15yr) participants scored this item on a four-point Likert-scale, with the following 
response option: “Seldom or never”, “Sometimes”, and “1-3 nights per week” and 
“4 nights per week or more often”. For the last 4 waves (ages 16, 18, 21 and 
23yr) the response options were “Seldom or never”, “Sometimes”, and “Very 
238 
often (weekly)”. To enable comparisons across all 7 waves, the 4 response 
options in the first 3 waves were reduced to 3 by combining “1-3 nights per week” 
and “4 nights per week or more often“ into “Very often  (weekly)”.   
12.4 Statistical analyses 
 
Pearson product-moment correlation coefficient (Pearson’s’ r) analyses were 
performed to determine how symptoms of depression were associated with DIS 
within each data collection wave as well as between the seven time points, for 
the whole group. A Wald test of parameter constraints was used to compare the 
autocorrelations of DIS and depression scores across time. To examine possible 
causal models of the relationship between symptoms of depression and difficulty 
initiating sleep, we employed structural equation modelling (SEM), and cross-
lagged longitudinal models were tested in Mplus version 7 using full information 
maximum-likelihood and MLR as estimator 19 (432). The cross-lagged 
longitudinal approach was chosen to perform an analysis including both variables 
(symptoms of depression and DIS) across multiple time points. The approach 
enables the simultaneous modelling of within-concept cross-time effects (for 
example symptoms of depression at t1, t2 and so on), cross-concept within-time 
relations (for example symptoms of depression and DIS at t2) and the cross-time 
cross-concept effects (for example symptoms of depression at t1 influencing DIS 
at t2). By employing SEM instead of other, more simpler models (like regression 
analysis), a complex and simultaneous investigation of how symptoms of 
depression and DIS affect each other across multiple time-points was possible, 
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and it is possible to shed light on the temporal relationship between the two 
phenomena. 
 
Four different models were investigated, from the simplest to the most complex 
model. In M1, autoregressions within each time span for both symptoms of 
depression and DIS were included (for example symptoms of depression at t2 
regressed on symptoms of depression at t1), and the cross-lagged effects of both 
symptoms of depression and DIS (for example DIS at t2 regressed on depression 
at t1). For both symptoms of depression and DIS, the variables at t1 were 
exogenous, while they were endogenous at all other time-points, meaning that 
the former is not thought to be caused by other variables in the model, while the 
latter is thought to be caused by other variables (here depression and DIS at t1) 
in the model. M2 expanded on M1 by allowing for the long-term effects within 
concepts to be estimated (for example symptoms depression at t3 regressed on 
t1). M3 also expanded on M1 by also including cross-concept cross-time effects 
(correlation of residual variance between symptoms of depression and problems 
initiating sleep at t2 and onwards). M4 was the most complex model, and 
included symptoms of depression and DIS as exogenous at t1, but also included 
intra-conceptual autoregressive paths, the long-term within-concept coefficients, 
cross-lagged paths and cross-concept cross-time effects. 
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12.5 Results 
12.5.1 Bivariate cross-sectional and longitudinal analyses 
 
Descriptive statistics for sex, DIS and symptoms of depression across all time 
points are presented in table 2a. Sex distribution is comparable across waves; 
however a higher proportion of males compared to females were seen in the first 
four data collection waves, and vice versa in the final three data collection waves. 
Mean depression scores were relatively stable over time; however an 
incremental reduction in mean depression scale scores was noted with 
increasing age. Mean DIS scores were also noted to be relatively stable over 
time, but were incrementally lower during the later data collection waves 4, 6 and 
7 (ages 16, 19 and 21yr, respectively) (F(6,1584) = 3.063, p= 0.006). 
 
Table 2a. Descriptive statistics for gender, symptoms of depression and 
difficulties initiating sleep (DIS) across time. 
aBased on participation in each wave for those with complete sleep and 
depression information 
 
Comparisons of baseline (age 13) variables between responders (individuals who 
completed all waves) and non-responders (those who dropped out at any of the 
Time Female (%)a      Symptoms of depression Difficulties initiating sleep  
   Mean SD N  Mean SD Weekly (%) CI95% N 
1 45.3  2.3 0.9 663  1.5 0.6 5.7 4.1-7.7 671
2 44.4  2.2 1.0 894  1.5 0.7 8.9 7.2-11.1 850
3 44.3  2.4 1.1 824  1.5 0.6 8.1 6.5-10.1 903
4 45.8  2.1 1.0 668  1.4 0.6 5.8 4.3-7.8 706
6 52.7  2.2 1.1 609  1.4 0.6 7.1 5.4-9.4 644
7 53.3  2.0 1.0 548  1.4 0.6 6.5 4.8-8.8 585
8 51.0  1.9 1.0 599  1.5 0.7 8.7 6.7-11.1 624
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waves following baseline) showed that there were no significant differences 
between responders and non-responders on either DIS or symptoms of 
depression, nor on reports of smoking, alcohol use, and BMI. Moreover, no 
differences were found for parental occupational or cohabitant status. However, 
significantly more girls completed all waves (48% compared to boys, 32%, p < 
.001). 
 
In all of the seven waves, DIS was consistently highly correlated with symptoms 
of depression, and the strength of these associations was noted to increase 
incrementally with advancing age (see table 2b). This association was strongest 
at data collection wave 8 (ages 23yr), and weakest at data collection wave 1 
(ages 13yr). 
 
Table 2b. Cross-conceptual bivariate cross-sectional correlations for symptoms 
of depression and DIS across time points. 
 Symptoms of depression and 
DIS 
p-value N 
  95% CI   
 R Lower Upper   
Time 1 0.26 0.20 0.32 <0.001 643 
Time 2 0.28 0.22 0.34 <0.001 802 
Time 3 0.36 0.30 0.41 <0.001 806 
Time 4 0.29 0.22 0.36 <0.001 666 
Time 6 0.30 0.23 0.37 <0.001 609 
Time 7 0.34 0.26 0.41 <0.001 544 
Time 8 0.40 0.33 0.49 <0.001 595 
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Table 2c shows the one-step cross-lagged bivariate correlations between DIS 
and symptoms of depression across time points. Associations between DIS and 
symptoms of depression were comparably high across time; however the 
association between symptoms of depression at tn with DIS at tn+1 were slightly 
stronger than the associations of DIS at tn with symptoms of depression at tn+1, 
with the exception of t3-t4 and t6-t7. 
 
Table 2c: Cross-conceptual bivariate cross-lagged correlations (tn correlated with 
tn+1) for symptoms of depression and DIS across time points. 
 Symptoms of depression 
at tn correlated with DIS at 
tn+1
p-value N DIS at tn correlated with 
symptoms of depression at 
tn+1
p-value N 
  95% CI    95% CI   
 R Lower Upper   R Lower Upper   
t1 and t2 0.21 0.13 0.28 <0.001 615 0.19 0.11 0.26 <0.001 636 
t2 and t3 0.27 0.22 0.34 <0.001 801 0.22 0.15 0.29 <0.001 720 
t3 and t4 0.23 0.15 0.30 <0.001 617 0.27 0.20 0.34 <0.001 627 
t4 and t6 0.21 0.13 0.29 <0.001 502 0.16 0.07 0.24 <0.001 500 
t6 and t7 0.23 0.14 0.31 <0.001 484 0.24 0.15 0.32 <0.001 475 
t7 and t8 0.29 0.20 0.37 <0.001 451 0.24 0.15 0.32 <0.001 470 
  
12.5.2 SEM: Cross-lagged longitudinal model 
 
Table 3 describes the standardized coefficients of the initial correlation, 
autoregressive and cross-lagged paths for insomnia and depression from wave 1 
to wave 8. The initial correlation between DIS and symptoms of depression 
indicated a moderate positive association (r = .27, p<0.001).  
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Autoregressive analyses were used to assess the stability of time for both DIS 
and symptoms of depression. Results indicated that both DIS and symptoms of 
depression at wave 1 remain relatively stable across waves (all p<0.001). The 
autocorrelations for DIS were, however, smaller across time than the 
autocorrelations for symptoms of depression. In order to compare the 
autocorrelations of DIS and depression scores across time, we performed as 
series Wald tests of parameter constraints. There was strong statistical evidence 
that the autocorrelations for depression scores were stronger than DIS, both 
when tested sequentially (all p-values <0.001) and collectively (p-value <0.001) 
(See Table 2). 
 
Table 2. Standardized coefficients of the correlations, autoregressive and cross-
lagged paths for symptoms of depression and DIS across time points (N=1,076). 
  T1 
Standardized 
coefficients 
(Standard 
error, SE) 
T2 
Standardized 
coefficients 
(SE) 
T3 
Standardized 
coefficients 
(SE) 
T4 
Standardized 
coefficients 
(SE) 
T6 
Standardized 
coefficients 
(SE) 
T7 
Standardized 
coefficients 
(SE) 
T8 
Standardized 
coefficients 
(SE) 
 
Correlation 
       
Sleep and 
depression 
 0.267*** 
(0.036) 
- - - - - - 
 
Autoregressive 
paths 
       
Sleep  - 0.346*** 
(0.035) 
0.313*** 
(0.033) 
0.343*** 
(0.036) 
0.258*** 
(0.041) 
0.306*** 
(0.042) 
0.281*** 
(0.042) 
         
Depression  - 0.524*** 
(0.029) 
0.618*** 
(0.023) 
0.612*** 
(0.027) 
0.556*** 
(0.032) 
0.626*** 
(0.028) 
0.596*** 
(0.030) 
 
Cross-lagged 
paths 
       
Lagged 
depression 
on sleep 
 - 0.063 
(0.034) 
0.063* 
(0.31) 
0.082* 
(0.034) 
0.035 
(0.037) 
0.090* 
(0.038) 
0.065 
(0.038) 
         
Lagged 
Sleep on 
depression 
 - 0.138*** 
(0.037) 
0.209*** 
(0.034) 
0.124** 
(0.041) 
0.149** 
(0.044) 
0.306*** 
(0.042) 
0.281*** 
(0.042) 
* p<0.05 
** p<0.01 
*** p<0.001 
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Considering model fit, there were differences between the models: 
M1, where both symptoms of depression and DIS were entered as exogenous at 
t1, had a moderate fit [root mean square error of approximation (RMSEA): 0.069 
(CI90% 0.063-0.076), comparative fit index (CFI): 0.826, Tucker-Lewis Index 
(TLI): 0.762)].  
 
M2, which assumed both symptoms of depression and DIS were entered as 
exogenous at t1, but also includes the long-term within-concept coefficients, 
demonstrated similar fit indices [(RMSEA): 0.068 (CI90% 0.062-0.072), (CFI): 
0.843, (TLI): 0.768)]. 
 
M3, where both symptoms of depression and DIS were entered as exogenous at 
t1, but also includes the cross-concept cross-time effects demonstrated an 
improved fit [(RMSEA): 0.053 (CI90% 0.046-0.060), (CFI): 0.907, (TLI): 0.860)]. 
M4, which assumes that symptoms of depression and DIS are exogenous at t1, 
but also includes intra-conceptual autoregressive paths, the long-term within-
concept coefficients, cross-lagged paths and cross-concept cross-time effects 
demonstrated the best fit;  [(RMSEA): 0.045 (CI90% 0.038-0.053), (CFI): 0.943, 
(TLI): 0.898)]. 
 
The differences between the four models in relation to the path coefficients of 
interest in the present study (auto-regressive and cross-lagged paths) were not 
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substantial. We therefore chose to present the results from M1 since this was the 
less complex model (see Figure 1). 
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Figure 1. Auto-regressive and cross-lagged paths for symptoms of depression 
and DIS across all data collection waves. 
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12.6 Discussion 
 
The results of the current study suggest that there is a strong cross-sectional 
association between symptoms of depression and DIS, and that the strength of 
this relationship is similarly observed from early adolescence to early adulthood. 
Longitudinally; we report that when assessed individually, symptoms of 
depression at baseline remain relatively and comparably stable from early 
adolescence to early adulthood. For DIS, this association is somewhat less 
stable across time. Notably, we report that although symptoms of depression are 
substantially and consistently associated with the lagged sleep score, DIS is only 
marginally and inconsistently associated with the lagged depression score across 
time.  
 
The results of our cross-sectional analyses are consistent with previous research 
which has demonstrated a strong association between depressive symptoms and 
sleep problems (433, 434). We report that the strength of this association was 
sustained in every data collection wave from early adolescence through to early 
adulthood, which is consistent with, and builds on, previous research which has 
demonstrated a close association between these factors during this age period. 
Markedly, our research is the first to describe that these associations remain 
significant across such an extended period of time, as much of the available 
literature is typically focussed on periods of childhood (433), brief period of 
adolescence, or periods of late adolescence/early adulthood (435).  
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Considering the longitudinal analyses, several interesting findings were noted. 
First, we report that when assessed cross-sectionally, DIS and symptoms of 
depression are moderately correlated. Moreover, when assessed individually at 
baseline, symptoms of depression demonstrated a moderate correlation but a 
high internal stability across data assessment waves over time from early 
adolescence to adulthood. Furthermore, we report a decline in severity of 
depressive symptoms and DIS at ages 13 and 23 years; a time when depression 
and insomnia are typically observe to increase in prevalence. Previous 
longitudinal assessments have demonstrated that depressive symptoms and 
depressive disorders that appear during periods of early adolescence have a 
lifetime prevalence of between 3.7-11.2% (436, 437), suggesting that a sensitive 
developmental period may exist which influences the natural development of 
these symptoms over time and thus help to maintain them throughout the 
lifespan. Thus, it is possible that these endogenous factors may in fact have a 
greater influence on the expression of depressive symptoms among young 
adolescence than external factors per se. For DIS, descriptions of the natural 
development of these symptoms across the lifespan and the lifetime prevalence 
rates are less clear. Some studies have found that the development of sleep 
problems during periods of adolescence are often associated with a number of 
biological, physiological and social transitions that often characterize 
adolescence and affect sleep/wake regulation during this time (438). It is 
therefore plausible that these symptoms are similarly developed during critical 
periods of early adolescence, and subsequently maintained throughout the 
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lifespan via continuous feedback from a variety of behavioural, physiological and 
biological inputs associated with these developmental periods during early 
adulthood. Such explanations, may, in part, help to explain our reported findings, 
and lend argument to the often high lifetime prevalence and disability observed 
among those who report chronic insomnia syndrome and often low rates of 
disease remission (439).   
 
We describe a significant and consistent unidirectional effect running from 
symptoms of depression to DIS from the time of early adolescence to early 
adulthood. A substantial portion of longitudinal studies suggest that the reverse is 
true; that sleep problems precede the onset of later mood disturbances (354, 
427), however it must be noted that the assessment framework employed are 
often confined to specific developmental stages, such as defined periods of 
adolescence (354) or adulthood  (421). Research investigating depression as a 
predictor of the later development of sleep problems are also limited, and are 
similarly restricted to periods of adolescence (266) or older age  (349), or focus 
on specific clinical populations only (430). At present, comprehensive and 
inclusive assessments of these relationships from periods of adolescence 
through to adulthood are inadequate, and thus assumptions regarding the 
underlying mechanistic assumptions are incomplete. Therefore, it is possible that 
the expression of these associations when evaluated during these transitional 
periods of adolescence/adulthood presents a hitherto unassessed characteristic 
in the depressive-sleep matrix. Thus, our findings lend weight to the small 
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number of previous studies which have shown depressive symptoms to predict 
later sleep problems and to our knowledge, present the first research which 
evaluates these relationships across these critical developmental periods (429, 
440). Additionally they build on previous studies which demonstrate the 
incidence, but not adequately described the persistence of comorbid sleep and 
psychiatric illness over time (429). When considering these findings, it is 
important to note that the reported longitudinal associations are of moderate 
strength. However, given that the long-term within concept coefficients, cross-
concept cross-time and autoregressive associations were controlled for in the 
development of the models, the cross-lagged associations should be weaker 
than in analyses in which no such adjustments are made. Despite this, the 
observed strength of the association was preserved and the model was robust, 
and thus the simplest model was chosen. Given these considerations, it is 
therefore unlikely that the observed associations are attributable to erroneous 
variance or error; rather, it is likely that these associations represent a true and 
persistent relationship between symptoms of depression and DIS scores across 
time.  
 
Unlike several studies assessing these factors, we did not find clear evidence for 
a bidirectional relationship between symptoms of depression and DIS, as DIS at 
age 13yr was not a significant risk factor for symptoms of depression at age 23yr. 
Conceptually, it is possible that this relationship is represented only among 
complete diagnoses of insomnia and depressive syndrome, as was shown in 
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previous studies (440), and that typical methodological considerations and 
statistical analyses used are insufficient at identifying more subtle aspects of 
individual symptoms of both conditions.  
 
Sex distribution is comparable across waves; however a higher proportion of 
females compared to males participated in the last three data collection waves. 
These values are reflective of participation trends and retention rates for the 
overall study (see reference (441)). Several population-based cross-sectional 
and longitudinal analyses have highlighted that female sex represents a 
significant and independent risk factor for both insomnia and depressive illness 
(442, 443), and that these symptoms are consistently more prevalent among 
women (444, 445). We did not stratify these data by sex for cross-sectional 
analyses; however, sex stratification techniques were initially employed for 
longitudinal models (data not shown). No effect for sex was identified, and thus 
these techniques were not maintained in the development in the development of 
the final model. It is possible that sex is not an attenuating factor when assessing 
individual symptom expression of these factors, as is often observed when 
assessing the whole syndrome. The primary strengths of the current study were 
the use of a longitudinal study design, which allowed for detailed assessment of 
the relative association between the target variables across all assessment 
periods, as well as the extended duration of total data collection from early 
adolescence to early adulthood (10yr). Such methods provided a detailed 
description of the strength of these associations across the transition period of 
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adolescence to adulthood, thus addressing the limitations of some past studies. 
Indeed, in the available comparable literature, there is a lack of studies tracking 
the natural development of these associations over such an extended testing 
period. Often, the longitudinal associations between symptoms of depression and 
sleep problems are ascribed following a brief total assessment period, or are 
based on retrospective analysis (354). 
 
There are still some limitations within the design of the current study. First, as 
depressive symptomology was assessed using a validated, but not widely used 
inventory; it is possible that the prevalence of these symptoms were under-
represented among this cohort. We also concede that the use of the relatively 
unknown depression scale in the current study also limits the generalizability of 
the reported findings. Despite this, other longitudinal studies utilising the NLHB 
have employed similar methodology (446), and psychometric assessment of the 
inventory have yielded similar indices to other, more well-known depression 
scales which utilise frequency indicators, such as the Centre for Epidemiological 
Studies Depression Scale (CES-D) (447-449). Moreover, as only a single sleep 
item assessing sleep onset difficulties was used in this study, we are unable to 
generalise these findings to other individual subtypes of sleep problems often 
characteristic of insomnia disorder, such as sleep maintenance problems or 
complaints of early morning awakenings. Despite this, the purpose of the current 
study was to assess this singular insomnia symptom, and not the whole 
syndrome, per se. Indeed, other, comparable studies have employed similar 
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sleep metrics when assessing these factors among cohort of children and 
adolescents (450, 451).We assessed the relative distribution and contribution of 
several health and lifestyle factors between responders (individuals who 
completed all waves) and non-responders (those who dropped out at any wave 
following baseline). We did not find any differences between groups with regard 
to characteristic factors and DIS or symptoms of depression, and thus these 
factors were not included in the development of our subsequent analytic strategy. 
It is acknowledged, however, that assessment of confounders was limited to 
those available, which differs from the list of theoretically possible, and thus 
analysis was limited to the data available and these factors may have influenced 
the reported findings. Despite this, the comprehensive assessment of these 
peripheral factors was not a primary aim of the current study, and as no 
differences were revealed at initial assessment, we do not anticipate that these 
factors significantly attenuated our reported findings. Finally, the changes in sex 
distribution and participant attrition rate over the course of the data collection 
waves may also restrict the generalizability of the findings. 
 
In conclusion, this study confirms cross-sectional and longitudinal findings 
showing that a strong relationship exists between symptoms of depression and 
DIS, and contributes more information suggesting the role of early depressive 
symptoms as a predictor of later sleep difficulties. Longitudinal assessment of 
symptoms of depression and DIS during the time of early adolescence is 
advantageous, as increasing evidence has suggested that these factors, which 
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may indicate proxy markers for depressive illness and insomnia, develop early, 
and often remain stable across the lifespan. As both depressive illness and sleep 
problems represent significant areas of morbidity and disability among both 
adolescents and adults, assessing and describing the developmental origins of 
these conditions are important for public health initiatives.
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CHAPTER 13:  The Association between Insomnia, Sleep 
Apnoea and Depression among Adults: Findings from 
the National Health and Nutrition Examination Survey, 
2005-2008.

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Abstract
Objective: To determine the association between insomnia, obstructive sleep apnoea (OSA), and comorbid insomnia-
OSA and depression, while controlling for relevant lifestyle and health factors, among a large population-based sample 
of US adults.
Method: We examined a sample of 11,329 adults (⩾18 years) who participated in the National Health and Nutrition 
Examination Survey (NHANES) during the years 2005–2008. Insomnia was classified via a combination of self-reported 
positive physician diagnosis and high-frequency ‘trouble falling asleep’, ‘waking during the night’, ‘waking too early’, and 
‘feeling unrested during the day’. OSA was classified as a combination of a positive response to a physician-diagnosed 
condition, in addition to a high frequency of self-reported nocturnal ‘snoring’, ‘snorting/stopping breathing’ and ‘feel-
ing overly sleepy during the day’. Comorbid insomnia-OSA was further assessed by combining a positive response to 
either insomnia (all), or sleep apnoea (all), as classified above. Depressive symptomology was assessed by the Patient 
Health Questionnaire-9 (PHQ-9), with scores of >9 used to indicate depression. Odds ratios (ORs) and 95% confidence 
intervals (CIs) for sleep disorders and depression were attained from logistic regression modelling adjusted for sex, age, 
poverty level, smoking status and body mass index (BMI).
Results: Those who reported insomnia, OSA or comorbid insomnia-OSA symptoms reported higher rates of depres-
sion (33.6%, 22.2%, 27.1%, respectively), and consistently reported poorer physical health outcomes than those who did 
not report sleep disorders. After adjusting for sex, age, poverty level, smoking status and BMI (kg/m2), insomnia (OR 
6.57, 95% CI 3.89-11.11), OSA (OR 5.14, 95% CI 3.14–8.41) and comorbid insomnia-OSA (OR 6.67, 95% CI 4.44–10.00) 
were associated with an increased likelihood of reporting depression.
Conclusions: Insomnia, OSA and comorbid insomnia-OSA are associated with significant depressive symptomology 
among this large population-based sample of adults.
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Introduction
Sleep disorders represent a significant social and personal 
burden, with research suggesting that as many as 10% of 
the population experience these problems during their life-
time (Ram et al., 2010). It is estimated that as many as 50–
60 million Americans have insomnia symptoms annually 
(Hossain, 2002). Similarly, population-based research has 
suggested that as many as 5% of adults in western countries 
meet classification for clinically significant obstructive 
sleep apnoea (OSA) (Davies and Stradling, 1996). The 
implications for these disorders are substantial, both in 
terms of direct and indirect costs for health care systems 
and individuals. Both insomnia and OSA are associated 
with poorer occupational and interpersonal functioning, 
increased medical expenditure and increased instances of 
work absenteeism and reduced productivity in the work-
place (Hossain, 2002). In addition, both disorders have pre-
viously been linked to increased medical and psychiatric 
comorbidity (such as cardiovascular risk) and all-cause 
mortality via a combination of these factors (Vgontzas 
et al., 2010; Yaggi et al., 2005).
OSA is a disorder characterised by repeated occlusions 
to the upper airway during periods of nocturnal sleep 
(Punjabi, 2008), resulting in snoring, nocturnal hypoxemia, 
fragmented sleep and daytime symptoms such as irritabil-
ity, reduced affect, and reduced quality of life (Engleman 
and Douglas, 2004). Insomnia is defined as the experience 
of subjective and objective poor or inadequate sleep despite 
ample time in bed (Summers et al., 2006). Patients may 
also report daytime symptoms (e.g. daytime fatigue and 
confusion), as well as deficits in interpersonal functioning 
(e.g. malaise, reduced motivation) (Summers et al., 2006). 
Research conducted among individuals attending sleep 
clinics has shown that as many as 26% of patients describe 
themselves as suffering from depression, and up to 67% of 
those patients reported an episode of major depression in 
the previous 5-year period (Mosko et al., 1989). Concordant 
research conducted by Vandeputte and de Weerd (2003) 
assessed the association between depression and sleep dis-
orders among a sample of patients presenting at a sleep 
clinic. It was demonstrated that the overall prevalence of 
depressive symptoms among those with a sleep disorder 
was high, with 60.5% of those with insomnia and 41% of 
those with OSA indicating significant levels of depression 
(Vandeputte and de Weerd, 2003).
Although both insomnia and OSA are often considered 
to represent mutually exclusive disorders, particularly in 
terms of clinical presentation, new evidence suggests that a 
high level of comorbidity exists between these two condi-
tions (Smith et al., 2004). Indeed, some studies cite a con-
cordance rate of as high as 50% (Krakow et al., 2001); 
however, others report more conservative numbers (Smith 
et al., 2004). Although speculative, it has been suggested 
that the sustained physiological arousal characteristic of 
insomnia may act to increase nocturnal heart rate and sym-
pathetic processes, thereby exacerbating existing symp-
toms of OSA. Concordantly, periods of nocturnal 
hypoventilation and hypoxemia experienced by OSA 
patients may act to increase nocturnal sympathetic pro-
cesses, thereby mimicking and promoting a negative feed-
back loop which acts to develop and sustain insomnia 
pathology (Luyster et al., 2010).
Despite the apparent relationship between sleep disor-
ders and depression among clinical samples, it is unclear if 
these findings are represented at a population level when 
assessing a non-clinical sample, or whether these findings 
are comparable among differing diagnoses using a hetero-
geneous sample. Moreover, there is little indication of the 
impact of OSA and insomnia on depression among a repre-
sentative sample, as the disorders are often assessed in iso-
lation (Schroder and O’Hara, 2005), or as a function of the 
other (Smith et al., 2004). Moreover, despite increasing 
evidence suggesting the high rates of concordance between 
these disorders, and given the established individual asso-
ciations with depression, there is a paucity of information 
pertaining to the association between these combined asso-
ciations and depressive symptomology. Indeed, of the pop-
ulation-based research available for analysis, 
generalisability of findings is often limited due to specific 
patient groups or samples used, and by use of individual 
assessment of these disorders. For example, research con-
ducted by Ohayon (2003) aimed to assess the association 
between depression and sleep-related breathing disorders 
in the general population of Europe (spanning five coun-
tries). Assessment of 18,940 adults revealed that 18% of 
individuals who met criteria for major depressive disorder 
were also identified as having a Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) 
breathing-related sleep disorder. Moreover, multivariate 
modelling demonstrated that those with major depressive 
disorder were five times more likely to have a DSM-IV 
diagnosis of a sleep-related breathing disorder (Ohayon, 
2003). Utilising the National Health and Nutrition 
Examination Survey (NHANES), Wheaton and colleagues 
(2012) explored the association between OSA-specific 
symptom items and depressive disorders. The findings 
indicated that men with physician-diagnosed OSA were 
two times more likely to report depressive symptoms, while 
for women the likelihood of having depression was 
increased by fivefold for those with OSA (Wheaton et al., 
2012). Of the available literature, however, comparable 
community-based research has indicated that a significant 
proportion (20%) of those with insomnia also reported con-
cordant depressive symptomology (Taylor et al., 2005).
Both OSA and insomnia are implicated in the expression 
of depression both among clinical and non-clinical samples, 
and represent a significant mediating factor in successful 
treatment outcomes. However, at present, only a small num-
ber of studies exist which investigate these combined 
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associations among a single large population-based sample 
pool. In order to assess this relationship in light of a number 
of health and lifestyle factors, we utilised data from the 
NHANES dataset across two points: 2005–2006 and 
2007–2008.
Method
Study population
NHANES is a stratified, cross-sectional, population-based 
sample of non-institutionalised individuals, spanning all 
age groups. Approximately 5000 individual assessments 
are performed each year, aimed at assessing aspects of 
health (disease burden) and nutrition. A more detailed 
description of the NHANES assessment protocol is availa-
ble elsewhere. NHANES 2005–2006 was the first time dur-
ing which questionnaire data were used to assess the 
presence of both physician-diagnosed sleep disorders and 
sleep-related subjective questionnaire items. All health 
interviews were conducted in respondents’ homes, and 
health measurements were performed in specially designed 
and equipped mobile centres located throughout the coun-
try. Interview teams conducting these assessments con-
sisted of physicians, medical and health technicians, and 
trained dietary and health interviewers. These items were 
also included for the 2007–2008 testing period. For the pur-
pose of this study, adults (aged ⩾18 years) who participated 
in NHANES at two sampling time points (2005–2006 and 
2007–2008) were included for analysis, resulting in a total 
sample of 11,329 individuals. The overall response rate for 
these surveys was 76.4% (Centers for Disease Control and 
Prevention, 2014). NHANES received approval from the 
National Center for Health Statistics Research Ethics 
Review Board and written informed consent was obtained 
for all participants.
Insomnia
The presence of insomnia was first determined by a posi-
tive response to a questionnaire item referring to physician-
diagnosed insomnia (n=185). Insomnia was also separately 
classified as a combination of frequency questionnaire data 
referring to subjective difficulties with sleep. For the pur-
pose of this study, a response to items of ‘often’ or ‘almost 
always’ for all four questions was classified to indicate the 
presence of insomnia symptoms (n=764). The use of fre-
quency indicators as markers of the disorder has previously 
been employed in population samples (Karacan et al., 
1976). Insomnia was then finally classified as the sum of a 
positive indication of diagnoses, and the sum of individuals 
classified as having insomnia via the application of subjec-
tive symptoms. Those individuals who met criteria for both 
objective and subjective insomnia classification were 
counted only once in the original files and thus removed 
from further analysis (n=58). Removing these cases avoided 
duplication in the subsequent analysis. After merging both 
the depression and sleep databases, those for whom depres-
sion information were not available (n=56) were excluded 
from further analysis. Using this criteria, a total of n=835 
cases were identified.
Sleep apnoea
The presence of sleep apnoea was first determined by a 
positive response to a questionnaire item referring to physi-
cian-diagnosed sleep apnoea (n=481). The presence of 
sleep apnoea was further separately indicated via frequency 
questionnaire items referring to common symptoms, such 
as ‘how often do you snore’. For the purpose of this study, 
a positive response to variable items ‘occasionally’ and 
‘frequently’ (nocturnal symptoms), and ‘often’ and ‘almost 
always’ (daytime sleepiness) on all three questions was 
considered to be indicative of sleep apnoea symptoms 
(n=290). The presence of sleep apnoea was then finally 
classified as the sum of positive response to disease diagno-
sis and positive response to subjective symptom items. 
Assessment of symptoms utilising frequency data has pre-
viously been used and validated among clinical (Netzer 
et al., 2003; Rowley et al., 2000) and population samples 
(Kapur et al., 2002), and is considered an effective and reli-
able screening method for identifying those at risk for the 
disorder (Maislin et al., 1995). Those individuals who met 
criteria for both objective and subjective sleep apnoea clas-
sification in the original files were counted once (n=83). 
Removing these cases avoided duplication in the subse-
quent analysis. After merging both the depression and sleep 
databases, those for whom depression information was not 
available (n=24) were excluded from analysis. Using this 
classification, a total of n=664 cases were identified.
Comorbid insomnia and OSA
The presence of comorbid insomnia and OSA was assessed 
by combining a positive response to either insomnia (all), 
or sleep apnoea (all), as classified above. Those who met 
criteria for both insomnia and sleep apnoea (n=136) were 
counted only once for analysis. Using this criteria, a total of 
n=1363 cases were identified. Of those who met the insom-
nia criteria (835), 136 (16.3%) also met criteria for comor-
bid OSA. Similarly, of those meeting the OSA criteria 
(664), 136 (20.5%) cases were comorbid with insomnia 
(Figure 1).
Depression assessment
Depressive symptoms were assessed via the Patient Health 
Questionnaire-9 (PHQ-9). The PHQ-9 is a self-adminis-
tered questionnaire aimed at assessing the presence of com-
mon mental disorders, as derived from the DSM-IV 
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classification system. The assessment tool includes nine 
frequency questionnaire items (0 = not at all, 3 = nearly 
every day) pertaining to aspects of anhedonia, depressed 
mood, difficulty concentrating, trouble sleeping, and guilt 
or worthlessness, among others (Sidebottom et al., 2012). 
The PHQ-9 is considered an effective tool for assessing 
depressive symptomology and is considered as a reliable 
tool for assessing instances of both major and sub-threshold 
depression among population samples (Kroenke and 
Spitzer, 2002), A total PHQ-9 score of >9 (out of possible 
27) has been indicated for use in the event of single screen-
ing assessments (Kroenke and Spitzer, 2002). For the cur-
rent study, a PHQ-9 score of >9 was used to indicate the 
presence of depression.
Lifestyle and health information
Information regarding health and lifestyle factors was col-
lected via home interview at the time of assessments. 
Demographic variables included: sex, race/ethnicity (e.g. 
Hispanic, non-Hispanic, white), age group (18–24, 25–34, 
35–44, 45–54, 55–64, ⩾65 years), education level (student, 
less than 9th grade, 9–11th grade, high school graduate, 
some college, college graduate and above), marital status 
(married, widowed, divorced, separated, never married, liv-
ing with partner), poverty level (below 100%, 100% to below 
200%, 200% or higher), and smoking status (current or for-
mer). Sedentary behaviour was indicated by self-reported 
daily average TV time (hours) and computer time (hours).
Information regarding health factors was obtained via 
self-report and by laboratory data. The presence of diabe-
tes, cancer and asthma was assessed utilising a self-report 
question asking the participant whether they have ever been 
told by a doctor or other health professional that they have 
diabetes or sugar diabetes, with responses categorised into 
yes, no and borderline or pre-diabetes. The presence of can-
cer and asthma was similarly assessed by asking the partici-
pant if they had been previously diagnosed with these 
conditions. The presence of cardiovascular disease (CVD) 
was classified as a positive response to the questionnaire 
item asking if participants had ever been told by a doctor or 
other health professional that they have coronary heart dis-
ease, congestive heart failure, angina/angina pectoris, heart 
attack or stroke. The presence of high blood pressure was 
similarly classified as a positive response to the question 
‘have you ever been told by a doctor or other health profes-
sional that they have high blood pressure?’.
Height and weight measurements were obtained at the 
time of the assessments via a mobile examination centre, 
and body mass index (BMI) was calculated as weight/
height squared (kg/m2). BMI categories were defined as 
underweight (BMI ⩽18.5), normal (BMI >18.5 to <25), 
overweight (BMI >25 to <30), and obese (BMI ⩾30) for 
all participants.
C-reactive protein (CRP) levels (ml/dL) were quantified 
using latex-enhanced nephelometry; analyses were con-
ducted in the Department of Laboratory Medicine, 
Immunology Division at the University of Washington 
Medical Center.
Dietary intake in the NHANES 99–00 is based on recol-
lection of foods eaten the previous day by the respondent, 
coupled with known nutritional content of each of these 
foods (24-hour recall). The total daily dietary intakes for 
magnesium were derived from the 24-hour recall informa-
tion about foods eaten the previous day. These interviews 
were conducted by trained personnel, and food intake 
information was coded using the USDA Food and Nutrient 
Database for Dietary Studies 3.0 (FNDDS 3.0). This data-
base was then used to produce nutrient intake values for 
magnesium (other nutrients not used).
Statistical analysis
Demographics variables and sleep data were merged into a 
master file and additional variables were created for analy-
sis. Weighting was applied to account for the stratified mul-
tistage survey design, oversampling and non-response and 
were constructed according to the CDC guidelines (Centers 
for Disease Control, 2013) . Differences in characteristics 
between those with and without sleep disorders (insomnia 
or OSA) were analysed using appropriate parametric tests 
where data were normally distributed, and non-parametric 
statistical tests for categorical or non-normal data. Odds 
ratios (ORs) with 95% confidence intervals (CIs) were 
determined using binary logistic regression models for cat-
egorical outcomes to investigate the association between 
the presence of sleep disorders and depression. In all mod-
els, sleep disorder (insomnia, OSA or comorbid insomnia/
OSA) was the exposure variable. Sex, age, poverty level, 
smoking status, BMI category, sedentary behaviours 
(expressed as average daily TV time and computer use) and 
CRP levels were tested sequentially, and potential con-
founders and effect modifiers were checked in all statistical 
models. Covariates that significantly influenced 
Figure 1. Proportional Venn diagram of the unweighted 
sample showing respondents with insomnia, OSA or both 
(comorbid).
Insomnia = 699 OSA = 528
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the outcome variable were retained and applied for all final 
statistical models (significance level set at p=0.05). Stata 
12 (survey procedures) (StataCorp., College Station, TX, 
USA) was used for all statistical analyses.
Results
Insomnia
Unweighted population characteristics for those with insom-
nia and OSA are presented in Table 1. Overall, 835 individu-
als were classified as having insomnia, and women were 
almost twice as likely to report insomnia as men (66% vs 
34%, respectively). Those who fell within the 45–54 years 
age bracket were most likely to report insomnia, with those 
in the 18–24 age group least likely to report these symptoms. 
In regard to ethnicity, non-Hispanic white adults were more 
than twice as likely to report insomnia as those who identi-
fied themselves as non-Hispanic black (50.2% vs 20.2%), 
and were more than five times more likely to report insomnia 
than Mexican Americans (50.2% vs 15%). Those individuals 
who identified themselves as ‘married’ were most likely to 
report insomnia, with those who were ‘separated’ reporting 
the least symptoms. Moreover, those regarded in the highest 
income bracket (above 200%) reported more insomnia than 
those in the 100–200% or <100% brackets. Those who 
reported never smoking were more likely to report insomnia 
than those who identified as either a ‘former or current’ 
smoker. In regard to body composition, those who were 
overweight or obese reported higher rates of insomnia than 
those who were classified as within the normal BMI range, 
or those who were considered underweight. Finally, although 
a greater proportion of those with insomnia reported ‘nor-
mal’ CRP levels (0–1 mg/dL), almost one in five reported 
clinically high levels (>1 mg/dL) (16.9%) (Table 1).
Univariate analysis of weighted data revealed that those 
with insomnia were significantly older at the time of assess-
ment, had a greater overall weight and BMI, and were more 
likely to report a greater time spent in sedentary activities 
than those without insomnia (all p<0.001) (Table 2). 
Similarly, individuals with insomnia were more likely to 
report depression than those without insomnia, and were 
more likely to report negative health status, such as 
instances of asthma, diabetes, high blood pressure and can-
cer (all p<0.001) (Table 3).
After adjusting for age, sex, poverty level, smoking sta-
tus and BMI, insomnia was associated with a 6.57-fold 
increased likelihood of reporting depression (OR 6.57, 95% 
CI 3.89-11.11). These findings were not explained by CRP 
levels or sedentary behaviour (Table 4).
Sleep apnoea
Overall, 664 individuals were classified as having OSA, 
with these symptoms more common among men than 
women (60.4% vs 39.6%, respectively). There was a gen-
eral trend of increased prevalence among increasing age 
brackets, and those aged 65+ years reported the highest 
instances of the disorder (Table 1). The highest proportion 
of OSA was seen among those who identified their ethnic-
ity as either non-Hispanic white or non-Hispanic black, 
with the lowest proportion seen among those who identi-
fied as ‘other Hispanic’ or ‘other race – including multi-
racial’ (5.3% and 3.2%, respectively). The largest proportion 
of those who reported OSA also identified themselves as 
‘married’, with those who are ‘separated’ or ‘widowed’ 
reporting the lowest prevalence. Similarly, those individu-
als who fell into the highest income bracket reported the 
highest proportion of OSA, with those in the lowest bracket 
concordantly reporting the lowest prevalence of the disor-
der. Those who reported having ‘never smoked’ had nearly 
a twofold increased proportion of OSA compared to those 
who identified themselves as a ‘current smoker’. Individuals 
who were classified as ‘overweight’ or ‘obese’ had the 
highest proportion of OSA, compared to those who were 
considered ‘underweight’ or within the ‘normal’ weight 
range, who reported the lowest (0.6% and 11%, respec-
tively). Lastly, those with OSA similarly reported the high-
est proportion of ‘normal’ CRP levels (Table 1).
Univariate analysis of weighted data revealed that those 
individuals who reported OSA were significantly older and 
had greater overall weight and BMI than those without 
OSA. Similarly, these individuals reported spending more 
time participating in sedentary activities than those who did 
not report the disorder (Table 2). Assessment of disease 
comorbidity revealed that those with OSA were signifi-
cantly more likely to report depression than those without 
OSA. Similarly, they reported significantly more medical 
comorbidity, such as diabetes, high blood pressure and 
CVD than those without the disorder (all p<0.001) 
(Table 3).
After adjusting for age, sex, poverty level, smoking sta-
tus and BMI, OSA was independently associated with a 
5.14-fold increased likelihood of reporting depression (OR 
5.14, 95% CI 3.14–8.41). These findings were not explained 
by sedentary behaviour (Table 5).
Comorbid insomnia and OSA
In total, 1363 individuals were classified as meeting criteria 
for comorbid insomnia-OSA, with higher rates of comor-
bidity seen among women compared to men (54.4% vs 
45.6%, respectively). A general trend of increased preva-
lence was noted among increasing age groups, with the 
highest incidence rate noted among those aged 65+ years 
(Table 1). The proportion of individuals of non-Hispanic 
white ethnicity reported nearly double the prevalence of 
comorbidity compared to non-Hispanic black individuals 
(54.2% vs 20.8%), and nearly triple that of the prevalence 
compared to Mexican American individuals (54.2% 
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vs13.5%). In regard to marital status, those who identified 
as ‘married’ also reported the highest rate of comorbidity 
(50.4%), with individuals who identified as ‘separated’ 
reporting the lowest incidence (4.6%). Those who identi-
fied as belonging to the highest income bracket similarly 
reported the highest incidence of comorbidity (47.3%), 
almost double that of the mid-range and lowest income 
brackets (25.0% and 27.7%, respectively). Those individu-
als who identified as having ‘never smoked’ were most 
likely to report comorbid insomnia and OSA, with almost 
double prevalence seen among these individuals compared 
to those who were classified as ‘current smokers’ (28.9%) 
or ‘former smokers’ (28.2%). Individuals who were classi-
fied as obese or overweight had the highest proportion of 
comorbidity, compared to those who identified as being of 
‘normal weight’ or ‘underweight’. Those who reported 
comorbidity similarly reported a higher rate of ‘normal’ 
CRP levels (Table 1).
Following the application of univariate analysis, those 
with comorbid insomnia-OSA were seen to be significantly 
older, and reported a higher overall weight and BMI than 
those who reported no comorbidities. Serum levels of CRP 
were also elevated among those individuals reporting 
comorbid insomnia and OSA. Assessment of the associa-
tion between comorbid insomnia and OSA showed signifi-
cantly higher rates of depression, asthma, CVD, high blood 
pressure, and cancer or malignancy among these individu-
als compared to those who reported no comorbidity (all 
p=<0.001).
After adjusting for sex, age, poverty level, smoking 
status and BMI (kg/m2), the presence of comorbid insom-
nia and OSA was independently associated with more 
than a sixfold increased likelihood of reporting depres-
sion (OR 6.67, 95% CI 4.44  10.00). These findings 
were not explained by CRP levels or sedentary behaviour 
(Table 6).
Table 4. Results of multivariable logistic regression analyses assessing predictors of depression including insomnia.
Independent variables OR 95% CI p
Sex 1.03 0.74 1.56 0.82
Age group, years  
 18–24 2.14 0.72 6.33 0.156
 25–34 2.17 0.91 5.20 0.078
 35–44 1.75 0.91 3.36 0.086
 45–54 3.33 1.65 6.75 0.002
 55–64 2.06 0.96 4.40 0.062
Poverty level  
 Below 100% 3.22 1.95 5.31 <0.001
 100% to <200% 1.80 1.14 2.83 0.015
Smoking  
 Current smoker 1.82 1.15 2.89 0.014
 Former smoker 1.37 0.73 2.58 0.303
BMI category  
 Underweight (10–18.49) 0.23 0.05 1.06 0.058
 Overweight (25–29.99) 0.71 0.45 1.14 0.145
 Obese (30–70) 0.95 0.54 1.67 0.849
C-reactive protein 1.04 0.99 1.09 0.121
Dietary magnesium 0.10 0.10 0.10 0.002
TV time, hours 1.16 1.03 1.31 0.018
Computer time, hours 1.01 0.93 1.09 0.826
High blood pressure: no 0.61 0.40 0.92 0.021
Insomnia: yes 6.57 3.89 11.11 <0.001
BMI: body mass index.
Reference categories: sex, male; age group, 65+ years; poverty level, 200% or higher; smoking, never smoked; body mass index, normal; insomnia, 
no; high blood pressure, yes.
Bold text represents a statistically significant value.
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Discussion
Within this large, cross-sectional population study of 
American adults, we identified a robust association between 
independent insomnia and OSA, as well as comorbid 
insomnia and OSA, and the experience of depressive symp-
toms. Moreover, after adjusting for relevant lifestyle and 
health factors, both insomnia and OSA (independent), and 
comorbid insomnia and OSA were associated with greater 
than a fivefold increased likelihood of also reporting 
depression. These findings were not related to CRP levels, 
dietary magnesium or sedentary behaviour.
The strong relationship between sleep disorders and 
depression has been demonstrated among a number of clin-
ical (Vandeputte and de Weerd, 2003) and intervention 
studies (Manber et al., 2008), with some studies suggesting 
that this relationship may also be considered bidirectional. 
Longitudinal research conducted by Morphy and col-
leagues (2007) demonstrated that individuals who reported 
insomnia at the time of baseline assessment were more 
likely to report instances of depression at the time of the 
12-month follow-up. These findings have also been sup-
ported by a number of review studies, with an almost unam-
biguous link between self-reported insomnia and the later 
development of depressive symptoms (Baglioni et al., 
2011). Analysis of individuals who participated in the 
Wisconsin Sleep Cohort Study revealed a dose–response 
relationship between the severity of sleep disordered 
breathing (SDB) symptoms and the subsequent risk for 
developing depressive symptoms (Peppard et al., 2006). 
The strength of this association has also been demonstrated 
among a number of treatment studies, with documented 
improvements in depressive symptoms following the appli-
cation of Continuous Positive Air Pressure (CPAP) therapy 
(Kawahara et al., 2005).
Possible mechanisms for the association between sleep 
disorders and depression have been cited as shared deficits in 
the quality or continuity of nocturnal sleep, albeit derived 
Table 5. Results of multivariable logistic regression analyses assessing predictors of depression, including sleep apnoea.
Independent variable OR 95% CI p
Sex 1.34 1.02 1.76 0.039
Age group, years  
 18–24 2.21 0.67 7.28 0.156
 25–34 2.59 0.95 7.03 0.078
 35–44 2.20 1.05 4.55 0.086
 45–54 3.89 1.79 8.46 0.002
 55–64 2.09 0.95 4.58 0.062
Poverty level  
 Below 100% 3.49 2.35 5.19 <0.001
 100% to <200% 2.01 1.24 3.25 0.008
Smoking  
 Current smoker 1.99 1.36 2.92 0.002
 Former smoker 1.28 0.68 2.43 0.422
BMI category  
 Underweight (10–18.49) 0.18 0.04 0.84 0.032
 Overweight (25–29.99) 0.75 0.46 1.21 0.217
 Obese (30–70) 0.78 0.43 1.41 0.389
C-reactive protein 1.07 1.01 1.14 0.035
Dietary magnesium 1.00 1.00 1.00 0.002
TV time, hours 1.24 1.10 1.40 0.001
Computer time, hours 1.02 0.94 1.09 0.631
High blood pressure: no 0.56 0.36 0.90 0.018
Sleep apnoea: yes 5.14 3.14 8.41 <0.001
Reference categories: Sex, male; age group, 65+ years; poverty level, 200% or higher; smoking, never smoked; body mass index, normal; sleep 
apnoea, no; high blood pressure, yes.
Bold text represents a statistically significant value.
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from different pathological origins, for both insomnia and 
OSA. Indeed, depressive symptoms in individuals with OSA 
are often attributed to periods of nocturnal hypoxemia and 
sleep fragmentation, which are characteristic of the disorder 
(Akashiba et al., 2002; Pochat et al., 1993; Schroder and 
O’Hara, 2005; Yue et al., 2003). Research conducted by 
Wheaton and colleagues (2012) demonstrated that individual 
symptoms characteristic of OSA, such as pauses in breath-
ing, but not snoring, are strongly associated with the experi-
ence of depression, supporting this view. Within the current 
study, individual symptoms were not assessed. Rather, the 
presence of the disorder was assessed via the cumulative 
response to relevant questionnaire items, in addition to a 
positive identification of a physician-diagnosed disorder. 
Such methods have been previously applied among similar 
samples (Kapur et al., 2002) and have demonstrated a higher 
overall prevalence of OSA than previous research. Within 
our study, utilising this method, we report a high overall 
prevalence of individuals reporting OSA, which may be due 
to the methodological characterisation of the syndrome. 
However, these figures are not standardised to the wider 
population, and thus need to be interpreted with some cau-
tion. Despite this, characterising the disorder in this manner 
allows for identification of possible sub-threshold cases of 
the disorder, of which has significant clinical usefulness in 
regard to indications of the burden of disease.
To our knowledge, this is the first research of its kind to 
demonstrate a strong association between comorbid insom-
nia and OSA and depression. As outlined previously, recent 
research suggests a high concordance rate between insom-
nia and OSA, with some authors suggesting this rate could 
be higher than 50% (Krell and Kapur, 2005). Given that the 
possible mechanisms of action supporting the association 
between both insomnia and OSA have been well-described 
individually, it is surprising, therefore, that there is such lit-
tle research investigating these conditions simultaneously. 
We postulate that the strength of the reported relationship 
may, in part, be attributed to the complementary 
Table 6. Results of multivariable logistic regression analyses assessing predictors of depression, including comorbid insomnia-OSA.
Independent variable OR 95% CI p-value1
Sex 1.18 0.88 1.59 0.246
Age group, years  
 18–24 2.20 0.69 7.07 0.170
 25–34 2.43 0.97 6.13 0.058
 35–44 1.85 0.94 3.64 0.071
 45–54 3.56 1.71 7.42 0.002
 55–64 1.93 0.87 4.25 0.098
Poverty level  
 Below 100% 3.25 2.08 5.07 <0.001
 100% to <200% 1.87 1.16 3.03 0.014
Smoking  
 Current smoker 1.84 1.20 2.81 0.008
 Former smoker 1.34 0.70 2.54 0.353
BMI category  
 Underweight (10–18.49) 0.23 0.05 1.09 0.062
 Overweight (25–29.99) 0.71 0.43 1.18 0.169
 Obese (30–70) 0.77 0.43 1.37 0.348
C-reactive protein 1.03 0.97 1.10 0.346
Dietary magnesium 1.00 1.00 1.00 0.002
TV time, hours 1.20 1.06 1.35 0.006
Computer time, hours 1.02 0.94 1.09 0.660
High blood pressure: no 0.64 0.41 1.00 0.052
Comorbidity: yes 6.67 4.44 10.00 <0.001
Reference categories: Sex, male; age group, 65+ years; poverty level, 200% or higher; smoking, never smoked; body mass index (BMI), normal; sleep 
disorder, no; high blood pressure, yes.
Bold text represents a statistically significant value.
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symptomatic characteristics associated with the disorder 
(i.e. systematic and chronic disrupted sleep), shared day-
time impairments, and manifest physiological effects of 
one or both of the disorders remaining untreated. Indeed, 
other studies have shown that treatment of OSA in insom-
nia patients improves subjective symptom ratings (Krakow 
et al., 2004), depressive symptoms improve among insom-
nia patients treated with cognitive behavioural therapy for 
insomnia (CBT-I) (Taylor et al., 2007), and amelioration of 
insomnia among patients with concordant mild OSA using 
CBT-I has been shown to improve objective measured 
sleep architecture (Guilleminault et al., 2008).
Depressive symptomology among insomnia patients has 
previously been ascribed to shared biological dysregulation 
of circadian clock genes (Serretti et al., 2003), as well as 
deviations from optimal neuroendocrine or neurological 
system functioning, such as that induced by reduced immune 
functioning or increased oxidative stress (Berk et al., 2013). 
Indeed, as both insomnia and OSA were found to be associ-
ated with a number of negative health outcomes in the cur-
rent research (such as diabetes, obesity and hypertension), 
which are both known to share these neurological pathways 
(Kahn and Flier, 2000), and often feature in the clinical pres-
entation of these disorders, such biological mechanisms 
may provide some explanation for these observed relation-
ships. Shared neuroinflammatory processes may also pro-
vide a possible explanation for these associations, as reduced 
cardiovascular and metabolic functioning has been shown to 
be impaired among insomnia and OSA patients (Kahn and 
Flier, 2000). Indeed, we demonstrated that the relationship 
between OSA and depression was somewhat attenuated by 
CRP. Elevation in these inflammatory biomarkers has also 
been attributed to increased risk for depressive symptomol-
ogy (Berk et al., 2013); however, this relationship may also 
be considered bidirectional (Motivala et al., 2005). As effec-
tive treatment of OSA has been shown to improve cardiac 
outcomes (Milleron et al., 2004), and untreated insomnia 
has been linked to reduced cardiac outcomes in specific 
patient groups (Chien et al., 2010), amelioration of these 
conditions may therefore provide a possible therapeutic tar-
get among these sleep-disordered patients, and thus improve 
treatment outcomes, particularly among patients with con-
cordant depressive symptoms.
The design of the current study does not allow for dif-
ferentiation between possible sub-types of insomnia (i.e. 
sleep maintenance, early morning awakening). However, 
similar methods have been applied among other studies 
(Ancoli-Israel and Roth, 1999) and classification grouping 
of symptoms does give some indication of disease burden 
among the sample. Future research may benefit from focus-
ing on the strength of the association among sub-types of 
insomnia and depression among this sample in order to 
investigate possible underlying mechanisms.
The primary strength of the current study includes the 
use of a large, population-based, representative cohort in 
the assessment of the relationship between sleep disorders 
and depression. Similarly, to our knowledge, this is the first 
study to assess the relationship between comorbid insomnia 
and OSA. Importantly, the use of the NHANES dataset 
addresses many of the limitations presented by previous 
research; it provides information on a large sample of the 
general public, as opposed to a specific patient group, and 
thus provides information regarding the degree of disease 
burden at this level. Similarly, the current study actively 
addressed the limitations of previous NHANES data which 
has assessed the association between sleep and depression 
by controlling for, and accounting for, a large number of 
associated health and lifestyle covariates during analysis. 
Such techniques provide more detailed assessment of the 
strength of these associations.
As inherent in any population-based survey that employs 
self-report symptom classification, the reported sleep disor-
ders may be under or over-reported, and thus may not be 
accurately representative of population prevalence. 
Specifically, those with insomnia may overestimate the 
degree of impairment, a bias which has been previously 
noted (Edinger and Means, 2005). Similarly, no report was 
obtained from the bed partners or third parties of those who 
were identified as having OSA. As these symptoms occur 
primarily when the patient is sleeping, symptom frequency 
may be under-reported. Despite this, methods of self-report 
for both insomnia and OSA have been found to have good 
reliability (Bliwise et al., 1991). Although a number of 
health and lifestyle factors were accounted for during anal-
ysis, information regarding medication use was not 
included. Treatment of underlying depressive illness has 
been shown to improve OSA symptom outcomes as a func-
tion of improved adherence to continuous positive air pres-
sure (CPAP) therapy (Harris et al., 2009), and antidepressant 
use among those with comorbid depression-insomnia can 
result in improvement in subjective symptoms (Serretti 
et al., 2005). As these factors were not assessed specifi-
cally, it is possible that reported associations may be under 
or over-reported. Lastly, the cross-sectional nature of the 
analysis does not allow for interpretation regarding the 
direction of the relationship, and thus it is recognised that 
the associations between insomnia, OSA and depression 
may be considered bidirectional.
In summary, this study provides population-relevant 
information regarding the association of the global assess-
ment of the two most common sleep disorders, insomnia 
and OSA, in addition to comorbid insomnia-OSA, and their 
robust relationship to depressive symptomology. The 
strength of these associations highlights the need for appro-
priate clinical screening for people reporting such symp-
toms, in order to optimise patient treatment and outcomes.
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14.1 Summary  
 
Self-reported poor sleep, pathological sleep disorders and instances of EDS are 
complex and multifaceted conditions, of which many of the contributing factors 
are largely understudied and thus poorly defined. Existing literature has 
highlighted some of the peripheral isolated effects of sleep disturbances and EDS 
on several aspects of neurobehavioural, endocrine and psychiatric health. 
However, less is known about the direct associations between these factors, 
whether peripheral health and lifestyle factors act to attenuate this relationship, 
and if these associations are observed beyond clinical contexts. In order to 
address these limitations, this thesis utilised findings from three large, 
representative population-based epidemiological studies to comprehensively 
explore the association between disturbed sleep and EDS on a number of health 
and lifestyle outcomes in adults. The use of standardised assessment tools, as 
well as in-depth assessment of a number of physical, medical and psychiatric 
health factors provided the first detailed assessment of these associations among 
representative, population-based cohorts. Indeed, such descriptions provide a 
holistic and comprehensive assessment of both the immediate and peripheral 
associations of these factors, and thus highlight the need for greater emphasis to 
be placed on these indicators as a possible source of clinical intervention.  
 
The relationship between EDS and a number of physical, psychiatric and general 
health outcomes was assessed, cross-sectionally, among a representative, 
population-based sample of Australian men and women (ages 20 years and 
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over) who participated in the GOS (studies 1-5). Key findings were noted with 
regard to the strength of the association between EDS and several lifestyle and 
health factors; many of which have not been previously described. These findings 
provide further evidence for the pervasive and significant role that EDS plays in 
the expression of these factors, and similarly highlights possible areas of clinical 
intervention and areas of therapeutic intervention among affected individuals.  
 
Longitudinal assessments of the stability and trajectory of sleep duration, as well 
as the association between symptoms of depression and difficulty initiating sleep 
were examined utilising the NLHB study. The use of the Norwegian Longitudinal 
Health behaviour study allowed for comprehensive assessments of sleep from 
the ages of early adolescence (age 13 years) to early adulthood (age 30years), 
and addressed some limitations of previous literature with regard to the general 
restricted assessments of age-ranges, or the inability to assess these 
associations across several critical developmental periods. Results indicated 
several common themes with regard to possible critical developmental periods in 
the expression of these relationships, highlighting possible areas of clinical 
intervention, as well as additional findings which may lend support for age-
specific normative values.  
 
The association between well-defined cases of sleep disorders, depression and a 
range of health and lifestyle factors was assessed cross-sectionally utilising data 
available as part of the National Health and Nutritional Examination Survey 
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assessments. Here, the relationship between cases of OSA, insomnia and 
comorbid insomnia/OSA were described, and the relative strength of these 
associations with relation to health, lifestyle and medical factors was examined. 
These findings provide additional evidence as to the strength of these 
associations, as well as highlight new information pertaining to the degree of this 
association among comorbid sleep disorders.  
 
Following are the key findings presented within this thesis:    
 
14.1.1 EDS is highly prevalent among this Australian population 
sample
At present, a large degree of variation is evident within the existing literature with 
regard to overall, sex and age-specific prevalence rates of EDS among non-
clinical, population-based samples. It is arguable that these discrepancies largely 
result from differing methodologies employed between studies. Specifically, of 
the available studies, there are often marked differences with regard to conflicting 
operational definitions used to characterise sleepiness. As such, any inferences 
regarding the true impact of EDS and associated health outcomes are equivocal 
at best. What is more, there is currently a paucity of accessible information 
pertaining to the prevalence of EDS among local cohorts, and thus it is unclear 
as to the impact of these symptoms within the Australian population.  
 
278 
In order to address these limitations and thus provide the first indication of these 
associations among an Australian sample, the current study aimed to 
systematically assess the standardised prevalence of EDS among a 
representative, population-based sample of adults (Chapter 6). Indeed, this 
thesis presents new data that describe the prevalence of EDS and associated 
lifestyle and health factors in a randomly selected population-based sample of 
Australian men and women. Specifically, these findings which suggest a higher 
overall prevalence of EDS than has been previously described, with as many as 
10.4% of men and 13.6% of women reporting these symptoms. These reported 
prevalence rates are similar to some of the exiting literature which utilise similar 
metrics and cut-offs (175); however, is notably higher than some other studies 
(452), and lower than others (181).  
 
In part, the discrepancies noted between available studies may be due to the 
different assessment tools used to quantify instances of EDS, as some use 
frequency indicators of sleepiness (181), whilst others use single-item 
assessment s or non-standardised inventories (180). The prevalence rate of EDS 
among this sample is higher among women than men, which is in opposition to 
much of the previous literature which have found male gender to be an 
independent predictor of EDS. It is possible that the generally lower rates 
observed among women in previous studies is somewhat attributable to the 
variable methodology employed to assess sleepiness, as well as the general 
over-representation of men in this type of research. Indeed, some studies have 
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similarly reported a higher overall prevalence among women compared to men 
(453), as well as higher overall ESS scores (454).  
 
A further novel finding of this study was that of an elevation in the prevalence of 
EDS among women who were classified as young (20-29 age group), peri- and 
post-menopausal (40-49 and 50-59 year age group), or older age (80+ age 
group). It is possible that among the younger age-group, this finding may be 
attributed to a number of health and lifestyle factors that have been shown to 
influence EDS within these cohorts at this time, such as changes in educational 
and/or occupational demands, or factors associated with changes in or initiation 
of childrearing duties (217). Further, among peri-and post-menopausal women, 
higher rates of EDS may in part be explained by hormonal changes that occur 
during menopause and the consequent influence on sleep patterns during pre- 
and postmenstrual periods (455, 456). For those aged 80 years and over, it is 
likely that increased instances of EDS are due to peripheral factors associated 
with the ageing process and sleep, such as reduced sleep efficiency and 
increased sleep fragmentation, as well as from the residual effect of medication 
use or concomitant medical conditions such as CVD. Prevalence trends for men 
were somewhat comparable, however did not demonstrate the increase in 
incidence among the younger age group (20-29 years). It is possible that during 
this time, individuals engage in compensatory methods such as increased 
caffeine consumptions, to reduce sleepiness associated with increased social or 
occupational demands during this time.   
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Overall, these findings provide valuable information as to both the overall sex 
specific rates of EDS, as well as the first indication of the distribution of EDS 
among different age groups. As these findings are the first to describe a higher 
prevalence of EDS in the Australian population than that which has been noted 
previously, longitudinal assessment of these trends over time would be useful in 
tracking the natural progression of these symptoms within the general population.  
 
14.1.2 EDS is associated with increased adiposity 
Obesity is a considerable problem both among local and international cohorts, 
and is associated with significant individual morbidity and mortality. Furthermore, 
excess weight and body fat, particularly that which is viscerally or centrally 
located, has been found to be a predisposing factor for an increased risk for a 
host of medical problems including type 2 diabetes, poorer cardiovascular 
outcomes, stroke, heart attacks, increased medical comorbidity, depression and 
increased risk of sleep disorders (457, 458). A limited number of clinical 
observations and experimental studies exist which have described the 
association between EDS and increased adiposity; albeit among samples of 
sleep-disordered breathing patients or among other pathological populations 
(321). However, a small but emerging body of literature has suggested that these 
factors may indeed be correlated, independent of underlying sleep pathology 
(306, 325). Despite these observations, at present there is a lack of research 
which systematically and comprehensively assesses these relationships using a 
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comprehensive assessment of both EDS and adiposity. Indeed, any inferences 
that are drawn are often derived from observations which utilise non-
standardised assessments of EDS (306), or only investigate limited measures of 
body composition such as BMI alone (305, 306). Thus, it is difficult to draw 
definitive conclusions regarding the strength and robustness of these 
associations, and whether these relationships apply when assessing other 
markers of adiposity. The study included within this thesis therefore aimed to 
methodically address these limitations by employing standardised assessments 
of EDS, as well as thorough and comprehensive evaluations of body composition 
among a population-based sample of men and women.    
 
Findings presented in Chapter 7 of this thesis highlighted an association between 
EDS and increased adiposity, independent of a number of lifestyle and health 
factors. Specifically, women within this sample who reported EDS were found to 
display what can be considered an ‘apple’ shaped adiposity profile; that is, 
greater instances of truncal distributed weight, as evident in greater waist 
circumference and BMI classification measurements. Viscerally located fat and 
waist measurements exceeding 88cm in women have been associated with 
increased risk for cardiovascular disease, diabetes and metabolic syndrome 
(459). Among the men examined, EDS was associated with greater BMI, as well 
as an increased likelihood of being obese, independent of several lifestyle and 
health factors.  
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That men did not display a clear characteristic adipose profile may be somewhat 
related to the measurements used within the study. Indeed, it is possible that the 
men in this study displayed differentially distributed weight (i.e., around the 
neck/shoulder region), of which was not explicitly examined using the available 
tools. Moreover, it is possible that in part, these distinctions were due to other, 
external factors, such as underlying sleep disordered breathing which may 
underlie this association. Peripheral assessments of neck circumference have 
been shown to be a reliable indicator of OSA among men, and detailed 
assessments of specific body fat composition has been shown to useful in the 
assessment of underlying sleep pathology (460). In the current study, no 
association was noted between EDS and measures of body composition as 
assessed by the whole body DXA scans for women or men, with the exception 
that men with EDS had lower %BMC than those who did not report EDS. Limited 
research has indicated that neck circumference is a predictor of higher ESS 
scores among morbidly obese men (461), however, it is unclear if this 
observation is valid among different classes of obesity. Further research is 
therefore needed to assess the association between EDS and the direct 
distribution of body fat and the possible relationship with different classes of 
obesity. Such assessments may provide a more detailed adiposity profile for 
men, and further expand and compliments the presented findings. 
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14.1.3 EDS is independently associated with metabolic 
syndrome 
Mechanistically, it is possible that the observed association between EDS and 
increased adiposity may, in part, be mediated by increased inflammatory 
processes and/or compromised endocrine functioning. Indeed, EDS has been 
previously linked to instances of metabolic disturbance with regard to dysfunction 
within the physiological systems thought to govern sleep processes and sleep 
regulation, which are similarly involved in metabolic processes. The endogenous 
inflammatory cytokines, tumour necrosis factor-Į (TNFĮ) and interleukin-1ȕ (IL-
1ȕ) are considered to be involved in the natural regulatory processes of the 
sleep-wake cycle in humans (86, 319, 462), whereas increases in subjective 
sleepiness and/or increased sleep have been found to be associated with the 
exogenous administration or increased secretions of  interleukin-6 (IL-6) (320). 
Research has demonstrated that that among OSA patients, both TNFĮ and IL-6 
plasma concentrations are positively correlated with the presence of EDS, and 
that that IL-6 plasma levels were positively correlated with BMI. Further, 
TNFĮ levels were naturally elevated in OSA patients and narcoleptics compared 
with that in normal controls, and IL-6 concentrations were markedly elevated in 
OSA patients compared to normal controls, which is suggestive of a naturally 
occurring metabolic dysfunction among these patients. However, some research 
studies examining the relationship between EDS, obesity and underlying sleep 
pathology have noted that the presence of EDS among non-clinical populations is 
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more closely associated with depressive illness or metabolic factors than 
underlying sleep-disordered breathing (153).  
 
In light of these discrepancies, it can be seen that mechanisms attenuating the 
association between EDS and metabolic dysfunction is currently unclear. 
Furthermore, as the aforementioned research studies typically assessed 
individual markers of metabolic dysfunction in isolation, it is currently unknown 
whether this association is sustained beyond individual symptom clusters (i.e., 
whether it is applicable to metabolic syndrome), or whether the association is 
attenuated by peripheral lifestyle and health factors. The current study therefore 
aimed to systematically assess the relationship between EDS and cases of well-
defined metabolic syndrome in population-based samples of men and women, in 
order to better define and clarify this association.  
 
Findings presented within Chapter 8 of this thesis suggest that among women, 
EDS was independently associated with the metabolic syndrome, however this 
was somewhat mediated by BMI. These findings lend support to the small 
epidemiological literature base in this study area which suggests the underlying 
role of metabolic disturbance as a resulting from obesity to be a mediating factor 
in the expression of EDS (321), and builds on previous studies which have 
shown a relationship between sleepiness and independent aspects of metabolic 
disturbance, such as diabetes (463). Among men in this sample, this association 
was seen to be primarily driven by age, with older age explaining the strength of 
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this relationship. Although a high prevalence of EDS among older men was 
described in Chapter 6, it is possible that the role of older age may be more 
important in the expression of metabolic syndrome among these men, rather than 
that of other factors per se. However, it was recognised that the somewhat small 
sample of these older men may influence these findings, and thus it is suggested 
that the study be replicated in a larger cohort to assess the true degree of this 
association.  
 
At present, a growing but relatively limited amount of epidemiological research 
has demonstrated that EDS is independently associated with several pro-
inflammatory state markers (321); and that such associations may have 
implications for subsequent metabolic functioning (322). Directly examining this 
association is necessary in order to better describe the direct nature of this 
relationship, and the reported findings lend valuable information as to the role of 
peripheral health factors in the expression of EDS and metabolic disturbance 
among population-based cohorts.    
 
14.1.4 EDS is associated with an increased risk for falls among 
older women, but not men 
The health and economic burden of falls among older individuals is substantial, 
and research has suggested that approximately 30% of older adults report 
sustaining one or more falls per year (230), and as many as 10-20% of these 
incidents are associated with moderate to severe injury, such as fractures or 
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severe head trauma (231). What is more, the incidence of sleep-related problems 
are observed to increase with age (359), and a reduction in both the quality and 
quantity of nocturnal sleep are often associated with instances of EDS. Among 
older individuals, EDS has been consistently and independently associated with 
an increased risk profile for several adverse health outcomes, such as reduced 
functional outcomes (219), depressive illness (217), and as much as a two-fold 
increased risk for falls (220).  
 
Despite these observations, systematic assessments regarding the nature of the 
fall and degree of disability incurred as result of the fall are currently lacking. 
Specifically, there is currently little detailed information regarding details such as 
the location, circumstances and consequences surrounding the fall; information 
which may assist in providing possible points of intervention among at-risk 
individuals. Last, there is currently an inadequate collation of data pertaining to 
the relative contribution of factors such as concurrent medication use and other 
health behaviours. As such, the current study aimed to methodically assess the 
relationship between EDS and falls occurrence, as well as comprehensively 
describe factors associated with falls, such as the location, circumstances and 
consequences of the incident (i.e., associated injuries) with relation to complaints 
of EDS among a population based sample of older adults (aged 60 years and 
over). As outlined in Chapter 9, this thesis presents findings which suggest that 
approximately 15% of those aged 60 years and over report clinically significant 
EDS. When the association between EDS and falls was assessed, it was 
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observed that among women, cases of EDS were associated with an increased 
risk for falls, independent of associated health and lifestyle factors.  
 
Extant research has noted comparable rates of falls among cohorts of older, 
population-based samples (234), however others have noted a higher rate (383). 
A number of limited studies have similarly cited EDS as a strong independent 
factor in this association (220). What is more, when fall location was assessed, it 
was seen that a greater proportion of women with EDS report a fall occurring 
whilst located outside. These findings may reflect the sample population; as 
activities such as gardening are often cited as the most frequently engaged form 
of physical activity among healthy older adults, particularly during the warmer 
months (i.e., summer/autumn) (389). Alternatively, such findings may be as a 
result of compensatory behaviours aimed towards reducing sleepiness 
symptoms. No association was noted for men with regard to EDS and falls, and 
only a trend towards significance was noted between EDS and an increased fall 
profile as measured by the EFST, and no difference was noted between men 
with and without EDS with regard to fall location. It is possible that there was an 
under-reporting of falls incidence among men, which is likely driven by values 
and beliefs associated with maintaining independent living status and perceived 
levels of functioning. Corroborating falls data with objective data such as 
Medicare registries may provide further information in this regard.  
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The ability of the current study to account for and systematically assess the role 
of several contributory lifestyle and health factors allows for greater translational 
applicability of the reported findings to real-life scenarios, and addresses the 
limitations of much of the available literature. Future research may benefit from 
corroborating subjective falls data with publicly available data files such as 
Medicare to ascertain the additional information. Amelioration of EDS symptoms 
among these individuals may assist in preventing future falls, and thus further 
benefiting affected individuals.  
 
14.1.5 EDS is associated with depressive, but not anxiety 
disorders 
Previous epidemiological research has demonstrated a strong relationship 
between EDS and instances of depression, more so than with common 
underlying contributory factors, such as obesity and/ or sleep-related breathing 
disorders (153).  
 
The findings presented within Chapter 10 of this thesis demonstrated that among 
this population-based sample of women, EDS was independently associated with 
reporting a current or lifetime history of a depressive illness. This relationship, 
however, was not observed among those with anxiety disorders. These findings 
build on both previous experimental studies which have shown a strong 
independent association between EDS and depressive disorders (153), and 
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presents new findings regarding the sustained strength of these associations and 
the natural course of the disease. Indeed, further investigation of the strength of 
the association within this study revealed that this relationship was maintained 
among those with lifetime history of depressive illness following the application of 
a more conservative cut-point (ESS score of 12 or more). No association was 
observed between current history of depressive illness and EDS at this cut-point. 
This is the first research to describe the association between EDS and both 
current and lifetime history of a depressive illness, and coupled with the 
sustained association at a more conservative cut-point, suggests the 
pervasiveness of these symptoms among this population. Indeed, only one 
somewhat comparable study exists in this field; of which demonstrated a link 
between EDS and lifetime history of manic and hypomanic episodes (175). When 
considering the findings from the current study in light of previous observations 
regarding these associations with lifetime manic and hypomanic episodes among 
clinical samples, it is possible that the reported findings in the current study 
reflect cases of atypical depression in particular. Indeed, clinical presentations of 
cases of atypical depression often feature symptoms of fatigue and hypersomnia 
(464), and thus it is suggested that any clinical assessment of these patients 
acknowledges these inherent associations.  
 
Both depressive illness and instances of EDS represent significant causes of 
clinical morbidity among affected those individuals. The presence of a lifetime 
association between these the factors signify the possibility of a chronic disease 
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course; and further highlights the need for intervention strategies. Additional 
research would benefit from longitudinal assessments of the natural course of 
these conditions over time in order to identify the most successful areas of 
clinical intervention.  
 
14.1.6 Habitual periods of short sleep duration in mid-adulthood 
(30 years) appear to be established in early adulthood (23 years) 
Effective and regular regulation of the sleep/wake cycle is fundamental in order to 
maintain optimal biological, metabolic and physical functioning; however it is 
often exogenously mediated by aspects of socio-cultural, psychosocial, 
occupational and familial demands (402). Both long and short habitual sleep 
periods present as independent risk factors for impaired cardiovascular 
functioning and subsequent increased rates of cardiovascular disease (403, 404), 
as well as instances of increased weight (405), and higher rates of obesity (406). 
Despite this, little research is available which systematically assesses the stability 
and natural trajectories sleep duration (continuous and categorical) from periods 
of adolescence to early adulthood. Therefore, the current study aimed to assess 
the natural development and stability of sleep duration from ages 13 years, 15 
years, and 23 years to 30 years and also to identify the association between 
short sleep duration at ages 13 years, 15 years, and 23 years on cases of short 
sleep duration at age 30 years. Such associations would lend valuable 
information as to the natural course of sleep duration across several critical 
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developmental periods, and highlight possible areas which may be sensitive to 
the development of pathology.  
 
As highlighted in Chapter 11, the presented results indicated a general trend of 
an overall reduction is total sleep time as a function of increasing age; a finding 
which mirrors much of the available literature (402), and which is often attributed 
to changes in sleep needs among different developmental periods throughout the 
lifespan (465). Assessments of categorised short and normal sleep duration from 
early adolescence to adulthood revealed that self-reported sleep duration 
(continuous) in early adolescence (13 years) was seen to be similarly associated 
with sleep duration reported at early adulthood (23 years), however, when 
dichotomised into short vs. normal sleep duration, short sleep at age 23 years 
was the only predictor of short sleep at age 30 years. These findings suggest that 
these pervasive habitual short sleep periods that are seen in middle adulthood 
(30 years) are formed during early adulthood (23 years), rather than carried on 
throughout the lifespan.  
 
Observations regarding the natural trajectories and course of habitual sleep 
duration from adolescence to adulthood may be advantageous for normative 
developmental assessments of children who may present clinically with 
chronically poor sleep at the time of early adolescence. Specifically, such findings 
may help to alleviate parental stress among cases of poor sleep among school-
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aged children, and provide tentative predications of possible later improvements 
with age. 
 
14.1.7 Symptoms of depression in early adolescence predict 
sleep initiation difficulties in early adulthood 
A number of cross-sectional and longitudinal studies have demonstrated that 
both individual symptomatic components of insomnia, such as sleep onset 
difficulties (266, 422) as well as defined clinical instances of insomnia are closely 
related to depressive illness (423, 424). Prospective studies have similarly  
shown that instances of insomnia in early adulthood predict the later 
development of depressive symptoms (425), and that depressive symptoms can 
precede the later onset of sleep problems (266). Despite this, comprehensive 
longitudinal assessments which include several critical developmental periods 
are currently lacking. Specifically, much of the available literature spans only brief 
periods of early adolescence or adulthood (266), includes only a limited number 
of sampling phases, or fails to accurately describe the strength of these 
associations and role of possible peripheral confounders (431). Indeed, the aim 
of the current study included within this thesis was, therefore, to assess the 
direction of the relationship and degree of shared associations between 
symptoms of depression and difficulty initiating sleep from periods of early 
adolescence to early adulthood. Such investigations may lend evidence to help 
delineate whether this relationship can be considered causal, or if it instead 
represents an epiphenomenon or occurs as a result of peripheral factors.    
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 The findings included in Chapter 12 presented valuable information regarding 
the direction and strength of these associations. Specifically, the use of a 
representative, longitudinal cohort study of children who were followed to 
adulthood allowed for comprehensive assessment of the strength of these 
associations across several critical developmental periods. Results indicated that 
when assessed cross-sectionally, symptoms of depression and difficulty initiating 
sleep were associated at all data points from periods of early adolescence to 
early adulthood. Moreover, it was observed that individually, DIS and symptoms 
of depression at age 13 years remains significant and somewhat stable across 
waves to early adulthood (23 years). These findings build on previous 
assessments which have suggested that depressive symptoms and depressive 
disorders which appear during periods of early adolescence have an increased 
lifetime prevalence, thus highlighting the possible critical developmental periods 
in the natural progression of these two factors (186, 343). Such observations 
highlight the possible role of clinical intervention during periods of early 
adolescence, which may improve the long-term outcomes for these individuals. 
 
When assessed longitudinally, a significant and consistent unidirectional cross-
lagged effect was noted running from symptoms of depression to DIS from the 
time of early adolescence to early adulthood, suggesting that symptoms of 
depression established in early adolescence are a strong predictor of DIS in early 
adulthood. These findings are significant, as they are in contrast to much of the 
previous literature in this area which typically suggest sleep problems as a risk 
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factor for the later development of depression, and contribute to the small body of 
literature which supports the model of opposed developmental progression. 
 
Both depressive illness and sleep problems represent significant areas of 
morbidity and disability among both adolescents and adults. Findings from this 
study lend argument as to the assentation that a strong relationship exists 
between symptoms of depression and DIS. This research contributes additional 
information suggesting the role of early depressive symptoms as a predictor of 
later sleep difficulties. Longitudinal assessment of symptoms of depression and 
DIS during the time of early adolescence is advantageous, as increasing 
evidence has suggested that these factors, which may indicate proxy markers for 
depressive illness and insomnia, develop early, and often remain stable across 
the lifespan. 
 
14.1.8 OSA, Insomnia and comorbid insomnia-OSA are strongly 
associated with depression among a non-clinical, population-
based sample 
It is estimated that as many as 50-60 million Americans have insomnia symptoms 
annually (17). Furthermore, population-based research has suggested that as 
many as 5% of adults in Western countries meet classification for clinically 
significant OSA (466), and some studies cite a clinical concordance rate of 
comorbid insomnia/OSA as high as 50% (467). The implications for these 
disorders are substantial, both in terms of direct and indirect costs for healthcare 
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systems and individuals. As previously highlighted, the role of sleep disorders in 
the expression and incidence of psychiatric illness among affected individuals 
represents a particular and significant personal and societal burden. Indeed, as 
many as 60.5% of those with insomnia and 41% of those with OSA have 
indicated significant levels of depressive symptoms (468).  
 
Although assessments of these associations is advantageous in characterising 
the burden of disease, it is unclear if these findings are represented at a 
population level when assessing a non-clinical sample, or whether these findings 
are comparable among differing diagnoses using a heterogeneous sample. 
Moreover, as the association between OSA and insomnia on instances of 
depression are often assessed in isolation, there is little indication of the impact 
of comorbid cases of insomnia/OSA with regard to depressive illness. Therefore, 
the current study aimed to address these limitations by employing a 
comprehensive evaluation of the association between insomnia, OSA and cases 
of comorbid insomnia/OSA among a population-based sample of adults. Given 
that both OSA and insomnia represent the highest proportion of individuals 
attending sleep-disorder clinics, and are similarly implicated in the expression of 
depression both among clinical and non-clinical samples, such descriptions 
represent a possible source of clinically useful information for both health-care 
providers and affected individuals.    
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A notable and collective limitation of the previously discussed literature is that of 
an inability to account for and explicitly assess instances of sleep disorders such 
as OSA, thus any assumptions regarding their association with health and 
lifestyle factors are equivocal. Using a large, representative sample of 
community-dwelling adults residing in the USA, it was revealed that well-defined 
instances of insomnia, OSA and comorbid insomnia/OSA were significantly 
associated with instances of depressive illness and poorer physical health 
outcomes, such as cardiovascular disease and various cancers. Sleep disorders 
have previously been linked to adverse health outcomes, such as higher rates of 
CVD (469), however, this is the first research to describe this association among 
comorbid insomnia/OSA, as well as across a comprehensive list of health and 
medical conditions. It was similarly demonstrated that insomnia, OSA and 
comorbid insomnia/OSA were independently associated with depressive illness 
after controlling for several associated health and lifestyle factors. This study was 
the first to demonstrate this observed relationship among comorbid 
insomnia/OSA and depression utilising this community-based sample, and 
contributes valuable insight into this small but important area of investigation. As 
previous estimates suggested a concordance rate between these factors to be as 
high as 50% (467), and given that the possible mechanisms of action supporting 
the association between both insomnia and OSA have been well described 
individually, it is surprising that there is such little research investigating these 
conditions simultaneously. As both of these conditions are similarly associated 
with depression in isolation, further assessment of these factors in combination 
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may provide new modes of clinical intervention, whereby effective treatment of 
one or both of the underlying pathologies works to significantly improve/alter the 
course of the psychiatric illness.  
 
14.2 Methodological Considerations 
One of the primary limitations inherent within epidemiological research is the 
relative difficulty in controlling for confounding variables which may otherwise be 
accounted for in smaller-scale laboratory or clinical studies. Most notably, it is 
acknowledged that the inability to account for the impact of underlying sleep 
disorders which are known to be implicated in the expression of EDS among 
clinical populations, such as OSA, and to a lesser extent, narcolepsy/idiopathic 
hypersomnolence, may have influenced some of the presented results, in 
particular the studies included in Chapters 6-10. Additional measures of objective 
sleep variables which may have given indication of the presence of absence of 
underlying sleep pathology such as OSA were not included within the presented 
studies. As the presented studies utilized non-clinical populations, and underlying 
sleep pathology is considered to poorly correlate with symptoms of EDS among 
community-based samples (105, 153, 304, 305, 456), it is proposed that although 
it is noteworthy to highlight this possible limitation, it is not expected that the non-
inclusion of these additional assessments significantly influenced the presented 
findings. Indeed, the use of peripheral markers of disease, such as adiposity 
profiles, and the thorough examination of a number of health and lifestyle factors 
(potential confounders) theoretically associated with underlying sleep pathology, 
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or which were found to be significantly associated with EDS in univariate 
analyses provided adequate contingency measures for these limitations.  
 
The use of self-reported sleep variables rather than the collation of objectively 
measured sleep within each of the presented studies may mean that the true 
impact of the reported associations is under or over reported. Indeed, some 
research has highlighted that a certain degree of response bias exists, even 
among healthy individuals (470). Despite this, recent studies have supported the 
ecological validity of certain self-report sleep symptom measures, such as the 
ESS and the Pittsburgh Sleep Quality Index (PSQI) among representative 
samples of sleep-disordered populations (471), and other similar diagnostic self-
report measures have been shown to accurately discriminate between the 
presence or absence of underlying sleep pathology using similar methods (472).  
 
As part of the presented studies utilising data from both the GOS and NLHB 
study, estimates of sleep duration was obtained via self-report, and was not 
corroborated by additional objective or questionnaire measures. Further, 
response options were confined to pre-determined categories (hour/half hour 
interval categories) (Chapters 11 and 12), therefore restricting the ability to make 
inferences regarding more sensitive assessments of sleep duration (such as 
minutes). Despite this, a number of longitudinal and cross sectional studies have 
utilised similar methods (420, 421), and the use of such methods allows for 
greater dissemination and indication of the burden of disease.  
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The presence of insomnia, OSA and comorbid insomnia-OSA was assessed by 
utilizing a multidimensional approach as part of the final study presented in 
Chapter 13. The use of frequency markers to assess the presence or absence of 
disease is a method commonly applied within epidemiological studies; 
particularly among those assessing sleep pathology among typically non-clinical 
samples (473, 474). Although a higher overall incidence of OSA, insomnia and 
comorbid OSA/insomnia is indicated compared to previous studies (see (475, 
476)), it is not anticipated that the methods used significantly contributed to this, 
and suggest that the use of these measures are second only to clinical interview. 
Indeed, the prevalence of these common sleep disorders among population 
samples varies significantly between studies, a finding which is often dependent 
on the methods of assessment used. For example, research employing a 
unidimensional approach (such as a y/n response option) often yield higher 
prevalence rates than those which employ more comprehensive assessment 
tools (such as frequency markers) (see; (477)). Despite the usefulness of these 
methods in descriptions regarding the burden of disease, particularly among non-
clinical contexts, it is conceded that the application of these methods precludes 
the ability to differentiate between sub-types of insomnia such as early morning 
awakening or sleep maintenance types. In light of the strong associations 
presented with regard to the relationship between insomnia and depression, no 
inferences can thus be made about the specific role of these sub-types in the 
pathological expression of depressive illness. This is also applicable to the noted 
associations between comorbid insomnia-OSA; as identical methodology was 
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employed to define these cases. As no clearly defined clinical sub-types of OSA 
are considered to exist; it is not anticipated that the measures used impeded the 
analyses and thus the clinical inferences drawn.        
 
Within the existing literature, there are marked differences across studies with 
regard to the quantitative measures used to assess sleep variables. Some of the 
studies examining EDS and associated factors utilized standardized 
measurement tools such as the ESS (127, 221) whilst others used alternative, 
non-standardised methodology (170, 171, 180, 348), or methodology which has 
been validated among local cohorts only (181). These discrepancies have likely 
contributed to the large variation seen among existing epidemiological studies 
assessing EDS in the context of health and lifestyle outcomes. As a result, it is 
difficult to fully elucidate the current findings with some of the results presented 
within previous studies. The presented studies aimed to address these limitations 
by utilising easily-replicable methodology with regard to quantitative measures 
used to assess sleep, health and psychiatric variables. It is acknowledged that 
dichotomising the ESS into pre-determined clinical cut-points (ESS scores <10, 
>10) may limit interpretation of these findings, and that perhaps some more 
subtle aspects of the reported associations may not be captured when applying 
these methods. However, the use of these typically adopted clinical thresholds 
promotes both the relevance and range of the observed associations, and thus is 
advantageous when reconciling the current results with that of existing literature. 
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A notable methodological feature of some -but not all- of the presented studies is 
the stratification of, or lack of distinction between the target variables and the 
outcome of interest in regard to sex differences; as men/women were either 
assessed separately (Chapters 6-10), or gender was not examined as a 
contributory factor beyond characteristic descriptive assessment (Chapters 11 
and 12). Within the GOS studies presented (Chapters 6-10), this distinction 
between genders was due to the inherent differences in the time/sampling frame 
that was employed when recruiting male and female participants. Female 
recruitment for the first sampling wave of the study commenced in 1993, whereas 
the first wave of the male recruitment began in 2001 (for more comprehensive 
description of GOS sampling procedures see; (357)). Therefore, it was deemed 
unfeasible to combine men and women. Despite these limitations, it is not 
anticipated that these factors significantly influenced the presented findings. 
Indeed, as inherent within epidemiological research, some degree of time lag 
between data collection and data analysis is expected due to the scope of the 
project. Further, it is argued that the notable advantages of epidemiological 
research with regard to the extent of information gathered and the ability to infer 
overall burden of disease far outweigh these highlighted limitations.  
 
Despite these aforementioned limitations, steps were taken within each 
epidemiological study to minimise the associated implications. Within the 
methodological section of this thesis (Chapter 5) and as part of each original 
manuscript presented, sufficient detail has been given to enable the replication of 
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this research in future studies. The use of standardized measures to assess 
sleep, health and lifestyle variables within an epidemiological context will allow 
for greater dissemination of these findings across different sample populations 
and between geographical locations in future studies. Effective collation of this 
information will enable more comparisons to be made in order to assess the 
impact of EDS and poor sleep on aspects of physical and psychological health 
among adults. 
 
14.3 Future Directions 
Although these studies present the first comprehensive assessment of the 
physical, psychiatric and general health implications of poor sleep and daytime 
symptoms, many areas of investigation remain. As highlighted in the above 
section, the primary limitation of this research is the inability to elucidate the 
underlying physiological and/or biological mechanism which may underpin the 
presented associations. Although a large number of potential sources of variance 
and erroneous bias were able to be accounted for within the studies presented, 
no inferences were able to be made regarding the role of more comprehensive 
physiological and biological factors. Detailed analyses of a number of biological 
and physiological biomarkers would lend information to the naturally occurring 
relationships observed among the presented studies, and would provide more 
detail as to the specific implications of these factors (i.e., EDS, short/long sleep). 
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Corroborating these presented findings with objectively assessed sleep variables 
and outcomes will assist in disseminating whether sleep represents a causative 
or peripheral factor in these observed associations. Therefore, the inclusion of 
PSG analyses on a subset of participants included for analyses would allow for a 
more naturalistic assessment of sleep variables on a number of health and 
general health outcomes than that which would be offered within strictly 
laboratory conditions. Such assessments would further complement the existing 
epidemiological protocol, and would allow for greater depth and breadth of 
assessment between factors than that which can be investigated using strict 
laboratory protocols. Cost considerations represent an important factor when 
assessing the utility of epidemiological research. Comprehensive assessments 
utilising PSG analysis, whilst useful for the accurate collation of several objective 
sleep variables, may present as a costly and time-consuming option for future 
research. Therefore, alternative monitoring devices such as wrist Actigraphy may 
present as a more cost-effective option for these studies. Such information, 
coupled with the currently used questionnaire data, would also give detailed 
assessment of sleep/wake time estimations and allow for more detailed 
assessment of the association between nocturnal sleep, daytime symptoms with 
regard to physical, psychiatric and general health outcomes among these 
population-based samples.    
 
Further assessment of these factors utilising prospective methodology would be 
advantageous in examining the direction of these relationships, and thus lend 
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argument as to whether sleep disruption and daytime symptoms represent a 
preceding or subsequent effect modifier with regard to health and lifestyle factors 
and the impact of disease. This would be beneficial when assessing the 
associations between EDS and related health and lifestyle factors, as at present, 
little, if any, research exists in this area. Indeed, such measures may be useful 
when considering the ecological value of imposed diagnostic and/or 
characterising tools during periods of childhood or adolescence with regard to the 
relative predictive value of later (adulthood) diagnostic categorisation. Such 
descriptions will complement the small amount of current literature in this field, 
and may also have significant implications for the development of future clinical 
and research avenues.  
 
Lastly, it is unclear if these relationships are sustained among different 
populations. This area of investigation can be considered to currently be in its 
infancy; and further studies assessing the strength of these relationships among 
different ethnic populations, across cultures and geographical location, as well as 
between sexes is warranted if more conclusive arguments are to be drawn 
regarding the strength and impact of these associations. 
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14.4 Conclusions  
14.4.1 Key Outcome Points 
 
 
1. EDS is common among adults and is differentially represented among age 
groups and between sexes. Specially, women reported a higher overall 
prevalence of EDS than men (13.6% vs. 10.4%), and higher rates of EDS 
were noted among the young (ages 20-29 years) as well as those who are 
of peri and post-menopausal age (ages 40-49 and 50-59 years). For men, 
peaks in EDS occurred among middle age (ages 50-59 years) and among 
the very old (ages 80 years and over). Further, EDS is temporally 
associated with several maladaptive health and lifestyle factors and 
instances of physical disease. 
2. EDS is associated with markers of adiposity among this population-based 
sample of adults, however, different adiposity profiles exist for men and 
women which may drive this association. Specifically, women with EDS 
exhibit what can be considered an ‘apple’ body shape, which may indicate 
higher levels of viscerally located fat. For men, it is speculated that those 
with EDS present with increased fat depositions around the neck and 
truncal region, which may have temporal associations with underlying 
sleep pathology. 
3. In this representative sample of Australian men and women, beyond that 
of individual metabolic symptom markers, EDS is independently 
associated with instances of metabolic syndrome. For women, this 
306 
relationship appears to be largely driven by adiposity factors, whereas for 
men, this is somewhat attributable to older age.   
4. In this sample of population-based older women, EDS is independently 
associated with an increased risk for reporting a fall in the previous 12 
months. Moreover, women with EDS are more likely to report a fall 
occurring outside. For men, only a trend towards an association was 
noted, and no difference was noted between those with and without EDS 
with regard to fall location. 
5. For women, EDS is associated with both a current and lifetime history of 
depressive illness, but not anxiety. This association is sustained following 
the application of more conservative diagnostic cut-points for lifetime 
history of depression only.  
6. Short sleep duration at age 15 and 23 years (whole group) is positively 
correlated with short sleep at age 30 years. When split by sex, at age 15 
years, this association was present among females only, however at age 
23 years, this association was present among both males and females. 
Categorical short sleep at age 23 years (whole group) was associated with 
short sleep at age 30 years, and this effect is significant for both men and 
women. From these findings, it is suggested that habitual short sleep in 
middle adulthood (30 years) appears to be formed during early adulthood 
(23 years). These trends are likely due to the interplay between reduced 
circadian drive and increased occupational and social demands 
characteristic of these developmental periods.  
307 
7. Symptoms of depression and DIS were associated from periods of early 
adolescence to early adulthood. Structural equation modelling indicated 
that DIS and symptoms of depression at age 13 years remain relatively 
stable across waves to early adulthood (23 years). In addition, a significant 
and consistent unidirectional cross-lagged effect was noted running from 
symptoms of depression to DIS from the time of early adolescence to early 
adulthood. These results suggest that symptoms of depression 
established in early adolescence are a strong predictor of DIS in early 
adulthood, and are in contrast to previous findings that typically suggest 
sleep problems as a risk factor for the later development of depression. 
8. Insomnia, OSA and comorbid insomnia-OSA are associated with 
significant depressive symptomology and consistently poorer physical 
health outcomes among a large population-based sample of adults. This is 
the first research assessing comorbid OSA/insomnia utilising this 
population-based sample.  
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Conclusion
 
In conclusion, this series of studies provides both cross-sectional and longitudinal 
findings which demonstrate a strong association between disturbed sleep, EDS 
and pathological sleep disorders and deleterious health outcomes in 
representative, population-based samples. Comprehensive and systematic 
epidemiological assessments of these factors are advantageous if the nature and 
mechanistic features of these relationships are to be described, and if greater 
dissemination of the role of peripheral lifestyle and health factors are to be 
considered. Given the substantial personal and societal burden associated with 
sleep disturbances and compromised health, assessing and describing the 
antecedent and consequences of these factors is important for the development 
of both clinical and allied-health treatment initiatives.       
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So depression is an inflammatory disease, but
where does the inflammation come from?
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Abstract
Background: We now know that depression is associated with a chronic, low-grade inflammatory response and
activation of cell-mediated immunity, as well as activation of the compensatory anti-inflammatory reflex system. It is
similarly accompanied by increased oxidative and nitrosative stress (O&NS), which contribute to neuroprogression in
the disorder. The obvious question this poses is ‘what is the source of this chronic low-grade inflammation?’
Discussion: This review explores the role of inflammation and oxidative and nitrosative stress as possible mediators
of known environmental risk factors in depression, and discusses potential implications of these findings. A range of
factors appear to increase the risk for the development of depression, and seem to be associated with systemic
inflammation; these include psychosocial stressors, poor diet, physical inactivity, obesity, smoking, altered gut
permeability, atopy, dental cares, sleep and vitamin D deficiency.
Summary: The identification of known sources of inflammation provides support for inflammation as a mediating
pathway to both risk and neuroprogression in depression. Critically, most of these factors are plastic, and potentially
amenable to therapeutic and preventative interventions. Most, but not all, of the above mentioned sources of
inflammation may play a role in other psychiatric disorders, such as bipolar disorder, schizophrenia, autism and
post-traumatic stress disorder.
Keywords: Depression, Inflammation, Cytokines, Diet, Obesity, Exercise, Smoking, Vitamin D, Dental cares, Sleep,
Atopic, Gut, Oxidative stress
Background
There is now an extensive body of data showing that
depression is associated with both a chronic low-grade
inflammatory response, activation of cell-mediated im-
munity and activation of the compensatory anti-
inflammatory reflex system (CIRS), characterized by
negative immunoregulatory processes [1,2]. New evi-
dence shows that clinical depression is accompanied
by increased oxidative and nitrosative stress (O&NS)
and autoimmune responses directed against O&NS
modified neoepitopes [3,4].
Not only is depression present in acute illness [4,5],
but higher levels of inflammation appear to increase the
risk for the development of de novo depression [6].
Indeed, cytokines induce depressive-like behaviors; in
studies where healthy participants are given endotoxin
infusions to trigger cytokines release, classical depressive
symptoms emerge [7]. Exogenous cytokine infusions also
cause the classical phenotypic behavioral and cognitive
features of depression. As an exemplar, a quarter of the
people given interferon for the treatment of hepatitis C
develop emergent major depression [8,9]. Intriguingly,
antidepressants, particularly selective serotonin reuptake
inhibitors (SSRIs), in vitro or ex vivo exert significant
negative immunoregulatory effects, decreasing the pro-
duction of pro-inflammatory cytokines, for example,
tumor necrosis factor (TNF)α and interleukin (IL)-1,
T cell cytokines, for example, interferon (IFN)γ, and
increasing that of anti-inflammatory cytokines, for
example, IL-10 [10,11]. They additionally alter leucocyte
mRNA gene expression of some immune markers.
Galecki first documented altered expression of mRNA
coding for cyclooxygenase-2, myeloperoxidase, inducible
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nitric oxide synthase and secretory phospholipase A2
type IIA in people with recurrent depressive disorder
[12]. Additionally, inflammatory gene expression second-
ary to antidepressant therapy has been examined, with
lowered levels of IL-1β and macrophage inhibiting
factors seen after treatment, changes which were not
associated with treatment response. However, lower-
ing of IL-6 levels was associated with antidepressant
response [13].
However, clinical depression is accompanied by a “re-
sistance” to these ex vivo or in vitro effects of antide-
pressants attenuating inflammation and T cell activation
[14]. Moreover, remission of clinical depression is ac-
companied by a normalization of inflammatory markers
[15], while lack of response is associated with persist-
ently elevated levels of inflammatory markers [16]. This
resistance to the immunosuppressive effects of antide-
pressants in depressed patients may be explained by
chronic inflammatory processes, chronic damage by
O&NS and the onset of autoimmune responses [14].
These data beg the question: what are the sources of
this chronic low-grade inflammatory and O&NS process
and the source of the resistance to the well documented
immunosuppressive effects of antidepressants? Any pro-
cesses that activate chronic inflammatory and cell-
mediated processes without a concomitant activation of
the CIRS may further aggravate the detrimental effects
of activated immuno-inflammatory pathways. It is well-
known that many inflammatory disorders (chronic ob-
structive pulmonary disease, cardiovascular disease (CVD)
and autoimmune disorders) and neuroinflammatory disor-
ders (multiple sclerosis and Parkinson’s disorder) and in-
flammatory conditions (hemodialysis and the postpartum
period) may trigger clinical depression [17]. However,
these factors are only present in a small percentage of the
larger population of depressed individuals. In contrast,
there are a variety of widely prevalent environmental
factors that are associated with increased risk for the de-
velopment of depression. The aim of this review was,
therefore, to collate extant data on the role of inflamma-
tion and O&NS as possible mediators of known environ-
mental risk factors in depression, and to discuss potential
implications of these findings, acknowledging the explora-
tory nature of these relationships. This paper will discuss
those salient environmental variables that are risk factors
for depression and examine immune dysregulation as a
potential mediator of the interaction. This relationship has
the potential to suggest both novel therapeutic and pre-
ventative approaches.
Stress and trauma
Of all the factors in this review, stressors and trauma
have attracted the greatest extant literature. Psychosocial
stressors, including acute psychological trauma or more
sub-chronic stressors, and early exposure to childhood
trauma robustly increase the risk of developing clinical
depression and mood symptoms, while impacting neuro-
immune circuits. There is now evidence that in experi-
mental animals, different types of psychosocial stressors
increase systemic and CNS levels of pro-inflammatory
cytokines, including IL-1 and IL-6. For example, im-
mobilization stress, mild inescapable foot shock, chronic
mild stress, tail restraint stress, and social isolation in ro-
dent models cause significant increases in IL-1 (mRNA)
levels in the plasma and brain [18-23]. Moreover, the
onset of depressive-like behaviors following external
stressors (for example, learned helplessness and chronic
mild stress) is associated with activated transcriptional fac-
tors (for example, nuclear factor κB), activation of other
inflammatory pathways (for example, cyclooxygenase 2
and prostaglandin production), and increased apoptosis
(for example, lowered levels of Bcl-2 and Bcl-2-associated
athanogene 1) [24].
In humans, there is evidence that different types of
psychosocial stressors may stimulate the pro-inflamma-
tory cytokine network, including increases in IL-6 and
TNFα [25-28]. Maes et al. [28,29] were the first to report
that stress-induced increases in IFNγ and stress-induced
Th1 dominance were significantly correlated with stress-
induced anxiety and distress. Thus, subjects with psy-
chological stress-induced distress and anxiety showed
significantly greater increases in IFNγ and lower IL-10
than those without distress and anxiety. Psychosocial
stress is also accompanied by lowered levels of endo-
genous, anti-inflammatory compounds, for example,
CC16 (uteroglobuline), which decreases the production
of IFNγ [30]. Individuals showing stress-induced
decreases in CC16 in the serum display higher stress-
induced anxiety and distress, and an increased produc-
tion of IFNγ during the stress condition [29,30]. Thus,
stress-induced increases in pro-inflammatory and Th1-
like cytokines may be mediated by lowered levels of en-
dogenous anti-inflammatory compounds, such as CC16.
Stress-induced production of pro-inflammatory cyto-
kines, for example, TNFα and IL-6, and Th1-like cyto-
kines, for example, IFNγ, are related to an increased
number of leukocytes and neutrophils, and expression of
immune cell activation markers, including CD2+CD26+
and CD2+HLADR, and different signs of an acute phase
response [29]. This indicates that psychosocial stress-
induced elevations in pro-inflammatory cytokines or-
chestrate stress-induced changes in peripheral blood
immune cells, inflammatory reactions and neurobeha-
vioral changes.
The findings that psychosocial stressors modulate the
production of pro-inflammatory versus anti-inflamma-
tory or negative immunoregulatory cytokines has impor-
tant implications for stress-related disorders, including
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depression and post-traumatic stress disorder (PTSD).
Thus, psychosocial stressors, such as negative life events,
and chronic psychosocial stress often precede the onset
of clinical depression. Translational models show that
pro-inflammatory cytokines, such as IL-1β, IL-6 and
TNFα, are depressogenic and anxiogenic. These mecha-
nisms may explain why psychosocial stressors and acute
psychotrauma may trigger mood disorders in vulnerable
subjects, for example, those with immune gene polymor-
phisms, lowered levels of pepdidases, including dipepti-
dylpeptidase and prolylendopeptidase, and those with
increased inflammatory burden [31].
Evidence from animal models has long suggested that
early exposure to trauma in childhood may increase the
subsequent risk of poor functioning of the immune,
endocrine and nervous systems. More recently, studies
conducted with humans have corroborated these find-
ings. Data from the Dunedin Multidisciplinary Health
and Development Study in New Zealand, a longitudinal
study following 1,000 participants from birth to 32 years,
have demonstrated that individuals experiencing stress
in childhood resulting from maltreatment, abuse, social
isolation and economic hardship are twice as likely to
suffer chronic inflammation [32]. The detrimental im-
pact of adversity on health in adulthood has also been
demonstrated in US populations. Kiecolt-Glaser [33]
found that childhood adversity can shorten the lifespan
by 7 to 15 years, arguing that stress associated with
abuse, death of a parent or parental relationship prob-
lems can lead to inflammation and premature cell aging,
when compared with individuals who have not experi-
enced such adversity. Miller et al. [34], in a further study
focusing on depression outcomes, compared C-Reactive
Protein (CRP) and IL-6 levels of women with and with-
out history of childhood adversity; the former group was
shown to have a greater likelihood of depression, re-
cording higher levels of inflammation using these bio-
markers. Studies exploring the influence of stress on
other inflammatory diseases, such as CVD [35] and me-
tabolic syndrome [36], have consistently shown similar
trends. Such findings highlight the fundamental idea that
stress occurring early in life can exert persistent effects
over long periods of time, not only increasing suscepti-
bility to somatic and psychiatric illness, but potentially
interfering with treatment response.
However, the association between childhood adversity
and vulnerability to inflammatory disease cannot fully be
explained by a prolonged period of stress initiated by
such an event. Rather, it is possible that learned, mal-
adaptive responses to stress occurring in early childhood
are also employed later in adult life in response to
stressors. Thus, stress in adulthood has become of in-
creasing interest as an instrumental risk factor for disease
onset. For example, there is evidence that personality and
the way in which an individual responds to psychosocial
stressors, such as examination stress or job strain, may
contribute to inflammatory processes [37]. Slavich et al.
[38] found that responses to social stress via neural activity
lead to marked increases in inflammatory activity. Simi-
larly, Emeny [39] found job strain to have a direct effect
on inflammation, and to influence other risk factors for in-
flammation. Job strain is known as a risk factor for other
inflammatory diseases, such as CVD, and more recently
has been shown to be strongly associated with depression
risk [40]. Indeed, it is clear that understanding modifiable
risk factors related to stress (and lifestyle) may be an im-
portant step in the prevention of inflammatory diseases
like depression.
Diet
There have been substantial changes to dietary habits
globally over recent decades, wherein dietary patterns
high in fiber, nutrient-dense foods and omega-3 poly-
unsaturated fatty acids have been replaced by diets
higher in saturated fats and refined sugars [41]. Whether
diet quality contributes to psychopathology, particularly
the common mental disorders (CMDs), depression and
anxiety, has been a focus of much recent research. Since
2009, there have been numerous studies reporting in-
verse associations between diet quality and CMDs,
both cross-sectionally [42-45] and prospectively [46-48].
These associations have also been shown in children
[49] and adolescents [50-52] and are notably concordant
across cultures. Individual nutrients are also related to
depression. As an example, lowered availability of selen-
ium in groundwater and lycopene contents in food are
both associated with clinical depression [53-55].
One of the primary mechanisms of action proposed to
explain these consistent relationships is that of inflam-
mation, where diet quality can impact upon immune
functioning and levels of systemic inflammation, which
subsequently predisposes to depression. Data from po-
pulation-based studies indicate an association between
habitual diet quality and systemic inflammation. For ex-
ample, in the Nurses’ Health Study, a healthy (‘prudent’)
dietary pattern, characterized by higher intakes of vege-
tables and fruit, whole grains, fish and legumes, was
associated with reduced plasma concentrations of in-
flammatory markers, including CRP and IL-6; con-
versely, an unhealthy (‘Western’) pattern, high in red
and processed meats, refined carbohydrate and other
processed foods, was associated with increased inflam-
matory markers [56]. Similarly, Fung et al. [57] found
that a Western dietary pattern was associated with higher
levels of CRP in men participating in the Health Pro-
fessionals Follow-up Study, while in the ATTICA study, a
Mediterranean diet pattern was associated with lower in-
flammatory markers [58].
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Various components of diet may also influence inflam-
mation. For example, the fiber contained in whole grain
foods appears to have immune modulating functions;
wholegrain foods are rich in beta-glucans and these are
known to promote immune functioning [59]. Fiber influ-
ences gut microbiota [60], and this has a knock-on effect
on immune functioning [61]. In support of this, the con-
sumption of whole grains is shown to be inversely asso-
ciated with death from non-cardiovascular, non-cancer
inflammatory diseases [62]. Whole grain foods are also
high in phytochemicals, which protect against the oxida-
tive stress that is a consequence of inflammation and a
feature of depressive illness [63]. High glycemic load
(GL) diets are a common feature of Western culture, be-
ing heavy in refined carbohydrates and added sugars. In
middle-aged, otherwise healthy, women, a high GL diet
was shown to be associated with higher levels of CRP
[64], while another larger study reported that a high gly-
cemic index diet was associated with a small but signifi-
cant increase in CRP in more than 18,000 middle- to
older-aged women [65]. Omega-3 fatty acids, which are
important components of many healthy foods, such as
seafood, nuts, legumes and leafy green vegetables, act to
reduce inflammation [66], while a diet disproportionately
high in omega-6 fatty acids, which are commonly used
in the production of processed foods, increases the pro-
duction of pro-inflammatory cytokines [67]. In the
Whitehall II cohort study, polyunsaturated fatty acid
levels were inversely associated with CRP, while higher
saturated fatty acid levels in serum phospholipids were
associated with higher CRP and fibrinogen [68]. Trans-
fatty acids similarly induce inflammation [69]. Finally,
magnesium intake, which is highly correlated with diet
quality [43], was shown to be inversely associated with
CRP levels in the large National Health and Nutrition
Survey (NHANES) in the US [70].
Intervention studies in humans support these observa-
tional data. Men randomized to a diet high in fruits and
vegetables (eight servings per day) for eight weeks dem-
onstrated a significant decrease in CRP compared with
those consuming only two servings per day [71]. Simi-
larly, Jenkins et al. [72] reported that a dietary inter-
vention using a whole-diet approach and emphasizing
the intake of soy, nuts and plant foods, resulted in
pronounced reductions in CRP levels in hyperlipide-
mic patients over one month, independently of chan-
ges in body weight. Esposito et al. [73] also reported
reductions in multiple inflammatory markers in pa-
tients with the metabolic syndrome randomized to a
Mediterranean-style diet, long recognized as a health-
ful dietary pattern, independent of observed decreases
in weight. Conversely, in an intervention study of
overweight adults, a sucrose-rich diet for 10 weeks
resulted in significant increases in the inflammatory
markers haptoglobin and transferrin, and small increases
in CRP [74].
Finally, studies in animal models explicate specific
mechanisms of action. Recent studies show that rodents
maintained on diets high in saturated fatty acids have el-
evated markers of brain inflammation [75]. This effect
appears to be trans-generational; rats born to dams fed
high saturated fat or high trans-fat diets were shown to
have increased levels of neuroinflammation in adult-
hood, even when fed a standard diet post-weaning [76].
Saturated and trans-fat intake may influence inflamma-
tion, at least in part, via the health of the gut. High fat
intake increases elements from gut microbiota, such as
the endotoxin lipopolysaccharide (LPS), in the circula-
tory system, and LPS are potent promoters of immune
system activation [77]. However, some of these deleteri-
ous effects on immune functioning may be addressed
through the consumption of certain types of resistant
starches and prebiotics [78]. In particular, short-chain
fatty acids (SCFAs), which are produced by fermentation
of dietary fiber by intestinal microbiota, appear to have a
positive impact on immune functioning, suggesting that
increasing intake of fermentable dietary fiber may be im-
portant in reducing inflammation [79]. There is an in-
creasing focus on the importance of gut microbiota in
depression and this is addressed in further detail below.
Exercise
There is a substantive evidence base on the role of exer-
cise as an effective treatment strategy for depression
[80,81]. It is also evident that habitual or regular exercise
protects against the development of new depressive ill-
nesses [82-84], and that physical inactivity during child-
hood is associated with an increased risk of depression
in adulthood [85]. In a nested case-control study of older
individuals, habitual physical activity reduced the likeli-
hood of new depressive and anxiety disorders; for each
standard deviation increase in physical activity score,
there was a halving in the likelihood of developing de-
pressive or anxiety disorders [82]. The relationship in
this, and other studies [86-88], was found to be driven
by leisure-time physical activity. Resistance training is a
recognized treatment strategy for slowing loss of skeletal
muscle mass and function [89]. A prospective cohort
study in Tasmania reported that leisure-time physical ac-
tivity is positively associated with leg strength and
muscle quality in older women [90]. Sarcopenia is linked
to elevated high sensitivity (hs) CRP [91], especially in
the presence of obesity. Sarcopenia is further linked to
cognitive decline in the elderly, which appears to be me-
diated by inflammation [92].
Acute exercise generates reactive oxygen species (ROS)
[93] and inflammatory cytokines [94] that can transiently
damage muscle cells, causing muscle fatigue, pain and
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inflammation. Contracting skeletal muscle produces a
number of ‘myokines’, such as IL-6 [95], which impact
systemically on lipid and glucose metabolism [96]. The
pattern of inflammatory markers produced during acute
exercise, characterized by a rapid elevation in levels of
IL-6 that is quickly followed by induction of anti-
inflammatory substances, including IL-1ra, IL-10 and
soluble tumor necrosis factor receptor (sTNF-R) [97],
differs markedly from that in other inflammatory condi-
tions, such as sepsis. Recovery after the exercise-induced
IL-6 spike dampens the inflammatory response and oxi-
dative burst activity [98]. Chronic or regular exercise,
therefore, down-regulates systemic inflammation via
homeostatic adaptation [99]. Similarly, fitness and exer-
cise reduces leptin [100], elevated levels of which are
also implicated in the development of depression [101]
and is the most evidence-based management strategy for
insulin resistance [102]. These data converge to provide
evidence supporting a role for inflammation in exercise-
induced mood improvements.
More recently and conversely to the association bet-
ween inflammation and exercise, the relationship bet-
ween sedentary behavior and inflammation has become
of increasing interest. Sedentary behavior is now consid-
ered an important and novel risk factor for a number of
physical health conditions, independent of moderate to
vigorous physical activity levels. Specifically, sedentary
behavior has been shown to be associated with elevated
adiposity and cardiovascular risk. For example, in a
multi-ethnic study of atherosclerosis Allison et al. (2012)
found sedentary behavior to be linked with “unfavorable”
levels of adiposity-associated inflammation [103]. Fur-
ther, in a national survey conducted in the US, Koster et
al. [104] found sedentary behavior to be a predictor of
mortality, after adjustment for relevant covariates. Com-
plicating interpretation is that factors that are predictive
of lower physical activity, such as lower self-efficacy,
medical co-morbidity, lower educational status and
social isolation, may be mediators or moderators of the
association [105]. While the underlying physiology associ-
ated with inactivity is also not fully understood, there is
evidence from animal studies that a sedentary lifestyle
may suppress skeletal muscle lipoprotein lipase [106]; re-
sponsible for controlling the process associated with meta-
bolic risk factors. Further research is required in order to
fully understand the links between inflammation and the
underlying physiology of sedentary behavior.
Obesity
Closely linked to diet are its consequences, including
obesity, which is a growing public health concern linked
to a host of chronic physical health conditions [107].
With the prevalence of obesity increasing to epidemic
proportions, efforts in understanding associated risk
factors and outcomes are continuing. The most recently
collected data have shown that in excess of 60% of the
Australian population exceed the recommended thres-
hold for healthy body habitus [108]; concordant with es-
timates from other countries [109]. With few exceptions,
both clinical- and community-based cross-sectional stu-
dies have consistently shown a relationship between
obesity and depression regardless of methodological
variability [110,111]. Prospective studies have suggested
that obesity may be a clinical condition that predisposes
to the development of depressive symptomatology as
well as clinical depression [112]. Depression has also
been shown to predispose to obesity in a bidirectional
manner [112]. A recent meta-analysis of prospective co-
hort studies found obesity to increase the risk of later
depression by 55%, while depression increased the risk
of developing obesity by 58% [113]. Further investiga-
tions into mechanistic pathways are much needed.
Obesity is an inflammatory state. Inflammatory cyto-
kines have been found in abundance in fat cells, are in-
volved in fat metabolism and have been observed to be
positively associated with all indices of obesity, in par-
ticular abdominal obesity [114]. Altered adipocyte func-
tion, fatty acid levels, leptin and hypothalamic pituitary
adrenal (HPA) axis dysfunction and oxidative stress are
hypothesized to play a crucial but synergistic role in
obesity-associated inflammation [114]. A reduction in
adipose tissue mass, through calorie restriction in a
group of obese women, was shown to reduce the ability
of adipose tissue to produce TNFa, IL-6, IL-8 and leptin
[115]. Cross-sectional and prospective studies indicating
obesity, independent of age and other potential con-
founders, leads to altered levels of inflammatory cyto-
kines (or vice visa) provides a likely explanation into the
observed increases in concomitant disease, including de-
pression [116,117]. Moreover, we and others have previ-
ously shown inflammation, in particular, serum hsCRP
to predict de novo major depressive disorder (MDD) [6].
Smoking
Rates of cigarette smoking are significantly higher in pa-
tients experiencing depression when compared with
non-depressed controls. This finding has been replicated
in numerous population-based epidemiological studies
[118,119]. The causal relationship between smoking and
depression is, however, a complex one. The three poten-
tial causal connections underpinning the cross-sectional
relationship, that smoking leads to depression [120,121],
that depression increases smoking behaviors [122], and
that shared-vulnerability factors [123] increase the risk
of both, are all supported by empirical evidence. Al-
though it is probable that cigarette smoking exerts diverse
psychological and neurobiological effects, which may in-
crease one’s predisposition to developing depression, one
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major pathway could be through enhancing systemic in-
flammatory and cell-mediated immune responses, and en-
hancing exposure to O&NS.
Cigarette smoke contains many thousands of che-
micals [124], including free radicals, metals, tars and
other substances that induce inflammatory responses in
bodily tissues and increase levels of O&NS. The noxious
effects of cigarette smoking in inducing altered inflam-
matory responses contribute to a number of chronic
physical illnesses, including asthma, chronic obstructive
pulmonary disease and atherosclerosis [125-127]. Smok-
ing has been associated with increased levels of acute
phase proteins, including CRP, and pro-inflammatory cy-
tokines, including IL-1β, IL-6 and TNF–α, which occur
secondary to direct effects in activation of microglia
and astrocytes [128]. These findings of increased pro-
inflammatory cytokines are similar to those found in de-
pressed patients [3]. Recent evidence also suggests that
enhanced inflammatory responses are additive between
cigarette smoking and depression, such that depressed
smokers exhibit higher levels of hsCRP, IL-6 and TNF –α
than non-depressed smokers [129].
The exogenous free radicals contained in cigarette
smoke lead to direct oxidative damage to cellular tissues,
including those in the CNS. Numerous studies have
demonstrated that animals exposed to cigarette smoke
exhibit increased markers of oxidative stress and de-
creased levels of antioxidants. Observed effects include
increased levels of thiobarbituric acid reactive substances
(TBARS), superoxide, carbonylated proteins [130] and
measures of lipid peroxidation [131-133], and reductions
in levels of antioxidant enzymes, such as catalase [134],
glutathione, superoxide dismutase [134], glutathione re-
ductase, glutathione peroxidase and Vitamins A, C and E
[135]. These findings appear most evident in models of
chronic cigarette exposure, suggesting the possibility that
early adaptive responses [136], which may increase anti-
oxidant levels in the short term [137], are overwhelmed by
chronic use. Once again, these findings are similar to
those found in patients in major depression, where there
appears to be a disturbance in the oxidant/antioxidant
balance [3].
Significant interaction occurs between markers of in-
flammation and O&NS, which further interact with nu-
merous other key elements of central nervous system
functioning, including neurotransmitter systems, neuro-
plastic neurotrophins, mitochondrial energy production
and epigenetic controls. Through these diverse effects,
in conjunction with its known ability to increase inflam-
matory and oxidative stress responses, cigarette smoking
may increase susceptibility for the development of de-
pression. The extent to which the susceptibility is in-
creased will likely differ between individuals based on
underlying depression risk, differing levels and timing of
exposure to cigarette smoke (for example, childhood ver-
sus adulthood) and presence and severity of cigarette-
related health and social consequences.
Gut permeability, the microbiome and the toll-like
receptor (TLR)-IV pathway
A new potential pathway that may mediate depression
pathogenesis is increased immune responses against LPS
of different commensal, gram negative bacteria. Clinical
depression has recently been shown to be accompanied
by increased plasma levels of immunoglobulin (Ig) A
and/or IgM directed against a number of gram negative
bacteria, including Hafnia alvei, Pseudomonas
aeruginosa, Morganella morganii, Proteus mirabilis,
Pseudomonas putida, Citrobacter koseri and Klebsielle
pneumoniae [138-140]. All these gram negative bacteria
belong to the normal gut flora [141,142]. These results
suggest that there is an IgA- and IgM-mediated immune
response directed against LPS, which is part of the bac-
terial wall of gram negative bacteria. LPS are toxic sub-
stances, which may activate immune cells by binding to
the CD14-Toll-like receptor-4 (TLR4) complex. This in
turn may activate intracellular signaling molecules, such
as nuclear factor (NF)-κβ, which in turn activates the
production of pro-inflammatory cytokines, including
TNFα and IL-1 and cyclo-oxygenase-2 (COX-2)
[143,144]. The same processes also induce O&NS path-
ways, for example, increased expression of inducible ni-
tric oxide (iNOS) and thus NO [143]. LPS further
activates nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase leading to an increased production of
ROS, for example, peroxides, and superoxide [145,146].
Moreover, LPS increases the production of lysozyme
(muramidase), which is produced by neutrophils, mono-
cytes and glandular cells and which may bind LPS and
therefore may decrease the activities of LPS [147].
The systemic IgM-mediated immune response in de-
pression directed against LPS suggests that bacterial
translocation may play a role in the inflammatory and
O&NS pathophysiology of clinical depression. Bacterial
translocation indicates the presence of “leaky gut” or an
increased permeability of the gut wall or loosening of
the tight junction barrier. Under normal conditions, im-
mune cells are geographically separated from gram nega-
tive bacteria in the gut. An increased permeability of the
gut wall may allow poorly invasive gram negative bac-
teria to translocate into the mesenteric lymph nodes
(MLNs) and sometimes into the systemic circulation
[148,149]. Consequently, in the systemic circulation,
IgM and IgA responses are mounted against the LPS of
the bacterial wall, while IgA responses may be mounted
even when the bacteria do not reach the blood stream,
but only translocate into the MLNs. Thus, the assay
of the IgA responses directed against LPS measures
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bacterial translocation into the blood stream and the
MNLs. Once primed, immune cells may produce pro-
inflammatory cytokines and stimulate O&NS pathways
[140]. Elevated plasma levels of IgA and IgM levels di-
rected against the LPS of gram negative commensals in-
directly indicate increased bacterial translocation and
thus increased gut permeability. Therefore, bacterial
translocation may drive inflammatory and O&NS pro-
cesses in depression, even in the absence of a specific
inflammatory lesion [138]. On the other hand, inflam-
matory and O&NS pathways may cause loosening of the
tight junction barrier through NF-κB and pro-inflamma-
tory cytokine-related mechanisms [150-154].
In a recent study, the IgM and/or IgA responses di-
rected against LPS were found to be associated with
signs of inflammation, O&NS processes and even auto-
immune responses [140]. More specifically, increased
IgM and IgA responses to LPS in depression are signifi-
cantly and positively correlated to plasma lysozyme,
serum oxidized LDL antibodies and the IgM responses
directed against azelaic acid and malondialdehyde and
phosphatidylinsositol, and NO-adducts, such as NO-
tryptophan and NO-tyrosine [140]. These findings not
only highlight O&NS processes, but also oxidative da-
mage to lipids and nitrosative damage to proteins, and
autoimmune responses mounted against neoepitopes
formed by O&NS damage to lipids and proteins [140].
Thus, increased bacterial translocation may be a pri-
mary factor in the onset of clinical depression and may
be a secondary factor further aggravating inflammatory
and O&NS pathways, leading to a vicious cycle between
loosening of the tight junction barrier and activation of
inflammatory and O&NS pathways [138]. In addition,
the IgM responses directed against LPS were signifi-
cantly higher in patients with chronic depression than in
those without chronic depression [155]. This may sug-
gest that the inflammatory, O&NS and autoimmune
processes that are induced by bacterial translocation
could be involved in the development of chronic depres-
sion and the neuroprogression that is observed in this
condition [3,4,139]. Recently, translational data further
underscored the importance of increased gut permeabil-
ity in mediating stress-related behavioral responses, in-
cluding depression [156]. Thus, stress activates the TLR-
IV pathway and associated inflammatory and O&NS
pathways, including central neuroinflammation. These
effects are at least in part mediated by stress-induced
intestinal permeability and bacterial translocation
[156].
Atopic disorders
An elevated IgE response to common allergen exposure,
leading to the development of allergic symptoms, such
as asthma, eczema or allergic rhinitis/hay fever is
defined as atopy [157]. The prevalence of atopic disor-
ders has been steadily increasing over the past few de-
cades [158,159]. Interestingly, atopy and depression have
recently been linked. Although methodologies differ
among studies, it has been consistently reported that
atopic disorders are associated with an increased risk of
both clinical depression and depressive symptomatology
in clinical settings [160-163]. Population-based studies
provide further support, showing a positive association
between depression and atopic disorders [164-168]. As
with all of the associations explored in this paper, the
causal pathways and their mediators merit exploration.
Atopic disorders are the product of an inflammatory
response. The interaction of an antigen, with antigen-
specific IgE antibodies fixed on the mast cell surface,
activates the mast cell to produce the release of inflam-
matory mediators [169]. There are three categories of
mediators released; secretory granule-associated me-
diators (for example, histamine, proteoglycans, neutral
proteases), lipid-derived mediators (for example, cyclo-
xygenase and lipoxygenase metabolites of arachidonic
acid) and cytokines (for example, Th2 response IL4, IL5
and IL13 and TNFa) [170]. This response results in an
immediate hypersensitivity reaction, such as edema or
itch of the skin, cough or bronchospasm, sneezing or in-
creased mucous secretion. Many hypersensitivity reac-
tions result in a second reaction, termed the late phase
reaction (for example, persistent asthma) [169,170].
Dental cares and periodontal diseases
Dental cares and periodontal diseases, including gingi-
vitis and periodontitis, are diseases of the oral cavity
where connective gum tissue gradually becomes de-
tached from the alveolar bone and often leads to tooth
loss [171]. Periodontal disease is a considerable public
health concern; a recent prevalence estimate in US
adults was 47% [172]. Correlates of periodontal disease
include psychological factors, such as low self-esteem
[173], loneliness [174] and high levels of stress [175]. It
has been reported that psychiatric patients have poorer
oral health status [176]. Recent research suggests that
depression in particular may be associated with peri-
odontal disease. For example, a large, epidemiological
study of over 80,000 adults found that adults with de-
pression were less likely to use oral health services, and
adults with anxiety or depression were more likely to
have tooth loss, even after controlling for various demo-
graphic and health factors, including use of oral health
services [177]. However, another study comprising an
older population found no association between depres-
sion and any measure of oral health, including periodontal
disease [178]. Much of the limited research on psycho-
logical factors and periodontal disease examines samples
from specialist or patient populations. Therefore, research
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which focuses on correlates of oral health and depression
from community samples that are more representative of
the general population, and that examines pathways and
mediators of this association, are required.
Periodontal disease is an inflammatory disease. The
accumulation of bacterial plaque on the teeth causes le-
sions in the periodontal tissue, leading to an acute, local
inflammatory response [179]. Local inflammation in gin-
givitis is concentrated in soft oral tissues, such as the
gum and connective tissue, while inflammation in sup-
porting structures, including the alveolar bone, is also
present in periodontitis [180]. Critically, periodontal di-
sease is also associated with high levels of systemic in-
flammation, such as elevated serum levels of CRP [181].
Furthermore, it is a significant predictor of other inflam-
matory illnesses, such as CVD [182], and health out-
comes, such as mortality in diabetes [183] and coronary
artery disease [184]. The inflammatory response re-
sulting from periodontal disease appears to be mediated
by macrophages, which produce various cytokines [185],
although periodontal tissues may also directly produce
cytokines, such as IL-6 and IL-8 [186]. As such, peri-
odontal disease may be a marker of a failure of the im-
mune system to resolve inflammation [187,188], a state
that may also result in vulnerability to depression [189].
Furthermore, there may also be direct causal links be-
tween depression and periodontal disease, such as when
periodontal disease increases risk for depression through
the psychosocial effects of poor oral hygiene (for ex-
ample, shame, isolation, loneliness) or more directly
through the systemic inflammatory effects of periodontal
disease that may potentiate inflammatory and O&NS
processes and thus depressive symptoms. Currently,
there remains a dearth of evidence that examines whe-
ther translocation of periodontal bacteria plays a role in
some patients with clinical depression, despite some evi-
dence that periodontal infections may play a role in neu-
rodegenerative disorders [190].
Sleep
Sleep is one of the most widely observed phenomena in
multi-cellular organisms [191] and is recognized to play
a vital regulatory role in a number of physiological and
psychological systems. Abnormal sleep patterns are asso-
ciated with a number of adverse health outcomes, such
as an increased risk for mortality [192], morbidity and
poorer quality of life [193]. Sleep disturbance is a com-
mon element in psychiatric disorders, and a
complimentary marker of psychopathology in mood dis-
orders [194]. It is estimated that up to 80 to 90% of indi-
viduals who suffer from a MDD also experience sleep
disturbances [194-196]. Typically, depressive patients ex-
hibit higher rates of sleep disturbances than those in the
general population [197] and, conversely, those who
report abnormal sleep patterns report higher levels of
depression than normal sleepers [198]. Several prospect-
ive and epidemiological studies have suggested that sleep
disturbances may also predispose individuals to subse-
quent development of mood disturbances. Indeed, a
meta-analysis comprising relevant longitudinal epi-
demiological studies conducted by Riemann and
Volderholzer [199] concluded that insomnia symptoms
unambiguously represented a risk factor for the later de-
velopment of depression. Similar research has suggested
that insomnia symptoms often increase the risk of re-
lapse in individuals previously diagnosed with MDD
[200], and that periods of sleeplessness often precede
manic episodes in bipolar patients [201].
Both chronic and acute sleep deprivation are associ-
ated with alteration in cellular and natural immune
functioning [202]; however, the direct mechanism by
which sleep affects inflammation is unclear. It is thought
that alterations in sleep as a result of lifestyle or medical
factors act as a moderator for inflammatory biomarkers
[203] via a bidirectional relationship that exists to modu-
late host-defense and sleep mechanisms [192]. Experi-
mental research has demonstrated that acute sleep
deprivation results in impairments in immune function-
ing [202], characterized by increased levels of the pro-
inflammatory cytokines, CRP, TFN-α [204] and IL-6
[205]. These alterations contribute to stroke and heart
attack due to long-term impaired vascular endothelial
function [206] and possible renal impairment [207]. Even
modest sleep restriction (from eight to six hours per
night) has been shown to result in elevation in levels of
IL-6 and TFN-α [208]; however, this has not been repli-
cated in epidemiological studies [209]. Increases in these
biomarkers have also been observed naturally in individ-
uals suffering primary insomnia [208,210]. Activation of
these pro-inflammatory pathways may result from in-
creased nocturnal sympathetic arousal [193] and an as-
sociated decline in natural immune functioning [202],
therefore, facilitating potentially poorer cardiovascular
outcomes and higher mortality risks previously seen in
these individuals [192,211].
Growing research has suggested that curtailment of
sleep is associated with similar neuroendocrine and
neurobiological abnormalities observed in mood distur-
bances [212]. Increases in pro-inflammatory cytokines
TFN-α and IL-6 following sleep deprivation are also
thought to be related to a reduction in adult neurogen-
esis (AN), comparable to those disturbances found in
depressive patients [213]. Cytokines are significant mo-
dulators of mood (Krishnan and Nestler, [214]). The re-
lease of low doses of IL-6 and TFN-α via administration
of IL-1 in rats generates ‘sickness behavior’ (social with-
drawal, decreased exploratory behavior) [2,215], while
deletion of the gene encoding IL-6 or TFNα promotes
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antidepressant-like behavior phenotypes (resistance to
helplessness, enhanced hedonic behavior) [216]. Increa-
sed activation of the immune system is often observed
in depressed patients; and those suffering immune dis-
eases often report higher rates of depression [215]. It
has, therefore, been proposed that inhibition of neuro-
genesis through the process of chronic sleep disruption
may also contribute to the etiology of depression [217].
As both improved nocturnal sleep and successful phar-
macological treatment of depression are associated with
decreased levels of IL-6 [208,218], and similar inflamma-
tory mechanisms appear to contribute to the pathogen-
esis of depression and expression of illness in chronic
sleep disordered patients, adaptive sleep habits may,
therefore, act as a protective factor against cardiovascu-
lar risk and poorer mental health outcomes.
Vitamin D
Low levels of Vitamin D, particularly 25-hydroxyvitamin
D are widespread among Western populations [219],
making it the most prevalent deficiency state. Low Vita-
min D is linked to a diversity of adverse health out-
comes, such as osteoporosis and cancer [220]. Notably,
the physiology of vitamin D overlaps with the patho-
physiology of depression. Vitamin D receptors are
expressed in key brain areas; and vitamin D has a role in
circadian rhythms and sleep, affects glucocorticoids and
influences neuronal growth, cell proliferation in the
developing brain and embryogenesis [221]. There is a
growing epidemiological evidence-base linking depres-
sive symptoms to low levels of serum 25-hydroxyvitamin
D. These studies include both cross-sectional studies, as
well as prospective data suggesting that low levels are
associated with increased risk for the development of de-
pression. There are positive trials of the potential anti-
depressant effects of vitamin D [222], although there are
equally negative trials [223].
Vitamin D has well documented modulatory effects on
immunity. It modulates immune responses to infections,
such as tuberculosis [224]. In rats given a high fat diet,
1α, 25-dihydroxyvitamin D3 (calcitriol) treatment re-
duced concentrations of various inflammatory markers,
including TNF-α, CRP and IL-6, and protected the liver
from inflammatory damage [225]. In human studies,
supplementation robustly reduces inflammatory markers
in people with cystic fibrosis, including TNF-α and IL-6,
but not other cytokines. Curiously, those two cytokines
are the most robustly associated with depression in
meta-analyses [226]. In multiple sclerosis, vitamin D re-
duces markers of inflammation and attenuates disease
progression [227]. A one-year clinical trial of supple-
mentation with Vitamin D in obese individuals reduced
TNF-α levels, but increased hsCRP. The implications of
these changes are unclear [225]. Inflammation and
oxidative stress are tightly interlinked, and in human
studies, vitamin D supplementation additionally reduced
oxidative stress markers [228]. Vitamin D is a proxy of
sunlight exposure, and it is useful to note that sunlight
may suppress immunity via pathways other than via vita-
min D. In fact, vitamin D derived from safe sunlight ex-
posure may reduce systemic inflammation. There are
additional skin photoreceptors that absorb ultraviolet
light, and play a role in immunoregulation, that include
DNA and lipids in skin cells and trans-urocanic acid
found in the stratum corneum [229].
Inflammation and immune activation across major
psychiatric disorders
There is also evidence that many other major psychiatric
disorders are accompanied by activation of inflammatory
and cell-mediated immune pathways, for example, mania,
schizophrenia, post-traumatic stress disorder (PTSD). The
first papers showing inflammation (increased levels of
pronflammtory cytokines, such as IL-6 and acute phase
proteins; [230,231] and immune activation (increased
levels of sIL-2Rs levels [230,232] in acute and euthymic
manic patients were published in the 1990s. A recent
meta-analysis confirmed that mania and bipolar disorder
are accompanied by activation of inflammatory, cell-
mediated and negative immunoregulatory cytokines [233].
Based on the first results obtained in schizophrenia, Smith
and Maes in 1995 launched the monocyte-T lymphocyte
theory of schizophrenia, which considered that activation
of immuno-inflammatory processes may explain the
neurodevelopmental pathology related to gestational in-
fections. Results of recent meta-analyses showed that
schizophrenia is accompanied by activation of inflamma-
tory and cell mediated pathways [234]. PTSD patients also
show higher levels of pro-inflammatory cytokines, inclu-
ding IL-1 [235], IL-6 [236,237] and TNFα [238].
It is evident that the sources of inflammation and im-
mune activation, which play a role in depression, may
contribute to the inflammatory burden in patients with
mania. Schizophrenia is also associated with some but
not all sources of inflammation and immune activation
that play a role in depression. For example, a recent re-
view showed that stress and trauma (first and second
hits), nutritional factors and vitamin D may play a role
in schizophrenia [239]. The strong associations among
schizophrenia and smoking [240], obesity [241], some
atopic disorders [242], sleep disorders [243] and poor
periodontal and oral health [244,245] may further con-
tribute to the inflammatory burden in schizophrenia pa-
tients. Other factors, however, may be more specific to
mood disorders than to schizophrenia. For example, there
is no significant association between schizophrenia and
increased bacterial translocation [Maes et al., personal
data]. There is strong comorbidity between depression
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and PTSD and patients with this comorbidity show
increased inflammatory responses as compared with
those with PTSD or depression alone [236,237]. The
severity of stress and trauma [236], and the association be-
tween PTSD and smoking [246], obesity/metabolic syn-
drome [247], oral health status [248] and sleep disorders
[249] may further aggravate the activation of immuno-in-
flammatory pathways in PTSD or comorbid PTSD and
depression.
Summary
In interpreting these data, a number of factors need to be
borne in mind. First, depression is a very pleomorphic and
heterogeneous phenotype, and there are likely to be sub-
stantial differences in results depending whether studies
examine clinical or non-clinical samples, use cut scores
on rating scales or formal structured interviews and so on.
Similarly, many studies do not control for potential con-
founders, and most of the literature is cross-sectional.
Last, the areas of interest diverge greatly in terms of the
quantity and quality of the extant literature, with a clear
picture emerging on some areas, such as trauma and
stress, and others remaining areas for future investigation.
The identification of a number of potential factors that
are known sources of inflammation, and their corre-
lation to quality evidence linking those factors to in-
creased risk of depression, provides mechanistic support
for inflammation as one of the mediating pathways to
both risk and neuroprogression in depression. The piv-
otal element is that most of these are plastic, and amen-
able to intervention, both therapeutic and preventative.
While inflammation has suggested a number of very
promising anti-inflammatory therapies, including statins,
aspirin, pioglitazone and celecoxib, the latter preventa-
tive need is perhaps the more pressing [14,250,251].
Psychiatry largely lacks an integrated model for concep-
tualizing modifiable risk factors for depression. It has,
therefore, lacked conceptually and pragmatically coher-
ent primary prevention strategies, prioritizing the treat-
ment of established disorders. Yet the rationale, targets
and imperative to focus on prevention of depression at a
population level is clear.
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a b  s  t  r  a c t
Many  studies  support a  crucial  role for oxidative  &  nitrosative  stress (O&NS)  in the  pathophysiology
of unipolar and  bipolar  depression.  These  disorders are  characterized  inter  alia  by  lowered antioxidant
defenses, including:  lower  levels  of  zinc,  coenzyme  Q10, vitamin  E  and glutathione;  increased  lipid  perox-
idation; damage to  proteins,  DNA  and  mitochondria;  secondary  autoimmune responses  directed  against
redox modiﬁed  nitrosylated  proteins  and oxidative  speciﬁc  epitopes.  This review examines and  details  a
model through  which  a  complex series  of  environmental  factors and biological  pathways  contribute  to
increased redox  signaling  and  consequently  increased O&NS  in  mood  disorders. This  multi-step  process
highlights the  potential  for future  interventions  that  encompass  a diverse range of  environmental and
molecular targets  in  the treatment  of  depression.
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1. Introduction
Many studies support dysregulated redox signaling as being
crucial in the pathophysiology and neuroprogressive nature of
major depression (Maes et al., 2011a).  Reactive oxygen and nitro-
gen  species (ROS and RNS), including peroxynitrite, superoxides,
peroxides and nitric oxide (NO), are produced during normal phys-
iologic processes and, through interacting with proteins, fatty acids
and DNA, perform numerous roles in regulation of cellular function.
When present in excess however, ROS/RNS can lead to structural
and  functional changes that produce cellular injury. These poten-
tially toxic effects are offset under normal conditions by intrinsic
antioxidant mechanisms that participate in the physiologic and/or
pathologic metabolism of ROS/RNS (Maes et al.). Increased oxida-
tive and nitrosative stress (O&NS), which can arise as a consequence
of raised production of  ROS and RNS and/or decreased availability
of  antioxidant defenses, may  cause damage to cellular components,
induce harmful autoimmune responses, and ultimately facilitate
failure of normal cellular processes.
People with unipolar and bipolar depression display dysregu-
lated redox signaling (Lee et al., 2013; Maes et al., 2011a; Moylan
et  al., 2013c; Scapagnini et al., 2012). Studies using clinical and
animal models have demonstrated that depression is  associated
with increased levels of redox products such as malondialdehyde
(MDA, a marker for lipid peroxidation) and 8-iso-prostaglandin F2
(8-iso) (a marker of arachidonic acid peroxidation) (Dimopoulos
et al., 2008; Forlenza and Miller, 2006; Galecki et al., 2009; Yager
et  al., 2010). Additionally, other studies have reported oxidative
damage to DNA, as measured by increased levels of 8-hydroxy-
2′-deoxyguanosine (8-OHdG) in serum (Forlenza and Miller, 2006)
oxidative damage to RNA in post-mortem hippocampus in depres-
sion (Che et al., 2010) and telomere shortening (Shalev et al.,
2014).
Studies conducted in depressed populations demonstrate sus-
tained increases in O&NS. These effects result in depleted levels
of n-3 fatty acid concentrations (Peet et al., 1998),  a  lowered
oxidative potential index of serum (Maes et al., 1999),  reduced
functioning of antioxidant systems represented by lower levels of
plasma concentrations of vitamin E (Maes et  al., 2000; Owen et al.,
2005) and C (Khanzode et al., 2003),  decreased albumin levels (Van
Hunsel et al., 1996),  lowered levels of antioxidants including zinc,
glutathione (GSH) and coenzyme Q10 (Maes et al.), and lower lev-
els of amino acids, such as tryptophan and tyrosine (Maes et  al.,
2000). Similarly, alterations of antioxidant-enzyme levels have
been reported. For example, levels of superoxide dismutase (SOD)
and glutathione peroxidase (GpX) are lower in depressed patients
(Maes et al.,  2011a).  Paraoxonase 1  (PON1), an antioxidant enzyme
bound to high-density lipoprotein (HDL), was signiﬁcantly reduced
in  unipolar, but not bipolar, depression (Vargas et al.,  submitted for Q2
publication). Impairment of these aforementioned antioxidant sys-
tems contributes to the pathophysiology of depression via lowered
protection to ROS and RNS, which may  result in increased risk of
sustained O&NS damage (Forlenza and Miller, 2006; Maes et  al.,
2011a).
NO is  an important mediator in many neural processes. Rodents
subjected to acute and chronic immobilization stress exhibit
increased levels of  inducible nitric oxide synthase (iNOS). Although
NO levels, iNOS and  neuronal NOS (nNOS) expression are increased
in depression, recent studies have indicated that NOS participates in
the mechanisms underlying antidepressant efﬁcacy (Galecki et al.,
2012; Maes et al., 2008b). This suggests that NO may have differ-
ential effects at different sites during the course and treatment of
depression. Persistently increased levels of NO and O2− may  lead
to  the formation of peroxynitrite (ONOO ) and subsequent oxida-
tion, nitration and nitrosylation of  proteins, thereby contributing
to  cellular injury (Maes et al., 2008b, 2011d).
Major depression and bipolar depression are also accompanied
by increased autoimmune responses against newly formed oxida-
tion speciﬁc epitopes (OSEs), following structural damage by O&NS
(Maes et al.,  2007, 2011d, 2013b). Immunoglobulin (Ig)G and IgM-
mediated immune responses against OSEs of membrane fatty acids,
like oxidized low density lipoprotein (LDL), oleic acid, MDA  and aze-
laic  acid, and anchorage molecules, such as phosphatidyl inositol,
palmitic acid, myristic acid and farnesyl-l-cysteine, can be seen in
depression (Maes et al., 2007, 2011d, 2013b).  This may  have pro-
found functional consequences as oxidative damage to membranes,
especially to the major anchorage molecules, may affect the opera-
tion of hundreds of functionally “anchored” proteins that regulate
basic cellular processes, including cell survival, growth, apoptosis,
cell-signaling, neuroplasticity and  neurotransmission (Maes et al.,
2011a).
Chronically increased NO, following iNOS activation, can nitro-
sylate (NSO or NO) proteins and amino acids yielding new
NO-adducts (NO-neoepitopes) like NO-tyrosine, NO-tryptophan,
NO-arginine, NSO-cysteine and NO-albumin. The consequent
hyper-nitrosylation may  cause dysfunction to intracellular signal-
ing,  as well as competitively inhibit the palmitoylation of anchored
proteins to the membrane (Maes et al., 2008b, 2011d, 2012a).
Moreover, some of  these NO adducts can be immunogenic and
therefore contribute to further autoimmune responses directed
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against “nitrosative speciﬁc epitopes” (NSEs) (Boullerne et al., 2002;
Maes et al., 2011d, 2012a). Finally, the autoimmune response
directed against some of these NSEs (e.g. NSO-cysteine) may  result
in serious neurotoxic effects (Boullerne et al., 2002).
Animal studies have demonstrated that various classes of
antidepressants can reduce levels of oxidative stress markers (Eren
et  al., 2007a,b; Maes et al., 2011a) and  increase some endogenous
antioxidants (Maes et al., 2011d). Further, some redox modulators
appear to have some promise as adjunctive treatments for depres-
sion (Maes et al., 2012a; Scapagnini et al., 2012).
The above observations provide greater insight into the pathol-
ogy  of depression, but also raise a  pertinent question: what are
the  underlying pathways and factors that contribute to the onset
and  maintenance of the increased O&NS state in depression?
Greater understanding of the pathways and factors that precip-
itate a state of subchronic O&NS in depression may  inform new
therapeutic and preventative strategies. Here, we review numer-
ous pathways and factors that may  contribute to increased O&NS
in  major depression, and discuss the potential implications of these
ﬁndings.
2.  Depression-related pathways causing O&NS
2.1.  Activated immune-inﬂammatory pathways
Considerable evidence supports the role of central and periph-
eral immune-inﬂammatory processes in depression pathogenesis.
Depression is associated with cell-mediated immune (CMI) acti-
vation, increased monocytic activation and a T  helper (Th)-1-
and Th-17-like cytokine response (Leonard and Maes, 2012).
In  addition, recent meta-analyses demonstrate that patients
with depression have higher serum levels of pro-inﬂammatory
cytokines (PICs) such interleukin (IL)-1, IL-6 and tumor necro-
sis  factor alpha (TNF) (Dowlati et al., 2010; Howren et al.,
2009). Depression is  also associated with increased levels of
acute phase proteins, including C-reactive protein and haptoglobin,
chemokines, adhesions molecules and complement factors (Berk
et  al., 1997; Maes et al., 1997a; Pasco et al., 2010).  An even
stronger association between pro-inﬂammatory cytokines and LPS
and depressive-like behaviors has been reported in rodent stud-
ies  where administration of IL-6, IL-1, TNF  or  LPS resulted
in depressive-like and anxiety-like-behaviors. Similar manifesta-
tions of depressive symptoms are also seen in patients undergoing
immunotherapy with IL-2 and INF- (Dutcher et al., 2000).
The reader is referred to three recent reviews demonstrating
that in depression and  bipolar disorder peripheral activation
of  immune-inﬂammatory pathways coupled with elevated lev-
els of circulating LPS may  contribute to neuroinﬂammation and
consequent neuroprogressive changes including decreased neu-
roplasticity, neurogenesis, and increased neurodegeneration and
neuronal apoptosis (Berk et al., 2011b; Leonard and Maes, 2012;
Moylan et al., 2013c). In addition, immune-inﬂammatory pathways
affect the expression of key neurotransmitters thought involved
in  depression pathogenesis (e.g. serotonin, noradrenaline) through
multiple pathways. One example is through effects on 5,6,7,8-
tetrahydrobiopterin (Bh4).  (BH4) is  a critical co-factor of numerous
amino acid converting enzymes responsible for the production
of  neurotransmitters including NO,  tryptophan, dopamine and
noradrenaline (Sperner-Unterweger et al., 2014). Under acute
inﬂammatory conditions these BH4 related enzymes are upreg-
ulated, leading to increased biosynthesis of neurotransmitters
in the short term. However, chronic low-grade inﬂammation
is  associated with “oxidative loss of BH4”, reducing capacity
for neurotransmitter biosynthesis (Sperner-Unterweger et al.,
2014).
Studies assessing the effect of antidepressants on immune-
inﬂammatory markers in depression provide further corroboration
for the role of immune-inﬂammatory processes in depression.
Administration of tricyclic antidepressants (TCAs) and selective
serotonin inhibitors (SSRI) has been shown to suppress CMI, whilst
attenuating inﬂammatory biomarkers and acute phase protein lev-
els  in animal models (Leonard and Maes, 2012).  Not surprisingly,
the  relationship between the immune-inﬂammatory response and
depression may  be driven, or modulated, by underlying genetic
vulnerability. A recent review of genetic variants in neurobiolog-
ical  pathways associated with immune activation and depression
demonstrates that allelic variants of IL-1, TNF- and CRP may
increase depression risk. SNPs in the IL-1, IL-6 and IL-11 genes may
also be associated with reduced responsiveness to antidepressants
(Bufalino et al., 2013).
Mutual inductions between immune-inﬂammatory and O&NS
pathways may  be key in depression pathogenesis (Maes et al.,
2011a, 2012a). Activation of immune-inﬂammatory pathways,
O&NS processes and lowered antioxidant defenses are insepara-
bly  interrelated (Maes et al., 2012a).  Activated phagocytes and M1
macrophages produce large quantities of ROS and RNS. Increased
levels  of TNF can upregulate the expression of iNOS via transloca-
tion  of nuclear factor kappa B  (NF-B), while interferon-gamma
(IFN) may activate the production of iNOS and thus NO by
macrophages. In different cell types, such as macrophages, neu-
trophils, epithelial cells and microglia, cytokines such as IL-1, TNF
and IFN  activate ROS production (superoxide) via the NADPH oxi-
dase complex (NOX). Neopterin, a surrogate marker of the Th-1-like
response, activates iNOS and NO production and the production
of hydrogen peroxide. On the other hand, activated O&NS path-
ways may  increase nuclear factor (NF)-B, activator protein-1
and mitogen-activated protein kinases (MAPK) thereby increas-
ing the production of  inﬂammatory mediators, such as PICs and
chemokines.
Inﬂammatory and O&NS processes may  also affect antioxidant
defenses. For example, the inﬂammatory processes in depression
are  associated with lowered levels of zinc and vitamin E (Maes
et al., 2011e).  ROS produced in physiological conditions and during
inﬂammation upregulate antioxidant defense systems. In  response
to  O&NS, cells increase their antioxidant defenses through activa-
tion  of nuclear factor erythroid 2-related factor (Nrf2) (Maes et al.,
2012a). Once activated, Nrf2 increases the expression of multiple
endogenous antioxidants. On  the other hand, severe inﬂamma-
tion accompanied by increased ROS, as observed in inﬂammatory
bowel disease, causes an increased consumption of tissue antioxi-
dant defenses masking increased antioxidant levels due to the mild
O&NS (Blau et al., 2000).
Since antioxidants, such as coenzyme Q10, zinc and glutathione,
have  anti-inﬂammatory effects, the lowered levels of those antiox-
idants  in depression increase the inﬂammatory and O&NS burden
(Maes et al.). Moreover, reduced glutathione (GSH) and the regula-
tion  of pro-inﬂammatory cytokines are intimately interlinked. For
example, the transcription of IL-1, IL-6, and TNF are regulated
by  the redox state of the cell and depletion of  GSH enhances the
transcription of these cytokines (Haddad, 2000).
Fig. 1  shows the associations between activated immune-
inﬂammatory pathways, lowered antioxidant defenses and
increased damage by O&NS in depression. Factors that are known
to activate immune-inﬂammatory pathways (review: (Berk et al.,
2013)) may  therefore lead to downstream activation of ROS/RNS
production and O&NS. It may  be concluded that in depression, low-
ered levels of antioxidants and activation of immune-inﬂammatory
and  O&NS pathways are complex processes that exacerbate each
other via multiple feedback loops. Interactions of these seem-
ingly enmeshed pathways further contribute to the complexity of
depression pathogenesis.
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Fig. 1. Depression is characterized by multiple associations between activated
immune-inﬂammatory pathways, lowered levels of key antioxidants and increased
reactive nitrogen species (RNS) and reactive oxygen species (ROS), which activate
nuclear factor erythroid 2-related factor (Nrf2) increasing the expression of endoge-
nous antioxidants. ROS, on the other hand, increases the consumption of antioxidant
defenses. The consequences of activated oxidative and nitrosative stress (O&NS)
pathways comprise the following: (a) formation of oxidative (OSEs) and nitrosative
(NSEs) speciﬁc epitopes, which may be immunogenic thereby causing autoimmune
responses; (b) oxidative and nitrosative damage to  various cellular components; and
(c) hyper-nitrosylation. These consequences of activated oxidative and nitrosative
stress pathways ultimately cause a wide variety of cellular dysfunctions.
2.2. Leaking gut and the microbiome
Clinically depressed patients display higher IgM and IgA
responses to lipopolysaccharides (LPS) from gram-negative bacte-
ria,  potentially as consequence of bacterial translocation secondary
to  increased gut permeability (Maes et al.,  2008a, 2012b).  Gram-
negative bacteria including Hafnia alvei,  Pseudomonas aeruginosa,
Morganella morganii, Proteus mirabilis, Pseudomonas putida, Cit-
robacter koseri and Klebsiella pneumoniae belong to the normal
gut  ﬂora and are termed commensal gut bacteria (Todar, 2006;
Wiest, 2005). Under normal conditions the immune system is  func-
tionally and geographically separated from these poorly invasive
commensal gut bacteria by an intact gut tight junction barrier (Berg
and Garlington, 1979; Wiest and Garcia-Tsao, 2005). Due to this,
immune cells are not normally primed against commensal gut bac-
teria. However, when the gut wall is weakened by increased gut
permeability, gram-negative bacteria can exploit the loosened gut
barrier, thereby translocating from the gut into the mesenteric
lymph nodes (MLNs) or the blood stream (Berg and Garlington,
1979; Chavez et al., 1999; Clark et al., 2005; Wiest and Garcia-Tsao,
2005; Yang et al., 2003).  Once bacteria are translocated, immuno-
cytes  can mount an IgA or IgM-mediated immune response directed
against the LPS of gut commensal bacteria. Measuring IgA and IgM
responses against LPS of commensal bacteria is  a more sensitive
method to detect bacterial translocation than the assay of serum
LPS, because it also detects bacterial LPS when bacteria have not
spread into the blood circulation but when the bacteria are translo-
cated into the MLNs (Maes et al., 2013a). The ﬁnding that clinical
depression is  associated with increased IgM/IgA responses to LPS
therefore indicates that immune cells are activated by LPS from
gram-negative bacteria, which is translocated into the MLNs, the
blood stream, or both. Because if  their particular role in mucosal
defence, Th17 cells, a  subset of T helper cells have a  particular role
against gut infections and  are associated with atopic, inﬂammatory,
and autoimmune disorders. Th17 cells may  disrupt the blood–brain
barrier leading to inﬁltration of the central nervous system, and
drive neuroprogression (Debnath and Berk, 2014).
Through binding with the Toll-like receptor (TLR)2 and
TLR4 complexes, LPS activates different intracellular signaling
molecules, including NF- and MAPK, thereby increasing expres-
sion  of PIC and O&NS genes (Tsukamoto et al., 2010; Wiest and
Garcia-Tsao, 2005).  For example, NF- induces the production of
IL-1, IL-6, TNF and  iNOS (Brasier, 2006). LPS additionally activates
NOX,  which in turn increases production of iNOS, NO, superox-
ide and peroxides (Chan and Riches, 2001; Check et al., 2010;
Peng et al., 2005). Previously, it has been shown that increased
gut permeability is accompanied by elevated plasma LPS and signs
of  inﬂammation and O&NS, with these processes being attenu-
ated or reversed upon successful treatment of  the leaky gut (Quan
et  al., 2004; Zhou et al., 2003). This is relevant to depression, as
LPS administration increases nitrite, nitrate and MDA  levels whilst
decreasing brain GSH levels (Tyagi et al., 2010).  LPS also  reduces the
levels of CC16 or uteroglobin, an endogenous anti-inﬂammatory
substance, thereby increasing inﬂammatory potential (Fransson
et  al., 2007).  CC16 is signiﬁcantly lowered in depressed subjects; in
part explaining the immune-inﬂammatory responses in that illness
(Rief et al., 2001).
In  patients with depression there are signiﬁcant and positive
correlations between bacterial translocation (increased IgA and
IgM responses to LPS) and signs of  increased O&NS (Maes et al.,
2012b) including increased plasma oxidized LDL antibodies, IgM
responses to NSEs, such as NO-tryptophan and NO-tyrosine, as
well as IgM responses directed against OSEs, including azelaic acid,
MDA  and phosphatidyl inositol (Maes et al., 2012b). These ﬁnd-
ings indicate that increased bacterial translocation in depression
drives chronically activated O&NS pathways (damage to fatty acids
and proteins) and autoimmune responses directed against OSEs
and NSEs (Maes et al., 2012b).  Gut bacteria produce a  plethora of
compounds that inﬂuence redox signaling, with different popula-
tions producing different compounds. One example is molecular
hydrogen which has wide-ranging biological effects, including
anti-oxidative, anti-apoptotic and anti-inﬂammatory properties
(Ghanizadeh and  Berk, 2013).
Recently a  review of the bidirectional connections between the
gut and the brain summarized the evidence that gastrointestinal
homeostasis may  modulate emotion, affect, neurocognitive func-
tions and motivation (Mayer, 2011).  Most importantly, animals
exposed to repeated restraint and acoustic stressors demonstrated
increased gut permeability, TLR4 activation and neuroinﬂam-
mation (Garate et al., 2013).  Moreover, attenuation of bacterial
translocation through antibiotic induced intestinal decontamina-
tion reduces stress-induced neuroinﬂammation, suggesting that
stress-induced neuroinﬂammation is  at least partially caused by
increased bacterial translocation. For these reasons, increased bac-
terial translocation may  be a promising drug target in stress-related
disorders, such as depression (Garate et al., 2013).
2.3. Activation of the Toll-like receptor radical cycle
Pattern recognition receptors (PRRs), which include TLR2 and
TLR4, are an important part of the host defense system (Lucas
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and Maes, 2013). PRRs recognize pathogen-associated molecu-
lar patterns (PAMPs) and damage-associated molecular patterns
(DAMPs), which consequently activate MAPK and/or NF-B  lead-
ing  to activation of immune-inﬂammatory and O&NS pathways.
The TLRs recognize mycoplasma, fungus, viruses and LPS, a  typi-
cal  PAMP derived from gram-negative bacteria. Since depression is
accompanied by increased IgM/IgA-mediated immune responses
directed against LPS of gut commensals, it may  be concluded that
the TLR2/TLR4 complexes are activated by PAMP-mediated pro-
cesses.
Typically DAMPs, including -defensin, high mobility group
protein 1 (HMGB1), heat shock proteins (HSPs), extracellular matrix
(ECM), cathelicidin (LL37), hyaluronic acid, heparin sulfate, sub-
stance P and redox-derived DAMPs, appear following injury and
inﬂammation (Carta et  al., 2009; Kaczmarek et  al., 2013; Lotze
et al., 2007; Rubartelli and Lotze, 2007; Uchida, 2013).  Redox-
derived DAMPs are produced during lipid peroxidation and consist
of  oxidatively modiﬁed molecules, such as oxidized phospholipids
(Ox-PLP), oxidized LDL (Ox-LDL), 4-HNE and MDA modiﬁed pro-
teins (Carta et al., 2009; Uchida, 2013). As reviewed in Section
1, depression is accompanied by increased levels of some redox-
derived DAMPS, including oxidized LDL, oxidized phospholipids
and  MDA-derived adducts (Maes et al., 2011d). These molecules
can activate the TLR2/TLR4 complex and play a  role in the down-
stream activation of immune-inﬂammatory and O&NS pathways
(Lucas and Maes, 2013).  As a  consequence, depression may  be
accompanied by a  vicious cycle between TLR2/TLR4 activation and
ROS production causing increased levels of redox-derived DAMPs,
which further stimulate the TLRs.
Exposure to TLR agonists has been shown to sensitize and prime
the  TLR response to subsequent stimulation by other agonists. Psy-
chosocial stressors may  additionally upregulate TLR4 expression
or  activation (Lucas and Maes, 2013). Thus, in depression differ-
ent  TLR2/TLR4 agonists, including bacterial LPS and redox-derived
DAMPs, and psychosocial stressors may  cause hypersensitivity
of the TLR complexes, thereby activating downstream immune-
inﬂammatory and O&NS pathways.
2.4. The tryptophan catabolite (TRYCAT) pathway
Interactions between inﬂammation, O&NS, lowered antioxi-
dant levels and bacterial translocation may  occur via changes in
the  tryptophan catabolite (TRYCAT) pathway. By diverting tryp-
tophan metabolism away from serotonin, N-acetylserotonin and
melatonin production, increased activation of indoleamine 2,3-
dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) have
long been identiﬁed as being associated with depression and asso-
ciated conditions (Maes et al., 1993, 2011c).
IDO, a heme-centered enzyme, is upregulated in pro-
inﬂammatory states in particular by INF,  but also IL-1, IL-6,
IL-18, TNF and LPS (Maes et al., 2011a). When IDO is in its fer-
rous form and in the presence of molecular oxygen, it acts to
cleave tryptophan to N-formylkynurenine, initiating induction of
further TRYCATs. Alternatively, when IDO is  in its ferric form it
utilizes O2− as a  reducing agent to trigger the TRYCAT pathway.
As  such, the inﬂammatory state and redox status regulates how
tryptophan is utilized, with signiﬁcant consequences for processes
classically associated with depression (Maes et al.,  2011c; Werner
and  Werner-Felmayer, 2007).  In addition, lowered tryptophan and
increased levels of  most TRYCATs have negative immunoregulatory
effects that suppress primary immune-inﬂammatory responses
(Maes et al., 2011c).  Thus, induction of the TRYCAT pathway may
have a protective function, but the longer-term consequence of
activation can be crucial to alterations in neuronal activity and
patterning in depression.
IDO is  predominantly expressed in microglia within the CNS
(Alberati-Giani and Cesura, 1998). Microglia are important reg-
ulators and coordinators of central changes in depression and
depression-associated neurodegenerative disorders (Maes et al.,
2011c).  The activation of IDO leads to production of neuroregu-
latory TRYCATs including kynurenic acid (KYNA) and quinolinic
acid (QUIN). KYNA is inhibitory at the 7 nicotinic receptor, whilst
QUIN is excitotoxic at N-methyl d-aspartate (NMDA) receptors by
increasing NO-mediated damage to neurons and astrocytes (Braidy
et al., 2009).
Moreover, TRYCATs have anti-oxidant and pro-oxidant effects.
For example, 3-hydroxykynurenine, 3-hydroxyanthranilic acid and
xanthurenic acid perform antioxidant functions including scaveng-
ing  free radicals, reducing lipid peroxidation, and preventing the
spontaneous oxidation of glutathione and damage to 2-deoxy-d-
ribose (Christen et al., 1990; Goda et al., 1999; Leipnitz et al., 2007).
However, 3-hydroxykynurenine, 3-hydroxyanthranilic and quino-
linic acid also display pro-oxidant effects by generating ROS (e.g.
superoxide and hydrogen peroxide) and causing lipid peroxidation
and oxidative cell damage (Dykens et al., 1987; Goldstein et  al.,
2000; Guidetti and Schwarcz, 1999; Murakami et al.,  2006; Okuda
et  al., 1998; Rios and Santamaria, 1991; Santamaria et al., 2001;
Smith et al., 2009).
Genetic variants of IDO genes may  inﬂuence inﬂammatory
status, thereby regulating the etiology, course and outcome of
depression (Bufalino et al., 2013). Another important regulator
of the TRYCAT pathways is TDO, which in the CNS is predom-
inantly expressed in astrocytes, although also  in some neurons
(Funakoshi et al., 2011).  The activation of TDO is  primarily mediated
by cortisol (Ren and Correia, 2000).  Therefore, increased immune-
inﬂammatory pathway activation and O&NS, through driving
increases in hypothalamic pituitary adrenal (HPA) axis activity
commonly found in depression (Carroll, 1980),  will also contribute
to  increased TDO, further depleting serotonin, N-acetylserotonin
and melatonin, whilst changing neuroregulation by the induction
of KYNA, which is  the TRYCAT predominantly produced follow-
ing  TDO induction. Overall, immune-inﬂammatory processes and
O&NS, including via the regulation of IDO and TDO, are intimately
linked to processes altered in depression.
2.5.  The glutamate–cystine cycle
Prolonged oxidative stress reduces the capacity of astrocytes
to  import glutamate facilitating an increase in extracellular gluta-
mate levels (Dallas et al., 2007).  Higher extrasynaptic and lower
synaptic glutamate may  play a role in depression (Sanacora et al.,
2003),  and depression is associated with glutamate supersensi-
tivity  (Berk et  al., 2001).  A genome-wide association study in
depression demonstrated involvement of glutamatergic synaptic
neurotransmission genes in depression (Lee et al., 2012).  Oxidative-
stress increased glutamate levels can inhibit cystine uptake by the
xc-antiporter system thereby causing intracellular GSH depletion
and consequently oxidative-stress-induced neurotoxicity through
excitotoxic effects, a  process called “oxidative glutamate toxicity”
(Murphy et al., 1989; Schubert and  Piasecki, 2001) that is at  least
in  part mediated by increased calcium signaling.
2.6.  Mitochondrial dysfunction
The mitochondrial electron transport chain (ETC) is  responsi-
ble  for cellular energy generation via adenosine-5-triphosphate
(ATP) production (Adam-Vizi and Starkov, 2010).  ATP is gener-
ated  by transferring electrons through complexes I–V (Green and
Kroemer, 2004; Lenaz, 2001). During this process electrons can
escape, resulting in the reduction of molecular oxygen, which
leads  to the generation of the superoxide anion (O2−) (Green and
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Kroemer, 2004). Mitochondria are therefore an endogenous phys-
iological source of ROS.
As a consequence of  high ROS production, mitochondria are
heavily reliant on local antioxidants and antioxidant enzymes,
including GSH, coenzyme Q10, zinc, SOD, selenium, vitamin C and
vitamin E, to maintain their function. The coordination of mito-
chondrial oxidant induction with antioxidant response is crucial
to  normal cellular plasticity, with alterations in this balance con-
tributing to the etiology and course of multiple disorders including
depression (Gardner and Boles, 2011; Maes et al., 2011a).
Mitochondrial dysfunction in depression, including reduced
activity of the ETC and its  enzymes, decreased production of adeno-
sine triphosphate (ATP), changes in mitochondrial structures in
the brain (e.g. prefrontal and frontal cortex), mitochondrial DNA
deletions and decreased expression of mitochondrial DNA-encoded
transcripts, have recently been reviewed (Gardner and Boles, 2011;
Maes et al., 2012a).  Increased activity of  immune-inﬂammatory
pathways in depression, such as increased levels of IL-1 and  TNF,
may  cause lowered ATP production and concomitant disorders in
the  ETC and thus impaired oxidative phosphorylation (Maes et al.,
2011a, 2012a). The depleted levels of the aforementioned impor-
tant mitochondrial antioxidants in depression likely contribute to
the  impact of immune-inﬂammatory stressors on mitochondrial
functions and structures. The consequent lipid peroxidation and
increased MDA  and 4-HNE production can cause mitochondrial
membrane dysfunction, including increased membrane permeabil-
ity; ultimately leading to mitochondrial dysfunction. Increased NO
signaling additionally inhibits mitochondrial respiration and may
generate peroxynitrite, which may  further reduce ETC functioning,
and damage mitochondrial DNA and functional proteins (Morris
and  Maes, 2013). These mitochondrial dysfunctions, in turn, may
lead to an increased production of superoxide, which causes further
damage to mitochondria and leads to lowered ATP production.
Some of the key processes altered by O&NS include damage to
DNA,  which results in an increase in poly(ADP-ribose) polymerase
(PARP), which, in turn, depletes nicotinamide (NAD+), leading to
decreased sirtuins. Both sirtuin-1 and sirtuin-3 are crucial regu-
lators of mitochondrial function. Sirtuin-1 increases peroxisome
proliferator-activated receptor gamma  coactivator-1alpha (PGC-
1), the master mitochondria regulator, whilst sirtuin-3 is located
at mitochondria where it is  crucial to optimal functioning (D’Aquila
et  al., 2012). As such increased O&NS, including when produced as
consequence of mitochondrial function, may  in fact contribute to
mitochondrial dysfunction via the consequences of  DNA damage.
Another new putative pathway that plays a  key role in
mitochondria-related oxidative stress and mitochondria-mediated
apoptosis is p66shc (Galimov et al., 2014).  p66shc is  an adaptor pro-
tein that activates the mitochondrial apoptosis pathway and may
downregulate cellular antioxidant defenses (Galimov et al., 2014).
Importantly, p66 gene deletion reduces emotionality and increases
brain plasticity in association with increased brain derived neu-
rotrophic factor (BDNF) levels, suggesting strong links between
mitochondrial-generated oxidative stress, emotional behavior and
central BDNF (Berry and Cirulli, 2013). Sirtuins and the p66shc gene
have been under-investigated in the course of depression; top-
ics  requiring further attention given their potential importance in
mitochondrial functioning.
These data suggest the potential for development of a  new class
of  antidepressant medications that prevent mitochondrial dysfunc-
tion,  especially the consequent oxidative damage to DNA, proteins
or  lipids (Maes et al., 2012a).
2.7. Conclusions
Fig. 2 shows the different pathways in depression that may
cause activation of O&NS pathways. The TLR2/TLR4 complexes
Fig. 2. Different pathways may  play  a role in the increased oxidative and nitrosative
stress (O&NS) in depression: (a) activated immune-inﬂammatory pathways; (b)
lowered levels of key antioxidants. Increased oxidative stress increases the  con-
sumption of antioxidant defenses and activates nuclear factor erythroid 2-related
factor (Nrf2), which increases the expression of endogenous antioxidants; (c) oxida-
tive stress induced activation of the  tryptophan catabolite (TRYCAT) pathway with
quinolinic acid (Quin)-induced increases in nitric oxide (NO)-mediated cell dam-
age; (d)  oxidative stress induced glutamate levels depleting intracellular glutathione
(GSH) and facilitating consequent “oxidative glutamate toxicity”; (e)  oxidative
stress-induced mitochondrial dysfunctions leading to increased production of reac-
tive oxygen species (ROS); (f) formation of oxidative (OSEs) and nitrosative (NSEs)
speciﬁc epitopes which may  be immunogenic and mount autoimmune responses
further driving O&NS processes; (g) formation of redox-derived damage associ-
ated molecular patterns (DAMPs) activating the Toll-like receptor (TLR) radical
cycle thereby inducing immune-inﬂammatory and O&NS pathways; (h) increased
pathogen associated molecular patterns, such as lipopolysaccharide (LPS), and psy-
chosocial stressors may  activate or sensitize TLRs.
may  be activated or  upregulated by LPS and psychosocial stressors
leading to downstream production of  proinﬂammtory cytokines
and activation of  O&NS pathways. Due to this, new redox-derived
DAMPs are formed which further activate the TLR radical cycle.
Prolonged oxidative stress may  cause activation of the TRYCAT
pathway leading to NMDA receptor-associated excitotoxicity by
increasing NO-mediated cell damage, and increased glutamate lev-
els that deplete intracellular GSH and facilitate oxidative glutamate
toxicity.
3. Depression-related factors causing dysregulated O&NS
pathways
3.1. Genetic polymorphisms in  O&NS genes
Depression is associated with single nucleotide polymorphisms
(SNP) in pro-oxidant and antioxidant enzyme genes (Maes et al.,
2011a).  Polymorphisms in the myeloperoxidase gene, in particular
GG homozygote and the G allele, increase the risk of depression
(Galecki et al., 2010).  This is important, as myeloperoxidase is  a
pro-oxidant and pro-inﬂammatory enzyme that is  increased in
inﬂammatory disorders. The G/A SNP of the iNOS gene signiﬁ-
cantly increases susceptibility to recurrent depression, while A/A
homozygous carriers demonstrate a lower risk of recurrent depres-
sion  (Galecki et al., 2011).  There is  also a  signiﬁcant association
between SNPs in MnSOD and depression, which may  lead to a
slower uptake of MnSOD in the mitochondria and to mRNA insta-
bility (Galecki et  al., 2010).  Variation on the GpX1 gene is  associated
with  increased depression risk (Johnson et al., 2013), and addi-
tionally modulates the effects of antioxidants, such as selenium
(Johnson et  al., 2013). Some, but not all, studies have demonstrated
that a functional polymorphism in the PON1 gene (Q → R at  the
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192 position) increases the odds of unipolar and bipolar depression
(Vargas et al., 2013).  In addition, gene by environmental effects may
be involved. For example, an interaction between PON1 gene SNP
and smoking is associated with bipolar depression (Vargas et al.,
submitted for publication). While polymorphisms of glutamate cys-
teine ligase, a key synthetic enzyme in the glutathione pathways
are associated with disorders such as schizophrenia, this does not
appear to be the case in depression (Berk et al., 2011a). SNPs of
pro-inﬂammatory cytokine genes, including IL-1 and IL-6, may  also
predict responsiveness to treatment with antidepressants (Baune
et al., 2010; Uher et al., 2010).
Therefore, underlying genetic vulnerabilities produced by poly-
morphisms in pro-oxidant, antioxidant and inﬂammatory genes
may  contribute to the O&NS processes in depression especially in
conditions of increased ROS/RNS production.
3.2. Psychological stressors
A vast literature suggests psychosocial stressors may  induce
O&NS pathways and reduce antioxidant defenses. Psychologi-
cal stress causes a pro-oxidant state and oxidative damage to
fatty acids (Aleksandrovskii Iu et al., 1988; Pertsov et al., 1995;
Sosnovskii and Kozlov, 1992).  Morimoto et al. (2008) reported
that in postmenopausal women, mental stress induces increased
lipid peroxidation as measured by plasma 4-HNE. In nurses with
high job stress, signiﬁcantly decreased levels of alpha-tocopherol
(vitamin E) and a  signiﬁcant relationship between MDA  levels and
perceived stress ratings have been detected (Tsuboi et al., 2006).
In  workers from a  pre-hospital emergency service, Casado et al.
(2006) observed a signiﬁcant association between occupational
stress and erythrocyte MDA  levels. In females, stress variables, such
as perceived stress and workload and less coping with stress, were
associated with increased levels of 8-OHdG (Irie et al., 2001). Stress-
ors such as examination stress decrease plasma antioxidant activity
and increases oxidative stress-induced damage to DNA (Sivonova
et al., 2004). Conversely, lifestyle-modifying programs may  signiﬁ-
cantly improve antioxidant defenses. For example, in patients with
coronary artery disease an  intensive lifestyle modiﬁcation program
resulted in statistically signiﬁcant increases in plasma total antiox-
idant capacity, vitamin E and  erythrocyte GSH (Jatuporn et  al.,
2003). In animal models, many different types of psychophysical
stressors, including immobilization stress, restraint stress, chronic
unpredictable stress and  chronic mild stress, were shown to cause
lowered levels of antioxidants, such as GSH, and increased lipid per-
oxidation, as measured with MDA  and 4-HNE (Ahmad et al., 2010;
Kubera et al., 2011; Moretti et al., 2012; Wang et al., 2012).
As  psychological stressors may  cause O&NS, the role of psycho-
logical trauma has been examined in animal models and individuals
with post-traumatic stress disorder (PTSD). An animal model of
PTSD demonstrated that increased expression of oxidative stress
and  pro-inﬂammatory cytokine mRNA in the brain and systemic
circulation are associated with the onset and exacerbation of PTSD
(Wilson et al., 2013).  In patients with PTSD, however, no changes
in  urinary 8-OHdG could be detected, while protein carbonyl lev-
els were lower in the PTSD group (Ceprnja et al., 2011).  Miller
et  al. (2013) identiﬁed a variant in the gene retinoid-related orphan
receptor alpha (RORA) as being protective against the effects of
stress on the brain, and subsequent development of PTSD. The
authors concluded that this gene plays a  crucial role in guarding
brain cells from the detrimental effects of oxidative stress (Logue
et  al., 2013).
3.3. Medical comorbid disorders and conditions
Depression is  highly comorbid with many systemic immune
and O&NS-related disorders (e.g. Chronic Obstructive Pulmonary
Disorder; COPD, atherosclerosis, rheumatoid arthritis, inﬂam-
matory bowel disease, psoriasis, diabetes type 1  and type 2,
HIV-infection), neuroinﬂammatory and O&NS-related brain disor-
ders (e.g. Parkinson’s disease, Alzheimer’s disease, stroke, multiple
sclerosis) and conditions accompanied by increased inﬂammatory
potential and O&NS (hemodialysis, IFN-based immunotherapy)
(Maes et al., 2011b). Depression may  be triggered by these disor-
ders or conditions, or worsen outcomes for those in whom these
disorders are present (Maes et al., 2011b).
Increased O&NS and immune-inﬂammatory pathways may
underpin the comorbidity and interaction between depression and
these related conditions (Maes et  al., 2011a; Wolkowitz et al.,
2011).  Recently, it has been proposed that the underlying biological
processes driving depression intimately overlap with neurodegen-
erative processes, suggesting that depression may  be more than a
comorbidity but rather is  intertwined with degenerative processes
(Anderson and Maes, 2013b).  Oxidative stress drives telomere
shortening, a  key mechanism underlying the aging process (Phillips
et al., 2013),  and therapies that reduce oxidative stress such as
lithium  are associated with longer telomeres (Martinsson et  al.,
2013).  There may  be additional effects of aging on O&NS pathways
and a  number of ‘age-related’ disorders such as cardiovascular dis-
ease (CVD) (Maes et al., 2011e),  stroke (El Kossi and Zakhary, 2000),
diabetes (Maritim et al., 2003), metabolic syndrome (Hansel et  al.,
2004),  and sleep apnea (Jelic et al., 2008); all  of which are recog-
nized to share common origins of increased O&NS (Forlenza and
Miller, 2006).
3.4. Obesity and metabolic syndrome
Accumulating clinical and epidemiological evidence suggests
that obesity contributes to the pathogenesis of  depression (Atlantis
et  al., 2009).  Cross-sectional studies have linked obesity with
depression (Atlantis and Baker, 2008; de Wit  et al., 2010) and neg-
ative affect (Pasco et al., 2013),  and a series of longitudinal studies
have demonstrated this association is  bi-directional (Luppino et al.,
2010; Pan et al., 2012).  Traditionally regarded as an energy storage
depot, adipose tissue is  now recognized as having a  role in both
physical and mental health.
Excessive accumulation of adipose tissue in obesity perturbs the
regulatory network of neural circuits and  circulatory messengers
that has evolved to maintain energy homeostasis. As one of the
cell types in adipose tissue, adipocytes (fat cells) serve as depots
for energy storage and mobilization. Adipocytes produce biolog-
ically active molecules known as adipokines (or adipocytokines)
that have pro-inﬂammatory or anti-inﬂammatory activities, and
these include leptin, TNF and adiponectin. Leptin is  a  pro-
inﬂammatory cytokine that plays a  key role in regulating energy
intake and expenditure and signals the brain when adipocytes
become enlarged to modify appetite and behavior (Jequier, 2002).
TNF is  a pro-inﬂammatory cytokine that stimulates the acute
phase  reaction and adiponectin is  an anti-inﬂammatory factor. Cir-
culating levels of leptin (Pasco et al.,  2008a; Solin et al., 1997) and
TNF (Kern et al., 1995) are elevated in obesity and raised levels of
both factors have been reported in depression (Halaris et al., 2012;
Pasco  et  al., 2008a). By  contrast, adiponectin levels are reduced in
obesity (Ryo et al., 2004) and depression (Leo et  al., 2006).
In the obese state, enlarged mature adipocytes become stressed
and  macrophages accumulate in the expanded adipose tissue,
releasing a host of pro-inﬂammatory cytokines and establishing
a  low-grade inﬂammatory state. Such adipose tissue dysregulation
also impairs the differentiation of pre-adipocytes and favors the
storage of excess lipid in other tissues (ectopic depots) (Gustafson
et  al., 2009),  which is metabolically toxic.
Adipose tissue dysregulation induces oxidative stress and adi-
pose tissue itself is  considered an important source of ROS
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(Furukawa et al., 2004; Houstis et  al., 2006; Lee et al., 2009), poten-
tially through the stimulation of NOX (Furukawa et  al., 2004).
Evidence from mouse models suggests that oxidative stress in adi-
pose tissue hampers adipogenesis through Wnt  signaling (Funato
and Miki, 2010), thereby promoting undesirable ectopic fat depo-
sition and further aggravating health. It is  even hypothesized that
imbalances in immune-inﬂammatory and O&NS pathways are the
common soil from which insulin resistance, dyslipidemia and obe-
sity may  develop (Bryan et al., 2013).
Metabolic syndrome, a  clustering of conditions including
abdominal (central) obesity, high blood pressure, plasma glucose,
triglycerides, and low HDL levels), is accompanied by increased
levels of MDA, advanced oxidation protein products, lipid hydrox-
yperoxides and nitric oxide metabolites (plasma concentrations of
nitrite and nitrate) (Bortolasci et al., 2014; Sankhla et al., 2012).
Patients with metabolic syndrome have higher MDA  levels, lipid
hydroxyperoxides and advanced oxidation protein products, but
not NO metabolites, when compared with controls; however the
status of serum total antioxidants in metabolic syndrome remains
equivocal (Vargas et al., submitted for publication). Interestingly,
paraoxonase Q192R functional genotypes or activity phenotypes
are  associated not only with depression, but also with the metabolic
syndrome (Bortolasci et al., 2014).
These ﬁndings suggest that activation of immune-inﬂammatory
pathways and oxidative stress balance may  underpin both depres-
sion and the metabolic syndrome. Therefore, the metabolic
syndrome when comorbid with depression may  increase the
immune-inﬂammatory and oxidative burden.
3.5.  Sleep disorders
Numerous studies have indicated a  bidirectional link between
sleep disturbances and depression (Tsuno et al., 2005). Prospective
and  longitudinal studies have demonstrated that sleep distur-
bances predict later episodes of major depression (Breslau et al.,
1996; Perlis et al., 1997),  and  symptomatic depression is  recognized
to act as a proxy for the later development of insomnia (Breslau
et  al., 1996; LeBlanc et al., 2009).  These ﬁndings have further been
sustained after accounting for possible lifestyle factors such as age
(Chang et al., 1997),  gender (Taylor et al., 2005), general medical
conditions (Taylor et al., 2005) and prior history of a depressive
or sleep disorder (Buysse et al., 2008; Neckelmann et al., 2007).
In  addition, numerous studies have demonstrated that individu-
als  with obstructive sleep apnea (OSA) often exhibit high rates of
depression (Harris et al., 2009; Schroder and O’Hara, 2005),  with
the degree of depressive symptoms thought to reﬂect nocturnal
biomarkers such as the hypoxemia nadir (McCall et  al., 2006) and
relative disease severity (Millman et al., 1989).  Despite this, the
mechanisms that underlie the association between disturbed sleep
and depression have not yet been fully elucidated.
Sleep has a number of restorative functions. Sleep disruption,
whether acute or chronic, endogenously or  exogenously mediated,
is  associated with increased risk for later development of seri-
ous medical illnesses to which O&NS contributes (Foster et al.,
2007; Ozkan et al., 2008).  Individuals with primary sleep disor-
ders and OSA typically exhibit activation of immune-inﬂammatory
pathways, including increased IL-6, IL-8 and prostaglandin E2
levels and lowered plasma tryptophan (Song et al., 1998) and
higher 8-isoprostane (Alonso-Fernandez et al., 2009) but lower NO
metabolites (Ozkan et  al., 2008).  Patients with primary sleep dis-
orders also show signiﬁcantly lower activity of GpX and higher
MDA  concentrations than controls (Gulec et al., 2012),  compa-
rable to research investigating individuals diagnosed with major
depression (Bilici et al., 2001).  Volna et al. (2011) found a strong
association between OSA symptomology and markers of oxidative
stress, and signiﬁcant inverse correlations between mean blood
hemoglobin oxygen saturation and  matrix metalloproteinase 9,  C-
reactive protein and ﬁbrinogen. The  oxygen desaturation index
was additionally correlated with advanced glycation end products.
Sleep fragmentation and intermittent hypoxia largely determine
the molecular signature of OSA, including oxidative stress and
inﬂammation, although comorbid obesity may  play a  role due to
its impact on shared molecular pathways (Arnardottir et al., 2009,
2012).  Mitigation of nocturnal symptoms via night-time therapy
also appears to neutralize the degree of O&NS damage in OSA
patients (Alonso-Fernandez et al., 2009).
Preliminary ﬁndings derived from animal studies have high-
lighted  the potential of melatonin administration as an effective
therapeutic agent in regard to its O&NS effects (Manda and Bhatia,
2003). Although the possible therapeutic beneﬁts of  this hormone
in the treatment of a  range O&NS speciﬁc disorders has been previ-
ously described (see review (Reiter et al., 2009)), and independent
reports have proﬁteered the usefulness of melatonin in a  range
of  sleep-disordered populations (Reiter et  al., 2007),  there is  lit-
tle information integrating this knowledge regarding the possible
efﬁcacy of  this hormone in targeting sleep-disorder speciﬁc O&NS.
Moreover, the availability of a  uniﬁed model describing the impact
of  O&NS damage in sleep disorders is  currently lacking, and thus
currently available treatment options are unable to effectively tar-
get underlying mechanisms associated with O&NS. Future research
will therefore beneﬁt from both further exploring the relationship
between insomnia and O&NS, as well as systematically assessing
the efﬁcacy of melatonin as a possible therapeutic option.
3.6. Cigarette smoking
The prevalence of cigarette smoking is signiﬁcantly higher
in individuals suffering from depressive and anxiety disorders
(Moylan et al., 2012; Pasco et al., 2008b) than those without. This
may  be linked, at least in part, to the inter-relationship between
cigarette smoking and precipitated oxidative stress (Moylan et al.,
2013b).  Cigarette smoke contains many chemicals that increase
levels of O&NS and is a  substantial source of  exogenous free radi-
cals (Stedman, 1968).  Multiple animal models have demonstrated
that exposure to cigarette smoke can lead to increases in levels
of  brain O&NS, as demonstrated by increased levels of reactive
oxygen species, including superoxide, thiobarbituric acid reactive
substances (TBARS), carbonylated proteins and markers of lipid
peroxidation (Anbarasi et  al., 2005; Luchese et al., 2009; Stangherlin
et  al., 2009; Thome et al., 2011; Tuon et al., 2010).  In additions to
these changes, exposure to cigarette smoke appears to be associ-
ated with lowered levels of antioxidant enzymes, such as catalase,
vitamins (A, C, E), GpX, glutathione reductase, PON1, glutathione
and SOD (Anbarasi et al., 2005; Luchese et al., 2009).
As  with other factors that stimulate production of O&NS, acute
exposure to cigarette smoke appears to provoke a  protective
increase in antioxidant enzymes. However, more chronic exposure
overwhelms these defences and  leaves the system vulnerable to
cellular damage. This is important, as factors which can assist the
adaptive protective mechanisms, such as augmentation with vita-
min  E or active exercise (Thome et al., 2011; Tuon et al., 2010),
appear to assist by limiting the increase in O&NS provoked by
exposure to cigarette smoke. Investigations also reveal that the
major addictive component of cigarette smoke, nicotine, may  be
responsible for the major proportion of increased O&NS attributed
to  cigarette smoke exposure. For example, studies utilizing exoge-
nous administration of nicotine to isolate cell lines in culture lead
to reduced production of antioxidant enzymes and increased mark-
ers of lipid peroxidation, lactate dehydrogenase activity and TBARS
(Bhagwat et al., 1998; Yildiz et al., 1998). Given the interaction
between cigarette smoking and O&NS balance, coupled with the
associative ﬁndings between O&NS and  depressive and anxiety
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disorders, it is possible that exposure to cigarette smoke, partic-
ularly in vulnerable individuals, plays a  contributing role in the
development of depression through modulation of O&NS. Indeed,
it  was recently demonstrated that interactions between PON1
genotypes and smoking signiﬁcantly increased the odds of bipolar
depression, while decreased PON1 activity levels, but not smok-
ing,  signiﬁcantly predicted unipolar major depression (Vargas et al.,
2013).
However, it should be noted that nicotine has some anti-stress
effects, with its activation of nicotinic receptors affording protec-
tion in a number of neurodegenerative and psychiatric conditions,
including Parkinson’s disease (Anderson and Maes, 2013a),  in part
via  improvements in arousal-associated cognition. Alpha7 nicotinic
receptor activation in murine regulatory T cells potentiates their
immuno-suppressive capacity (Wang et al., 2010),  exacerbating the
effects of nicotine via immune system regulation in different CNS
disorders (Quik et al., 2012).  Given the role of gut permeability in
the modulation of depression, it is  of note that nicotine amelio-
rates ulcerative colitis, partly by increasing regulatory T cells, but
worsens Crohn’s disease, where it increases Th17 cells (Galitovskiy
et  al., 2011). Cigarette smokers also show a decreased incidence of
some inﬂammatory and allergic disorders, partly mediated by  nico-
tine  effects on mast cells (Linneberg et al., 2001).  As such, nicotine
effects on O&NS in isolated cells require balance with its  effects on
immune system regulation.
Some of the effects of cigarette smoke are mediated by
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), which activates the
aryl hydrocarbon receptor, which, as well as inducing oxidants
and antioxidants also increases IDO, contributing to TRYCAT
induction and serotonin depletion. TCDD-inducible poly (ADP-
ribose) polymerase (TiPARP/ARTD14) (Opitz et al., 2011) decreases
NAD+, in turn lowering sirtuins and PGC-1 and thereby inhibit-
ing mitochondrial function (Diani-Moore et al., 2010). However,
nicotine may  have some direct protective effects at mitochon-
dria, suggesting that nicotine effects will interact with those of
TCDD in the regulation of mitochondrial function. Other factors
in  cigarette smoke including 2,3,6-trimethyl-1,4-naphthoquinone
(TMN), a MAO-A/B inhibitor, also provide protection, partly via
the decreased metabolism of serotonin and dopamine (Castagnoli
et  al., 2003). Taking these diverse effects together, it is possible
that the level of stimulated oxidative stress induced by nicotine
and cigarette smoke may  alter the balance between protective and
damaging effects to cellular structures. Nicotine stimulates acetyl-
choline receptors in a  more sustained fashion than normally occurs
in acetylcholine transmission. Depending upon the conditions, this
may  lead to production of a  small, but still regulated amount
of  oxidative stress that can potentially even augment important
aspects of cell signaling that may  exert protective effects to cellular
function. However, persistent exposure to increased signaling may
overwhelm intrinsic protective mechanisms, leading to chronically
increased oxidative stress leading to cellular damage (Moylan et  al.,
2013b; Newman et al., 2002).  As such, depending on the individual
conditions present, nicotine and cigarette smoke may  have diverse
effects on processes driving the biological underpinnings of depres-
sion, including via the regulation of O&NS, immune-inﬂammatory
processes and their interaction.
3.7. Dietary factors
Levels of ROS/RNS and an individual’s endogenous antioxidant
capacity are inﬂuenced by dietary factors. Fruits, vegetables, olive
oil, nuts and other plant foods are all potent sources of antioxidants,
while a range of dietary derived amino acids, found in meats, veg-
etables, whole grains, eggs and  yoghurt, are important precursors
for  the body’s endogenous antioxidant, GpX. In contrast, high satu-
rated fat diets (Morrison et al., 2010) and hyperglycaemia (Yu et al.,
2006) increase ROS. The effects of dietary factors on the incidence
of depression are exempliﬁed in the PREDIMED randomized trial
(Sanchez-Villegas et al.,  2013).  In patients with comorbid type 2
diabetes, 3-year exposure to a  Mediterranean diet (rich in olive oil,
fruit, vegetables, legumes, tomato, garlic, onion and ﬁsh, but low in
meat, cream, butter, fast foods and sugar) supplemented with nuts
was signiﬁcantly and inversely associated with a lower incidence
of  depression.
The dietary minerals selenium, copper, manganese and zinc are
required as cofactors by oxidative enzymes (Parletta et al., 2013).
Selenium is  also a co-factor in the synthesis of  GSH and its related
enzymes. Selenium appears to play a role in modulating mood
and has been shown to be inversely associated with an increased
likelihood of de  novo major depressive disorder (Pasco et al.,
2012).  In West Texas, residential selenium levels in groundwater
have  been signiﬁcantly and negatively associated with depressive
symptoms, explaining up 17% of their variance (Johnson et al.,
2013).
Reduced dietary intakes of zinc-rich foods have been associated
with increased odds for depression (Jacka et  al., 2012).  Decreased
serum zinc is  commonly described in individuals with depres-
sion  (Maes et al., 1994, 1997b; McLoughlin and Hodge, 1990) and
is  negatively correlated with illness severity (Maes et al., 1994).
A  meta-analysis showed that zinc supplementation has clinical
efﬁcacy in treatment-resistant depression as an  adjunct to antide-
pressants as well as a  stand-alone intervention (Lai  et al., 2012).
Zinc’s antidepressant activity can be explained by its anti-oxidative
and anti-inﬂammatory effects, and also by its neuroprotective
effects related to the modulation of neurogenesis, n-3 metabolism,
NMDA receptor and glutamate levels (Szewczyk et al., 2011). For
example, zinc administration mitigated apoptosis and behavioral
changes in rats exposed to malathion, a  toxic insecticide known
to  induce depressive behaviors and  oxidative damage to the brain
(Brocardo et al., 2007).
Vitamins A,  C and E, present in fruits, vegetables and nuts,
(Bolling et al., 2011), are antioxidants that scavenge free rad-
icals,  protect against cell damage, and upregulate antioxidant
capacity (Parletta et al., 2013). As noted previously, vitamins
E  and C  are signiﬁcantly lowered in depressed patients. There
are  few intervention studies examining vitamins in relation to
depression, although one randomized, double-blinded, placebo
controlled trial did demonstrate improvements in subjective mood
in healthy middle-aged men using a high-dose B  vitamin com-
plex with vitamin C and minerals (Kennedy et al., 2010).  In  animal
models of depression, administration of vitamin E yields a signif-
icant  antidepressant-like effect, while long-term treatment also
improves the antioxidant defenses in the prefrontal cortex and
hippocampus (Lobato et  al., 2010).
Another vitamin that appears important in depression patho-
genesis is vitamin B6. The active form of vitamin B6, pyridoxol-5-
phosphate, can inﬂuence synthesis of  key neurotransmitters due
to  its role in tryptophan metabolism. Deﬁciency in pyridoxol-5-
phosphate is  associated with depression expression (Hvas et  al.,
2004) and higher intakes of vitamin B6 appear to be protective
against depression expression (Skarupski et al., 2010).
Reduced folate intake (Tolmunen et  al., 2004) and folate status
(Nanri et al., 2012) is  associated with an increased risk for depres-
sion. A  Cochrane review supports the use of folate as an  adjunctive
treatment in major depression, although it is  still unclear as to
whether supplementation will beneﬁt both those with low and nor-
mal  levels of  folate (Taylor et al., 2004).  At this time however there
is  no evidence that folate is useful as a monotherapy (Luberto et al.,
2013).  Recent reviews concluded that folic acid levels should be
measured and corrected in treatment-resistant depression and  in
subjects with increased risk for deﬁciencies in folic acid (Lazarou
and Kapsou, 2010).
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In elderly (>70 years of age) Japanese individuals, a tomato-rich
diet, which contains high levels of lycopene, was inversely associ-
ated with depressive symptoms (Niu et al., 2013).  In the same study
no  signiﬁcant association was detected between depressive symp-
toms and the intake of other vegetables, suggesting that lycopenes
may  have the potential to prevent depressive symptoms.
Polyphenols, found in particular abundance in herbs and spices,
berries, green tea, nuts, red wine and other plant foods, also have
potent antioxidant properties. In elderly subjects, the higher intake
of  green tea polyphenols is accompanied by a  reduced incidence of
depressive symptoms, while in animal models green tea polyphe-
nols show antidepressant-like effects, which are in part related
to  their antioxidant effects (Liu et al., 2013; Zhu et al., 2012).  A
recent paper reviewed the antidepressant potential of polyphe-
nols, such as curcumin, ferulic acid, hesperidin, rutin, quercetin and
resveratrol (Pathak et al., 2013).  Resveratrol, one of the phenolic
compounds abundant in berries, grapes, red wine, and peanuts, is
not only a strong antioxidant and anti-inﬂammatory compound,
but also is neuroprotectant (Joseph et al.,  1999).  Polyphenols may
enhance brain plasticity by modulating signaling pathways to
induce the activation of  key  molecules and proteins, such as BDNF
(Williams et al., 2008).
The brain is particularly vulnerable to oxidative damage due
to  the high content of polyunsaturated fatty acids in erythrocyte
membranes. The activated immune-inﬂammatory and O&NS path-
ways that commonly accompany depression result in increased
lipid peroxidation, which may  account for the decreased levels of
long chain fatty acids regularly observed in those with depressive
disorders (Berk and Jacka, 2012).  Such peroxidation decreases cell
membrane ﬂuidity and  can damage membrane proteins. While long
chain n-3 fatty acids help to mitigate the impact of these processes,
supplementation with nutritional antioxidants, such as vitamins A
and E, polyphenols, lycopenes and zinc might prevent lipid per-
oxidation. Pre-treatment with antioxidants can prevent cell loss
in animal models of acute stress (Lee et al., 2006), while studies
in  rodents demonstrate that the adverse effects of high fat diets
on  BDNF expression are ameliorated by antioxidants (Wu  et al.,
2004b). Similarly, adverse effects of induced traumatic brain injury
are  ameliorated by n-3 PUFAs (Wu  et al., 2004a). Moreover vitamins
B6,  B12 and folate can reduce levels of  homocysteine, increases
oxidative stress in endothelial cells (Parletta et al., 2013). These
data indicate that nutrient sufﬁciency is  likely to play an impor-
tant role in reducing the impact of O&NS on the brain via increased
antioxidant and anti-inﬂammatory effects and related neuropro-
tection.
3.8. Vitamin D status
Vitamin D is a secosteroid that has a  primary role in bone
and  muscle health. Widespread vitamin D deﬁciency, particularly
25-hydroxyvitamin D, has been identiﬁed among western pop-
ulations at higher latitudes and cultures with restrictive dress
codes  (Pasco et al., 2001). Many adverse health outcomes including
CVD, osteoporosis and cancer are linked to vitamin D  insufﬁciency
(Nowson et al., 2012).  Additionally, Vitamin D has many less well-
appreciated roles in neural physiology and immune regulation that
notably overlap with the pathophysiology of depression. Vitamin D
also impacts on sleep and circadian rhythms. Receptors for vitamin
D  are found in brain regions important in mood regulation. Vitamin
D  inﬂuences cell proliferation in the developing brain and embryo-
genesis as well as inﬂuencing neuronal growth. It also plays a  role
in  glucocorticoid physiology (Eyles et al., 2011).
Cross-sectional and prospective data suggest that serum 25-
hydroxyvitamin D insufﬁciency is associated with an increased risk
of  developing depression (Kjaergaard et al., 2012). There is, how-
ever, inconsistent clinical trial data of the antidepressant effects of
Fig. 3. This ﬁgure shows the  wide array of factors that may  contribute to increased
oxidative and nitrosative stress (O&NS) in depression. Increased O&NS, in turn,
activates the Toll-like receptor (TLR) radical cycle through formation of redox-
derived damage associated molecular patters (DAMPs), including malondialdehyde
(MDA) and oxidized low density lipoprotein (ox-LDL) and phospholipids (ox-PLP),
which further activate immune-inﬂammatory and O&NS pathways by stimulating
TLRs. The TLR  radical cycle is  further activated or sensitized by increased levels of
lipopolysaccharide (LPS) from gram-negative bacteria, psychosocial stressors and
autoimmune responses directed against oxidative (OSEs) and nitrosative (NSEs)
speciﬁc epitopes.
supplementation with vitamin D, with both positive and null trials
reported (Lansdowne and Provost, 1998; Sanders et al., 2011).
Vitamin D  also has roles in preventing DNA damage and regu-
lating cell growth. Preclinical data suggest that vitamin D  reduces
oxidative stress mediated damage, particularly to DNA, evidenced
by reduced 8-OHdg, reduced chromosomal aberrations, the pre-
vention of telomere shortening and the inhibition of telomerase
activity. It also regulates the cell cycle, preventing propagation of
damaged DNA, and regulates cell death pathways and  apoptosis
(Nair-Shalliker et al., 2012). Vitamin D3 can reverse the induction
of  diabetes by streptozotocin in animal models; a  state which is
associated with reduced antioxidant defenses including superox-
ide dismutase and GpX (George et al., 2012). In elderly subjects with
glucose intolerance, a  signiﬁcant association has been observed
between oxidative stress markers, particularly advanced glycation
end products, advanced oxidation protein products, LDL suscep-
tibility to oxidation and NO metabolic pathway products with
25(OH)D levels. This effect was  more marked in hyperglycemic sub-
jects, a state known to be linked to oxidative stress (Gradinaru et al.,
2012).
Early life vitamin D deﬁciency is  associated with increased
blood pressure and vascular oxidative stress (Argacha et  al., 2011).
Calcitriol can  reduce expression of inﬂammation and oxidative
stress markers in patients receiving hemodialysis with secondary
hyperparathyroidism (Wu et al., 2011). Calcitriol increases brain
glutathione levels, and is  a  catalyst for GSH production, a  ﬁnd-
ing concordant with both the role of  GSH as a  principal redox
defense, and in the modulation of depression (Garcion et al., 2002).
Some of the efﬁcacy of valproate in bipolar disorder is  mediated by
an  increase in bcl-2 associated anthanogen-1 (BAG-1), which pre-
vents the nuclear translocation of cortisol’s glucocorticoid receptor,
thereby preventing many of the effects of this stress hormone,
including in neuroinﬂammatory disorders such as multiple sclero-
sis (Anderson and Rodriguez, 2011). BAG-1 also transports vitamin
D3  to the nuclear vitamin D  receptor, suggesting that stress and
depression associated O&NS may  be intimately involved in the reg-
ulation of  vitamin D3 effects, partly via BAG-1 regulation. Together
these ﬁndings suggest that oxidative stress may  play a modulatory
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Fig. 4. This ﬁgure demonstrates a model depicting the interrelationship between (neuro)inﬂammation, oxidative and nitrosative stress (O&NS), mood disorders and the
process of neuroprogression. Multiple medical, environmental and genetic factors predispose to (neuro)inﬂammation and increased O&NS. (Neuro)inﬂammation and O&NS
products contribute to expression of mood disorder symptoms and to  neuroprogressive processes. These products also lead to direct cell damage and dysfunction that
contribute to disorder expression, neuroprogression, and to development of autoimmune responses that reinforce a (neuro)inﬂammatory and O&NS state. This reinforcing
cycle contributes to further neuroprogression, and subsequent staging of depression characterized by increasing sensitivity to  relapse, treatment resistance and symptom
chronicity. LPS – lipopolysaccharide.
role in the interaction between vitamin D and mood (Autier et al.,
2013).
3.9. Sedentary lifestyle and exercise
Despite the known health beneﬁts of exercise it  is estimated
that more than 30% of the global population are physically inactive
(Organisation, 2002).  With increasing sedentary behavior comes
the risk of many diseases, including depression. Physical inactiv-
ity  across the lifespan has been cross-sectionally and prospectively
associated with depression (Teychenne et al., 2008).  In a  study
investigating self-reported levels of physical activity in childhood
and adult depression, low physical activity levels throughout the
early years was associated with up to a 35% increased risk of self-
reported depression in adulthood (Jacka et al., 2010).  Furthermore,
epidemiological studies of younger, middle aged and older adults,
have shown habitual physical activity to reduce the likelihood of
de  novo depression (Brown et al., 2005; Pasco et al., 2011; Sagatun
et al., 2007; Strawbridge et al., 2002). These observational ﬁndings
are somewhat supported by intervention studies where exercise
has been demonstrated to be effective in treating depression (Rimer
et  al., 2012). For example, older patients with depression random-
ized to a twice-weekly exercise group for 10 weeks demonstrated
a  modest reduction in depression scores compared to non-exercise
controls (weekly health education talks) (Mather et al., 2002).
Larger effect sizes are reported when comparison is made to a
waiting list or placebo treatment (Rimer et al., 2012).
Exercise is likely to inﬂuence the rate of depression and related
disorders through numerous biochemical, physiological and  psy-
chological pathways (Eyre and Baune, 2012; Moylan et al., 2013a).
However, O&NS is  likely to act as a  prominent mechanism by which
this occurs. O&NS has been shown to be increased in those who
are physically inactive as well as in individuals following acute
exercise, whereas chronic or habitual exercise has been shown
to  be associated with a  reduction in O&NS via an up regulation
of antioxidant defenses (Gomes et al., 2012). For example, in a
small group of physical inactive medical students, levels of MDA
were shown to be increased when compared with age-matched
football players under regular training (Metin et al., 2003). Antioxi-
dant enzyme levels are increased in response to exercise, indicating
that physical activity has the ability to diminish lipid peroxidation
(Djordjevic et  al., 2012; Evelson et al., 2002; Fisher-Wellman and
Bloomer, 2009; Metin et al., 2003). Exercise, like antidepressants,
is  a  signiﬁcant inducer of neurogenesis, with melatonin further
potentiating the effects of exercise on rodent neurogenesis (Liu Q3
et al., in press). Given the role of O&NS in both depression and
exercise, these data highlight the possibility of O&NS modulating
exercise-induced mood improvements. However, further research
into  the optimal type, duration and intensity of the exercise is
required.
4.  Conclusions
Fig. 3  summarizes the pathways and factors that may contribute
to O&NS in depression. A vicious cycle of  activated immune-
inﬂammatory pathways, lowered antioxidant levels, redox-derived
DAMPs and activation of  the TLR4 complex with downstream
production of immune-inﬂammatory mediators and ROS/RNS
characterizes depression. Psychosocial stressors, metabolic syn-
drome and obesity, sleep disorders, smoking, lowered vitamin
D  status, a  diet low in antioxidants, such as selenium, folate,
zinc, lycopenes and polyphenols, and a sedentary lifestyle may
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contribute to activated O&NS pathways in depression. Neu-
roinﬂammatory brain disorders and systemic immune- and
O&NS-related disorders and conditions characterized by O&NS are
additionally associated with the onset of depression.
Activated peripheral immune-inﬂammatory pathways and low-
ered peripheral antioxidant defenses may  have consequences for
central immune-inﬂammatory and O&NS pathways. As previously
summarized (Leonard and Maes, 2012), peripherally increased lev-
els of LPS and pro-inﬂammatory cytokines, driven by activated
O&NS pathways and lowered antioxidant defenses, may  cause brain
neuroinﬂammation. The latter involves not only inﬂammation but
also  O&NS processes fueled by a  systemic loss of antioxidant
defenses and increased gut permeability. Activated central O&NS
pathways may  cause lipid peroxidation, and result in new forma-
tion of redox-derived DAMPs that in turn may  further activate
the TLR radical cycle in the brain. Increased levels of peripheral
TRYCATs, such as kynurenine, may  pass the blood brain bar-
rier to exert depressogenic and neurotoxic activities in the brain.
The  peripheral autoimmune processes directed against OSEs and
NSEs may  have grave consequences for CNS functions. In patients
and animals with autoimmune conditions, including lupus ery-
thematosus, associations have been detected between serum and
brain autoantibodies and neuropsychiatric symptoms (Zameer and
Hoffman, 2001). These behavioral changes accompanying autoim-
mune diseases are centrally mediated through increased blood
brain barrier permeability and inﬁltration of white blood cells
through the choroid plexus (Zameer and Hoffman, 2001). More-
over, some of the IgM autoantibodies directed against NSEs that are
increased in depressed patients (e.g. S–NO–cysteine) are known to
be  highly neurotoxic and to cause demyelination (Boullerne et  al.,
2002).
Fig. 4 depicts the wide-angle lens picture emerging from the
reviewed research literature, demonstrating that activation of
peripheral and central immune-inﬂammatory and O&NS pathways
are  linked to expression of mood disorder symptoms, staging of
depression and to neuroprogressive processes. A  series of medi-
cal,  environmental and genetic factors predispose and contribute
to  development of increased levels of peripheral inﬂammation
that can precipitate development of neuroinﬂammation. Activated
O&NS pathways and lowered antioxidant defenses also drive this
process. Increased neuroinﬂammation and central activation of
O&NS pathways have two broad, non-mutually exclusive, effects.
First, they can inﬂuence development of depressive symptoms
through effects on cellular functioning and through inﬂuencing
key factors underpinning depression effects (e.g. through impair-
ing  normal neurotransmitter synthesis and metabolism). Second,
neuroinﬂammatory and O&NS products cause direct cellular dam-
age (e.g. lipid peroxidation) and dysfunction. Cellular damage and
dysfunction contributes to expression of depressive symptoms (as
above) and to processes underlying neuroprogression, including
increased neuronal apoptosis and decreased neurogenesis and neu-
roplasticity. The cell damage in addition can further stimulate
autoimmune pathways, leading to further increases in central neu-
roinﬂammation and O&NS and reinforcing further depressogenic
and  neuroprogressive effects. These effects contribute to the stag-
ing  of depression, increasing the likelihood of recurrence, treatment
resistance and a chronic depressive state. The delineation of these
pathways highlights multiple opportunities for therapeutic inter-
vention in preventing and/or reducing levels of neuroinﬂammation
and O&NS in depression. Future research should delineate whether
the  pathways involved in the immune-inﬂammatory and O&NS
pathophysiology of depression are useful as state, trait or  stag-
ing  biomarkers for depression. Lastly, understanding of the process
and  its constituents offers both molecular targets for pharmacolog-
ical intervention and environmental targets for public health and
preventive approaches.
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PLAIN LANGUAGE STATEMENT
THE EPIDEMIOLOGY OF OSTEOPOROSIS IN AUSTRALIA:
A POPULATION-BASED STUDY IN GEELONG
92/01-4 Bone size and bone turnover: relationship to fracture risk over 10 years
Principal Researchers: A/Prof MA Kotowicz, Prof E Seeman, Prof GC Nicholson, Dr JA Pasco
This Plain Language Statement and Consent Form is 5 pages long. Please make sure
you have all the pages.
1. Your Consent
You are invited to take part in this research project.
This Plain Language Statement contains detailed information about the research
project. Its purpose is to explain to you as openly and clearly as possible all the
procedures involved in this project before you decide whether or not to take part in it.
Please read this Plain Language Statement carefully. Feel free to ask questions about
any information in the Statement.
Once you understand what the project is about and if you agree to take part in it, you
will be asked to sign the Consent Form. By signing the Consent Form you indicate that
you understand the information and that you give your consent to participate in the
research project. You will be given a copy of both the Consent Form and this Plain
Language Statement to keep as a record.
2. Description of the Project
This study is designed to provide information about osteoporosis. The aims of the
study are to determine:
• how bone mass (amount of bone) and bone size are associated with ageing
• risk factors for low bone mass and fracture
• bone quality and bone mass using ultrasound (sound wave) measurements of the
heel
Approximately 1000 women will participate in this phase of the project.
GEELONG OSTEOPOROSIS STUDY
THE UNIVERSITY OF MELBOURNE
DEPARTMENT OF CLINICAL AND BIOMEDICAL SCIENCES:
BARWON HEALTH
PO BOX 281, GEELONG, VIC 3220
TELEPHONE (+61 3) 5226 7397/7393
FACSIMILE: (+61 3) 5222 2420
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Your participation in this project will involve:
• completion of questionnaires seeking information concerning risk factors for the
development of osteoporosis. There will be questions concerning your health,
medication history, diet, falls, fractures, exercise patterns and lifestyles. A clinical
assessment will include measurement of your blood pressure, skin type, height,
weight, arm span and waist and hip circumferences.
• we will be asking you separately for your consent to ask questions concerning mood
and anxiety disorders to analyse the links between these disorders and osteoporosis.
• an assessment of the skin texture on the back of your hands as an indicator for
lifetime exposure to sunlight. To measure skin texture, a small amount of silicone gel
is placed on the back of your hands and then peeled off.
• collection of a blood sample (approximately 6 tablespoons) after an overnight fast for
biochemical and hormonal analyses.
• we will be asking you separately for your consent to use your blood sample for genetic
analysis.
• a scan which measures your bone mass in the spine, hip, forearm and total body to
measure the calcium content of your bones using a dual energy x-ray densitometer.
The painless procedure takes less than an hour while you are lying on an x-ray table
and does not involve any injections.
• an ultrasound measurement at the heel. During this procedure you will be required to
place your foot in the ultrasound machine for a few minutes.
• participation in these tests to assess your potential for falling
muscle strength, measured with a manual muscle tester, requiring you to resist the
examiner’s force pushing on your leg.
 a vision test using a standard eye chart
Data from this study may also be used as reference data to identify risk factors for
other diseases. In the event that we establish collaborations (partnerships) with
industry, your information and samples may be used for further research into metabolic
disorders. For such partnerships to work, it is important that you assign ownership of
all the information and coded blood samples to The University of Melbourne,
Department of Clinical and Biomedical Sciences-Barwon Health. You may withhold
consent for your information and samples to be used by collaborators if you wish.
3. Possible Benefits
We cannot guarantee or promise that you will receive any benefits from this project but
the information from the study may benefit people in the future.
4. Possible Risks
Possible risks, side effects and discomforts include possible bruising during
collection of blood samples.
During the program you will be exposed to a tiny amount of radiation (200μSv). This
amount of radiation is about the same as 37 days of natural background radiation. All
people on earth are exposed to background radiation. Background radiation comes
from the sun, the earth, the air and all around us.
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The ill effects at very high doses of radiation have been well documented, for example
increased life threatening cancer rates and sometimes death has been reported in
populations exposed to nuclear explosions or in patients undergoing radiotherapy
treatment. However, at tiny or trivial doses of radiation, similar to those being received
from being a participant in this research, the risks are not completely known and have
to be estimated using theoretical models based on the very high radiation dose data.
The acknowledged theoretical model suggests that the risk is about 1 in 10,000. This
model is based on a conservative approach and the actual risk maybe a lot smaller.
Compared to other risks in everyday life this risk is considered negligible. For example
this theoretical risk is approximately the same to (a) smoking 16 cigarettes, (b)
travelling 800 km by car, or (c) travelling 8,000 km by commercial aircraft.
The ultrasound measurement is a rapid, painless procedure, not involving x-rays.
5. Alternatives to Participation
Your participation is voluntary but because of the nature of the study, your total
involvement is important to the quality of the data. You may choose not to be involved
with this study.
6. Confidentiality and Disclosure of Information
Any information obtained in connection with this project and that can identify you will
remain confidential. It will only be disclosed with your permission, except as required
by law. If you give us your permission by signing the Consent Form, we plan to use
your results in presentations at scientific meetings and for publication in
scientific/medical journals. However, information will be provided in such a way that
you cannot be identified.
7. New Information Arising During the Project
During the research project, new information about the risks and benefits of the project
may become known to the researchers. If this occurs, you will be told about this new
information.
8. Results of Project
Periodically you will be sent newsletters summarising research findings and informing
you of the progress of the project. Bone mineral density results will be routinely sent to
you and your doctor if you request it.
9. Further Information or Any Problems
If you require further Information or if you have any problems concerning this project,
you can contact one of the principal researchers on 5226 7393. The researchers
responsible for this project are A/Prof MA Kotowicz, Prof E Seeman, Prof GC
Nicholson, Dr JA Pasco.
If you have any further questions about the research procedures or risks in this study,
you may contact Ms Bernice Davies, Secretary of the Research and Ethics Advisory
Committee, on 5226 7978.
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10. Other Issues
In addition, this study includes a genetic sub-study in which we ask you to consider
participation. There is a separate consent for this part of the study that you will be
asked to sign.
11. Participation is Voluntary
Participation in any research project is voluntary. If you do not wish to take part you
are not obliged to. If you decide to take part and later change your mind, you are free
to withdraw from the project at any stage. Your decision whether to take part or not to
take part, or to take part and then withdraw, will not affect your routine treatment, your
relationship with those treating you or your relationship with Barwon Health (The
Geelong Hospital).
Before you make your decision, a member of the research team will be available so
that you can ask any questions you have about the research project. You can ask for
any information you want. Only sign the Consent Form once you have had a chance to
ask your questions and have received satisfactory answers.
Before deciding whether or not to take part, you may wish to discuss the project with a
relative or friend or your local health worker. Feel free to do this. If you decide to
withdraw from this project, please notify a member of the research team before you
withdraw.
12. Ethical Guidelines
This project will be carried out according to the National Statement on Ethical Conduct
in Research Involving Humans (June 1999) produced by the National Health and
Medical Research Council of Australia. This statement has been developed to protect
the interests of people who agree to participate in human research studies.
This research project has been approved by the Research and Ethics Advisory
Committee, Barwon Health.
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CONSENT FORM
THE EPIDEMIOLOGY OF OSTEOPOROSIS IN AUSTRALIA:
A POPULATION-BASED STUDY IN GEELONG
92/01-4 Bone size and bone turnover: relationship to fracture risk over 10 years
I have read, or have had read to me in my first language, and I understand the Plain
Language Statement version 2, dated 2/04/2004.
I have a copy of the Plain Language Statement and the Consent Form to keep.
The researcher has agreed not to reveal my identity and personal details if information
about this project is published or presented in any public form.
I freely agree / do not agree (strike out non-applicable) to participate in this project
according to the conditions in the Plain Language Statement.
I freely agree / do not agree (strike out non-applicable) to allow members of the
Geelong Osteoporosis research team access to my medical records.
I freely agree / do not agree (strike out non-applicable) to transfer my questionnaire
information and blood samples to The University of Melbourne, Department of Clinical
and Biomedical Sciences-Barwon Health.
I freely agree / do not agree (strike out non-applicable) to allow transfer of my coded
questionnaire information and blood samples to collaborators, including commercial
partners.
Participant’s Name (printed) ……………………………………………………
Signature Date
Witness Name (printed) ……………………………………………………
Signature Date
Researcher’s Name (printed) ……………………………………………………
Signature Date
Note: All parties signing the Consent Form must date their own signature.
GEELONG OSTEOPOROSIS STUDY
THE UNIVERSITY OF MELBOURNE
DEPARTMENT OF CLINICAL AND BIOLOGICAL SCIENCES:
BARWON HEALTH
PO BOX 281, GEELONG, VIC 3220
TELEPHONE (+61 3) 5226 7397/7393
FACSIMILE: (+61 3) 5222 2420
Appendix 9: Questionnaire, Geelong Osteoporosis Study (GOS): Women 10 year 
follow-up.
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Date ____/ ____/ ____
Weight kg
Height cm
Cancer Q Date ____/ ____/ ____
Doctor’s Name: Code
GEELONG OSTEOPOROSIS STUDY: 10-YR FOLLOW-UP QUESTIONNAIRE
(a) Vision (corrected) R L
(b) Circumferences: Waist cm Hip cm
(c) HIP FLEXION R (1) (2) (3) kg
L (1) (2) (3) kg
(c) HIP ABDUCTION R (1) (2) (3) kg
L (1) (2) (3) kg
(c) QUADRICEPS R (1) (2) (3) kg
L (1) (2) (3) kg
(d) Blood pressure (seated): Systolic Diastolic mmHg; (e) Pulse
(f) Arm span (half) sternal notch to fingertip cm
(g) Eye colour: Brown[ ](1) Hazel[ ](2) Green[ ](3) Blue/Grey[ ](4)
(h) Spectrophotometer Back of hand Inner arm Shoulder
400 nm ______ ______ (1a,b) ______ ______ (2a,b) ______ ______ (3a,b)
420 nm ______ ______ (4a,b) ______ ______ (5a,b) ______ ______ (6a,b)
(i) Ultrasound SI (1) (2)
BUA (3) (4)
SOS (5) (6)
(j) Silicone mould of back of hand Yes [ ](1) No [ ](2)
(k) Lateral Scan Yes [ ](1) No [ ](2)
(If Requested)
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P1 Have you made any changes to your diet, activity levels or lifestyle since your last visit?
P2 Give details of any serious illnesses you have suffered over the past decade (ie since baseline visit).
P3 Are you currently breast-feeding? Yes[ ](1) No[ ](2)
We all fall from time to time. The definition of a fall is “when you suddenly find yourself on the ground,
without intending to get there, after you were in either a lying sitting or standing position”.
P4 Have you had a fall during the past year? Yes [ ](1) No[ ](2) Don’t know[ ](3)
If YES: complete the following table:
Fall (a) Where it happened
eg. inside home,
outside the home, in the
street or parks, on
steps, public transport,
kerbs, shops.
(b)
Month
&
year
(c) Describe the fall
eg. slipped on carpet,
fell down steps,
tripped over hose,
tripped on uneven
surface
(d) Was the fall
from greater than
standing height?
(e) Describe
any injuries
(write
‘NONE’ if
no injuries)
(f) Treatment eg.
none, GP,
emergency dept,
home treatment,
physiotherapy or
other
1 YES [ ] NO [ ]
2 YES [ ] NO [ ]
3 YES [ ] NO [ ]
4 YES [ ] NO [ ]
Others
P5 How would you best describe your mobility now? Tick one box only.
P6 Do you use a walking aid? Yes [ ](1) If YES, since when (year)?
No [ ](2)
Very active Moves, walks and works energetically.
Participates in vigorous exercise. [ ](1)
Active Walks at brisk pace, does normal housework or other work.
Engages in light exercise. [ ](2)
Sedentary Walks reasonable distances, does light housework, shopping or equivalent.
Normal activities of day-to-day living, but no appreciable exercise. [ ](3)
Limited Little walking outside home, but prepares meals.
Does very light housework or equivalent. [ ](4)
Inactive Sits in chair or lies in bed most of the time. Walks independently from bed to
chair to toilet but requires assistance for greater movement. [ ](5)
Chair or
bedridden
Cannot walk from bed to chair to toilet without considerable assistance.
[ ](6)
Bedfast Not able to walk. [ ](7)
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P7 (a) Which statement is correct for you?
I am still having regular menstrual periods [ ](1)
I had already gone through menopause when I last visited [ ](2)
I have gone through menopause since my last visit [ ](3)
I am having irregular periods Reason [ ](4)
(b) Date of last menstrual period ____/ ____/ ____
(c) Since last visit have you had a hysterectomy and/or removal of ovaries?
Yes [ ](1) No [ ](2)
If YES, give code and details (refer to list of codes): Code
Details
(d) Have you ever taken HRT? Yes [ ](1) No [ ](2) If YES, when
(e) Are you currently taking HRT? Yes [ ](1) No [ ](2
P8 (a) How many cigarettes do you have each day?
P9 How many cups of these beverages do you consume each day?
(a) Tea
(i) Black (with or without milk)
(ii) Green
(iii) Other (Herbal)
(b) Caffeinated coffee
(i) instant
(ii) brewed
(c) Decaffeinated coffee
(d) Chocolate eg Milo, Cocoa
P10 What is the tallest height you remember (cm) (a) for you
(b) your mother (c) your father
P11 How many of the following standard serves do you usually eat in a week? (eg 1/2, 1, 2).
Food Standard serve Serves/wk
(a) Butter 1 tsp (5g)
(b) Margarine 1 tsp (5g)
(c)Cheese (hard/cheddar/tasty) 1 slice/2.5cm cube (16g)
(d) Cheese (soft/cream/cottage) 1 tbsp (20g)
(e) Eggs 1 medium (48g)
(f) Sardines (canned) 5 sardines (75g)
(g) Salmon (canned) 1/2 cup (105g)
(h) Tuna (canned) 1/2 cup (100g)
(i) Herring/Mackerel 1/2 cup (105g)
(j)Cola drinks eg Coke, Pepsi 1 can (375g)
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P12 If you currently take these medications, please tick and list details.
TYPE YES BRAND NAME DOSE FREQ SINCE YEAR
a anabolic agent
b antacid
c antiangina
d anticonvulsant
e antihistamine
f antihypertensive
g aspirin
h diabetic medication (eg
tablets, insulin)
i diuretic (fluid tablet)
j GI motility agent (for
diarrhoea, constipation)
k heparin
l sedative
m anti-anxiety
n sleeping tablet
o antidepressant
p lithium/mood stabilizer
q antipsychotic
r sex hormone (eg HRT)
s ‘natural’ menopausal
preparation
t steroid/corticosteroid
u contraceptive pill
v bisphosphonate
w SERM
x calcitriol
y PTH
z calcium
aa vitamin D or fish oils
bb antioxidants (eg
vitamins C, E, or A)
cc multivitamin
dd treatment for
acne/excess body hair
ee Others (including herbal
medicines)
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P13Have you ever had a fracture? Yes [ ](1) No [ ](2) Don’t know [ ](3)
If YES: complete the following table:
Frac
(a) Site
(bone)
(b) Where it happened
eg. Inside or outside
the home, in the street
or parks, on steps,
public transport, kerbs,
shops.
(c)
Year
(d) Place
of x-ray
(e) Describe the
circumstances of the
fracture eg. MVA, fall:
slipped on carpet, fell
down steps, tripped
over hose, tripped on
uneven surface
(f) If it was
the result of
a fall, was
the fall from
greater than
standing
height?
(g) Were
you admitted
to hospital
for
treatment?
(other than
the ED)
1 YES [ ](1)
NO [ ](2)
YES [ ](1)
NO [ ](2)
2 YES [ ](1)
NO [ ](2)
YES [ ](1)
NO [ ](2)
3 YES [ ](1)
NO [ ](2)
YES [ ](1)
NO [ ](2)
4 YES [ ](1)
NO [ ](2)
YES [ ](1)
NO [ ](2)
Others
P14 Have you had the following (note: solar keratosis = a flaky skin irregularity):
(a) solar keratosis on dorsum (back) of the hand? Yes[ ](1) No[ ](2) Don’t know[ ](3)
(b) solar keratosis on the rest of the body? Yes[ ](1) No[ ](2) Don’t know[ ](3)
P15 At the end of summer or after a 2-week holiday in the sun, what kind of tan would you have?
A dark tan [ ](1)
A medium tan [ ](2)
A light tan [ ](3)
Practically no tan [ ](4)
P16 How does your skin react when you go out in the sun, for one hour in the middle of the day, for
the first time in summer, without sunscreen?
Burn then peel [ ](1)
Burn then tan [ ](2)
Tan only [ ](3)
P17 In your lifetime, how many times have you been sunburnt, where the pain has lasted 2 or
more days?
Never [ ](1)
Once [ ](2)
2-5 times [ ](3)
6-10 times [ ](4)
More than 10 times [ ](5)
P18 How many times in the last year have you had any sunburn? times.
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P19 In summer, during weekends and holidays, how much time per day would you normally have
spent in the sun?
Less than 15min 15min to 1hr 1 to 2 hrs 2 to 3 hrs 3 to 4 hrs more than 4hrs
(a) as a child (<13) [ ](1) [ ](2) [ ](3) [ ](4) [ ](5) [ ](6)
(b) as a teenager [ ](1) [ ](2) [ ](3) [ ](4) [ ](5) [ ](6)
(c) the last 3 years [ ](1) [ ](2) [ ](3) [ ](4) [ ](5) [ ](6)
(d) last summer [ ](1) [ ](2) [ ](3) [ ](4) [ ](5) [ ](6)
P20 In winter, during weekends and holidays, how much time per day would you normally have
spent in the sun?
Less than 15min 15min to 1hr 1 to 2 hrs 2 to 3 hrs 3 to 4 hrs more than 4hrs
(a) as a child (<13) [ ](1) [ ](2) [ ](3) [ ](4) [ ](5) [ ](6)
(b) as a teenager [ ](1) [ ](2) [ ](3) [ ](4) [ ](5) [ ](6)
(c) in the last 3 years [ ](1) [ ](2) [ ](3) [ ](4) [ ](5) [ ](6)
(d) last winter [ ](1) [ ](2) [ ](3) [ ](4) [ ](5) [ ](6)
P21 How often do you take holidays in a sunny climate during winter?
Never [ ](1)
Sometimes [ ](2)
Every year [ ](3)
P22 Did you take holidays in a sunny climate last winter?
Yes [ ](1) Where? Which month? Duration?
No [ ](2)
P23 Have you ever had sunburn that was severe enough to cause blistering?
Yes [ ](1)
No [ ](2)
Don’t know [ ](3)
P24 Overall, have your jobs been:
Mainly indoors [ ](1)
Both indoors and outdoors [ ](2)
Mainly outdoors [ ](3)
P25 Have you ever used a solarium?
Yes [ ](1) If YES, how often in last year?
No [ ](2)
Don’t know [ ](3)
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P26 Last summer, whenever you were outside in the sun, how often did you:
(a)Wear sunglasses?Never [ ](1)
Less than 50% of the time [ ](2)
More than 50% of the time [ ](3)
All the time [ ](4)
(a)Wear a hat? Never [ ](1)
Less than 50% of the time [ ](2)
More than 50% of the time [ ](3)
All the time [ ](4)
(c)Apply sunscreen?Never [ ](1)
Less than 50% of the time [ ](2)
More than 50% of the time [ ](3)
All the time [ ](4)
P27 Approximately how many hours sleep do you have each night? hours
P28 Do you usually get up in the night to go to the toilet?
Yes [ ](1) If YES, how many times each night? No [ ](2)
P29 The following question refers to how likely you are to doze off or fall asleep in the following
situations, in contrast to feeling just tired. This refers to your usual way of life in recent times.
Even if you haven’t done some of these things recently try to work out how they would have
affected you. Use the following scale to choose the most appropriate number for each situation:
0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing. Circle your response (0 to 3) for each of the 8 boxes.
Situation Chance of dozing (0, 1, 2 or 3)
a) Sitting and reading 0----1----2----3
b) Watching TV 0----1----2----3
c) Sitting inactive in a public place (eg a theatre or a meeting) 0----1----2----3
d) As a passenger in a car for an hour without a break 0----1----2----3
e) Lying down to rest in the afternoon when circumstances permit 0----1----2----3
f) Sitting and talking to someone 0----1----2----3
g) Sitting quietly after a lunch without alcohol 0----1----2----3
h) In a car, while stopped for a few minutes in the traffic 0----1----2----3
P30 In general, would you say your health is:
Excellent[ ](1) Very good[ ](2) Good[ ](3) Fair[ ](4) Poor[ ](5)
P31 The following items are about activities you might do during a typical day. Does your health now
limit you in these activities? If so, how much?
(a) Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling or playing golf.
Yes, limited a lot[ ](1) Yes, limited a little[ ](2) No, not limited at all[ ](3)
(b) Climbing several flights of stairs.
Yes, limited a lot[ ](1) Yes, limited a little[ ](2) No, not limited at all[ ](3)
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P32 Please answer YES if you or your close relatives have been diagnosed with the following:
You Parent Grandparent Brother/sister Offspring
Heart attack
Angina
Stroke/TIA
Peripheral vascular disease
High cholesterol
Diabetes
Deep vein thrombosis, DVT
Pulmonary embolism
Coronary angiogram
Congestive heart failure
Arrhythmia/Palpitations
Fainting spells/Blackouts
Depression
Alcoholism
Anxiety
Schizophrenia
Bipolar/Manic depression
Suicidal thoughts
P33 Below is a series of questions regarding your experience of overall pain during the past week. Note
that the experience of pain is often confused with the experience of discomfort. Feelings of
discomfort are generally described as “numb”, “fatigued”, “heavy”, etc, whereas feelings of pain are
generally described as “throbbing”, “achy”, “stabbing”, etc.
Indicate your answer by placing a vertical mark on the line as follows:
Not at all ⏐ All the time
a) Indicate the severity of your overall pain(s) during the past week.
No pain(s) As severe as I can imagine
b) During the past week, how severe were your headaches?
No headache As severe as I can imagine
c) During the past week, how severe was your back pain?
No back pain As severe as I can imagine
d) During the past week, how severe was your shoulder pain?
No shoulder pain As severe as I can imagine
e) During the past week, how much has your overall pain(s) interfered with your ability to do daily
activities? (includes work, school, housework, recreational, social, and family activities)
Not at all Complete disability
(unable to do any activities)
f) During the past week, how much of the time that you were awake did you have pain(s)?
None of the time All of the time
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P34 The following questions relate to mood disorders. Circle YES or NO to each response.
1 Has there ever been a period of time when you were not your usual self and...
a ...you felt so good or so hyper that other people thought you were not your normal self, or
you were so hyper that you got into trouble?
Yes No
b ...you were so irritable that you shouted at people or started fights or arguments? Yes No
c ...you felt much more self-confident than usual? Yes No
d ...you got much less sleep than usual and found you didn't really miss it? Yes No
e ...you were much more talkative or spoke faster than usual? Yes No
f ...thoughts raced through your head or you couldn't slow you mind down? Yes No
g ...you were so easily distracted by things around you that you had trouble concentrating or
staying on track?
Yes No
h ...you had much more energy than usual? Yes No
i ...you were much more active or did many more things than usual? Yes No
j ...you were much more social or outgoing than usual; for example, you telephoned friends in
the middle of the night?
Yes No
k ...you were much more interested in sex than usual? Yes No
l ...you did things that were unusual for you or that other people might have thought were
excessive, foolish, or risky?
Yes No
m...spending money got you or your family into trouble? Yes No
2. If you checked YES to more than one of the above, have several of these ever happened during the
same period of time?
YES NO
3. How much of a problem did any of these cause you -- like being unable to work; having family,
money, or legal troubles; getting into arguments or fights?
No Problem = 1 Minor Problem = 2 Moderate Problem = 3 Serious Problem = 4
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P35 Have you ever had any of these medical conditions? Yes [ ] No [ ]
If yes, please tick the YES box and state the age of onset and whether or not the condition has been present
in the last 12 months.
Disease/Infection/Medical condition Tick
if
YES
Age of
onset
(years)
Has the
condition
been present
in the last 12
months?
Yes/No
aa Osteoporosis
ab Osteomalacia
ac Rickets
ad Paget’s disease of bone
ae Osteogenesis imperfecta
af Osteoarthritis
ag Rheumatoid arthritis
ah Disc disease
ai Hip disease (specify )
aj Kidney stones
ak Milk intolerance
al High blood calcium
am Hypoparathyroidism
an Hyperparathyroidism
ao Goitre
ap Hypothyroidism (underactive thyroid)
aq Hyperthyroidism (overactive thyroid)
ar Graves’ Disease
as Hashimoto’s Disease
at Thyroiditis
au Other thyroid disease (specify )
av Diabetes
aw Hypoglycaemia
ax Acromegaly
ay Cushing’s Syndrome
az Hyperprolactinaemia
ba Addison’s Disease
bb Turner’s Syndrome
bc Chronic gastritis
bd Hiatus Hernia/Oesophageal Reflux
be Peptic ulcer disease
bf Gastric surgery
bg Anorexia nervosa
bh Bulimia
bi Pernicious anaemia
bj Cirrhosis of the liver
bk Liver (hepatic) failure
bl Pancreatitis
bm Kidney (renal failure)
bn Nephrotic syndrome
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Disease/Infection/Medical condition Tick
if
YES
Age of
onset
(years)
Has the
condition
been present
in the last 12
months?
Yes/No
bo Bowel surgery
bp Malabsorption
bq Chronic diarrhoea
br Irritable bowel syndrome
bs Inflammatory bowel disease (Crohn’s, ulcerative colitis)
bt Coeliac Disease (gluten enteropathy)
bu Stroke
bv Blackouts or fainting
bw Dizzy spells
bx Transient weakness/numbness
by Parkinson’s Disease
bz Muscle weakness or disease
ca Multiple Sclerosis
cb Epilepsy
cc Decreased vision
cd Macular degeneration
ce Pterigium (small fleshy growth on eye)
cf Cataract (cloudy lens of eye)
cg Co-ordination disorder
ch Frequent falls
ci Low blood pressure (hypotension)
cj High blood pressure (hypertension)
ck Cardiac arrhythmias
cl Angina
cm High cholesterol (hypercholesterolemia)
cn Coronary artery disease
co Pulmonary embolism
cp Deep vein thrombosis (DVT)
cq Depression
cr Anxiety
cs Phobia (specify )
ct Panic disorder
cu Obsessive compulsive disorder
cv Social phobia/social anxiety
cw Generalized anxiety disorder
cx Post traumatic stress
cy Alcoholism
cz Schizophrenia
da Bipolar/Manic depression
db Attention deficit hyperactive disorder (ADHD)
dc Seasonal affective disorder
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Disease/Infection/Medical condition Tick
if
YES
Age of
onset
(years)
Has the
condition
been present
in the last 12
months?
Yes/No
de Asthma
df Hayfever
dg Emphysema
dh Chronic bronchitis
di Other lung disease (specify )
dj Chronic pain
dk Chronic fatigue syndrome
dl Cancer Lung
dm Bowel
dn Breast
do Uterus
dp Cervix
dq Throat
dr Brain tumour
ds Melanoma
dt Non-melanoma skin cancer eg BCC, SCC
du Leukaemia
dv Other (specify )
dw Myeloma
dx Measles
dy Mumps
dz Chicken pox
ea Poliomyelitis
eb Rheumatic fever
ec Diphtheria
ed Whooping cough (Pertussis)
ee Eczema
ef German measles (Rubella)
eg Cold sores (Herpes Labialis)
eh Herpes Genitalis
ei Glandular fever
ej School sores (Impetigo)
ek Meningitis
el Encephalitis
em Scarlet Fever
en Croup
eo Lupus (systemic lupus erythematosis)
ep Psoriasis
Any other diseases or medical conditions?
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General Health Questionnaire (GHQ-12)
Please read this carefully:
We should like to know if you have had any medical complaints, and how your health has been in general, over the past few weeks.
Please answer ALL the questions simply by circling the answer which you think most nearly applies to you. Remember that we want to
know about present and recent complaints, not those you had in the past. It is important that you try to answer ALL the questions
Thank-you very much for your co-operation.
HAVE YOU RECENTLY:
1 - been able to concentrate on whatever you’re doing? Better than
usual
Same as
usual
Less than
usual
Much less
than usual
2 - lost much sleep over worry? Not at all No more
than usual
Rather more
than usual
Much more
than usual
3 - felt that you are playing a useful part in things? More so
than usual
Same as
usual
Less useful
than usual
Much less
useful
4 - felt capable of making decisions about things? More so
than usual
Same as
usual
Less so than
usual
Much less
capable
5 - felt constantly under strain? Not at all No more
than usual
Rather more
than usual
Much more
than usual
6 - felt you couldn’t overcome your difficulties? Not at all No more
than usual
Rather more
than usual
Much more
than usual
7 - been able to enjoy your normal day-to-day activities? More so
than usual
Same as
usual
Less so than
usual
Much less
than usual
8 - been able to face up to your problems? More so
than usual
Same as
usual
Less able
than usual
Much less
able
9 - been feeling unhappy and depressed? Not at all No more
than usual
Rather more
than usual
Much more
than usual
10 - been losing confidence in yourself? Not at all No more
than usual
Rather more
than usual
Much more
than usual
11 - been thinking of yourself as a worthless person? Not at all No more
than usual
Rather more
than usual
Much more
than usual
12 - been feeling reasonably happy, all things considered? More so
than usual
About same
as usual
Less so than
usual
Much less
than usual
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PROT NO……………………
PLEASE CIRCLE YOUR ANSWER: Y=Yes and N=No
SR1. Have you ever been diagnosed as suffering by depresssion?…………….……………Y / N
SR2. Have youever been treated for depression?……………………………… …………...Y / N
SR3. Has anyone in your family, (parents, grandparents, siblings, aunts or uncles) ever had:-
Depression Y / N
Alcoholism Y / N
Suicide Y / N
Anxiety Y / N
Have you had for a two week period: In the last year? Ever?
SR4. Depressed mood most of the day nearly every day?…………………Y / N Y / N
SR5. Markedly diminished interest or pleasure in almost all activities,
most of the day nearly every day?……………………………………Y / N Y / N
SR6. Significant weight loss or weight gain when not dieting?………… Y / N Y / N
SR7. Increased sleep or insomnia?……………………………………… Y / N Y / N
SR8. Feelings of restlessness or being slowed down that is
noticeable by others?………..…………………………………….. Y / N Y / N
SR9. Fatigue or loss of energy?………………………………………… Y / N Y / N
SR10. Feelings of worthlessness or excessive or inappropriate guilt?… … Y / N Y / N
SR11. Diminished ability to think or concentrate or indecisiveness, most of the day
nearly every day?…………………………………………………… Y / N Y / N
SR12. Recurrent thoughts of death or thoughts of suicide, or a plan for committing
suicide?……………………………………………………………… Y / N Y / N
Thank you for completing the questionnaire.
Appendix 10: Participant Information and Consent Form, Geelong Osteoporosis 
Study (GOS): Men 5 year follow-up. 
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GEELONG OSTEOPOROSIS STUDY 
THE UNIVERSITY OF MELBOURNE 
DEPARTMENT OF CLINICAL AND BIOMEDICAL SCIENCES 
THE GEELONG HOSPITAL 
PO BOX 281, GEELONG, VIC 3220 
TELEPHONE: (+61 3) 5226 7397/7393 
FACSIMILE: (+61 3) 5222 2420 
PLAIN LANGUAGE STATEMENT 
 
MALE OSTEOPOROSIS; A POPULATION-BASED STUDY IN GEELONG 
 
Principal Researchers: Dr MA Kotowicz, Dr JA Pasco, Prof GC Nicholson 
This Plain Language Statement and Consent Form is 5 pages long. Please make 
sure you have all the pages. 
1. Your Consent 
You are invited to take part in this research project. 
This Plain Language Statement contains detailed information about the research 
project. Its purpose is to explain to you as openly and clearly as possible all the 
procedures involved in this project before you decide whether or not to take part in it. 
Please read this Plain Language Statement carefully. Feel free to ask questions 
about any information in the Statement. 
Once you understand what the project is about and if you agree to take part in it, you 
will be asked to sign the Consent Form. By signing the Consent Form you indicate 
that you understand the information and that you give your consent to participate in 
the research project. You will be given a copy of both the Consent Form and this 
Plain Language Statement to keep as a record.  
2. Description of the Project 
This study is designed to provide information about male osteoporosis, a neglected 
public health problem in Australia. The aims of the study are to determine: 
 bone mineral density normal ranges for Australian men 
 how many men are affected by low bone mass (osteoporosis) 
 how bone mass (amount of bone) and bone size are associated with ageing  
 risk factors for low bone mass 
 the similarity between bone mass measurements at different parts of the 
skeleton 
 bone quality and bone mass using ultrasound (sound wave) measurements of 
the heel 
 associations between inherited factors and bone mass or other metabolic 
processes 
 age-related changes in muscle strength, balance and sexual function.  
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A total of 1400 men will participate in this project. Previous experience has shown 
that osteoporosis is an unrecognised problem in men. 
It is vital to the success of the project that we measure a representative collection of 
men from the community to identify factors which cause low bone mass 
(osteoporosis) or high bone mass (strong, dense bones). A strength of this study is 
that observation from this region can be generalised to the Australian community. 
Your participation in this project will involve: 
 completion of a questionnaire seeking information concerning risk factors for the 
development of osteoporosis. There will be questions concerning your health, 
medication history, diet, exercise patterns and lifestyles. A clinical assessment 
will include measurement of your blood pressure, height, weight, arm span and 
waist and hip circumferences. 
 collection of a blood sample (approximately 6 tablespoons) after an overnight 
fast for biochemical and hormonal analyses. 
 we will be asking you separately for your consent to use your blood sample for 
genetic analysis. 
 a scan which measures your bone mass in the spine, hip, forearm and total body 
to measure the calcium content of your bones using a dual energy x-ray 
densitometer. The painless procedure takes less than an hour while you are 
lying on an x-ray table and does not involve any injections.  
 an ultrasound measurement at the heel. During this procedure you will be 
required to place your foot in the ultrasound machine for a few minutes. 
 participation in these tests to assess your potential for falling 
 muscle strength, measure with a manual tester, requiring you to resist the 
examiner’s force pushing on your leg. 
 a timed ‘up and go’ test, in which you are required to rise from a chair, walk 3 
metres, return and sit down again. 
 timed walk over a distance of 5 m will be recorded and your gait assessed. 
 functional reach test by reaching forward with your arm raised 900 without 
losing balance. 
Data from this study may also be used as reference data to identify risk factors for 
other diseases. In the event that we establish collaboration (partnerships) with 
industry, your information and samples may be used for further research into 
metabolic disorders. For such partnerships to work, it is important that you assign 
ownership of all the information and coded blood samples to The University of 
Melbourne, Department of Clinical and Biomedical Sciences-Barwon Health. You 
may withhold consent for your information and samples to be used by collaborators if 
you wish. 
3. Possible Benefits. 
We cannot guarantee or promise that you will receive any benefits from this project 
but the information from the study may benefit people in the future.  
4. Possible Risks 
Possible risks, side effects and discomforts include possible bruising during collection 
of blood samples.  
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The bone density measurement uses x-rays to measure the amount of bone at the 
scanning sites and delivers an x-ray that is about one third that delivered by the 
standard chest x-ray. This is less than the total radiation exposure that any member 
of our community encounters in a year and is not associated with any known health 
risk. 
 
The ultrasound measurement is a rapid, painless procedure, not involving x-rays. 
 
5. Alternative to Participation 
Your participation is voluntary but because of the nature of the study, your total 
involvement is important to the quality of the data. You may choose no to be involved 
with this study. 
 
6. Confidentiality and disclosure of Information 
Any information obtained in connection with this project and that can identify you will 
remain confidential. It will only be disclosed with your permission, except as required 
by law. If you give us your permission by signing the Consent Form, we plan to use 
your results in presentations at scientific meetings and for publication in 
scientific/medical journals. However, information will be provided in such a way that 
you cannot be identified.  
 
7. New information Arising During the Project 
During the research project, new information about the risks and benefits of the 
project may become known to the researchers. If this occurs, you will be told about 
this new information.  
 
8. Results of Project 
Periodically you will be sent newsletters summarising research findings and informing 
you of the progress of the project.  
 
9. Further Information of Any Problems 
If you require further Information or if you have any problems concerning this project, 
you can contact one of the principal researchers on 5226 7393. The researchers 
responsible for this project are Prof GC Nicholson, Dr JA Pasco and Dr MA 
Kototwicz. 
 
If you have any further questions about the research procedures or subject risks in 
this study, you may contact the independent patient representative, Ms Jill Linklater, 
Director of Clinical Services, Nursing on 5226 7216. 
 
10. Other Issues 
In addition, this study includes a genetic sub-study in which we ask you to consider 
participation. There is a separate consent for this part of the study that you will be 
asked to sign. 
 
11. Participation in Voluntary 
Participation in any research project is voluntary. If you do not wish to take part you 
are not obliged to. If you decide to take part and later change your mind, you are free 
to withdraw from the project at any stage. Your decision whether to take part or not to 
take part, or to take part and then withdraw, will not affect your routine treatment, 
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your relationship with those treating you or your relationship with Barwon Health (The 
Geelong Hospital).  
 
Before you make your decision, a member of the research team will be available so 
that you can ask any questions you have about the research project. You can ask for 
any information you want. Only sign the Consent Form once you have had a chance 
to ask your questions and have received satisfactory answers. 
 
Before deciding whether or not to take part, you may wish to discuss the project with 
a relative or friend or your local health worker. Feel free to do this. If you decide to 
withdraw from this project, please notify a member of the research team before you 
withdraw. 
 
12. Ethical Guidelines 
This project will be carried out according to the National Statement on Ethical 
Conduct in Research Involving Humans (June 1999) produced by the National Health 
and Medical Research Council of Australia.  This statement has been developed to 
protect the interests of people who agree to participate in human research studies. 
 
This research project has been approved by the Research and Ethics Advisory 
Committee, Barwon Health.  
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GEELONG OSTERPROOSIS STUDY 
THE UNIVERSITY OF MELBOURNE 
DEPARTMENT OF LINICAL AND BIOMEDICAL SCIENCES 
THE GEELONG HOSPITAL  
PO BOX 281, GEELONG, VIC 3220 
TELEPHONE: (+61 3) 52267397/7393 
FACSIMILE: (+61 3) 52222420 
 
 
CONSENT FORM 
 
MALE OSTEOPOROSIS: A POPULATION-BASED STUDY IN GEELONG 
 
     
I have read, or have had read to me in my first language, and I understand the Plain 
Language Statement version 2 dated 28/10/03. 
 
I have a copy of the Plain Language Statement and the Consent Form to keep. 
 
The researcher has agreed not to reveal my identity and personal details if 
information about this project is published or presented in any public form. 
 
I freely agree / do not agree (strike out non-applicable) to participate in this project 
according to the conditions in the Plain Language Statement.  
 
I freely agree / do not agree (strike out non-applicable) to transfer my questionnaire 
information, clinical measurements and blood samples to the University of 
Melbourne, Department of Clinical and Biomedical Sciences-Barwon Health. 
 
I freely agree / do not agree (strike out non-applicable) to the use of my coded 
questionnaire information, clinical measurements and blood samples to be used as 
part of studies relating to other diseases. 
 
I freely agree /do not agree (strike out non-applicable) to allow transfer of my coded 
questionnaire information, clinical measurements and blood samples to collaborators, 
including commercial partners.  
 
Participant’s name (printed) 
 
 
Signature Date 
 
Witness name (printed) 
 
 
Signature Date 
 
Researcher’s name (printed) 
 
 
Signature Date 
 
Note: All parties signing the Consent Form must date their own signature. 
Appendix 11: Questionnaire, Geelong Osteoporosis Study (GOS): Men 5 year 
follow-up.

















Appendix 12: Participant Information and Consent Form (parent), Norwegian 
Longitudinal Health Behavior (NLHB) Study. 


Appendix 13: Participant Information and Consent Form (participant), Norwegian 
Longitudinal Health Behavior (NLHB) Study. 

Appendix 14: Participant Information Sheet, American National Health and 
Nutrition Examination Survey (NHANES). 
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Welcome NHANES Participants
You, or a member of your family, may have a chance to take part in an important national
health survey. The National Center for Health Statistics, a part of the Centers for Disease
Control and Prevention, is responsible for this survey -  The National Health and Nutrition
Examination Survey (NHANES).  This survey teaches us about the health and diet of people in
the United States.  Over the years, this survey has led to improvements in the food we eat and
the health care we receive.
 
Participant Video
Watch a short video about participating in NHANES (/nchs/nhanes/participant_video.htm)
Vietnamese Translation
Xin xem video ngắn về việc tham gia NHANES
(/nchs/nhanes/participant_video_vietnamese.htm)
Simplified Chinese Translation
请观看关于参加 NHANES 调查的短片
(/nchs/nhanes/participant_video_chinese_simplified.htm)
Traditional Chinese Translation
觀賞有關參與 NHANES 調查的短片 (/nchs/nhanes/participant_video_chinese_traditional.htm)
Korean Translation
NHANES 참여에 관한 비디오 보기 (/nchs/nhanes/participant_video_korean.htm)
Spanish Translation
Vea un corto video acerca de la participación en NHANES
(/nchs/nhanes/participant_video_spanish.htm)
French Translation
Regardez une vidéo courte sur la participation dans NHANES
(/nchs/nhanes/participant_video_french.htm)
Haitian Creole Translation
Gade yon videyo kout sou patisipasyon nan NHANES
(/nchs/nhanes/participant_video_haitian_creole.htm)
Amharic Translation
ይህንን አጭር ቢድዮ ስለ የጤንነትና የአመጋገብ ጥናት ተሳታፊ ለመሆን ይመልከቱ
(/nchs/nhanes/participant_video_amharic.htm)
Hindi TranslationएनहेÛस सवȶक्षण (NHANES) मɅ प्रितभाग लेने के बारे मɅ यह संिक्षÜत वीिडयो देखɅ।
(/nchs/nhanes/participant_video_hindi.htm)
 
Additional Video
An in-depth look at participating in this unique health survey
(/nchs/nhanes/recruitment_video.htm)
Spanish translation
Invitación a participar en NHANES (/nchs/nhanes/recruitment_video_spanish.htm) 
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Who are participants?
The information gathered by NHANES provides a snapshot of the health and nutrition of the
U.S. population. Because of this, persons in this survey are from a broad range of age groups
and racial/ethnic backgrounds. Each participant represents approximately 50,000 other U.S.
residents. The identities of our participants are held strictly confidential.
 
How was I selected?
Participants are selected through a complex statistical process using the most current
Census information. In simple terms, NHANES divides the United States into communities.
The communities are divided into neighborhoods. The neighborhoods are selected at random.
From each neighborhood, housing units are selected at random.  Selected households are
approached by our interviewers who ask residents a few short questions to determine if their
household is eligible for the study. (You may have received our introductory letter, sent to
"resident" at your home address.)
You have a unique health profile; if you are selected to be a participant, no other person can be
substituted for you.  You were selected based on your age, gender, and racial/ethnic
background.  No one can take your place in this survey.
 
How do I know this is a legitimate survey?
NHANES History - NHANES has a long history (/nchs/nhanes/History.htm) ; it has been in
existence since the early 1960s and has surveyed over 140,000 people. NHANES was born out
of The National Health Survey Act, 1956. This law authorized a survey to provide current
statistical data on the amount, distribution, and effects of illness and disability in the United
States.
Past Participants - Participants have gained new insight into their health and have enjoyed
taking part in the survey. The feedback we have received from participants includes:
"My daughter and I went through the survey and exam and we were both glad we did it.
Everyone was so nice."
"I was impressed by how professional everyone was."
"I think it is great that the government helps keep us informed about health issues."
"I was impressed by all of the high tech equipment."
Other Organizations - Additionally, many national and local organizations, such as the AARP,
NAACP, and the National Council of La Raza endorse NHANES through letters of endorsement
(/nchs/nhanes/letters_of_endorsement.htm) .
Staff - The NHANES staff consist of professional individuals with a variety of health, research,
and academic backgrounds. The staff at the mobile examination center include: a doctor, a
phlebotomist, health technicians and highly trained interviewers. The home interviewers have
varied backgrounds in fields such as social work, the military, and education.  The staff at
headquarters include: medical doctors, PhDs, nurses, health educators, and engineers.
Watch a video describing NHANES history - The NHANES Story
(/nchs/video/nhanes50th_ppf/intro/ppf_intro.htm)
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Is my information confidential?
Public laws keep all information participants give confidential. We will hold all data we collect
in the strictest confidence. We gather and protect all information in keeping with the
requirements of Federal Law: the Public Health Service Act (42 USC 242k) authorizes
collection and Section 308(d) of that law (42 USC 242m), the Privacy Act of 1974 (5 USC
552A), and the Confidential Information Protection and Statistical Efficiency Act (PL 107-
347)prohibit us from giving out information that identifies you or your family without your
consent. This means that we cannot give out any fact about you, even if a court of law asks for
it. We will keep all survey data safe and secure. When we allow researchers to use survey data,
we protect your privacy. We assign code numbers in place of names or other facts that could
identify you.
 
What are the Benefits of Participating?
Examination - Many of the measurements and tests performed in the Mobile Exam Center are
unique, and they are not commonly done in doctor's offices during routine physical exams. The
DXA body scan is used to measure bone density.  This is a chance for you to have many
important tests and gain additional health information about yourself.  These tests are done at
no expense to you. To determine which tests you will have see: Health Exam Tests
(/nchs/nhanes/testcomp.htm) .
**This exam is not a substitute for your regular health care examination.
Report of Findings - You will receive results from your examination.  You will get a preliminary
report of findings when you leave the mobile exam center.  Some results, like those for sexually
transmitted disease (STD) tests are not put in writing but you will be given a toll-free number,
a password, and the dates to call for your results. A final report of findings will be sent to you in
the mail 12-16 weeks after your exam. These results are yours to discuss with your doctor or
keep for your own medical records.  To view an example of a Final Report of Findings  [PDF
- 78 KB] (/nchs/data/nhanes/nhanes_07_08/ROF_07_08_eng.pdf) . Your Final Report of Findings
will be mailed to your home.
Contributing to the Health Knowledge in the U.S. - Information gathered from NHANES has
been used to influence policy and improve the health of the U.S. population in many ways. See:
Data Accomplishments (/nchs/nhanes/DataAccomp.htm) .
A Cash Remuneration - All participants, regardless of age, are given a cash payment as a
"thank-you" for their time and effort. NHANES will also reimburse participants for
transportation and baby/elder care.
 
What is Involved in Participating?
There are two main parts to this survey, the home interview and the health examination.
The Interview
An NHANES interviewer will come to your home to talk to you about the survey. This
interviewer should present a photo identification badge which identifies this person as being
from the National Health and Nutrition Examination Survey.  The interviewer will ask you a
few questions to see if you qualify to participate. If you do, the interviewer will set up an
appointment with you for an in-home interview. During this interview you will be asked
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questions about your health, disease history, and diet. The interview is approximately one hour
and responses are recorded on a laptop computer.
Examples of  questions:
Has a doctor or other health professional ever told you that you had arthritis?
Have you heard of MyPyramid?
Again, anything you say during this interview is confidential.  At the end of your interview, an
appointment will be made at our Mobile Examination Center.
The Health Examination
The Mobile Exam Center (MEC) is made up of four trailers, linked sideways, which contain
high-tech medical equipment. The MEC is situated in a location convenient for participants.
The NHANES staff can help you with transportation to the MEC if needed. 
To view the MEC, watch our virtual tour (/nchs/nhanes/mec_tour/mectour.htm) .
You will have a health examination consisting of a number of measurements and tests. The
exams  will depend on your age and gender and current medical conditions. To determine
which tests you will have see Health Exam Tests (/nchs/nhanes/testcomp.htm) .
**This exam is not a substitute for your regular health care examination. There
will be no invasive internal exam and no drug testing.
 
What do you do with my blood and urine samples that I
consented to have stored?
In 1999 and later years, there were two consent forms – one for specimen storage and
continuing studies and another for specimen storage and continuing studies using DNA. If you
signed one or both forms, you can click the links for the appropriate type of sample and year
you participated in to see summaries of research studies that used these samples.
Studies using stored specimens
2005-present – To date, no studies using stored blood and/or urine samples have been
completed. Please check back for updates.
What studies were done if I was examined between 1999-2004?
(http://wwwn.cdc.gov/nchs/nhanes/storedspecimens/)
Studies using DNA samples
1999-present (/nchs/nhanes/dna_researchsummaries.htm)
1988-1994 (/nchs/nhanes/dna_researchsummaries.htm)
 
Who can I contact if I have questions?
To discuss any aspect of the survey, you can make a free call to Dr. Kathryn Porter of the U.S.
Public Health Service at 1-800-452-6115.  If you have questions about your rights as a survey
participant, call the Research Ethics Review Board at the National Center for Health Statistics
at 1-800-223-8118. Leave a brief message containing your name, phone number, and your
NHANES survey concerns. Your call will be returned as soon as possible. Thank you.
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